CRISPR-CAS SYSTEMS, CRYSTAL STRUCTURE AND USES THEREOF

Abstract

The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.

Description

RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

[0001] This application is a Continuation of U.S. application Ser. No. 15/171,141 filed Jul. 2, 2016, which is a Continuation-In-Part of International Application Number PCT/US2014/069925 filed Dec. 12, 2014 which published as PCT Publication Number WO2015/089364 on Jun. 18, 2015. This application claims priority from U.S. provisional patent applications: 61/915,251, filed Dec. 12, 2013; and 61/930,214 filed Jan. 22, 2014.

[0002] The foregoing applications, and all documents cited therein or during their prosecution ("appln cited documents") and all documents cited or referenced in the appln cited documents, and all documents cited or referenced herein ("herein cited documents"), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

STATEMENT REGARDING SEQUENCE LISTING

[0004] The sequence listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the sequence listing is 114203-5779_Sequence.txt. The text file is 323 kb, was created on Jul. 19, 2019, and is being submitted electronically via EFS-Web.

FIELD OF THE INVENTION

[0005] The present invention generally relates to systems, methods and compositions used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that may use vector systems related to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and components thereof.

[0006] This invention was made with government support under PRESTO (Precursory Research for Embryonic Science and Technology, Sakigake) in the field of "Structural life science and advanced core technologies for innovative life science research", awarded by JST (Japan Science and Technology Agency) in 2012. JST has certain rights in the invention.

[0007] This invention was made with government support under CREST in the field of "Creation of Basic Medical Technologies to Clarify and Control the Mechanisms Underlying Chronic Inflammation", awarded by JST (Japan Science and Technology Agency) in 2013. JST has certain rights in the invention.

BACKGROUND OF THE INVENTION

[0008] Recent advances in genome sequencing techniques and analysis methods have significantly accelerated the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. Precise genome targeting technologies are needed to enable systematic reverse engineering of causal genetic variations by allowing selective perturbation of individual genetic elements, as well as to advance synthetic biology, biotechnological, and medical applications. Although genome-editing techniques such as designer zinc fingers, transcription activator-like effectors (TALEs), or homing meganucleases are available for producing targeted genome perturbations, there remains a need for new genome engineering technologies that are affordable, easy to set up, scalable, and amenable to targeting multiple positions within the eukaryotic genome.

SUMMARY OF THE INVENTION

[0009] There exists a pressing need for alternative and robust systems and techniques for sequence targeting with a wide array of applications. This invention addresses this need and provides related advantages. The CRISPR/Cas or the CRISPR-Cas system (both terms are used interchangeably throughout this application) does not require the generation of customized proteins to target specific sequences but rather a single Cas enzyme can be programmed by a short RNA molecule to recognize a specific DNA target, in other words the Cas enzyme can be recruited to a specific DNA target using said short RNA molecule. Adding the CRISPR-Cas system to the repertoire of genome sequencing techniques and analysis methods may significantly simplify the methodology and accelerate the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. To utilize the CRISPR-Cas system effectively for genome editing without deleterious effects, it is critical to understand aspects of engineering and optimization of these genome engineering tools, which are aspects of the claimed invention.

[0010] In one aspect, the invention provides a method for altering or modifying expression of a gene product. The said method may comprise introducing into a cell containing and expressing a DNA molecule encoding the gene product an engineered, non-naturally occurring CRISPR-Cas system comprising a Cas protein and guide RNA that targets the DNA molecule, whereby the guide RNA targets the DNA molecule encoding the gene product and the Cas protein cleaves the DNA molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the guide RNA do not naturally occur together. The invention comprehends the guide RNA comprising a guide sequence fused to a tracr sequence. The invention further comprehends the Cas protein being codon optimized for expression in a Eukaryotic cell. In a preferred embodiment the Eukaryotic cell is a mammalian cell and in a more preferred embodiment the mammalian cell is a human cell. In a further embodiment of the invention, the expression of the gene product is decreased.

[0011] In one aspect, the invention provides an engineered, non-naturally occurring CRISPR-Cas system comprising a Cas protein and a guide RNA that targets a DNA molecule encoding a gene product in a cell, whereby the guide RNA targets the DNA molecule encoding the gene product and the Cas protein cleaves the DNA molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the guide RNA do not naturally occur together. The invention comprehends the guide RNA comprising a guide sequence fused to a tracr sequence. In an embodiment of the invention the Cas protein is a type II CRISPR-Cas protein and in a preferred embodiment the Cas protein is a Cas9 protein. The invention further comprehends the Cas protein being codon optimized for expression in a Eukaryotic cell. In a preferred embodiment the Eukaryotic cell is a mammalian cell and in a more preferred embodiment the mammalian cell is a human cell. In a further embodiment of the invention, the expression of the gene product is decreased.

[0012] In another aspect, the invention provides an engineered, non-naturally occurring vector system comprising one or more vectors comprising a first regulatory element operably linked to a CRISPR-Cas system guide RNA that targets a DNA molecule encoding a gene product and a second regulatory element operably linked to a Cas protein. Components (a) and (b) may be located on same or different vectors of the system. The guide RNA targets the DNA molecule encoding the gene product in a cell and the Cas protein cleaves the DNA molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the guide RNA do not naturally occur together. The invention comprehends the guide RNA comprising a guide sequence fused to a tracr sequence. In an embodiment of the invention the Cas protein is a type II CRISPR-Cas protein and in a preferred embodiment the Cas protein is a Cas9 protein. The invention further comprehends the Cas protein being codon optimized for expression in a Eukaryotic cell. In a preferred embodiment the Eukaryotic cell is a mammalian cell and in a more preferred embodiment the mammalian cell is a human cell. In a further embodiment of the invention, the expression of the gene product is decreased.

[0013] In one aspect, the invention provides a vector system comprising one or more vectors. In some embodiments, the system comprises: (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence; wherein components (a) and (b) are located on the same or different vectors of the system. In some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the system comprises the tracr sequence under the control of a third regulatory element, such as a polymerase III promoter. In some embodiments, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. Determining optimal alignment is within the purview of one of skill in the art. For example, there are publically and commercially available alignment algorithms and programs such as, but not limited to, ClustalW, Smith-Waterman in matlab, Bowtie, Geneious, Biopython and SeqMan. In some embodiments, the CRISPR complex comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR complex in a detectable amount in the nucleus of a eukaryotic cell. Without wishing to be bound by theory, it is believed that a nuclear localization sequence is not necessary for CRISPR complex activity in eukaryotes, but that including such sequences enhances activity of the system, especially as to targeting nucleic acid molecules in the nucleus. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is S. pneumoniae, S. pyogenes, or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length. In general, and throughout this specification, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. One type of vector is a "plasmid," which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses). Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors." Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.

[0014] Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).

[0015] The term "regulatory element" is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes). Regulatory elements may also direct expression in a temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. In some embodiments, a vector comprises one or more pol III promoter (e.g. 1, 2, 3, 4, 5, or more pol I promoters), one or more pol II promoters (e.g. 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g. 1, 2, 3, 4, 5, or more pol I promoters), or combinations thereof. Examples of pol III promoters include, but are not limited to, U6 and H1 promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the .beta.-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1.alpha. promoter. Also encompassed by the term "regulatory element" are enhancer elements, such as WPRE; CMV enhancers; the R-U5' segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit .beta.-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc. A vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).

[0016] Advantageous vectors include lentiviruses and adeno-associated viruses, and types of such vectors can also be selected for targeting particular types of cells.

[0017] In one aspect, the invention provides a eukaryotic host cell comprising (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence. In some embodiments, the host cell comprises components (a) and (b). In some embodiments, component (a), component (b), or components (a) and (b) are stably integrated into a genome of the host eukaryotic cell. In some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the eukaryotic host cell further comprises a third regulatory element, such as a polymerase III promoter, operably linked to said tracr sequence. In some embodiments, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity. In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length. In an aspect, the invention provides a non-human eukaryotic organism; preferably a multicellular eukaryotic organism, comprising a eukaryotic host cell according to any of the described embodiments. In other aspects, the invention provides a eukaryotic organism; preferably a multicellular eukaryotic organism, comprising a eukaryotic host cell according to any of the described embodiments. The organism in some embodiments of these aspects may be an animal; for example a mammal. Also, the organism may be an arthropod such as an insect. The organism also may be a plant. Further, the organism may be a fungus.

[0018] In one aspect, the invention provides a kit comprising one or more of the components described herein. In some embodiments, the kit comprises a vector system and instructions for using the kit. In some embodiments, the vector system comprises (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence. In some embodiments, the kit comprises components (a) and (b) located on the same or different vectors of the system. In some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the system further comprises a third regulatory element, such as a polymerase III promoter, operably linked to said tracr sequence. In some embodiments, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. In some embodiments, the CRISPR enzyme comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is S. pneumoniae, S. pyogenes or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity. In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length.

[0019] In one aspect, the invention provides a method of modifying a target polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expressed from a gene comprising the target sequence. In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cell, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence. In some embodiments, said vectors are delivered to the eukaryotic cell in a subject. In some embodiments, said modifying takes place in said eukaryotic cell in a cell culture. In some embodiments, the method further comprises isolating said eukaryotic cell from a subject prior to said modifying. In some embodiments, the method further comprises returning said eukaryotic cell and/or cells derived therefrom to said subject.

[0020] In one aspect, the invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cells, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence.

[0021] In one aspect, the invention provides a method of generating a model eukaryotic cell comprising a mutated disease gene. In some embodiments, a disease gene is any gene associated an increase in the risk of having or developing a disease. In some embodiments, the method comprises (a) introducing one or more vectors into a eukaryotic cell, wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, and a tracr sequence; and (b) allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said disease gene, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, thereby generating a model eukaryotic cell comprising a mutated disease gene. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expression from a gene comprising the target sequence.

[0022] In one aspect, the invention provides a method for developing a biologically active agent that modulates a cell signaling event associated with a disease gene. In some embodiments, a disease gene is any gene associated an increase in the risk of having or developing a disease. In some embodiments, the method comprises (a) contacting a test compound with a model cell of any one of the described embodiments; and (b) detecting a change in a readout that is indicative of a reduction or an augmentation of a cell signaling event associated with said mutation in said disease gene, thereby developing said biologically active agent that modulates said cell signaling event associated with said disease gene.

[0023] In one aspect, the invention provides a recombinant polynucleotide comprising a guide sequence upstream of a tracr mate sequence, wherein the guide sequence when expressed directs sequence-specific binding of a CRISPR complex to a corresponding target sequence present in a eukaryotic cell. In some embodiments, the target sequence is a viral sequence present in a eukaryotic cell. In some embodiments, the target sequence is a proto-oncogene or an oncogene.

[0024] In one aspect the invention provides for a method of selecting one or more cell(s) by introducing one or more mutations in a gene in the one or more cell (s), the method comprising: introducing one or more vectors into the cell (s), wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, a tracr sequence, and an editing template; wherein the editing template comprises the one or more mutations that abolish CRISPR enzyme cleavage; allowing homologous recombination of the editing template with the target polynucleotide in the cell(s) to be selected; allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said gene, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein binding of the CRISPR complex to the target polynucleotide induces cell death, thereby allowing one or more cell(s) in which one or more mutations have been introduced to be selected. In a preferred embodiment, the CRISPR enzyme is Cas9. In another preferred embodiment of the invention the cell to be selected may be a eukaryotic cell. Aspects of the invention allow for selection of specific cells without requiring a selection marker or a two-step process that may include a counter-selection system.

[0025] In another aspect the invention comprehends a CRISPR-cas9 (S. pyogenes) system having an X-ray diffraction pattern corresponding to or resulting from any or all of the foregoing and/or a crystal having the structure defined by the co-ordinates of the Crystral Structure Table in Example 1 (the CRISPR-cas9 crystal structure).

[0026] In a further aspect, the invention involves a computer-assisted method for identifying or designing potential compounds to fit within or bind to CRISPR-cas9 system or a functional portion thereof or vice versa (a computer-assisted method for identifying or designing potential CRISPR-cas9 systems or a functional portion thereof for binding to desired compounds) or a computer-assisted method for identifying or designing potential CRISPR-cas9 systems (e.g., with regard to predicting areas of the CRISPR-cas9 system to be able to be manipulated--for instance, based on crystral structure data or based on data of cas9 orthologs, or with respect to where a functional group such as an activator or repressor can be attached to the CRISPR-cas9 system, or as to cas9 truncations or as to designing nickases), said method comprising:

[0027] using a computer system, e.g., a programmed computer comprising a processor, a data storage system, an input device, and an output device, the steps of:

[0028] (a) inputting into the programmed computer through said input device data comprising the three-dimensional co-ordinates of a subset of the atoms from or pertaining to the CRISPR-cas9 crystal structure, e.g., in the CRISPR-cas9 system binding domain or alternatively or additionally in domains that vary based on variance among cas9 orthologs or as to cas9s or as to nickases or as to functional groups, optionally with structural information from CRISPR-cas9 system complex(es), thereby generating a data set;

[0029] (b) comparing, using said processor, said data set to a computer database of structures stored in said computer data storage system, e.g., structures of compounds that bind or putatively bind or that are desired to bind to a CRISPR-cas9 system or as to cas9 orthologs (e.g., as cas9s or as to domains or regions that vary amongst cas9 orthologs) or as to the CRISPR-cas9 crystal structure or as to nickases or as to functional groups;

[0030] (c) selecting from said database, using computer methods, structure(s)--e.g., CRISPR-cas9 structures that may bind to desired structures, desired structures that may bind to certain CRISPR-cas9 structures, portions of the CRISPR-cas9 system that may be manipulated, e.g., based on data from other portions of the CRISPR-cas9 crystral structure and/or from cas9 orthologs, truncated cas9s, novel nickases or particular functional groups, or positions for attaching functional groups or functional-group-CRISPR-cas9 systems;

[0031] (d) constructing, using computer methods, a model of the selected structure(s); and

[0032] (e) outputting to said output device the selected structure(s);

[0033] and optionally synthesizing one or more of the selected structure(s);

[0034] and further optionally testing said synthesized selected structure(s) as or in a CRISPR-cas9 system;

[0035] or, said method comprising: providing the co-ordinates of at least two atoms of the CRISPR-cas9 crystal structure, e.g., at least two atoms of the herein Crystral Structure Table of the CRISPR-cas9 crystal structure or co-ordinates of at least a sub-domain of the CRISPR-cas9 crystral structure ("selected co-ordinates"), providing the structure of a candidate comprising a binding molecule or of portions of the CRISPR-cas9 system that may be manipulated, e.g., based on data from other portions of the CRISPR-cas9 crystral structure and/or from cas9 orthologs, or the structure of functional groups, and fitting the structure of the candidate to the selected coordinates, to thereby obtain product data comprising CRISPR-cas9 structures that may bind to desired structures, desired structures that may bind to certain CRISPR-cas9 structures, portions of the CRISPR-cas9 system that may be manipulated, truncated cas9s, novel nickases, or particular functional groups, or positions for attaching functional groups or functional-group-CRISPR-cas9 systems, with output thereof; and optionally synthesizing compound(s) from said product data and further optionally comprising testing said synthesized compound(s) as or in a CRISPR-cas9 system.

[0036] The testing can comprise analyzing the CRISPR-cas9 system resulting from said synthesized selected structure(s), e.g., with respect to binding, or performing a desired function.

[0037] The output in the foregoing methods can comprise data transmission, e.g., transmission of information via telecommunication, telephone, video conference, mass communication, e.g., presentation such as a computer presentation (eg POWERPOINT), internet, email, documentary communication such as a computer program (eg WORD) document and the like. Accordingly, the invention also comprehends computer readable media containing: atomic co-ordinate data according to the herein Crystal Structure Table and/or the Figures, said data defining the three dimensional structure of CRISPR-cas9 or at least one sub-domain thereof, or structure factor data for CRISPR-cas9, said structure factor data being derivable from the atomic co-ordinate data of herein Crystal Structure Table and/or the Figures. The computer readable media can also contain any data of the foregoing methods. The invention further comprehends methods a computer system for generating or performing rational design as in the foregoing methods containing either: atomic co-ordinate data according to herein Crystal Structure Table and/or the Figures, said data defining the three dimensional structure of CRISPR-cas9 or at least one sub-domain thereof, or structure factor data for CRISPR-cas9, said structure factor data being derivable from the atomic co-ordinate data of herein Crystal Structure Table and/or the Figures. The invention further comprehends a method of doing business comprising providing to a user the computer system or the media or the three dimensional structure of CRISPR-cas9 or at least one sub-domain thereof, or structure factor data for CRISPR-cas9, said structure set forth in and said structure factor data being derivable from the atomic co-ordinate data of herein Crystal Structure Table and/or the Figures, or the herein computer media or a herein data transmission.

[0038] A "binding site" or an "active site" comprises or consists essentially of a site (such as an atom, a functional group of an amino acid residue or a plurality of such atoms and/or groups) in a binding cavity or region, which may bind to a compound such as a nucleic acid molecule, which is/are involved in binding.

[0039] By "fitting", is meant determining by automatic, or semi-automatic means, interactions between one or more atoms of a candidate molecule and at least one atom of a structure of the invention, and calculating the extent to which such interactions are stable. Interactions include attraction and repulsion, brought about by charge, steric considerations and the like. Various computer-based methods for fitting are described further

[0040] By "root mean square (or rms) deviation", we mean the square root of the arithmetic mean of the squares of the deviations from the mean.

[0041] By a "computer system", is meant the hardware means, software means and data storage means used to analyze atomic coordinate data. The minimum hardware means of the computer-based systems of the present invention typically comprises a central processing unit (CPU), input means, output means and data storage means. Desirably a display or monitor is provided to visualize structure data. The data storage means may be RAM or means for accessing computer readable media of the invention. Examples of such systems are computer and tablet devices running Unix, Windows or Apple operating systems.

[0042] By "computer readable media", is meant any medium or media, which can be read and accessed directly or indirectly by a computer e.g. so that the media is suitable for use in the above-mentioned computer system. Such media include, but are not limited to: magnetic storage media such as floppy discs, hard disc storage medium and magnetic tape; optical storage media such as optical discs or CD-ROM; electrical storage media such as RAM and ROM; thumb drive devices; cloud storage devices and hybrids of these categories such as magnetic/optical storage media.

[0043] Accordingly, it is an object of the invention not to encompass within the invention any previously known product, process of making the product, or method of using the product such that Applicants reserve the right and hereby disclose a disclaimer of any previously known product, process, or method. It is further noted that the invention does not intend to encompass within the scope of the invention any product, process, or making of the product or method of using the product, which does not meet the written description and enablement requirements of the USPTO (35 U.S.C. .sctn. 112, first paragraph) or the EPO (Article 83 of the EPC), such that Applicants reserve the right and hereby disclose a disclaimer of any previously described product, process of making the product, or method of using the product.

[0044] It is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as "comprises", "comprised", "comprising" and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean "includes", "included", "including", and the like; and that terms such as "consisting essentially of" and "consists essentially of" have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention. It may be advantageous in the practice of the invention to be in compliance with Art. 53(c) EPC and Rule 28(b) and (c) EPC. Nothing herein is to be construed as a promise.

[0045] These and other embodiments are disclosed or are obvious from and encompassed by, the following Detailed Description.

BRIEF DESCRIPTION OF THE DRAWINGS

[0046] The patent application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0047] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

[0048] FIGS. 1A-M provide: a diagram showing the topology of the Cas9 protein. Helices are shown as tubes and beta sheets are shown as arrows and various views of the CRISPR-cas complex crystal structure (A-I), chimeric RNA architecture from the crystal structure (J-K), an interaction schematic from the crystal structure (L) and a topology schematic from the crystal structure (M). FIG. 1J discloses SEQ ID NO: 108. FIG. 1L discloses SEQ ID NOS 109 and 110.

[0049] FIGS. 2A-C show, from the crystal structure, a schematic of showing catalytic domains of SpCas9, sites of mutagenesis for new nickases (A), a schematic showing locations of sgRNAs for testing double nicking (B), and results of a Surveyor gel test results showing 1 HNH mutant N854A that retains nickase activity, and 1 HNH mutant that shows nickase activity (N863A), and 2 RuvCIII mutants that show nickase activity (H983A, D986A) (C).

[0050] FIGS. 3A-B show Surveyor gel test results of SpCas9 truncation mutants from the crystal structure that retain cleavage activity (A) and a table showing the amino acid truncations and flexible (GGGS) (SEQ ID NO: 1) or rigid (A(EAAAK)) (SEQ ID NO: 2) linker substitutions of the lanes of the gels of FIG. 25A (B). FIG. 3B discloses linker sequences as SEQ ID NOS 45, 47, 49, 53, 111, 112, 113, 53, 111, 47, and 51, respectively, top to bottom, left to right, in order of appearance.

[0051] FIGS. 4A-B show SpCas9 sgRNAs from the crystal structure including those mutated to investigate contribution to activity of specific bases or groups to basses. FIG. 4A discloses SEQ ID NOS 114-137, and FIG. 4B discloses SEQ ID NOS 138-152, all respectively, in order of appearance.

[0052] FIGS. 5A-C show truncation and creation of chimeric (S. pyogenes) Cas9s based on the herein crystal structure, including mutants for mapping essential functional domains (A), chimeras that contain regions from S. thermophilus Cas9 (B), and designs for chemically inducible dimerization of SpCas9 (C).

[0053] FIG. 6 shows a picture of Cas9 crystals (0.2 mm).

[0054] FIG. 7 shows a structural figure of showing Cas9 in a surface representation; red, sgRNA; cyan, the guide region of sgRNA; gold, target DNA.

[0055] FIG. 8A-D shows the overall structure. (A) Domain organization of S. pyogenes Cas9, and schematic of the sgRNA:target DNA complex. (B) Ribbon representation of the Cas9-sgRNA-DNA complex. Disordered linkers are shown as red dotted lines. (C) Surface representation of the Cas9-sgRNA-DNA complex. The active sites of the RuvC (D10A) and HNH (H840A) domains are indicated by dashed yellow circles. (D) Electrostatic surface potential of the Cas9-sgRNA-DNA complex. The HNH domain is omitted for clarity. Molecular graphic images were prepared using CueMol (see website at cuemol.org). Also refer to FIGS. 37 and 38.

[0056] FIG. 9A-E shows the REC lobe and PI domain. (A) Structure of the REC lobe. The REC2 domain and Bridge helix are colored dark gray and green, respectively. The REC1 domain is colored gray, with the repeat-interacting and anti-repeat-interacting regions colored pale blue and pink, respectively. The bound sgRNA:DNA is shown as semi-transparent ribbon representation. (B) Schematics indicating positions of SpCas9 truncations in the REC1 and REC2 domains. Bars on the right show indel mutations generated by the truncation mutants, measured by SURVEYOR assay (n=3, error bars show mean.+-.S.E.M., N.D., not detectable). (C) Western blot showing expression of truncation mutants in HEK 293FT cells. (D) Structure of the PI domain. The bound sgRNA is shown as semi-transparent ribbon representation. (E) Schematics showing wild-type SpCas9 and St3Cas9, chimeric Cas9, as well as SpCas9 PI domain truncation constructs. Cas9s are assayed for indel generation at target sites upstream of either NGG (left bar graph) or NGGNG (right bar graph) PAMs (n=3, error bars show mean.+-.S.E.M., N.D., not detectable). See also FIGS. 39-41. FIG. 9E discloses SEQ ID NOS 153 and 107, respectively, in order of appearance.

[0057] FIG. 10A-F shows the NUC lobe. (A) Structure of the RuvC domain. The core structure of the RNase H fold core is highlighted in cyan. The active-site residues are shown as stick models. (B) Structure of the T. thermophilus RuvC dimer in complex with a Holliday junction (PDB ID 4LD0). The two protomers are colored cyan and gray, respectively. (C) Sequence (top) (SEQ ID NO: 154) illustrates Cas9 nicking targets on opposite strands of DNA. Targets 1 and 2 are offset by a distance of 4-bp in between. Heatmap (bottom) shows the ability of each catalytic mutant to induce double- (with either sgRNA 1 or 2) or single-stranded breaks (only with both sgRNA together). Gray boxes: not assayed. (D) Indel formation by Cas9 nickases depends on off-set distance between sgRNA pairs (right panel). Off-set distance is defined as the number of base pairs between the PAM-distal (5') ends of the guide sequence of a given sgRNA pair (n=3, error bars show mean.+-.S.E.M., N.D., not detectable). (E) Structure of the HNH domain. The core structure of the .beta..beta..alpha.-metal fold is highlighted in magenta. The active-site residues are shown as stick models. (F) Structure of the T4 Endo VII dimer in complex with a Holliday junction (PDB ID 2QNC). The two protomers are colored pink and gray, respectively, with the .beta..beta..alpha.-metal fold core highlighted in magenta. The bound Mg.sup.2+ ion is shown as an orange sphere.

[0058] FIG. 11A-D shows sgRNA and its target DNA. (A) Schematic of the sgRNA:DNA complex. The guide and repeat regions of the crRNA sequence are colored skyblue and blue, respectively. The tracrRNA sequence is colored red, with the linker region colored violet. The target DNA and tetraloop are colored yellow and black, respectively. The numbering of the 3' tails of tracrRNA is shown on red background. Watson-Crick and non-Watson-Crick base pairs are indicated by black and gray lines, respectively. Disordered nucleotides are boxed by dashed lines. (B) Structure of the sgRNA:DNA complex. (C) Structure of the repeat:anti-repeat duplex and three-way junction. Key interactions are shown as gray dashed lines. (D) Effect of sgRNA mutations on ability to induce indels. Base changes from the +83 sgRNA scaffold are shown at respective positions, with dashes indicating unaltered bases (n=3, error bars show mean.+-.S.E.M., p values based on unpaired Student's t-test, N.D., not detectable). See also FIG. 42. FIG. 11A discloses SEQ ID NOS 155 and 156, and FIG. 11D discloses SEQ ID NSO 157-170, all respectively, in order of appearance.

[0059] FIG. 12A-K shows Recognition of the sgRNA:DNA. (A) Schematic of sgRNA:DNA recognition by Cas9. Residues that interact with the sgRNA:DNA via their main chain are shown in parentheses. (B and C-K) Recognition of the guide (B), guide:DNA duplex (D), repeat (E), anti-repeat (F), three-way junction (G), stem loop 1 (H), linker (I), stem loop 2 (J) and stem loop 3 (K). Hydrogen bonds and salt bridges are shown as dashed lines. (C) Effect of Cas9 (top) and sgRNA (bottom) mutations on ability to induce indels (n=3, error bars show mean.+-.S.E.M., p values based on unpaired Student's t-test. N.D., not detectable). FIG. 12A discloses SEQ ID NOS 171 and 172.

[0060] FIG. 13A-D shows Structural flexibility of the complex. (A) Structural comparison of Mol A and Mol B. In Mol A (left), disordered linker between the RuvC and HNH domain is indicated by a dotted line. In Mol B (right), the disordered HNH domain is shown as a dashed circle. The flexible connecting segment (.alpha.40 and .alpha.41) in the RuvC domain is highlighted in orange. (B) Superimposition of the Cas9 proteins in Mol A and Mol B. The two complexes are superimposed based on the core .beta.-sheet of their RuvC domains. The HNH domain and bound sgRNA:DNA are omitted for clarity. (C) Superimposition of the bound sgRNA:DNA in Mol A and Mol B. After superimposition of the two complexes as in (B), the Cas9 proteins are omitted to show the sgRNA:DNA. (D) Molecular surface of Cas9. The HNH domain and bound sgRNA:DNA complex are omitted for clarity. Note that there is no direct contact between the REC and NUC lobes, expect for the interactions between the a2-.alpha.3 loop and .beta.17-.beta.18 loop.

[0061] FIG. 14 shows a Model of RNA-guided DNA cleavage by Cas9.

[0062] FIG. 15 shows Electron density map. The 2mFo-DF.sub.S electron density map around the three-way junction is shown as a gray mesh (contoured at 2.5.sigma.).

[0063] FIG. 16A-C shows Di-cysteine mutant (C80L/C574E) is functional in HEK 293FT cells. (A) Schematic illustrating positions of cysteine mutations (C80L and C574E) in Cas9. (B) Sequence of the target site (SEQ ID NO: 173) used to test the function of the C80L/C574E mutant of Cas9. (C) SURVEYOR nuclease assay showing indels generated by either the wild-type or C80L/C574E mutant (n=3).

[0064] FIG. 17 shows a schematic drawing of the secondary structural elements of Cas9.

[0065] FIG. 18A-B shows the sequence alignment of Cas9 orthologs in families II-A and II-C (SEQ ID NOS 174-179, respectively, in order of appearance). The catalytic residues are shown in red triangles. Critical arginine residues on Bridge helix are shown in green triangles. The secondary structure of S. pyogenes Cas9 is shown above the sequences. The figure was prepared using TCoffee (Notredame et al., 2000) and ESPript (Gouet et al., 1999). Sp, S. pyogenes; Sm, Streptococcus mutans; St3, Streptococcus thermophilus CRISPR-3; St1, Streptococcus thermophilus CRISPR-1; Cj, Campylobacter jejuni; Mm; Neisseria meningiditis.

[0066] FIG. 19 shows the sequence alignment of Cas9 orthologs in families II-A, II-B and II-C. 35 Cas9 orthologs from families IIA, IIB and IIC are aligned (BLOSUM62) and clustered (Jukes-Cantor model Neighbor-Joining method, with S. pyogenes Cas9 as outgroup). Bars on top show conservation by amino acid. In each line, black bars show residues with at least 75% consensus, and gray bars non-conserved residues.

[0067] FIG. 20 shows the comparison of the sgRNA:DNA heteroduplex with a canonical A-form RNA duplex. The sgRNA:DNA heteroduplex are superimposed on an A-form RNA duplex based on their phosphorus atoms. The A-form RNA duplex is colored dark gray. Nucleotides 51-97 of the sgRNA are omitted for clarity.

[0068] The figures herein are for illustrative purposes only and are not necessarily drawn to scale.

DETAILED DESCRIPTION OF THE INVENTION

[0069] With respect to general information on CRISPR-Cas Systems, components thereof, and delivery of such components, including methods, materials, delivery vehicles, vectors, particles, AAV, and making and using thereof, including as to amounts and formulations, all useful in the practice of the instant invention, reference is made to: U.S. Pat. Nos. 8,697,359, 8,771,945, 8,795,965, 8,865,406, 8,871,445, 8,889,356, 8,889,418 and 8,895,308; US Patent Publications US 2014-0310830 (U.S. application Ser. No. 14/105,031), US 2014-0287938 A1 (U.S. application Ser. No. 14/213,991), US 2014-0273234 A1 (U.S. application Ser. No. 14/293,674), US2014-0273232 A1 (U.S. application Ser. No. 14/290,575), US 2014-0273231 (U.S. application Ser. No. 14/259,420), US 2014-0256046 A1 (U.S. application Ser. No. 14/226,274), US 2014-0248702 A1 (U.S. application Ser. No. 14/258,458), US 2014-0242700 A1 (U.S. application Ser. No. 14/222,930), US 2014-0242699 A1 (U.S. application Ser. No. 14/183,512), US 2014-0242664 A1 (U.S. application Ser. No. 14/104,990), US 2014-0234972 A1 (U.S. application Ser. No. 14/183,471), US 2014-0227787 A1 (U.S. application Ser. No. 14/256,912), US 2014-0189896 A1 (U.S. application Ser. No. 14/105,035), US 2014-0186958 (U.S. application Ser. No. 14/105,017), US 2014-0186919 A1 (U.S. application Ser. No. 14/104,977), US 2014-0186843 A1 (U.S. application Ser. No. 14/104,900), US 2014-0179770 A1 (U.S. application Ser. No. 14/104,837) and US 2014-0179006 A1 (U.S. application Ser. No. 14/183,486), US 2014-0170753 (U.S. application Ser. No. 14/183,429); European Patent Applications EP 2 771 468 (EP13818570.7), EP 2 764 103 (EP13824232.6), and EP 2 784 162 (EP14170383.5); and PCT Patent Publications WO 2014/093661 (PCT/US2013/074743), WO 2014/093694 (PCT/US2013/074790), WO 2014/093595 (PCT/U52013/074611), WO 2014/093718 (PCT/US2013/074825), WO 2014/093709 (PCT/US2013/074812), WO 2014/093622 (PCT/US2013/074667), WO 2014/093635 (PCT/US2013/074691), WO 2014/093655 (PCT/US2013/074736), WO 2014/093712 (PCT/US2013/074819), WO2014/093701 (PCT/U52013/074800), and WO2014/018423 (PCT/US2013/051418). Reference is also made to U.S. provisional patent applications 61/758,468; 61/802,174; 61/806,375; 61/814,263; 61/819,803 and 61/828,130, filed on Jan. 30, 2013; Mar. 15, 2013; Mar. 28, 2013; Apr. 20, 2013; May 6, 2013 and May 28, 2013 respectively. Reference is also made to U.S. provisional patent application 61/836,123, filed on Jun. 17, 2013. Reference is additionally made to U.S. provisional patent applications 61/835,931, 61/835,936, 61/836,127, 61/836, 101, 61/836,080 and 61/835,973, each filed Jun. 17, 2013. Further reference is made to U.S. provisional patent applications 61/862,468 and 61/862,355 filed on Aug. 5, 2013; 61/871,301 filed on Aug. 28, 2013; 61/960,777 filed on Sep. 25, 2013 and 61/961,980 filed on Oct. 28, 2013. Reference is yet further made to: PCT Patent applications Nos: PCT/US2014/041803, PCT/US2014/041800, PCT/US2014/041809, PCT/US2014/041804 and PCT/US2014/041806, each filed Jun. 10, 2014 Jun. 10, 2014; PCT/US2014/041808 filed Jun. 11, 2014; and PCT/US2014/62558 filed Oct. 28, 2014, and U.S. Provisional Patent Applications Ser. Nos. 61/915,150, 61/915,301, 61/915,267 and 61/915,260, each filed Dec. 12, 2013; 61/757,972 and 61/768,959, filed on Jan. 29, 2013 and Feb. 25, 2013; 61/835,936, 61/836,127, 61/836,101, 61/836,080, 61/835,973, and 61/835,931, filed Jun. 17, 2013; 62/010,888 and 62/010,879, both filed Jun. 11, 2014; 62/010,329 and 62/010,441, each filed Jun. 10, 2014; 61/939,228 and 61/939,242, each filed Feb. 12, 2014; 61/980,012, filed Apr. 15,2014; 62/038,358, filed Aug. 17, 2014; 62/054,490, 62/055,484, 62/055,460 and 62/055,487, each filed Sep. 25, 2014; and 62/069,243, filed Oct. 27, 2014. Each of these patents, patent publications, and applications, and all documents cited therein or during their prosecution ("appln cited documents") and all documents cited or referenced in the appln cited documents, together with any instructions, descriptions, product specifications, and product sheets for any products mentioned therein or in any document therein and incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. All documents (e.g., these patents, patent publications and applications and the appln cited documents) are incorporated herein by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

[0070] Also with respect to general information on CRISPR-Cas Systems, mention is made of:

[0071] Multiplex genome engineering using CRISPR/Cas systems. Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., & Zhang, F. Science February 15; 339(6121):819-23 (2013);

[0072] RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Jiang W., Bikard D., Cox D., Zhang F, Marraffini L A. Nat Biotechnol March; 31(3):233-9 (2013);

[0073] One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering. Wang H., Yang H., Shivalila C S., Dawlaty M M., Cheng A W., Zhang F., Jaenisch R. Cell May 9; 153(4):910-8 (2013);

[0074] Optical control of mammalian endogenous transcription and epigenetic states. Konermann S, Brigham M D, Trevino A E, Hsu P D, Heidenreich M, Cong L, Platt R J, Scott D A, Church G M, Zhang F. Nature. 2013 Aug. 22; 500(7463):472-6. doi: 10.1038Nature12466. Epub 2013 Aug. 23;

[0075] Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity. Ran, F A., Hsu, P D., Lin, C Y., Gootenberg, J S., Konermann, S., Trevino, A E., Scott, D A., Inoue, A., Matoba, S., Zhang, Y., & Zhang, F. Cell August 28. pii: S0092-8674(13)01015-5. (2013);

[0076] DNA targeting specificity of RNA-guided Cas9 nucleases. Hsu, P., Scott, D., Weinstein, J., Ran, F A., Konermann, S., Agarwala, V., Li, Y., Fine, E., Wu, X., Shalem, O., Cradick, T J., Marraffini, L A., Bao, G., & Zhang, F. Nat Biotechnol doi:10.1038/nbt.2647 (2013);

[0077] Genome engineering using the CRISPR-Cas9 system. Ran, F A., Hsu, P D., Wright, J., Agarwala, V., Scott, D A., Zhang, F. Nature Protocols November; 8(11):2281-308. (2013);

[0078] Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Shalem, O., Sanjana, N E., Hartenian, E., Shi, X., Scott, DA., Mikkelson, T., Heckl, D., Ebert, BL., Root, D E., Doench, J G., Zhang, F. Science December 12. (2013). [Epub ahead of print];

[0079] Crystal structure of cas9 in complex with guide RNA and target DNA. Nishimasu, H., Ran, F A., Hsu, P D., Konermann, S., Shehata, S I., Dohmae, N., Ishitani, R., Zhang, F., Nureki, O. Cell February 27. (2014). 156(5):935-49;

[0080] Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Wu X., Scott D A., Kriz A J., Chiu A C., Hsu P D., Dadon D B., Cheng A W., Trevino A E., Konermann S., Chen S., Jaenisch R., Zhang F., Sharp P A. Nat Biotechnol. (2014) April 20. doi: 10.1038/nbt.2889,

[0081] CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling, Platt et al., Cell 159(2): 440-455 (2014) DOI: 10.1016/j.ce11.2014.09.014,

[0082] Development and Applications of CRISPR-Cas9 for Genome Engineering, Hsu et al, Cell 157, 1262-1278 (Jun. 5, 2014) (Hsu 2014),

[0083] Genetic screens in human cells using the CRISPR/Cas9 system, Wang et al., Science. 2014 Jan. 3; 343(6166): 80-84. doi:10.1126/science.1246981,

[0084] Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation, Doench et al., Nature Biotechnology published online 3 Sep. 2014; doi:10.1038/nbt.3026, and

[0085] In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9, Swiech et al, Nature Biotechnology; published online 19 Oct. 2014; doi:10.1038/nbt.3055. each of which is incorporated herein by reference, and discussed briefly below:

[0086] Cong et al. engineered type II CRISPR-Cas systems for use in eukaryotic cells based on both Streptococcus thermophilus Cas9 and also Streptoccocus pyogenes Cas9 and demonstrated that Cas9 nucleases can be directed by short RNAs to induce precise cleavage of DNA in human and mouse cells. Their study further showed that Cas9 as converted into a nicking enzyme can be used to facilitate homology-directed repair in eukaryotic cells with minimal mutagenic activity. Additionally, their study demonstrated that multiple guide sequences can be encoded into a single CRISPR array to enable simultaneous editing of several at endogenous genomic loci sites within the mammalian genome, demonstrating easy programmability and wide applicability of the RNA-guided nuclease technology. This ability to use RNA to program sequence specific DNA cleavage in cells defined a new class of genome engineering tools. These studies further showed that other CRISPR loci are likely to be transplantable into mammalian cells and can also mediate mammalian genome cleavage. Importantly, it can be envisaged that several aspects of the CRISPR-Cas system can be further improved to increase its efficiency and versatility.

[0087] Jiang et al. used the clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated Cas9 endonuclease complexed with dual-RNAs to introduce precise mutations in the genomes of Streptococcus pneumoniae and Escherichia coli. The approach relied on dual-RNA:Cas9-directed cleavage at the targeted genomic site to kill unmutated cells and circumvents the need for selectable markers or counter-selection systems. The study reported reprogramming dual-RNA:Cas9 specificity by changing the sequence of short CRISPR RNA (crRNA) to make single- and multinucleotide changes carried on editing templates. The study showed that simultaneous use of two crRNAs enabled multiplex mutagenesis. Furthermore, when the approach was used in combination with recombineering, in S. pneumoniae, nearly 100% of cells that were recovered using the described approach contained the desired mutation, and in E. coli, 65% that were recovered contained the mutation.

[0088] Konermann et al. addressed the need in the art for versatile and robust technologies that enable optical and chemical modulation of DNA-binding domains based CRISPR Cas9 enzyme and also Transcriptional Activator Like Effectors

[0089] As discussed in the present specification, the Cas9 nuclease from the microbial CRISPR-Cas system is targeted to specific genomic loci by a 20 nt guide sequence, which can tolerate certain mismatches to the DNA target and thereby promote undesired off-target mutagenesis. To address this, Ran et al. described an approach that combined a Cas9 nickase mutant with paired guide RNAs to introduce targeted double-strand breaks. Because individual nicks in the genome are repaired with high fidelity, simultaneous nicking via appropriately offset guide RNAs is required for double-stranded breaks and extends the number of specifically recognized bases for target cleavage. The authors demonstrated that using paired nicking can reduce off-target activity by 50- to 1,500-fold in cell lines and to facilitate gene knockout in mouse zygotes without sacrificing on-target cleavage efficiency. This versatile strategy enables a wide variety of genome editing applications that require high specificity.

[0090] Hsu et al. characterized SpCas9 targeting specificity in human cells to inform the selection of target sites and avoid off-target effects. The study evaluated >700 guide RNA variants and SpCas9-induced indel mutation levels at >100 predicted genomic off-target loci in 293T and 293FT cells. The authors that SpCas9 tolerates mismatches between guide RNA and target DNA at different positions in a sequence-dependent manner, sensitive to the number, position and distribution of mismatches. The authors further showed that SpCas9-mediated cleavage is unaffected by DNA methylation and that the dosage of SpCas9 and sgRNA can be titrated to minimize off-target modification. Additionally, to facilitate mammalian genome engineering applications, the authors reported providing a web-based software tool to guide the selection and validation of target sequences as well as off-target analyses.

[0091] Ran et al. described a set of tools for Cas9-mediated genome editing via non-homologous end joining (NHEJ) or homology-directed repair (HDR) in mammalian cells, as well as generation of modified cell lines for downstream functional studies. To minimize off-target cleavage, the authors further described a double-nicking strategy using the Cas9 nickase mutant with paired guide RNAs. The protocol provided by the authors experimentally derived guidelines for the selection of target sites, evaluation of cleavage efficiency and analysis of off-target activity. The studies showed that beginning with target design, gene modifications can be achieved within as little as 1-2 weeks, and modified clonal cell lines can be derived within 2-3 weeks.

[0092] Shalem et al. described a new way to interrogate gene function on a genome-wide scale. Their studies showed that delivery of a genome-scale CRISPR-Cas9 knockout (GeCKO) library targeted 18,080 genes with 64,751 unique guide sequences enabled both negative and positive selection screening in human cells. First, the authors showed use of the GeCKO library to identify genes essential for cell viability in cancer and pluripotent stem cells. Next, in a melanoma model, the authors screened for genes whose loss is involved in resistance to vemurafenib, a therapeutic that inhibits mutant protein kinase BRAF. Their studies showed that the highest-ranking candidates included previously validated genes NF1 and MED12 as well as novel hits NF2, CUL3, TADA2B, and TADA1. The authors observed a high level of consistency between independent guide RNAs targeting the same gene and a high rate of hit confirmation, and thus demonstrated the promise of genome-scale screening with Cas9.

[0093] Nishimasu et al. reported the crystal structure of Streptococcus pyogenes Cas9 in complex with sgRNA and its target DNA at 2.5 A.degree. resolution. The structure revealed a bilobed architecture composed of target recognition and nuclease lobes, accommodating the sgRNA:DNA heteroduplex in a positively charged groove at their interface. Whereas the recognition lobe is essential for binding sgRNA and DNA, the nuclease lobe contains the HNH and RuvC nuclease domains, which are properly positioned for cleavage of the complementary and non-complementary strands of the target DNA, respectively. The nuclease lobe also contains a carboxyl-terminal domain responsible for the interaction with the protospacer adjacent motif (PAM). This high-resolution structure and accompanying functional analyses have revealed the molecular mechanism of RNA-guided DNA targeting by Cas9, thus paving the way for the rational design of new, versatile genome-editing technologies.

[0094] Wu et al. mapped genome-wide binding sites of a catalytically inactive Cas9 (dCas9) from Streptococcus pyogenes loaded with single guide RNAs (sgRNAs) in mouse embryonic stem cells (mESCs). The authors showed that each of the four sgRNAs tested targets dCas9 to between tens and thousands of genomic sites, frequently characterized by a 5-nucleotide seed region in the sgRNA and an NGG protospacer adjacent motif (PAM). Chromatin inaccessibility decreases dCas9 binding to other sites with matching seed sequences; thus 70% of off-target sites are associated with genes. The authors showed that targeted sequencing of 295 dCas9 binding sites in mESCs transfected with catalytically active Cas9 identified only one site mutated above background levels. The authors proposed a two-state model for Cas9 binding and cleavage, in which a seed match triggers binding but extensive pairing with target DNA is required for cleavage.

[0095] Hsu 2014 is a review article that discusses generally CRISPR-Cas9 history from yogurt to genome editing, including genetic screening of cells, that is in the information, data and findings of the applications in the lineage of this specification filed prior to Jun. 5, 2014. The general teachings of Hsu 2014 do not involve the specific models, animals of the instant specification.

[0096] In general, the CRISPR-Cas or CRISPR system is as used in the foregoing documents, such as WO 2014/093622 (PCT/US2013/074667) and refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated ("Cas") genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a "direct repeat" and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer" in the context of an endogenous CRISPR system), or "RNA(s)" as that term is herein used (e.g., RNA(s) to guide Cas9, e.g. CRISPR RNA and transactivating (tracr) RNA or a single guide RNA (sgRNA) (chimeric RNA)) or other sequences and transcripts from a CRISPR locus. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system). In the context of formation of a CRISPR complex, "target sequence" refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between a target sequence and a guide sequence promotes the formation of a CRISPR complex. A target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides. In some embodiments, a target sequence is located in the nucleus or cytoplasm of a cell. In some embodiments, direct repeats may be identified in silico by searching for repetitive motifs that fulfill any or all of the following criteria: 1. found in a 2 Kb window of genomic sequence flanking the type II CRISPR locus; 2. span from 20 to 50 bp; and 3. interspaced by 20 to 50 bp. In some embodiments, 2 of these criteria may be used, for instance 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all 3 criteria may be used. In some embodiments it may be preferred in a CRISPR complex that the tracr sequence has one or more hairpins and is 30 or more nucleotides in length, 40 or more nucleotides in length, or 50 or more nucleotides in length; the guide sequence is between 10 to 30 nucleotides in length, the CRISPR/Cas enzyme is a Type II Cas9 enzyme.

[0097] In embodiments of the invention the terms guide sequence and guide RNA are used interchangeably as in foregoing cited documents such as WO 2014/093622 (PCT/US2013/074667). In general, a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more. Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g. the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies; available at www.novocraft.com), ELAND (Illumina, San Diego, Calif.), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net). In some embodiments, a guide sequence is about or more than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, a guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length. The ability of a guide sequence to direct sequence-specific binding of a CRISPR complex to a target sequence may be assessed by any suitable assay. For example, the components of a CRISPR system sufficient to form a CRISPR complex, including the guide sequence to be tested, may be provided to a host cell having the corresponding target sequence, such as by transfection with vectors encoding the components of the CRISPR sequence, followed by an assessment of preferential cleavage within the target sequence, such as by Surveyor assay as described herein. Similarly, cleavage of a target polynucleotide sequence may be evaluated in a test tube by providing the target sequence, components of a CRISPR complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions. Other assays are possible, and will occur to those skilled in the art.

[0098] A guide sequence may be selected to target any target sequence. In some embodiments, the target sequence is a sequence within a genome of a cell. Exemplary target sequences include those that are unique in the target genome. In some embodiments, a guide sequence is selected to reduce the degree secondary structure within the guide sequence. In some embodiments, about or less than about 75%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, or fewer of the nucleotides of the guide sequence participate in self-complementary base pairing when optimally folded. Optimal folding may be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimal Gibbs free energy. An example of one such algorithm is mFold, as described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133-148). Another example folding algorithm is the online webserver RNAfold, developed at Institute for Theoretical Chemistry at the University of Vienna, using the centroid structure prediction algorithm (see e.g. A. R. Gruber et al., 2008, Cell 106(1): 23-24; and P A Carr and G M Church, 2009, Nature Biotechnology 27(12): 1151-62).

[0099] In general, a tracr mate sequence includes any sequence that has sufficient complementarity with a tracr sequence to promote one or more of: (1) excision of a guide sequence flanked by tracr mate sequences in a cell containing the corresponding tracr sequence; and (2) formation of a CRISPR complex at a target sequence, wherein the CRISPR complex comprises the tracr mate sequence hybridized to the tracr sequence. In general, degree of complementarity is with reference to the optimal alignment of the tracr mate sequence and tracr sequence, along the length of the shorter of the two sequences. Optimal alignment may be determined by any suitable alignment algorithm, and may further account for secondary structures, such as self-complementarity within either the tracr sequence or tracr mate sequence. In some embodiments, the degree of complementarity between the tracr sequence and tracr mate sequence along the length of the shorter of the two when optimally aligned is about or more than about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or higher. In some embodiments, the tracr sequence is about or more than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, or more nucleotides in length. In some embodiments, the tracr sequence and tracr mate sequence are contained within a single transcript, such that hybridization between the two produces a transcript having a secondary structure, such as a hairpin. In an embodiment of the invention, the transcript or transcribed polynucleotide sequence has at least two or more hairpins. In preferred embodiments, the transcript has two, three, four or five hairpins. In a further embodiment of the invention, the transcript has at most five hairpins. In a hairpin structure the portion of the sequence 5' of the final "N" and upstream of the loop corresponds to the tracr mate sequence, and the portion of the sequence 3' of the loop corresponds to the tracr sequence Further non-limiting examples of single polynucleotides comprising a guide sequence, a tracr mate sequence, and a tracr sequence are as follows (listed 5' to 3'), where "N" represents a base of a guide sequence, the first block of lower case letters represent the tracr mate sequence, and the second block of lower case letters represent the tracr sequence, and the final poly-T sequence represents the transcription terminator: (1) NNNNNNNNNNNNNNNNNNNNgtttttgtactctcaagatttaGAAAtaaatcttgcagaagctacaaagataa ggcttcatgccgaaatcaacaccctgtcattttatggcagggtgttttcgttatttaaTTTTTT (SEQ ID NO: 3); (2) NNNNNNNNNNNNNNNNNNNNgtttttgtactctcaGAAAtgcagaagctacaaagataaggcttcatgccg aaatcaacaccctgtcattttatggcagggtgttttcgttatttaaTTTTTT (SEQ ID NO: 4); (3) NNNNNNNNNNNNNNNNNNNNgtttttgtactctcaGAAAtgcagaagctacaaagataaggcttcatgccg aaatcaacaccctgtcattttatggcagggtgtTTTTTT (SEQ ID NO: 5); (4) NNNNNNNNNNNNNNNNNNNNgttttagagctaGAAAtagcaagttaaaataaggctagtccgttatcaactt gaaaaagtggcaccgagtcggtgcTTTTTT (SEQ ID NO: 6); (5) NNNNNNNNNNNNNNNNNNNNgttttagagctaGAAATAGcaagttaaaataaggctagtccgttatcaac ttgaaaaagtgTTTTTTT (SEQ ID NO: 7); and (6) NNNNNNNNNNNNNNNNNNNNgttttagagctagAAATAGcaagttaaaataaggctagtccgttatcaTT TTTTTT (SEQ ID NO: 8). In some embodiments, sequences (1) to (3) are used in combination with Cas9 from S. thermophilus CRISPR1. In some embodiments, sequences (4) to (6) are used in combination with Cas9 from S. pyogenes. In some embodiments, the tracr sequence is a separate transcript from a transcript comprising the tracr mate sequence.

[0100] In some embodiments, candidate tracrRNA may be subsequently predicted by sequences that fulfill any or all of the following criteria: 1. sequence homology to direct repeats (motif search in Geneious with up to 18-bp mismatches); 2. presence of a predicted Rho-independent transcriptional terminator in direction of transcription; and 3. stable hairpin secondary structure between tracrRNA and direct repeat. In some embodiments, 2 of these criteria may be used, for instance 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all 3 criteria may be used.

[0101] In some embodiments, chimeric synthetic guide RNAs (sgRNAs) designs may incorporate at least 12 bp of duplex structure between the direct repeat and tracrRNA.

[0102] For minimization of toxicity and off-target effect, it will be important to control the concentration of CRISPR enzyme mRNA and guide RNA delivered. Optimal concentrations of CRISPR enzyme mRNA and guide RNA can be determined by testing different concentrations in a cellular or non-human eukaryote animal model and using deep sequencing the analyze the extent of modification at potential off-target genomic loci. For example, for the guide sequence targeting 5'-GAGTCCGAGCAGAAGAAGAA-3' (SEQ ID NO: 9) in the EMX1 gene of the human genome, deep sequencing can be used to assess the level of modification at the following two off-target loci, 1: 5'-GAGTCCTAGCAGGAGAAGAA-3' (SEQ ID NO: 10) and 2: 5'-GAGTCTAAGCAGAAGAAGAA-3' (SEQ ID NO: 11). The concentration that gives the highest level of on-target modification while minimizing the level of off-target modification should be chosen for in vivo delivery. Alternatively, to minimize the level of toxicity and off-target effect, CRISPR enzyme nickase mRNA (for example S. pyogenes Cas9 with the D10A mutation) can be delivered with a pair of guide RNAs targeting a site of interest. The two guide RNAs need to be spaced as follows. Guide sequences and strategies to mimize toxicity and off-target effects can be as in WO 2014/093622 (PCT/US2013/074667).

[0103] The CRISPR system is derived advantageously from a type II CRISPR system. In some embodiments, one or more elements of a CRISPR system is derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes. In preferred embodiments of the invention, the CRISPR system is a type II CRISPR system and the Cas enzyme is Cas9, which catalyzes DNA cleavage. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cash, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologues thereof, or modified versions thereof.

[0104] In some embodiments, the unmodified CRISPR enzyme has DNA cleavage activity, such as Cas9. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence. In some embodiments, a vector encodes a CRISPR enzyme that is mutated to with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence. For example, an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from S. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand). Other examples of mutations that render Cas9 a nickase include, without limitation, H840A, N854A, and N863A. As a further example, two or more catalytic domains of Cas9 (RuvC I, RuvC II, and RuvC III or the HNH domain) may be mutated to produce a mutated Cas9 substantially lacking all DNA cleavage activity. In some embodiments, a D 10A mutation is combined with one or more of H840A, N854A, or N863A mutations to produce a Cas9 enzyme substantially lacking all DNA cleavage activity. In some embodiments, a CRISPR enzyme is considered to substantially lack all DNA cleavage activity when the DNA cleavage activity of the mutated enzyme is about no more than 25%, 10%, 5%, 1%, 0.1%, 0.01%, or less of the DNA cleavage activity of the non-mutated form of the enzyme; an example can be when the DNA cleavage activity of the mutated form is nil or negligible as compared with the non-mutated form. Where the enzyme is not SpCas9, mutations may be made at any or all residues corresponding to positions 10, 762, 840, 854, 863 and/or 986 of SpCas9 (which may be ascertained for instance by standard sequence comparison tools). In particular, any or all of the following mutations are preferred in SpCas9: D10A, E762A, H840A, N854A, N863A and/or D986A; as well as conservative substitution for any of the replacement amino acids is also envisaged. The same (or conservative substitutions of these mutations) at corresponding positions in other Cas9s are also preferred. Particularly preferred are D10 and H840 in SpCas9. However, in other Cas9s, residues corresponding to SpCas9 D10 and H840 are also preferred. Orthologs of SpCas9 can be used in the practice of the invention. A Cas enzyme may be identified Cas9 as this can refer to the general class of enzymes that share homology to the biggest nuclease with multiple nuclease domains from the type II CRISPR system. Most preferably, the Cas9 enzyme is from, or is derived from, spCas9 (S. pyogenes Cas9) or saCas9 (S. aureus Cas9). StCas9'' refers to wild type Cas9 from S. thermophilus, the protein sequence of which is given in the SwissProt database under accession number G3ECR1. Similarly, S. pyogenes Cas9 or spCas9 is included in SwissProt under accession number Q99ZW2. By derived, Applicants mean that the derived enzyme is largely based, in the sense of having a high degree of sequence homology with, a wildtype enzyme, but that it has been mutated (modified) in some way as described herein. It will be appreciated that the terms Cas and CRISPR enzyme are generally used herein interchangeably, unless otherwise apparent. As mentioned above, many of the residue numberings used herein refer to the Cas9 enzyme from the type II CRISPR locus in Streptococcus pyogenes. However, it will be appreciated that this invention includes many more Cas9s from other species of microbes, such as SpCas9, SaCa9, St1Cas9 and so forth. Enzymatic action by Cas9 derived from Streptococcus pyogenes or any closely related Cas9 generates double stranded breaks at target site sequences which hybridize to 20 nucleotides of the guide sequence and that have a protospacer-adjacent motif (PAM) sequence (examples include NGG/NRG or a PAM that can be determined as described herein) following the 20 nucleotides of the target sequence. CRISPR activity through Cas9 for site-specific DNA recognition and cleavage is defined by the guide sequence, the tracr sequence that hybridizes in part to the guide sequence and the PAM sequence. More aspects of the CRISPR system are described in Karginov and Hannon, The CRISPR system: small RNA-guided defence in bacteria and archaea, Mole Cell 2010, Jan. 15; 37(1): 7. The type II CRISPR locus from Streptococcus pyogenes SF370, which contains a cluster of four genes Cas9, Cas1, Cas2, and Csn1, as well as two non-coding RNA elements, tracrRNA and a characteristic array of repetitive sequences (direct repeats) interspaced by short stretches of non-repetitive sequences (spacers, about 30 bp each). In this system, targeted DNA double-strand break (DSB) is generated in four sequential steps. First, two non-coding RNAs, the pre-crRNA array and tracrRNA, are transcribed from the CRISPR locus. Second, tracrRNA hybridizes to the direct repeats of pre-crRNA, which is then processed into mature crRNAs containing individual spacer sequences. Third, the mature crRNA:tracrRNA complex directs Cas9 to the DNA target consisting of the protospacer and the corresponding PAM via heteroduplex formation between the spacer region of the crRNA and the protospacer DNA. Finally, Cas9 mediates cleavage of target DNA upstream of PAM to create a DSB within the protospacer. A pre-crRNA array consisting of a single spacer flanked by two direct repeats (DRs) is also encompassed by the term "tracr-mate sequences"). In certain embodiments, Cas9 may be constitutively present or inducibly present or conditionally present or administered or delivered. Cas9 optimization may be used to enhance function or to develop new functions, one can generate chimeric Cas9 proteins. And Cas9 may be used as a generic DNA binding protein.

[0105] With respect to mutations of the CRISPR enzyme, when the enzyme is not SpCas9, mutations may be made at any or all residues corresponding to positions 10, 762, 840, 854, 863 and/or 986 of SpCas9 (which may be ascertained for instance by standard sequence comparison tools). In particular, any or all of the following mutations are preferred in SpCas9: D10A, E762A, H840A, N854A, N863A and/or D986A; as well as conservative substitution for any of the replacement amino acids is also envisaged. In an aspect the invention provides as to any or each or all embodiments herein-discussed wherein the CRISPR enzyme comprises at least one or more, or at least two or more mutations, wherein the at least one or more mutation or the at least two or more mutations is as to D10, E762, H840, N854, N863, or D986 according to SpCas9 protein, e.g., D10A, E762A, H840A, N854A, N863A and/or D986A as to SpCas9, or N580 according to SaCas9, e.g., N580A as to SaCas9, or any corresponding mutation(s) in a Cas9 of an ortholog to Sp or Sa, or the CRISPR enzyme comprises at least one mutation wherein at least H840 or N863A as to Sp Cas9 or N580A as to Sa Cas9 is mutated; e.g., wherein the CRISPR enzyme comprises H840A, or D10A and H840A, or D10A and N863A, according to SpCas9 protein, or any corresponding mutation(s) in a Cas9 of an ortholog to Sp protein or Sa protein.

[0106] Typically, in the context of an endogenous CRISPR system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near (e.g. within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence. Without wishing to be bound by theory, the tracr sequence, which may comprise or consist of all or a portion of a wild-type tracr sequence (e.g. about or more than about 20, 26, 32, 45, 48, 54, 63, 67, 85, or more nucleotides of a wild-type tracr sequence), may also form part of a CRISPR complex, such as by hybridization along at least a portion of the tracr sequence to all or a portion of a tracr mate sequence that is operably linked to the guide sequence.

[0107] An example of a codon optimized sequence, is in this instance a sequence optimized for expression in a eukaryote, e.g., humans (i.e. being optimized for expression in humans), or for another eukaryote, animal or mammal as herein discussed; see, e.g., SaCas9 human codon optimized sequence in WO 2014/093622 (PCT/US2013/074667). Whilst this is preferred, it will be appreciated that other examples are possible and codon optimization for a host species other than human, or for codon optimization for specific organs is known. In some embodiments, an enzyme coding sequence encoding a CRISPR enzyme is codon optimized for expression in particular cells, such as eukaryotic cells. The eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, or non-human eukaryote or animal or mammal as herein discussed, e.g., mouse, rat, rabbit, dog, livestock, or non-human mammal or primate. In some embodiments, processes for modifying the germ line genetic identity of human beings and/or processes for modifying the genetic identity of animals which are likely to cause them suffering without any substantial medical benefit to man or animal, and also animals resulting from such processes, may be excluded. In general, codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon (e.g. about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence. Various species exhibit particular bias for certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, at the "Codon Usage Database" available at www.kazusa.orjp/codon/ and these tables can be adapted in a number of ways. See Nakamura, Y., et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000" Nucl. Acids Res. 28:292 (2000). Computer algorithms for codon optimizing a particular sequence for expression in a particular host cell are also available, such as Gene Forge (Aptagen; Jacobus, Pa.), are also available. In some embodiments, one or more codons (e.g. 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons) in a sequence encoding a CRISPR enzyme correspond to the most frequently used codon for a particular amino acid.

[0108] In some embodiments, a vector encodes a CRISPR enzyme comprising one or more nuclear localization sequences (NLSs), such as about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs. In some embodiments, the CRISPR enzyme comprises about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the amino-terminus, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the carboxy-terminus, or a combination of these (e.g. zero or at least one or more NLS at the amino-terminus and zero or at one or more NLS at the carboxy terminus). When more than one NLS is present, each may be selected independently of the others, such that a single NLS may be present in more than one copy and/or in combination with one or more other NLSs present in one or more copies. In a preferred embodiment of the invention, the CRISPR enzyme comprises at most 6 NLSs. In some embodiments, an NLS is considered near the N- or C-terminus when the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N- or C-terminus. Non-limiting examples of NLSs include an NLS sequence derived from: the NLS of the SV40 virus large T-antigen, having the amino acid sequence PKKKRKV (SEQ ID NO: 12); the NLS from nucleoplasmin (e.g. the nucleoplasmin bipartite NLS with the sequence KRPAATKKAGQAKKKK (SEQ ID NO: 13)); the c-myc NLS having the amino acid sequence PAAKRVKLD (SEQ ID NO: 14) or RQRRNELKRSP (SEQ ID NO: 15); the hRNPA1 M9 NLS having the sequence NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY (SEQ ID NO: 16); the sequence RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV (SEQ ID NO: 17) of the IBB domain from importin-alpha; the sequences VSRKRPRP (SEQ ID NO: 18) and PPKKARED (SEQ ID NO: 19) of the myoma T protein; the sequence PQPKKKPL (SEQ ID NO: 20) of human p53; the sequence SALIKKKKKMAP (SEQ ID NO: 21) of mouse c-abl IV; the sequences DRLRR (SEQ ID NO: 22) and PKQKKRK (SEQ ID NO: 23) of the influenza virus NS1; the sequence RKLKKKIKKL (SEQ ID NO: 24) of the Hepatitis virus delta antigen; the sequence REKKKFLKRR (SEQ ID NO: 25) of the mouse Mx1 protein; the sequence KRKGDEVDGVDEVAKKKSKK (SEQ ID NO: 26) of the human poly(ADP-ribose) polymerase; and the sequence RKCLQAGMNLEARKTKK (SEQ ID NO: 27) of the steroid hormone receptors (human) glucocorticoid. In general, the one or more NLSs are of sufficient strength to drive accumulation of the CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. In general, strength of nuclear localization activity may derive from the number of NLSs in the CRISPR enzyme, the particular NLS(s) used, or a combination of these factors. Detection of accumulation in the nucleus may be performed by any suitable technique. For example, a detectable marker may be fused to the CRISPR enzyme, such that location within a cell may be visualized, such as in combination with a means for detecting the location of the nucleus (e.g. a stain specific for the nucleus such as DAPI). Cell nuclei may also be isolated from cells, the contents of which may then be analyzed by any suitable process for detecting protein, such as immunohistochemistry, Western blot, or enzyme activity assay. Accumulation in the nucleus may also be determined indirectly, such as by an assay for the effect of CRISPR complex formation (e.g. assay for DNA cleavage or mutation at the target sequence, or assay for altered gene expression activity affected by CRISPR complex formation and/or CRISPR enzyme activity), as compared to a control no exposed to the CRISPR enzyme or complex, or exposed to a CRISPR enzyme lacking the one or more NLSs.

[0109] Aspects of the invention relate to the expression of the gene product being decreased or a template polynucleotide being further introduced into the DNA molecule encoding the gene product or an intervening sequence being excised precisely by allowing the two 5' overhangs to reanneal and ligate or the activity or function of the gene product being altered or the expression of the gene product being increased. In an embodiment of the invention, the gene product is a protein. sgRNA pairs creating 5' overhangs with less than 8bp overlap between the guide sequences (offset greater than -8 bp) were able to mediate detectable indel formation. Importantly, each guide used in these assays is able to efficiently induce indels when paired with wildtype Cas9, indicating that the relative positions of the guide pairs are the most important parameters in predicting double nicking activity. Since Cas9n and Cas9H840A nick opposite strands of DNA, substitution of Cas9n with Cas9H840A with a given sgRNA pair should have resulted in the inversion of the overhang type; but no indel formation is observed as with Cas9H840A indicating that Cas9H840A is a CRISPR enzyme substantially lacking all DNA cleavage activity (which is when the DNA cleavage activity of the mutated enzyme is about no more than 25%, 10%, 5%, 1%, 0.1%, 0.01%, or less of the DNA cleavage activity of the non-mutated form of the enzyme; whereby an example can be when the DNA cleavage activity of the mutated form is nil or negligible as compared with the non-mutated form, e.g., when no indel formation is observed as with Cas9H840A in the eukaryotic system in contrast to the biochemical or prokaryotic systems). Nonetheless, a pair of sgRNAs that will generate a 5' overhang with Cas9n should in principle generate the corresponding 3' overhang instead, and double nicking. Therefore, sgRNA pairs that lead to the generation of a 3' overhang with Cas9n can be used with another mutated Cas9 to generate a 5' overhang, and double nicking. Accordingly, in some embodiments, a recombination template is also provided. A recombination template may be a component of another vector as described herein, contained in a separate vector, or provided as a separate polynucleotide. In some embodiments, a recombination template is designed to serve as a template in homologous recombination, such as within or near a target sequence nicked or cleaved by a CRISPR enzyme as a part of a CRISPR complex. A template polynucleotide may be of any suitable length, such as about or more than about 10, 15, 20, 25, 50, 75, 100, 150, 200, 500, 1000, or more nucleotides in length. In some embodiments, the template polynucleotide is complementary to a portion of a polynucleotide comprising the target sequence. When optimally aligned, a template polynucleotide might overlap with one or more nucleotides of a target sequences (e.g. about or more than about 1, 5, 10, 15, 20, or more nucleotides). In some embodiments, when a template sequence and a polynucleotide comprising a target sequence are optimally aligned, the nearest nucleotide of the template polynucleotide is within about 1, 5, 10, 15, 20, 25, 50, 75, 100, 200, 300, 400, 500, 1000, 5000, 10000, or more nucleotides from the target sequence.

[0110] In some embodiments, one or more vectors driving expression of one or more elements of a CRISPR system are introduced into a host cell such that expression of the elements of the CRISPR system direct formation of a CRISPR complex at one or more target sites. For example, a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operably linked to separate regulatory elements on separate vectors. Or, RNA(s) of the CRISPR System can be delivered to a transgenic Cas9 animal or mammal, e.g., an animal or mammal that constitutively or inducibly or conditionally expresses Cas9; or an animal or mammal that is otherwise expressing Cas9 or has cells containing Cas9, such as by way of prior administration thereto of a vector or vectors that code for and express in vivo Cas9. Alternatively, two or more of the elements expressed from the same or different regulatory elements, may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector. CRISPR system elements that are combined in a single vector may be arranged in any suitable orientation, such as one element located 5' with respect to ("upstream" of) or 3' with respect to ("downstream" of) a second element. The coding sequence of one element may be located on the same or opposite strand of the coding sequence of a second element, and oriented in the same or opposite direction. In some embodiments, a single promoter drives expression of a transcript encoding a CRISPR enzyme and one or more of the guide sequence, tracr mate sequence (optionally operably linked to the guide sequence), and a tracr sequence embedded within one or more intron sequences (e.g. each in a different intron, two or more in at least one intron, or all in a single intron). In some embodiments, the CRISPR enzyme, guide sequence, tracr mate sequence, and tracr sequence are operably linked to and expressed from the same promoter. Delivery vehicles, vectors, particles, nanoparticles, formulations and components thereof for expression of one or more elements of a CRISPR system are as used in the foregoing documents, such as WO 2014/093622 (PCT/US2013/074667). In some embodiments, a vector comprises one or more insertion sites, such as a restriction endonuclease recognition sequence (also referred to as a "cloning site"). In some embodiments, one or more insertion sites (e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites) are located upstream and/or downstream of one or more sequence elements of one or more vectors. In some embodiments, a vector comprises an insertion site upstream of a tracr mate sequence, and optionally downstream of a regulatory element operably linked to the tracr mate sequence, such that following insertion of a guide sequence into the insertion site and upon expression the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell. In some embodiments, a vector comprises two or more insertion sites, each insertion site being located between two tracr mate sequences so as to allow insertion of a guide sequence at each site. In such an arrangement, the two or more guide sequences may comprise two or more copies of a single guide sequence, two or more different guide sequences, or combinations of these. When multiple different guide sequences are used, a single expression construct may be used to target CRISPR activity to multiple different, corresponding target sequences within a cell. For example, a single vector may comprise about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more guide sequences. In some embodiments, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more such guide-sequence-containing vectors may be provided, and optionally delivered to a cell. In some embodiments, a vector comprises a regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, such as a Cas protein. CRISPR enzyme or CRISPR enzyme mRNA or CRISPR guide RNA or RNA(s) can be delivered separately; and advantageously at least one of these is delivered via a nanoparticle complex. CRISPR enzyme mRNA can be delivered prior to the guide RNA to give time for CRISPR enzyme to be expressed. CRISPR enzyme mRNA might be administered 1-12 hours (preferably around 2-6 hours) prior to the administration of guide RNA. Alternatively, CRISPR enzyme mRNA and guide RNA can be administered together. Advantageously, a second booster dose of guide RNA can be administered 1-12 hours (preferably around 2-6 hours) after the initial administration of CRISPR enzyme mRNA+guide RNA. Additional administrations of CRISPR enzyme mRNA and/or guide RNA might be useful to achieve the most efficient levels of genome modification.

[0111] In one aspect, the invention provides methods for using one or more elements of a CRISPR system. The CRISPR complex of the invention provides an effective means for modifying a target polynucleotide. The CRISPR complex of the invention has a wide variety of utility including modifying (e.g., deleting, inserting, translocating, inactivating, activating) a target polynucleotide in a multiplicity of cell types. As such the CRISPR complex of the invention has a broad spectrum of applications in, e.g., gene therapy, drug screening, disease diagnosis, and prognosis. An exemplary CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within the target polynucleotide. The guide sequence is linked to a tracr mate sequence, which in turn hybridizes to a tracr sequence. In one embodiment, this invention provides a method of cleaving a target polynucleotide. The method comprises modifying a target polynucleotide using a CRISPR complex that binds to the target polynucleotide and effect cleavage of said target polynucleotide. Typically, the CRISPR complex of the invention, when introduced into a cell, creates a break (e.g., a single or a double strand break) in the genome sequence. For example, the method can be used to cleave a disease gene in a cell. The break created by the CRISPR complex can be repaired by a repair processes such as the error prone non-homologous end joining (NHEJ) pathway or the high fidelity homology-directed repair (HDR). During these repair process, an exogenous polynucleotide template can be introduced into the genome sequence. In some methods, the HDR process is used modify genome sequence. For example, an exogenous polynucleotide template comprising a sequence to be integrated flanked by an upstream sequence and a downstream sequence is introduced into a cell. The upstream and downstream sequences share sequence similarity with either side of the site of integration in the chromosome. Where desired, a donor polynucleotide can be DNA, e.g., a DNA plasmid, a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), a viral vector, a linear piece of DNA, a PCR fragment, a naked nucleic acid, or a nucleic acid complexed with a delivery vehicle such as a liposome or poloxamer. The exogenous polynucleotide template comprises a sequence to be integrated (e.g., a mutated gene). The sequence for integration may be a sequence endogenous or exogenous to the cell. Examples of a sequence to be integrated include polynucleotides encoding a protein or a non-coding RNA (e.g., a microRNA). Thus, the sequence for integration may be operably linked to an appropriate control sequence or sequences. Alternatively, the sequence to be integrated may provide a regulatory function. The upstream and downstream sequences in the exogenous polynucleotide template are selected to promote recombination between the chromosomal sequence of interest and the donor polynucleotide. The upstream sequence is a nucleic acid sequence that shares sequence similarity with the genome sequence upstream of the targeted site for integration. Similarly, the downstream sequence is a nucleic acid sequence that shares sequence similarity with the chromosomal sequence downstream of the targeted site of integration. The upstream and downstream sequences in the exogenous polynucleotide template can have 75%, 80%, 85%, 90%, 95%, or 100% sequence identity with the targeted genome sequence. Preferably, the upstream and downstream sequences in the exogenous polynucleotide template have about 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the targeted genome sequence. In some methods, the upstream and downstream sequences in the exogenous polynucleotide template have about 99% or 100% sequence identity with the targeted genome sequence. An upstream or downstream sequence may comprise from about 20 bp to about 2500 bp, for example, about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 bp. In some methods, the exemplary upstream or downstream sequence have about 200 bp to about 2000 bp, about 600 bp to about 1000 bp, or more particularly about 700 bp to about 1000 bp. In some methods, the exogenous polynucleotide template may further comprise a marker. Such a marker may make it easy to screen for targeted integrations. Examples of suitable markers include restriction sites, fluorescent proteins, or selectable markers. The exogenous polynucleotide template of the invention can be constructed using recombinant techniques (see, for example, Sambrook et al., 2001 and Ausubel et al., 1996). In a method for modifying a target polynucleotide by integrating an exogenous polynucleotide template, a double stranded break is introduced into the genome sequence by the CRISPR complex, the break is repaired via homologous recombination an exogenous polynucleotide template such that the template is integrated into the genome. The presence of a double-stranded break facilitates integration of the template. In other embodiments, this invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell. The method comprises increasing or decreasing expression of a target polynucleotide by using a CRISPR complex that binds to the polynucleotide. In some methods, a target polynucleotide can be inactivated to effect the modification of the expression in a cell. For example, upon the binding of a CRISPR complex to a target sequence in a cell, the target polynucleotide is inactivated such that the sequence is not transcribed, the coded protein is not produced, or the sequence does not function as the wild-type sequence does. For example, a protein or microRNA coding sequence may be inactivated such that the protein or microRNA or pre-microRNA transcript is not produced. In some methods, a control sequence can be inactivated such that it no longer functions as a control sequence. As used herein, "control sequence" refers to any nucleic acid sequence that effects the transcription, translation, or accessibility of a nucleic acid sequence. Examples of a control sequence include, a promoter, a transcription terminator, and an enhancer are control sequences. The target polynucleotide of a CRISPR complex can be any polynucleotide endogenous or exogenous to the eukaryotic cell. For example, the target polynucleotide can be a polynucleotide residing in the nucleus of the eukaryotic cell. The target polynucleotide can be a sequence coding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a junk DNA). Examples of target polynucleotides include a sequence associated with a signaling biochemical pathway, e.g., a signaling biochemical pathway-associated gene or polynucleotide. Examples of target polynucleotides include a disease associated gene or polynucleotide. A "disease-associated" gene or polynucleotide refers to any gene or polynucleotide which is yielding transcription or translation products at an abnormal level or in an abnormal form in cells derived from a disease-affected tissues compared with tissues or cells of a non disease control. It may be a gene that becomes expressed at an abnormally high level; it may be a gene that becomes expressed at an abnormally low level, where the altered expression correlates with the occurrence and/or progression of the disease. A disease-associated gene also refers to a gene possessing mutation(s) or genetic variation that is directly responsible or is in linkage disequilibrium with a gene(s) that is responsible for the etiology of a disease. The transcribed or translated products may be known or unknown, and may be at a normal or abnormal level. The target polynucleotide of a CRISPR complex can be any polynucleotide endogenous or exogenous to the eukaryotic cell. For example, the target polynucleotide can be a polynucleotide residing in the nucleus of the eukaryotic cell. The target polynucleotide can be a sequence coding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a junk DNA). Without wishing to be bound by theory, it is believed that the target sequence should be associated with a PAM (protospacer adjacent motif); that is, a short sequence recognized by the CRISPR complex. The precise sequence and length requirements for the PAM differ depending on the CRISPR enzyme used, but PAMs are typically 2-5 base pair sequences adjacent the protospacer (that is, the target sequence) Examples of PAM sequences are given in the examples section below, and the skilled person will be able to identify further PAM sequences for use with a given CRISPR enzyme. In some embodiments, the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In one aspect, the invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. Similar considerations and conditions apply as above for methods of modifying a target polynucleotide. In fact, these sampling, culturing and re-introduction options apply across the aspects of the present invention. In one aspect, the invention provides for methods of modifying a target polynucleotide in a eukaryotic cell, which may be in vivo, ex vivo or in vitro. In some embodiments, the method comprises sampling a cell or population of cells from a human or non-human animal, and modifying the cell or cells. Culturing may occur at any stage ex vivo. The cell or cells may even be re-introduced into the non-human animal or plant. For re-introduced cells it is particularly preferred that the cells are stem cells.

[0112] Indeed, in any aspect of the invention, the CRISPR complex may comprise a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence, wherein said guide sequence may be linked to a tracr mate sequence which in turn may hybridize to a tracr sequence.

[0113] The invention relates to the engineering and optimization of systems, methods and compositions used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that relate to the CRISPR-Cas system and components thereof. In advantageous embodiments, the Cas enzyme is Cas9. An advantage of the present methods is that the CRISPR system minimizes or avoids off-target binding and its resulting side effects. This is achieved using systems arranged to have a high degree of sequence specificity for the target DNA.

[0114] Crystallization of CRISPR-Cas9 and Crystal Structure

[0115] Crystallization of CRISPR-cas9 and Characterization of Crystal Structure: The crystals of the invention can be obtained by techniques of protein crystallography, including batch, liquid bridge, dialysis, vapor diffusion and hanging drop methods. Generally, the crystals of the invention are grown by dissolving substantially pure CRISPR-cas9 and a nucleic acid molecule to which it binds in an aqueous buffer containing a precipitant at a concentration just below that necessary to precipitate. Water is removed by controlled evaporation to produce precipitating conditions, which are maintained until crystal growth ceases.

[0116] Uses of the Crystals, Crystal Structure and Atomic Structure Co-Ordinates: The crystals of the invention, and particularly the atomic structure co-ordinates obtained therefrom, have a wide variety of uses. The crystals and structure co-ordinates are particularly useful for identifying compounds (nucleic acid molecules) that bind to CRISPR-cas9, and CRISPR-cas9s that can bind to particular compounds (nucleic acid molecules). Thus, the structure co-ordinates described herein can be used as phasing models in determining the crystal structures of additional synthetic or mutated CRISPR-cas9s, cas9s, nickases, binding domains. The provision of the crystal structure of CRISPR-cas9 complexed with a nucleic acid molecule as in the herein Crystal Structure Table and the Figures provide the skilled artisan with a detailed insight into the mechanisms of action of CRISPR-cas9. This insight provides a means to design modified CRISPR-cas9s, such as by attaching thereto a functional group, such as a repressor or activator. While one can attach a functional group such as a repressor or activator to the N or C terminal of CRISPR-cas9, the crystal structure demonstrates that the N terminal seems obscured or hidden, whereas the C terminal is more available for a functional group such as repressor or activator. Moreover, the crystal structure demonstrates that there is a flexible loop between approximately CRISPR-cas9 (S. pyogenes) residues 534-676 which is suitable for attachment of a functional group such as an activator or repressor. Attachment can be via a linker, e.g., a flexible glycine-serine (GlyGlyGlySer) (SEQ ID NO: 1) or (GGGS)3 (SEQ ID NO: 28) or a rigid alpha-helical linker such as (Ala(GluAlaAlaAlaLys)Ala) (SEQ ID NO: 29). In addition to the flexible loop there is also a nuclease or H3 region, an H2 region and a helical region. By "helix" or "helical", is meant a helix as known in the art, including, but not limited to an alpha-helix. Additionally, the term helix or helical may also be used to indicate a c-terminal helical element with an N-terminal turn.

[0117] The provision of the crystal structure of CRISPR-cas9 complexed with a nucleic acid molecule allows a novel approach for drug or compound discovery, identification, and design for compounds that can bind to CRISPR-cas9 and thus the invention provides tools useful in diagnosis, treatment, or prevention of conditions or diseases of multicellular organisms, e.g., algae, plants, invertebrates, fish, amphibians, reptiles, avians, mammals; for example domesticated plants, animals (e.g., production animals such as swine, bovine, chicken; companion animal such as felines, canines, rodents (rabbit, gerbil, hamster); laboratory animals such as mouse, rat), and humans. Accordingly, the invention provides a computer-based method of rational design of CRISPR-cas9 complexes. This rational design can comprise: providing the structure of the CRISPR-cas9 complex as defined by some or all (e.g., at least 2 or more, e.g., at least 5, advantageously at least 10, more advantageously at least 50 and even more advantageously at least 100 atoms of the structure) co-ordinates in the herein Crystal Structure Table and/or in Figure(s); providing a structure of a desired nucleic acid molecule as to which a CRISPR-cas9 complex is desired; and fitting the structure of the CRISPR-cas9 complex as defined by some or all co-ordinates in the herein Crystal Structure Table and/or in Figures to the desired nucleic acid molecule, including in said fitting obtaining putative modification(s) of the CRISPR-cas9 complex as defined by some or all co-ordinates in the herein Crystal Structure Table and/or in Figures for said desired nucleic acid molecule to bind for CRISPR-cas9 complex(es) involving the desired nucleic acid molecule. The method or fitting of the method may use the co-ordinates of atoms of interest of the CRISPR-cas9 complex as defined by some or all co-ordinates in the herein Crystal Structure Table and/or in Figures which are in the vicinity of the active site or binding region (e.g., at least 2 or more, e.g., at least 5, advantageously at least 10, more advantageously at least 50 and even more advantageously at least 100 atoms of the structure) in order to model the vicinity of the active site or binding region. These co-ordinates may be used to define a space which is then screened "in silico" against a desired or candidate nucleic acid molecule. Thus, the invention provides a computer-based method of rational design of CRISPR-cas9 complexes. This method may include: providing the co-ordinates of at least two atoms of the herein Crystal Structure Table ("selected co-ordinates"); providing the structure of a candidate or desired nucleic acid molecule; and fitting the structure of the candidate to the selected co-ordinates. In this fashion, the skilled person may also fit a functional group and a candidate or desired nucleic acid molecule. For example, providing the structure of the CRISPR-cas9 complex as defined by some or all (e.g., at least 2 or more, e.g., at least 5, advantageously at least 10, more advantageously at least 50 and even more advantageously at least 100 atoms of the structure) co-ordinates in the herein Crystal Structure Table and/or in Figure(s); providing a structure of a desired nucleic acid molecule as to which a CRISPR-cas9 complex is desired; fitting the structure of the CRISPR-cas9 complex as defined by some or all co-ordinates in the herein Crystal Structure Table and/or in Figures to the desired nucleic acid molecule, including in said fitting obtaining putative modification(s) of the CRISPR-cas9 complex as defined by some or all co-ordinates in the herein Crystal Structure Table and/or in Figures for said desired nucleic acid molecule to bind for CRISPR-cas9 complex(es) involving the desired nucleic acid molecule; selecting putative fit CRISPR-cas9-desired nucleic acid molecule complex(es), fitting such putative fit CRISPR-cas9-desired nucleic acid molecule complex(es) to the functional group (e.g., activator, repressor), e.g., as to locations for situating the functional group (e.g., positions within the flexible loop) and/or putative modifications of the putative fit CRISPR-cas9-desired nucleic acid molecule complex(es) for creating locations for situating the functional group. As alluded to, the invention can be practiced using co-ordinates in the herein Crystal Structure Table and/or in Figures which are in the vicinity of the active site or binding region; and therefore, the methods of the invention can employ a sub-domain of interest of the CRISPR-cas9 complex. Methods of the invention can be practiced using coordinates of a domain or sub-domain. The methods can optionally include synthesizing the candidate or desired nucleic acid molecule and/or the CRISPR-cas9 systems from the "in silico" output and testing binding and/or activity of "wet" or actual a functional group linked to a "wet" or actual CRISPR-cas9 system bound to a "wet" or actual candidate or desired nucleic acid molecule. The methods can include synthesizing the CRISPR-cas9 systems (including a functional group) from the "in silico" output and testing binding and/or activity of "wet" or actual a functional group linked to a "wet" or actual CRISPR-cas9 system bound to an in vivo "wet" or actual candidate or desired nucleic acid molecule, e.g., contacting "wet" or actual CRISPR-cas9 system including a functional group from the "in silico" output with a cell containing the desired or candidate nucleic acid molecule. These methods can include observing the cell or an organism containing the cell for a desired reaction, e.g., reduction of symptoms or condition or disease. The step of providing the structure of a candidate nucleic acid molecule may involve selecting the compound by computationally screening a database containing nucleic acid molecule data, e.g., such data as to conditions or diseases. A 3-D descriptor for binding of the candidate nucleic acid molecule may be derived from geometric and functional constraints derived from the architecture and chemical nature of the CRISPR-cas9 complex or domains or regions thereof from the herein crystal structure. In effect, the descriptor can be a type of virtual modification(s) of the CRISPR-cas9 complex crystal structure herein for binding CRISPR-cas9 to the candidate or desired nucleic acid molecule. The descriptor may then be used to interrogate the nucleic acid molecule database to ascertain those nucleic acid molecules of the database that have putatively good binding to the descriptor. The herein "wet" steps can then be performed using the descriptor and nucleic acid molecules that have putatively good binding.

[0118] "Fitting" can mean determining, by automatic or semi-automatic means, interactions between at least one atom of the candidate and at least one atom of the CRISPR-cas9 complex and calculating the extent to which such an interaction is stable. Interactions can include attraction, repulsion, brought about by charge, steric considerations, and the like. A "sub-domain" can mean at least one, e.g., one, two, three, or four, complete element(s) of secondary structure. Particular regions or domains of the CRISPR-cas9 include those identified in the herein Crystal Structure Table and the Figures.

[0119] In any event, the determination of the three-dimensional structure of CRISPR-cas 9 (S. pyogenes cas9) complex provides a basis for the design of new and specific nucleic acid molecules that bind to CRISPR-cas 9 (e.g., S. pyogenes cas9), as well as the design of new CRISPR-cas9 systems, such as by way of modification of the CRISPR-cas9 system to bind to various nucleic acid molecules, by way of modification of the CRISPR-cas9 system to have linked thereto to any one or more of various functional groups that may interact with each other, with the CRISPR-cas9 (e.g., an inducible system that provides for self-activation and/or self-termination of function), with the nucleic acid molecule nucleic acid molecules (e.g., the functional group may be a regulatory or functional domain which may be selected from the group consisting of a transcriptional repressor, a transcriptional activator, a nuclease domain, a DNA methyl transferase, a protein acetyltransferase, a protein deacetylase, a protein methyltransferase, a protein deaminase, a protein kinase, and a protein phosphatase; and, in some aspects, the functional domain is an epigenetic regulator; see, e.g., Zhang et al., U.S. Pat. No. 8,507,272, and it is again mentioned that it and all documents cited herein and all appln cited documents are hereby incorporated herein by reference), by way of modification of cas9, by way of novel nickases). Indeed, the herewith CRISPR-cas9 (S. pyogenes cas9) crystal structure has a multitude of uses. For example, from knowing the three-dimensional structure of CRISPR-cas9 (S. pyogenes cas9) crystal structure, computer modelling programs may be used to design or identify different molecules expected to interact with possible or confirmed sites such as binding sites or other structural or functional features of the CRISPR-cas9 system (e.g., S. pyogenes cas9). Compound that potentially bind ("binder") can be examined through the use of computer modeling using a docking program. Docking programs are known; for example GRAM, DOCK or AUTODOCK (see Walters et al. Drug Discovery Today, vol. 3, no. 4 (1998), 160-178, and Dunbrack et al. Folding and Design 2 (1997), 27-42). This procedure can include computer fitting of potential binders ascertain how well the shape and the chemical structure of the potential binder will bind to a CRISPR-cas9 system (e.g., S. pyogenes cas9). Computer-assisted, manual examination of the active site or binding site of a CRISPR-cas9 system (e.g., S. pyogenes cas9) may be performed. Programs such as GRID (P. Goodford, J. Med. Chem, 1985, 28, 849-57)--a program that determines probable interaction sites between molecules with various functional groups--may also be used to analyze the active site or binding site to predict partial structures of binding compounds. Computer programs can be employed to estimate the attraction, repulsion or steric hindrance of the two binding partners, e.g., CRISPR-cas9 system (e.g., S. pyogenes cas9) and a candidate nucleic acid molecule or a nucleic acid molecule and a candidate CRISPR-cas9 system (e.g., S. pyogenes cas9); and the CRISPR-cas9 crystral structure (S. pyogenes cas9) herewith enables such methods. Generally, the tighter the fit, the fewer the steric hindrances, and the greater the attractive forces, the more potent the potential binder, since these properties are consistent with a tighter binding constant. Furthermore, the more specificity in the design of a candidate CRISPR-cas9 system (e.g., S. pyogenes cas9), the more likely it is that it will not interact with off-target molecules as well. Also, "wet" methods are enabled by the instant invention. For example, in an aspect, the invention provides for a method for determining the structure of a binder (e.g., target nucleic acid molecule) of a candidate CRISPR-cas9 system (e.g., S. pyogenes cas9) bound to the candidate CRISPR-cas9 system (e.g., S. pyogenes cas9), said method comprising, (a) providing a first crystal of a candidate CRISPR-cas9 system (S. pyogenes cas9) according to the invention or a second crystal of a candidate a candidate CRISPR-cas9 system (e.g., S. pyogenes cas9), (b) contacting the first crystal or second crystal with said binder under conditions whereby a complex may form; and (c) determining the structure of said a candidate (e.g., CRISPR-cas9 system (e.g., S. pyogenes cas9) or CRISPR-cas9 system (S. pyogenes cas9) complex. The second crystal may have essentially the same coordinates discussed herein, however due to minor alterations in CRISPR-cas9 system (e.g., from the cas9 of such a system being e.g., S. pyogenes cas9 versus being S. pyogenes cas9), wherein "e.g., S. pyogenes cas9" indicates that the cas9 is a cas9 and can be of or derived from S. pyogenes or an ortholog thereof), the crystal may form in a different space group.

[0120] The invention further involves, in place of or in addition to "in silico" methods, other "wet" methods, including high throughput screening of a binder (e.g., target nucleic acid molecule) and a candidate CRISPR-cas9 system (e.g., S. pyogenes cas9), or a candidate binder (e.g., target nucleic acid molecule) and a CRISPR-cas9 system (e.g., S. pyogenes cas9), or a candidate binder (e.g., target nucleic acid molecule) and a candidate CRISPR-cas9 system (e.g., S. pyogenes cas9) (the foregoing CRISPR-cas9 system(s) with or without one or more functional group(s)), to select compounds with binding activity. Those pairs of binder and CRISPR-cas9 system which show binding activity may be selected and further crystallized with the CRISPR-cas9 crystal having a structure herein, e.g., by co-crystallization or by soaking, for X-ray analysis. The resulting X-ray structure may be compared with that of the herein Crystal Structure Table and the information in the Figures for a variety of purposes, e.g., for areas of overlap. Having designed, identified, or selected possible pairs of binder and CRISPR-cas9 system by determining those which have favorable fitting properties, e.g., predicted strong attraction based on the pairs of binder and CRISPR-cas9 crystral structure data herein, these possible pairs can then be screened by "wet" methods for activity. Consequently, in an aspect the invention can involve: obtaining or synthesizing the possible pairs; and contacting a binder (e.g., target nucleic acid molecule) and a candidate CRISPR-cas9 system (e.g., S. pyogenes cas9), or a candidate binder (e.g., target nucleic acid molecule) and a CRISPR-cas9 system (e.g., S. pyogenes cas9), or a candidate binder (e.g., target nucleic acid molecule) and a candidate CRISPR-cas9 system (e.g., S. pyogenes cas9) (the foregoing CRISPR-cas9 system(s) with or without one or more functional group(s)) to determine ability to bind. In the latter step, the contacting is advantageously under conditions to determine function. Instead of, or in addition to, performing such an assay, the invention may comprise: obtaining or synthesizing complex(es) from said contacting and analyzing the complex(es), e.g., by X-ray diffraction or NMR or other means, to determine the ability to bind or interact. Detailed structural information can then be obtained about the binding, and in light of this information, adjustments can be made to the structure or functionality of a candidate CRISPR-cas9 system or components thereof. These steps may be repeated and re-repeated as necessary. Alternatively or additionally, potential CRISPR-cas9 systems from or in the foregoing methods can be with nucleic acid molecules in vivo, including without limitation by way of administration to an organism (including non-human animal and human) to ascertain or confirm function, including whether a desired outcome (e.g., reduction of symptoms, treatment) results therefrom.

[0121] The invention further involves a method of determining three dimensional structures of CRISPR-cas systems or complex(es) of unknown structure by using the structural co-ordinates of the herein Crystal Structure Table and the information in the Figures. For example, if X-ray crystallographic or NMR spectroscopic data are provided for a CRISPR-cas system or complex of unknown crystal structure, the structure of a CRISPR-cas9 complex as defined in the herein Crystal Structure Table and the Figures may be used to interpret that data to provide a likely structure for the unknown system or complex by such techniques as by phase modeling in the case of X-ray crystallography. Thus, an inventive method can comprise: aligning a representation of the CRISPR-cas system or complex having an unknown crystral structure with an analogous representation of the CRISPR-cas(9) system and complex of the crystal structure herein to match homologous or analogous regions (e.g., homologous or analogous sequences); modeling the structure of the matched homologous or analogous regions (e.g., sequences) of the CRISPR-cas system or complex of unknown crystal structure based on the structure as defined in the herein Crystal Structure Table and/or in the Figures of the corresponding regions (e.g., sequences); and, determining a conformation (e.g. taking into consideration favorable interactions should be formed so that a low energy conformation is formed) for the unknown crystal structure which substantially preserves the structure of said matched homologous regions. "Homologous regions" describes, for example as to amino acids, amino acid residues in two sequences that are identical or have similar, e.g., aliphatic, aromatic, polar, negatively charged, or positively charged, side-chain chemical groups. Homologous regions as of nucleic acid molecules can include at least 85% or 86% or 87% or 88% or 89% or 90% or 91% or 92% or 93% or 94% or 95% or 96% or 97% or 98% or 99% homology or identity. Identical and similar regions are sometimes described as being respectively "invariant" and "conserved" by those skilled in the art. Advantageously, the first and third steps are performed by computer modeling. Homology modeling is a technique that is well known to those skilled in the art (see, e.g., Greer, Science vol. 228 (1985) 1055, and Blundell et al. Eur J Biochem vol 172 (1988), 513). The computer representation of the conserved regions of the CRISPR-cas9 crystral structure herein and those of a CRISPR-cas system of unknown crystral structure aid in the prediction and determination of the crystral structure of the CRISPR-cas system of unknown crystal structure. Further still, the aspects of the invention which employ the CRISPR-cas9 crystral structure in silico may be equally applied to new CRISPR-cas crystral structures divined by using the herein CRISPR-cas9 crystral structure. In this fashion, a library of CRISPR-cas crystral structures can be obtained. Rational CRISPR-cas system design is thus provided by the instant invention. For instance, having determined a conformation or crystral structure of a CRISPR-cas system or complex, by the methods described herein, such a conformation may be used in a computer-based methods herein for determining the conformation or crystal structure of other CRISPR-cas systems or complexes whose crystral structures are yet unkown. Data from all of these crystal structures can be in a database, and the herein methods can be more robust by having herein comparisons involving the herein crystral structure or portions thereof be with respect to one or more crystal structures in the library. The invention further provides systems, such as computer systems, intended to generate structures and/or perform rational design of a CRISPR-cas system or complex. The system can contain: atomic co-ordinate data according to the herein Crystal Structure Table and the Figures or be derived therefrom e.g., by modeling, said data defining the three-dimensional structure of a CRISPR-cas system or complex or at least one domain or sub-domain thereof, or structure factor data therefor, said structure factor data being derivable from the atomic co-ordinate data of the herein Crystal Structure Table and the Figures. The invention also involves computer readable media with: atomic co-ordinate data according to the herein Crystal Structure Table and/or the Figures or derived therefrom e.g., by homology modeling, said data defining the three-dimensional structure of a CRISPR-cas system or complex or at least one domain or sub-domain thereof, or structure factor data therefor, said structure factor data being derivable from the atomic co-ordinate data of the herein Crystal Structure Table and/or the Figures. "Computer readable media" refers to any media which can be read and accessed directly by a computer, and includes, but is not limited to: magnetic storage media; optical storage media; electrical storage media; cloud storage and hybrids of these categories. By providing such computer readable media, the atomic co-ordinate data can be routinely accessed for modeling or other "in silica" methods. The invention further comprehends methods of doing business by providing access to such computer readable media, for instance on a subscription basis, via the Internet or a global communication/computer network; or, the computer system can be available to a user, on a subscription basis. A "computer system" refers to the hardware means, software means and data storage means used to analyze the atomic co-ordinate data of the present invention. The minimum hardware means of computer-based systems of the invention may comprise a central processing unit (CPU), input means, output means, and data storage means. Desirably, a display or monitor is provided to visualize structure data. The invention further comprehends methods of transmitting information obtained in any method or step thereof described herein or any information described herein, e.g., via telecommunications, telephone, mass communications, mass media, presentations, internet, email, etc. The crystal structures of the invention can be analyzed to generate Fourier electron density map(s) of CRISPR-cas systems or complexes; advantageously, the three-dimensional structure being as defined by the atomic co-ordinate data according to the herein Crystal Structure Table and/or the Figures. Fourier electron density maps can be calculated based on X-ray diffraction patterns. These maps can then be used to determine aspects of binding or other interactions. Electron density maps can be calculated using known programs such as those from the CCP4 computer package (Collaborative Computing Project, No. 4. The CCP4 Suite: Programs for Protein Crystallography, Acta Crystallographica, D50, 1994, 760-763). For map visualization and model building programs such as "QUANTA" (1994, San Diego, Calif.: Molecular Simulations, Jones et al., Acta Crystallography A47 (1991), 110-119) can be used.

[0122] The herein Crystal Structure Table (see Example 1) gives atomic co-ordinate data for a CRISPR-cas9 (S. pyogenes), and lists each atom by a unique number; the chemical element and its position for each amino acid residue (as determined by electron density maps and antibody sequence comparisons), the amino acid residue in which the element is located, the chain identifier, the number of the residue, co-ordinates (e.g., X, Y, Z) which define with respect to the crystallographic axes the atomic position (in angstroms) of the respective atom, the occupancy of the atom in the respective position, "B", isotropic displacement parameter (in angstroms.sup.2) which accounts for movement of the atom around its atomic center, and atomic number. See also the text herein and the Figures.

[0123] Nucleic Acids, Amino Acids and Proteins, Regulatory Sequences, Vectors, etc

[0124] Nucleic acids, amino acids and proteins: The invention uses nucleic acids to bind target DNA sequences. This is advantageous as nucleic acids are much easier and cheaper to produce than proteins, and the specificity can be varied according to the length of the stretch where homology is sought. Complex 3-D positioning of multiple fingers, for example is not required. The terms "polynucleotide", "nucleotide", "nucleotide sequence", "nucleic acid" and "oligonucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. The term also encompasses nucleic-acid-like structures with synthetic backbones, see, e.g., Eckstein, 1991; Baserga et al., 1992; Milligan, 1993; WO 97/03211; WO 96/39154; Mata, 1997; Strauss-Soukup, 1997; and Samstag, 1996. A polynucleotide may comprise one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. As used herein the term "wild type" is a term of the art understood by skilled persons and means the typical form of an organism, strain, gene or characteristic as it occurs in nature as distinguished from mutant or variant forms. A "wild type" can be a base line. As used herein the term "variant" should be taken to mean the exhibition of qualities that have a pattern that deviates from what occurs in nature. The terms "non-naturally occurring" or "engineered" are used interchangeably and indicate the involvement of the hand of man. The terms, when referring to nucleic acid molecules or polypeptides mean that the nucleic acid molecule or the polypeptide is at least substantially free from at least one other component with which they are naturally associated in nature and as found in nature. "Complementarity" refers to the ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick base pairing or other non-traditional types. A percent complementarity indicates the percentage of residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary). "Perfectly complementary" means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence. "Substantially complementary" as used herein refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions. As used herein, "stringent conditions" for hybridization refer to conditions under which a nucleic acid having complementarity to a target sequence predominantly hybridizes with the target sequence, and substantially does not hybridize to non-target sequences. Stringent conditions are generally sequence-dependent, and vary depending on a number of factors. In general, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes to its target sequence. Non-limiting examples of stringent conditions are described in detail in Tijssen (1993), Laboratory Techniques In Biochemistry And Molecular Biology-Hybridization With Nucleic Acid Probes Part I, Second Chapter "Overview of principles of hybridization and the strategy of nucleic acid probe assay", Elsevier, N.Y. Where reference is made to a polynucleotide sequence, then complementary or partially complementary sequences are also envisaged. These are preferably capable of hybridising to the reference sequence under highly stringent conditions. Generally, in order to maximize the hybridization rate, relatively low-stringency hybridization conditions are selected: about 20 to 25.degree. C. lower than the thermal melting point (T.sub.m). The T.sub.m is the temperature at which 50% of specific target sequence hybridizes to a perfectly complementary probe in solution at a defined ionic strength and pH. Generally, in order to require at least about 85% nucleotide complementarity of hybridized sequences, highly stringent washing conditions are selected to be about 5 to 15.degree. C. lower than the T.sub.m. In order to require at least about 70% nucleotide complementarity of hybridized sequences, moderately-stringent washing conditions are selected to be about 15 to 30.degree. C. lower than the T.sub.m. Highly permissive (very low stringency) washing conditions may be as low as 50.degree. C. below the T.sub.m, allowing a high level of mis-matching between hybridized sequences. Those skilled in the art will recognize that other physical and chemical parameters in the hybridization and wash stages can also be altered to affect the outcome of a detectable hybridization signal from a specific level of homology between target and probe sequences. Preferred highly stringent conditions comprise incubation in 50% formamide, 5.times.SSC, and 1% SDS at 42.degree. C., or incubation in 5.times.SSC and 1% SDS at 65.degree. C., with wash in 0.2.times.SSC and 0.1% SDS at 65.degree. C. "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding may occur by Watson Crick base pairing, Hoogstein binding, or in any other sequence specific manner. The complex may comprise two strands forming a duplex structure, three or more strands forming a multi stranded complex, a single self-hybridizing strand, or any combination of these. A hybridization reaction may constitute a step in a more extensive process, such as the initiation of PCR, or the cleavage of a polynucleotide by an enzyme. A sequence capable of hybridizing with a given sequence is referred to as the "complement" of the given sequence. As used herein, the term "genomic locus" or "locus" (plural loci) is the specific location of a gene or DNA sequence on a chromosome. A "gene" refers to stretches of DNA or RNA that encode a polypeptide or an RNA chain that has functional role to play in an organism and hence is the molecular unit of heredity in living organisms. For the purpose of this invention it may be considered that genes include regions which regulate the production of the gene product, whether or not such regulatory sequences are adjacent to coding and/or transcribed sequences. Accordingly, a gene includes, but is not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions. As used herein, "expression of a genomic locus" or "gene expression" is the process by which information from a gene is used in the synthesis of a functional gene product. The products of gene expression are often proteins, but in non-protein coding genes such as rRNA genes or tRNA genes, the product is functional RNA. The process of gene expression is used by all known life--eukaryotes (including multicellular organisms), prokaryotes (bacteria and archaea) and viruses to generate functional products to survive. As used herein "expression" of a gene or nucleic acid encompasses not only cellular gene expression, but also the transcription and translation of nucleic acid(s) in cloning systems and in any other context. As used herein, "expression" also refers to the process by which a polynucleotide is transcribed from a DNA template (such as into and mRNA or other RNA transcript) and/or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. Transcripts and encoded polypeptides may be collectively referred to as "gene product." If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell. The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. As used herein the term "amino acid" includes natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics. As used herein, the term "domain" or "protein domain" refers to a part of a protein sequence that may exist and function independently of the rest of the protein chain. As described in aspects of the invention, sequence identity is related to sequence homology. Homology comparisons may be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs may calculate percent (%) homology between two or more sequences and may also calculate the sequence identity shared by two or more amino acid or nucleic acid sequences. In some preferred embodiments, the capping region of the dTALEs described herein have sequences that are at least 95% identical or share identity to the capping region amino acid sequences provided herein. Sequence homologies may be generated by any of a number of computer programs known in the art, for example BLAST or FASTA, etc. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A; Devereux et al., 1984, Nucleic Acids Research 12:387). Examples of other software than may perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999 ibid--Chapter 18), FASTA (Atschul et al., 1990, J. Mol. Biol., 403-410) and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999 ibid, pages 7-58 to 7-60). However it is preferred to use the GCG Bestfit program. Percentage (%) sequence homology may be calculated over contiguous sequences, i.e., one sequence is aligned with the other sequence and each amino acid or nucleotide in one sequence is directly compared with the corresponding amino acid or nucleotide in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues. Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion may cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without unduly penalizing the overall homology or identity score. This is achieved by inserting "gaps" in the sequence alignment to try to maximize local homology or identity. However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible--reflecting higher relatedness between the two compared sequences--may achieve a higher score than one with many gaps. "Affinity gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties may, of course, produce optimized alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example, when using the GCG Wisconsin Bestfit package the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension. Calculation of maximum % homology therefore first requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (Devereux et al., 1984 Nuc. Acids Research 12 p387). Examples of other software than may perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999 Short Protocols in Molecular Biology, 4.sup.th Ed.--Chapter 18), FASTA (Altschul et al., 1990 J. Mol. Biol. 403-410) and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999, Short Protocols in Molecular Biology, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. A new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequences (see FEMS Microbiol Lett. 1999 174(2): 247-50; FEMS Microbiol Lett. 1999 177(1): 187-8 and the website of the National Center for Biotechnology information at the website of the National Institutes for Health). Although the final % homology may be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pair-wise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix--the default matrix for the BLAST suite of programs. GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table, if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62. Alternatively, percentage homologies may be calculated using the multiple alignment feature in DNASIS

.TM. (Hitachi Software), based on an algorithm, analogous to CLUSTAL (Higgins D G & Sharp P M (1988), Gene 73(1), 237-244). Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result. The sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance. Deliberate amino acid substitutions may be made on the basis of similarity in amino acid properties (such as polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues) and it is therefore useful to group amino acids together in functional groups. Amino acids may be grouped together based on the properties of their side chains alone. However, it is more useful to include mutation data as well. The sets of amino acids thus derived are likely to be conserved for structural reasons. These sets may be described in the form of a Venn diagram (Livingstone C. D. and Barton G. J. (1993) "Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation" Comput. Appl. Biosci. 9: 745-756) (Taylor W. R. (1986) "The classification of amino acid conservation" J. Theor. Biol. 119; 205-218). Conservative substitutions may be made, for example according to the table below which describes a generally accepted Venn diagram grouping of amino acids.

TABLE-US-00001 Set Sub-set Hydrophobic F W Y H K M I L V A G C Aromatic F W Y H Aliphatic I L V Polar W Y H K R E D C S T N Q Charged H K R E D Positively charged H K R Negatively charged E D Small V CA G S P T N D Tiny A G S

[0125] Embodiments of the invention include sequences (both polynucleotide or polypeptide) which may comprise homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue or nucleotide, with an alternative residue or nucleotide) that may occur i.e., like-for-like substitution in the case of amino acids such as basic for basic, acidic for acidic, polar for polar, etc. Non-homologous substitution may also occur i.e., from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyriylalanine, thienylalanine, naphthylalanine and phenylglycine. Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or .beta.-alanine residues. A further form of variation, which involves the presence of one or more amino acid residues in peptoid form, may be well understood by those skilled in the art. For the avoidance of doubt, "the peptoid form" is used to refer to variant amino acid residues wherein the .alpha.-carbon substituent group is on the residue's nitrogen atom rather than the .alpha.-carbon. Processes for preparing peptides in the peptoid form are known in the art, for example Simon R J et al., PNAS (1992) 89(20), 9367-9371 and Horwell D C, Trends Biotechnol. (1995) 13(4), 132-134.

[0126] For purpose of this invention, amplification means any method employing a primer and a polymerase capable of replicating a target sequence with reasonable fidelity. Amplification may be carried out by natural or recombinant DNA polymerases such as TaqGold.TM., T7 DNA polymerase, Klenow fragment of E. coli DNA polymerase, and reverse transcriptase. A preferred amplification method is PCR.

[0127] In certain aspects the invention involves vectors. A used herein, a "vector" is a tool that allows or facilitates the transfer of an entity from one environment to another. It is a replicon, such as a plasmid, phage, or cosmid, into which another DNA segment may be inserted so as to bring about the replication of the inserted segment. Generally, a vector is capable of replication when associated with the proper control elements. In general, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. One type of vector is a "plasmid," which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses (AAVs)). Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors." Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.

[0128] Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). With regards to recombination and cloning methods, mention is made of U.S. patent application Ser. No. 10/815,730, published Sep. 2, 2004 as US 2004-0171156 A1, the contents of which are herein incorporated by reference in their entirety.

[0129] Aspects of the invention relate to bicistronic vectors for chimeric RNA and Cas9. Bicistronic expression vectors for chimeric RNA and Cas9 are preferred. In general and particularly in this embodiment Cas9 is preferably driven by the CBh promoter. The chimeric RNA may preferably be driven by a Pol III promoter, such as a U6 promoter. Ideally the two are combined. The chimeric guide RNA typically consists of a 20bp guide sequence (Ns) and this may be joined to the tracr sequence (running from the first "U" of the lower strand to the end of the transcript). The tracr sequence may be truncated at various positions as indicated. The guide and tracr sequences are separated by the tracr-mate sequence, which may be GUUUUAGAGCUA (SEQ ID NO: 30). This may be followed by the loop sequence GAAA as shown. Both of these are preferred examples. Applicants have demonstrated Cas9-mediated indels at the human EMX1 and PVALB loci by SURVEYOR assays. ChiRNAs are indicated by their "+n" designation, and crRNA refers to a hybrid RNA where guide and tracr sequences are expressed as separate transcripts. Throughout this application, chimeric RNA may also be called single guide, or synthetic guide RNA (sgRNA). The loop is preferably GAAA, but it is not limited to this sequence or indeed to being only 4 bp in length. Indeed, preferred loop forming sequences for use in hairpin structures are four nucleotides in length, and most preferably have the sequence GAAA. However, longer or shorter loop sequences may be used, as may alternative sequences. The sequences preferably include a nucleotide triplet (for example, AAA), and an additional nucleotide (for example C or G). Examples of loop forming sequences include CAAA and AAAG. In practicing any of the methods disclosed herein, a suitable vector can be introduced to a cell or an embryo via one or more methods known in the art, including without limitation, microinjection, electroporation, sonoporation, biolistics, calcium phosphate-mediated transfection, cationic transfection, liposome transfection, dendrimer transfection, heat shock transfection, nucleofection transfection, magnetofection, lipofection, impalefection, optical transfection, proprietary agent-enhanced uptake of nucleic acids, and delivery via liposomes, immunoliposomes, virosomes, or artificial virions. In some methods, the vector is introduced into an embryo by microinjection. The vector or vectors may be microinjected into the nucleus or the cytoplasm of the embryo. In some methods, the vector or vectors may be introduced into a cell by nucleofection.

[0130] The term "regulatory element" is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes). Regulatory elements may also direct expression in a temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. In some embodiments, a vector comprises one or more pol III promoter (e.g. 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g. 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g. 1, 2, 3, 4, 5, or more pol I promoters), or combinations thereof. Examples of pol III promoters include, but are not limited to, U6 and H1 promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the .beta.-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1.alpha. promoter. Also encompassed by the term "regulatory element" are enhancer elements, such as WPRE; CMV enhancers; the R-U5' segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit .beta.-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc. A vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.). With regards to regulatory sequences, mention is made of U.S. patent application Ser. No. 10/491,026, the contents of which are incorporated by reference herein in their entirety. With regards to promoters, mention is made of PCT publication WO 2011/028929 and U.S. application Ser. No. 12/511,940, the contents of which are incorporated by reference herein in their entirety.

[0131] Vectors can be designed for expression of CRISPR transcripts (e.g. nucleic acid transcripts, proteins, or enzymes) in prokaryotic or eukaryotic cells. For example, CRISPR transcripts can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

[0132] Vectors may be introduced and propagated in a prokaryote or prokaryotic cell. In some embodiments, a prokaryote is used to amplify copies of a vector to be introduced into a eukaryotic cell or as an intermediate vector in the production of a vector to be introduced into a eukaryotic cell (e.g. amplifying a plasmid as part of a viral vector packaging system). In some embodiments, a prokaryote is used to amplify copies of a vector and express one or more nucleic acids, such as to provide a source of one or more proteins for delivery to a host cell or host organism. Expression of proteins in prokaryotes is most often carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, such as to the amino terminus of the recombinant protein. Such fusion vectors may serve one or more purposes, such as: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Example fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89). In some embodiments, a vector is a yeast expression vector. Examples of vectors for expression in yeast Saccharomyces cerivisae include pYepSec1 (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa (Kuijan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.). In some embodiments, a vector drives protein expression in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39).

[0133] In some embodiments, a vector is capable of driving expression of one or more sequences in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6: 187-195). When used in mammalian cells, the expression vector's control functions are typically provided by one or more regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, simian virus 40, and others disclosed herein and known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

[0134] In some embodiments, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. EMBO J. 8: 729-733) and immunoglobulins (Baneiji, et al., 1983. Cell 33: 729-740; Queen and Baltimore, 1983. Cell 33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. Proc. Natl. Acad. Sci. USA 86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985. Science 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. Science 249: 374-379) and the .alpha.-fetoprotein promoter (Campes and Tilghman, 1989. Genes Dev. 3: 537-546). With regards to these prokaryotic and eukaryotic vectors, mention is made of U.S. Pat. No. 6,750,059, the contents of which are incorporated by reference herein in their entirety. Other embodiments of the invention may relate to the use of viral vectors, with regards to which mention is made of U.S. patent application Ser. No. 13/092,085, the contents of which are incorporated by reference herein in their entirety. Tissue-specific regulatory elements are known in the art and in this regard, mention is made of U.S. Pat. No. 7,776,321, the contents of which are incorporated by reference herein in their entirety. In some embodiments, a regulatory element is operably linked to one or more elements of a CRISPR system so as to drive expression of the one or more elements of the CRISPR system. In general, CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats), also known as SPIDRs (SPacer Interspersed Direct Repeats), constitute a family of DNA loci that are usually specific to a particular bacterial species. The CRISPR locus comprises a distinct class of interspersed short sequence repeats (SSRs) that were recognized in E. coli (Ishino et al., J. Bacteriol., 169:5429-5433

[1987]; and Nakata et al., J. Bacteriol., 171:3553-3556

[1989]), and associated genes. Similar interspersed SSRs have been identified in Haloferax mediterranei, Streptococcus pyogenes, Anabaena, and Mycobacterium tuberculosis (See, Groenen et al., Mol. Microbiol., 10:1057-1065

[1993]; Hoe et al., Emerg. Infect. Dis., 5:254-263

[1999]; Masepohl et al., Biochim. Biophys. Acta 1307:26-30

[1996]; and Mojica et al., Mol. Microbiol., 17:85-93

[1995]). The CRISPR loci typically differ from other SSRs by the structure of the repeats, which have been termed short regularly spaced repeats (SRSRs) (Janssen et al., OMICS J. Integ. Biol., 6:23-33

[2002]; and Mojica et al., Mol. Microbiol., 36:244-246

[2000]). In general, the repeats are short elements that occur in clusters that are regularly spaced by unique intervening sequences with a substantially constant length (Mojica et al.,

[2000], supra). Although the repeat sequences are highly conserved between strains, the number of interspersed repeats and the sequences of the spacer regions typically differ from strain to strain (van Embden et al., J. Bacteriol., 182:2393-2401

[2000]). CRISPR loci have been identified in more than 40 prokaryotes (See e.g., Jansen et al., Mol. Microbiol., 43:1565-1575

[2002]; and Mojica et al.,

[2005]) including, but not limited to Aeropyrum, Pyrobaculum, Sulfolobus, Archaeoglobus, Halocarcula, Methanobacterium, Methanococcus, Methanosarcina, Methanopyrus, Pyrococcus, Picrophilus, Thermoplasma, Corynebacterium, Mycobacterium, Streptomyces, Aquifex, Porphyromonas, Chlorobium, Thermus, Bacillus, Listeria, Staphylococcus, Clostridium, Thermoanaerobacter, Mycoplasma, Fusobacterium, Azarcus, Chromobacterium, Neisseria, Nitrosomonas, Desulfovibrio, Geobacter, Myxococcus, Campylobacter, Wolinella, Acinetobacter, Erwinia, Escherichia, Legionella, Methylococcus, Pasteurella, Photobacterium, Salmonella, Xanthomonas, Yersinia, Treponema, and Thermotoga.

[0135] In some embodiments, the CRISPR enzyme is part of a fusion protein comprising one or more heterologous protein domains (e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more domains in addition to the CRISPR enzyme). A CRISPR enzyme fusion protein may comprise any additional protein sequence, and optionally a linker sequence between any two domains. Examples of protein domains that may be fused to a CRISPR enzyme include, without limitation, epitope tags, reporter gene sequences, and protein domains having one or more of the following activities: methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity and nucleic acid binding activity. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Examples of reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP). A CRISPR enzyme may be fused to a gene sequence encoding a protein or a fragment of a protein that bind DNA molecules or bind other cellular molecules, including but not limited to maltose binding protein (MBP), S-tag, Lex A DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. Additional domains that may form part of a fusion protein comprising a CRISPR enzyme are described in US20110059502, incorporated herein by reference. In some embodiments, a tagged CRISPR enzyme is used to identify the location of a target sequence.

[0136] In some embodiments, a CRISPR enzyme may form a component of an inducible system. The inducible nature of the system would allow for spatiotemporal control of gene editing or gene expression using a form of energy. The form of energy may include but is not limited to electromagnetic radiation, sound energy, chemical energy and thermal energy. Examples of inducible system include tetracycline inducible promoters (Tet-On or Tet-Off), small molecule two-hybrid transcription activations systems (FKBP, ABA, etc), or light inducible systems (Phytochrome, LOV domains, or cryptochrome). In one embodiment, the CRISPR enzyme may be a part of a Light Inducible Transcriptional Effector (LITE) to direct changes in transcriptional activity in a sequence-specific manner. The components of a light may include a CRISPR enzyme, a light-responsive cytochrome heterodimer (e.g. from Arabidopsis thaliana), and a transcriptional activation/repression domain. Further examples of inducible DNA binding proteins and methods for their use are provided in U.S. 61/736465 and U.S. 61/721,283, which is hereby incorporated by reference in its entirety.

[0137] The practice of the present invention employs, unless otherwise indicated, conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA, which are within the skill of the art. See Sambrook, Fritsch and Maniatis, MOLECULAR CLONING: A LABORATORY MANUAL, 2nd edition (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel, et al. eds., (1987)); the series METHODS IN ENZYMOLOGY (Academic Press, Inc.): PCR 2: A PRACTICAL APPROACH (M. J. MacPherson, B. D. Hames and G. R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE (R. I. Freshney, ed. (1987)).

EXAMPLES

[0138] The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. The present examples, along with the methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.

Example 1

Crystal Structure

[0139] FIGS. 1A-M provide: various views of the CRISPR-cas complex crystal structure (A-I), chemieric RNA architecture from the crystal structure (J-K), an interaction schematic from the crystal structure (L) and a topology schematic from the crystal structure (M).

[0140] FIGS. 1J-K concern a SpCas9 sgRNA structural study, and FIGS. 4A-B also pertain to sgRNA mutations. SpCas9 sgRNAs were mutated to investigate contribution of specific bases or groups of bases to activity. These include mutations in the direct repeat (DR) and tracrRNA regions of the sgRNA, divided into: stem 1 (base-pairing region between DR and tracrRNA), bulge (un-paired bases between DR and tracrRNA), loop 1 (artificial GAAA connector between DR and tracrRNA), linker 1 (between stem 1 and stem 2), stem 2 (first hairpin formed by tracrRNA tail), loop 2 (loop in between stem 2), stem 3 (second, or last hairpin formed by tracrRNA tail), and loop 3 (loop in between stem 3). Mutations were chosen based on predicted secondary structure as well as secondary structure as illustrated in FIGS. 1A-M, especially FIG. 1J. In addition, three (3) sgRNA scaffolds were designed to incorporate MS2 loops in loop regions for interaction/binding to recruit functional domains fused to MBP. sgRNAs were synthesized as U6::PCR amplicon and tested in co-transfection with wildtype SpCas9.

[0141] 400 ng of Cas9 plasmid, 100 ng of sgRNA into 200,000 HEK 293FT cells with Lipofectamine 2000; DNA was harvested 3 days post-transfection for SURVEYOR analysis.

[0142] The invention comprehends a CRISPR-cas9 (S. pyogenes) system having a crystal having the structure defined by the co-ordinates of following Table A (the CRISPR-cas9 crystal structure). Table A discloses SEQ ID NOS 180-202, respectively, in order of appearance.

TABLE-US-00002 Lengthy table referenced here US20200080067A1-20200312-T00001 Please refer to the end of the specification for access instructions.

Example 2

S. pyogenes (Sp) SpCas9 Truncations from Crystal Structure

[0143] FIGS. 3A-B pertain to SpCas9 truncations from full length SpCas9. These figures show Surveyor gel test results of SpCas9 truncation mutants from the crystal structure that retain cleavage activity (A) and a table showing the amino acid truncations and flexible (GGGS) (SEQ ID NO: 1) or rigid (A(EAAAK)) (SEQ ID NO: 2) linker substitutions of the lanes of the gels of FIG. 3A (B)

[0144] In this Example, SpCas9 sequences were analyzed by 1. Comparing against orthologs (S. aureus, S. thermophilus CRISPR1, S. thermophilus CRISPR3, and N. meningiditis), including smaller Cas9s (S. aureus, S. thermophilus CRISPR1, and N. meningiditis) for regions that are conserved or variable, and 2. Boundaries identified by crystallography as being potentially non-critical for contacting target DNA: sgRNA duplex. A region of SpCas9 (helical domain 2) was not present in many smaller Cas9 orthologs, and predicted to be dispensable for function. Two similar sets of truncations were made, one by sequence alignment with smaller Cas9s, one by crystal prediction. In addition, several sets of flexible glycine-serine (GlyGlyGlySer) (SEQ ID NO: 1) or rigid alpha-helical linkers (Ala(GluAlaAlaAlaLys)Ala) (SEQ ID NO: 29) in groups of 3, 6, 9, or 12 repeats were also used to replace helical domain 2 for potential structural stabilization and/or aiding of retaining SpCas9:sgRNA specificity. All of the helical region 2 truncations and linker substitutions retained SpCas9 activity. SpCas9 was truncated systematically in Helical 1, 2, and 3 domains, as well as the C'-terminal putative PAM-recognizing domain. Truncation mutants were transfected into HEK 293FT cells as follows: 400 ng of truncation Cas9 plasmid and 100 ng of sgRNA co-transfected into 200,000 cells by Lipofectamine 2000. DNAs from cells were harvested for SURVEYOR analysis.

[0145] Below: full length SpCas9 DNA sequence and sequences of the subdomains; followed by helical domain 2 truncation and variants.

TABLE-US-00003 >Full length NLS-SpCas9-NLS (SEQ ID NO: 31) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGG TGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGAC GCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGAT CGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGATTGCCCTGA GCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAA CTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGAT CGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCT GCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCT CTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTC GTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAA CGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCA TCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAAC AGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCA GATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATT CCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACT ACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGC GAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGC CCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGG TGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCA AAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAG AAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCA GCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCG GCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTA TCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATC GTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAAC CTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACA CCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCC GGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATG CAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGT GTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCG CCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTG ATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGA CCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGG CATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGC TGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTG GACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCC TCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACA AGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAA GAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACA ATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATC AAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGG ACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAA GTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTAC AAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGT CGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACG GCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATC GGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACC GAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGG CGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAG TGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGC TTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAA GAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATT CTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTG AAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCAT CGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGC TGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTG CCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTC CTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCA GAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGA TCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGT CCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATC CACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACC ACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGAT CCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAG GCGACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa >N'-terminal NLS (SEQ ID NO: 32) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCC >RuvCI domain (SEQ ID NO: 33) GACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCC GTGATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACAC CGACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCG AAACA >Bridging helix (SEQ ID NO: 34) GCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAA GAACCGGATCTGCTATCTGCAAGAGATCTTC >Helical domain 1 (SEQ ID NO: 35) AGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCC TTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGT GGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAAC TGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCAC ATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGAC >Helical domain 2 (dispensable) (SEQ ID NO: 36) CTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACC TACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGC CATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGATCGCCCAGC TGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGATTGCCCTGAGCCTGGGC CTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCAGCT GAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACC AGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCG ACATCCTGAGAGTGAACACCGAG >Helical domain 3 (SEQ ID NO: 37) ATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCAC CAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAA AGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAG CCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGC ACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGA CCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTC TGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAG AAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGC AGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGA GGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACT TCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAG TACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAG AAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCA AGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATC GAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTG GGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGA GGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACA GAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTG ATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGC TGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAG TCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGAC CTTTAAAGAGGACATCCAGAAAGCC >Flexible linker (SEQ ID NO: 38)

CAGGTGTCCGGCCAGGGCGAT >RuvC II (SEQ ID NO: 39) ATCGTGATCGAAATGGCCAGAGAG >HNH (SEQ ID NO: 40) GACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCG ACAACAAGGTGCTGACCAGAAGCGACAAGAAC >RuvCIII (SEQ ID NO: 41) CACCACGCCCACGACGCCTACCTG >C-terminal (PAM recognizing domain) (SEQ ID NO: 42) ACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAAC AGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTT CGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCA AGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGA AGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGT GAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACG GCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCC CTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAG GGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTA CCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCG ACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATC AGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCT GCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAA AGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACAC GGATCGACCTGTCTCAGCTGGGAGGCGAC C'-NLS (SEQ ID NO: 43) AAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAG 6. Sp_.DELTA._hel 2(174-311) helical domain 2 deletion (from ortholog alignment) (SEQ ID NO: 44) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACATCACCAAGGCaCCaCTGAGCGCCTCTATGATCAAGAGATACGACGA GCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGA AGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGAC GGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGAT GGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAG CAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCA CGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAA AGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGG GAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGG AACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGAT GACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGC TGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAG GGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCT GCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCA AGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAAC GCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTG GACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTT TGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACG ACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAG CCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATT TCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGAC AGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAG CCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCC TGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCC GAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGA AGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAG CCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGT ACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATC AACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGAC GACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCG ACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTG CTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAG AGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAA CCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAG TACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAA GCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAA CTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCA AAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGAC GTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGT ACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACG GCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGT GTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAG TGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATC CTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTA AGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCA AAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGAT CACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCA AGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTG TTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAA GGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCA CTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGG AACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAG AGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCA CCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGA CCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGA GGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACC GGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAAAGGCCGGC GGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa 7. Sp_.DELTA._hel 2-(GGGGS)3 helical domain 2 deletion (from ortholog alignment)("(GGGGS)3" disclosed as SEQ ID NO: 45) (SEQ ID NO: 46) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgATCA CCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGAC CTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGAT TTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCC AGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAG GAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGA CAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGC GGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATC CTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTC GCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGT GGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATA AGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTC ACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCC CGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCA ACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGC TTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACA TACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAA CGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGA TGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAG

CAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCA ACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGAC GGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAA GAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACAT TGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGG TGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATC GAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGA GAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGA ACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGC AGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGAC TACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAAC AAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCG AAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTG ATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGA ACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAA AGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGAC AAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTC CGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCA CGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGC TGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATC GCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAA CATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGC GGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGG GATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAA GACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACA GCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTC GACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAA GTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAA GCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTG AAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGG CCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCC TGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGG GCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTAC CTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGA CGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCA GAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTG CCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAA GAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACG GATCGACCTGTCTCAGCTGGGAGGCGACAAAAGGCCGGCGGCCACGAAAAAGGCC GGCCAGGCAAAAAAGAAAAAGtaa 8. Sp_.DELTA._hel 2-(GGGGS)6 helical domain 2 deletion (from ortholog alignment)("(GGGGS)6" disclosed as SEQ ID NO: 47) (SEQ ID NO: 48) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgGGTG GCGGTGGCtcgGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgATCACCAAGGCCCCCCTGA GCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAA GCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGC AAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAA GTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGC TGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCC CACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTA CCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCC CCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGA AAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCG CTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACG AGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAG CTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGG CGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCG TGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAA ATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTG AAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGA AGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGC TGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGG AGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAA GCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAA ACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAA GCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGG CAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCG TGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAG AACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCG AAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAA CACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATA TGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCAT ATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAG AAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAG AAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAA GTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCG GCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAG ATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGA AGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCA GTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGA ACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTC GTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCA GGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTT CAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGA CAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTG CGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGAC AGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCG CCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTG GCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAA GAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGA ATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATC ATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCT GGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATG TGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGAT AATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCAT CGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACA AAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAG AATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTAC TTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGC CACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCA GCTGGGAGGCGACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAG AAAAAGtaa 9. Sp_.DELTA._hel 2-(GGGGS)9 helical domain 2 deletion (from ortholog alignment)("(GGGGS)9" disclosed as SEQ ID NO: 49) (SEQ ID NO: 50) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgGGTG GCGGTGGCtcgGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgGGTGG

CGGTGGCtcgGGTGGCGGTGGCtcgATCACCAAGGCCCCCCTGAGCGCCTCTATGATCA AGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAG CAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGC CGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCA TCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGAC CTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCT GGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGG ACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGC CCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAA CCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGC TTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCC CAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGA AATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAA GGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGA AAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTG GAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAG GACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCT GACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATG CCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGC TGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAA GACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCT GATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCG GCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATT AAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGG CCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCC AGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAA AGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGA ACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAG GAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAG CTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACC GGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTA CTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGA CCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAG ACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCC GGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATC ACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTG CGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGG AACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACT ACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAA GGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGAT TACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAA CCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTG AGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAG CAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGG ACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGC TGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGA GCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACT TTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCT AAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGG CGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGT ACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAA CAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAG CGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGC CTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACC TGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCA TCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCAC CAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGA CAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa 10. Sp_.DELTA._hel 2-(GGGGS)12 helical domain 2 deletion (from ortholog alignment)("(GGGGS)12" disclosed as SEQ ID NO: 51) (SEQ ID NO: 52) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgGGTG GCGGTGGCtcgGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgGGTGG CGGTGGCtcgGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgGGTGGCGGTGGCtcgGGTGGC GGTGGCtcgATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAG CACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAA GTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACG GCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATG GACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGC AGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCAC GCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAA GATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGG AAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGA ACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATG ACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCT GTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGG GAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTG CTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAA GAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACG CCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGG ACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTT GAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGA CAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGC CGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTT CCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACA GCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGC CTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCT GCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCG AGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAA GAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGC CAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTA CCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCA ACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACG ACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGA CAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGC TGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGA GGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAAC CCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGT ACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAG CTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAAC TACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAA AAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACG TGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTA CTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGG CGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGT GGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTG AATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCT GCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAG AAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAA GTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCA CCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAG GGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTT CGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAG GGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCAC TATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGA ACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGA GAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCAC

CGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGAC CAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAG GTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCG GCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAAAGGCCGGCG GCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa 11. Sp_.DELTA._hel 2-A(EAAAK)3A helical domain 2 deletion (from ortholog alignment)("A(EAAAK)3A" disclosed as SEQ ID NO: 53) (SEQ ID NO: 54) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGCTAA AgctATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCA CCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACA AAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGA GCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGG CACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGG ACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCAT TCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCG AGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACA GCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTC GAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAA CTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACG AGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATG AGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTT CAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAA ATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCC CTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAA TGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGG ACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAA GTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGA AGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTG AAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCT GACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGC ACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAG ACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGA ACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAA CAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAG ATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCT GTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACC GGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACT CCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAA CGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGA ACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGC GGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCG GCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACG ACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTG GTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTAC CACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAA GTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGC GGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTC TTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAG ATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGA TAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATA TCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCC AAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGT ACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGG AAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATC ATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTA CAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGC TGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAA CGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGA GAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGC ACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTG ATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGA TAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCT GGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACA CCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTG TACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAAAGGCCGGCGGCCAC GAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa 12. Sp_.DELTA._hel 2-A(EAAAK)3ALEA(EAAAK)3A helical domain 2 deletion (from ortholog alignment)("A(EAAAK)3ALEA(EAAAK)3A" disclosed as SEQ ID NO: 55) (SEQ ID NO: 56) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACgctGAAGCCGCTGCTAAAGAAGCcGCTGCTAAAGAAGCcGCTGCTAAA GccCTGGAGgctGAAGCcGCTGCTAAAGAAGCcGCTGCTAAAGAAGCCGCTGCTAAAgct ATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCA GGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAG AGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCC AGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCAC CGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCT TCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTG CGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAA GATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAG ATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGG AAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTC GATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTA CTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAA AGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAG ACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGA GTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGG CACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGG AAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGA GAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGAT GAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTG ATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTC CGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTT TAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGC ACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTG AAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGT GATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGC GAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGA AAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTAC CTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTC CGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGA CAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCC TCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAA GCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGA GCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATC ACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAA TGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCG ATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACG

CCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCT AAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGAT GATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACA GCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGG AAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGG GCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTG AAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAG GAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGC GGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAG GGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGA AAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAG AAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAA AACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAAC TGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGC TGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAG CACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCT GGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGC CCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGA GCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGC ACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGA GACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAAAGGCCGGCGGCCACGAAA AAGGCCGGCCAGGCAAAAAAGAAAAAGtaa 13. Sp_.DELTA._hel 2-A(EAAAK)3ALEA(EAAAK)3ALEA(EAAAK)3A helical domain 2 deletion (from ortholog alignment)("A(EAAAK)3ALEA(EAAAK)3 ALEA(EAAAK)3A" disclosed as SEQ ID NO: 57) (SEQ ID NO: 58) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGCTAA AGccCTGGAGgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGCTAAA GccCTGGAGgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAgc tATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCA GGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAG AGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCC AGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCAC CGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCT TCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTG CGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAA GATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAG ATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGG AAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTC GATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTA CTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAA AGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAG ACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGA GTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGG CACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGG AAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGA GAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGAT GAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTG ATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTC CGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTT TAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGC ACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTG AAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGT GATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGC GAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGA AAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTAC CTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTC CGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGA CAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCC TCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAA GCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGA GCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATC ACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAA TGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCG ATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACG CCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCT AAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGAT GATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACA GCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGG AAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGG GCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTG AAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAG GAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGC GGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAG GGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGA AAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAG AAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAA AACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAAC TGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGC TGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAG CACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCT GGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGC CCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGA GCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGC ACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGA GACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAAAGGCCGGCGGCCACGAAA AAGGCCGGCCAGGCAAAAAAGAAAAAGtaa 14. Sp_del_hel 2-A(EAAAK)3LE(EAAAK)3LE(EAAAK)3LE(EAAAK)3A helical domain 2 deletion (from ortholog alignment)("A(EAAAK)3LE(EAAAK)3LE (EAAAK)3LE(EAAAK)3A" disclosed as SEQ ID NO: 59) (SEQ ID NO: 60) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGCTAA AGccCTGGAGgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGCTAAA GccCTGGAGgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAG ccCTGGAGgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAgct ATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCA GGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAG AGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCC AGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCAC CGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCT TCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTG CGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAA GATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAG ATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGG AAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTC GATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTA CTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAA AGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAG ACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGA GTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGG

CACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGG AAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGA GAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGAT GAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTG ATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTC CGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTT TAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGC ACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTG AAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGT GATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGC GAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGA AAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTAC CTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTC CGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGA CAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCC TCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAA GCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGA GCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATC ACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAA TGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCG ATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACG CCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCT AAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGAT GATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACA GCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGG AAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGG GCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTG AAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAG GAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGC GGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAG GGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGA AAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAG AAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAA AACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAAC TGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGC TGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAG CACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCT GGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGC CCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGA GCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGC ACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGA GACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAAAGGCCGGCGGCCACGAAA AAGGCCGGCCAGGCAAAAAAGAAAAAGtaa 30. Sp_del (175-307)(from crystal data) (SEQ ID NO: 61) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGA TCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGG CAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTA CGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGC CCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAG GACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCA CCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAA GGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGG GCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGA AACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGA GCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTG CCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGT GAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAA AAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCT GAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCG TGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCA AGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTG CTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTA TGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCG GCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGC AAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAG CTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTC CGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCA TTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATG GGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCA CCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCAT CAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGC AGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGAC CAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCA GAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGA ACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAA CTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATC TGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAG AGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTC CCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGA TCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAG TGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTG GGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGA CTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCA AGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGA TTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAA ACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCT GAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCA GCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAG GACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTG CTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAG AGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGAC TTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCC TAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCG GCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTG TACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAA ACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCA GCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCG CCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCAC CTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACC ATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCA CCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCG ACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa 31. Sp_del (1098-end) (SEQ ID NO: 62) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGG TGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGAC

GCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGAT CGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGATTGCCCTGA GCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAA CTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGAT CGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCT GCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCT CTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTC GTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAA CGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCA TCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAAC AGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCA GATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATT CCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACT ACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGC GAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGC CCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGG TGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCA AAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAG AAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCA GCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCG GCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTA TCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATC GTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAAC CTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACA CCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCC GGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATG CAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGT GTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCG CCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTG ATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGA CCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGG CATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGC TGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTG GACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCC TCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACA AGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAA GAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACA ATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATC AAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGG ACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAA GTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTAC AAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGT CGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACG GCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATC GGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACC GAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGG CGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAG TGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCAAAAGGCCGGCGGCCACG AAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa 32. Sp_del (175-307)-(GGGGS)3 ("(GGGGS)3" disclosed as SEQ ID NO: 45) (SEQ ID NO: 63) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGGGTGGaGGTGGCtcgGGTGGaGGTGGCtcgGGTGGaGGTGGCtcgGT GAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACG AGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAG AAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGA CGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGA TGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAG CAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCA CGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAA AGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGG GAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGG AACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGAT GACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGC TGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAG GGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCT GCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCA AGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAAC GCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTG GACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTT TGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACG ACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAG CCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATT TCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGAC AGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAG CCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCC TGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCC GAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGA AGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAG CCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGT ACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATC AACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGAC GACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCG ACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTG CTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAG AGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAA CCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAG TACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAA GCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAA CTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCA AAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGAC GTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGT ACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACG GCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGT GTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAG TGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATC CTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTA AGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCA AAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGAT CACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCA AGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTG TTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAA GGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCA CTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGG AACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAG AGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCA CCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGA CCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGA GGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACC GGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAAAGGCCGGC GGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa 33. Sp_del (175-307)-(GGGGS)6 ("(GGGGS)6" disclosed as SEQ ID NO: 47) (SEQ ID NO: 64) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG

AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGGGTGGaGGTGGCtcgGGTGGaGGTGGCtcgGGTGGaGGTGGCtcgGG TGGaGGTGGCtcgGGTGGaGGTGGCtcgGGTGGaGGTGGCtcgGTGAACACCGAGATCACC AAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCT GACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTT TCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAG GAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGA ACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACA ACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGG CAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCT GACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGC CTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGG TGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAG AACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCAC CGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCG CCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAAC CGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTT CGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATA CCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACG AGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATG ATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCA GCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAAC GGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGG CTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGA GGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTG CCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTG GTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGA AATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGA ATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAAC ACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAG AATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTA CGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAA GGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAA GAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGAT TACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAAC TGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAG CACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGACAA GCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCG GAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACG ACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTG GAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGC CAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACA TCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGG CCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGA TTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGA CCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGC GATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGA CAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGT CCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGC AGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAA AAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCC GGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTG CCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGC TCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCT GGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACG CTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGA GAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCC GCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGA GGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGA TCGACCTGTCTCAGCTGGGAGGCGACAAAAGGCCGGCGGCCACGAAAAAGGCCGGC CAGGCAAAAAAGAAAAAGtaa 34. Sp_del (175-307)-(GGGGS)9 ("(GGGGS)9" disclosed as SEQ ID NO: 49) (SEQ ID NO: 65) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGGGTGGaGGTGGCtcgGGTGGaGGTGGCtcgGGTGGaGGTGGCtcgGG TGGaGGTGGCtcgGGTGGaGGTGGCtcgGGTGGaGGTGGCtcgGGTGGaGGTGGCtcgGGTG GaGGTGGCtcgGGTGGaGGTGGCtcgGTGAACACCGAGATCACCAAGGCCCCCCTGAGC GCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGC TCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCA AGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAG TTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCT GAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCC ACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTAC CCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCC CTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAA AGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCT TCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGA GAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCT GACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCG AGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTG AAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAAT CTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAA AATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAG ATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTG AAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAG ATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGC AGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAAC TTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGC CCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCA GCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTG AAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGA ACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGA AGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAAC ACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATAT GTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATA TCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGA AGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGA AGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAG TTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGG CTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGA TCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAA GTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAG TTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAA CGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCG TGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAG GAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTC AAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGAC AAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGC GGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACA GGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGC CAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGG CCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAG AGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAA

TCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCA TCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTG GCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGT GAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATA ATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATC GAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAA AGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGA ATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTT TGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCA CCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGC TGGGAGGCGACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAA AAAGtaa 35. Sp_del (175-307)-(GGGGS)12 ("(GGGGS)12" disclosed as SEQ ID NO: 51) (SEQ ID NO: 66) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGGGTGGaGGTGGttcgGGTGGCGGTGGCtcgGGTGGaGGTGGatcgGGT GGCGGTGGttcgGGTGGaGGTGGCtcgGGcGGaGGTGGatcgGGTGGCGGTGGCtcgGGTGGa GGTGGCtcgGGTGGaGGTGGCtcgGGTGGCGGTGGatcgGGTGGaGGTGGatcgGGTGGaGG TGGttcgGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGA TACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCT GCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCT ACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTG GAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCT GCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAG AGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACC GGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGG CCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCAC CCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCG AGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCAC AGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTG ACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGT GGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACT ACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGT TCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGAC TTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGAC ACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGT TCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAG GCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCC TGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACG ACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGC GATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGG CATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACA AGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGG ACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTG GGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGA AGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTG GACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTG AAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCA AGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGG CAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGC CGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGG TGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAAC ACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAA GTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGAT CAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCC TGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTG TACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCG CCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGG CCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGA GATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGC CCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAG TCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGA CCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGT GGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTG GGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGA AGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACT CCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTG CAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCC AGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTT TGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCT CCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAAC AAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTAC CCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCG GAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCA TCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAAAGG CCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa 36. Sp_del(175-307)-A(EAAAK)3A ("(EAAAK)3A" disclosed as SEQ ID NO: 53) (SEQ ID NO: 67) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGC TAAAgctGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAG ATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGC TGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGC TACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCT GGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTG CTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGG AGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAA CCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCT GGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATC ACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCAT CGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGC ACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATAC GTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCA TCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAG GACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGAT CGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAA GGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCC TGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCAC CTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGG CAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACA ATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATC CACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCA GGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGA AGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGG CACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGA AGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGA GCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACG AGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAA

CTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTT CTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGG GCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGG CGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAA GGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAG CTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGAT GAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCC TGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCG AGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACC GCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAA GGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCT ACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACC CTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGG GGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCA TGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAA GAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTG GGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGT GGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTG CTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCT GGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGT ACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAA CTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTG GCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCT GTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGT TCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACA ACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTT ACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGAC CGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAG CATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAAA GGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa 37. Sp_del(175 -307)-A(EAAAK)3ALEA(EAAAK)3A ("A(EAAAK)3 ALEA(EAAAK)3A" disclosed as SEQ ID NO: 55) (SEQ ID NO: 68) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGgctGAAGCCGCTGCTAAAGAAGCcGCTGCTAAAGAAGCcGCTGCT AAAGccCTGGAGgctGAAGCcGCTGCTAAAGAAGCcGCTGCTAAAGAAGCCGCTGCTA AAgctGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGAT ACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTG CCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTA CATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGG AAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTG CGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGA GCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCG GGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGC CAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACC CCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGA GCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACA GCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGA CCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTG GACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTA CTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTT CAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACT TCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACA CTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTT CGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGG CTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCT GGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGA CGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCG ATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGC ATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAA GCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGA CAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGG GCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAA GCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGG ACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGA AGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAA GAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGC AGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCC GAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGT GGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACA CTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAG TCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATC AACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCT GATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGT ACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGC CAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGC CAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAG ATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCC CCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGT CTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGAC CCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTG GCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGG GGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAA GCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTC CCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGC AGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCC AGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTT TGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCT CCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAAC AAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTAC CCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCG GAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCA TCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAAAGG CCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa 38. Sp_del(175-307)-A(EAAAK)3ALEA(EAAAK)3ALEA(EAAAK)3A ("A(EAAAK)3ALEA(EAAAK)3ALEA(EAAAK)3A" disclosed as SEQ ID NO: 57) (SEQ ID NO: 69) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGC TAAAGccCTGGAGgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGCT AAAGccCTGGAGgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGCTA AAgctGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGAT ACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTG CCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTA CATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGG AAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTG CGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGA GCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCG GGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGC CAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACC

CCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGA GCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACA GCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGA CCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTG GACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTA CTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTT CAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACT TCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACA CTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTT CGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGG CTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCT GGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGA CGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCG ATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGC ATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAA GCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGA CAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGG GCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAA GCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGG ACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGA AGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAA GAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGC AGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCC GAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGT GGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACA CTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAG TCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATC AACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCT GATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGT ACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGC CAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGC CAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAG ATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCC CCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGT CTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGAC CCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTG GCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGG GGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAA GCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTC CCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGC AGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCC AGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTT TGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCT CCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAAC AAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTAC CCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCG GAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCA TCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAAAGG CCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa 39. Sp_del(175-307)-A(EAAAK)3LE(EAAAK)3LE(EAAAK)3LE(EAAAK)3A ("A(EAAAK)3LE(EAAAK)3LE(EAAAK)3LE(EAAAK)3A" disclosed as SEQ ID NO: 59) (SEQ ID NO: 70) ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGC TAAAGccCTGGAGgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGCT AAAGccCTGGAGgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGCTA AAGccCTGGAGgctGAAGCTGCTGCTAAAGAAGCTGCTGCTAAAGAAGCTGCTGCTAA AgctGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATA CGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGC CTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTAC ATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGA AAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGC GGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAG CTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGG GAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCC AGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCC CCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAG CGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAG CCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGAC CGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTG GACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTA CTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTT CAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACT TCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACA CTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTT CGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGG CTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCT GGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGA CGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCG ATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGC ATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAA GCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGA CAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGG GCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAA GCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGG ACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGA AGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAA GAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGC AGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCC GAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGT GGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACA CTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAG TCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATC AACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCT GATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGT ACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGC CAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGC CAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAG ATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCC CCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGT CTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGAC CCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTG GCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGG GGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAA GCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTC CCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGC AGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCC AGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTT TGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCT CCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAAC AAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTAC CCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCG GAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCA TCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAAAGG CCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa

Example 3

New Nickases

[0146] FIGS. 2A-C pertain to new SpCas9 nickases and provide A. Schematic showing catalytic domains of SpCas9, and sites of mutagenesis for putative new nickases. RuvC domains I, II, and III are shown in orange, HNH domain in white between RuvCII and RuvCIII. Domain sizes not drawn to scale. B. Schematic showing locations of sgRNAs used for testing double nicking: when sgRNAs are transfected singly (A1 or C1 alone) with SpCas9 nickases, no indels should result. The combination of A1+Cl, used in combination with RuvCIII mutation nickases result in 5'-overhang, where as D1+A1 and C7+A1 would result in 3'-overhangs. Conversely, those three combinations used with HNH mutation nickases would result in 3'-, 5'-, and 5'-overhangs, respectively. C. Surveyor test showing 1 HNH mutant that retains nuclease activity (N854A), and 1 HNH mutant that shows nickase activity (N863A), as well as 2 RuvCIII mutants that show nickase activity (H983A, D986A).

[0147] In this Example, five potential nicking mutation sites were chosen based on sequence homology between Cas9 orthologs. And three additional sites were chosen based on herein crystallography data. A subset of these sets of nickase mutant Cas9s were re-cloned to incorporate both N' and C'-NLS sequences that are identical to those of optimized SpCas9. Sequences are below.

[0148] Nickase mutants were re-cloned to incorporated designated mutations into pAAV-vector under Cbh promoter and sequence validated.

[0149] Nuclease and double-nicking activities for all potential nickases were tested in HEK 293FT cells as follows: co-transfection of 400 ng of nickase and 100 ng of U6-driven sgRNA (100 ng for one guide, or 50 ng each for a pair of sgRNAs) by Lipofectamine 2000 into .about.200,000 cells. DNAs from transfected cells were collected for SURVEYOR analysis. Nickases do not result in indel mutations when co-transfected with a single sgRNA, but do when co-transfected with a pair of appropriately off-set sgRNAs. Based on data from the original D10A SpCas9 nickase, the pair of sgRNA chosen (A1/C1) for RuvC domain mutants have 0-bp offset and 5'-overhang for maximal cleavage.

TABLE-US-00004 Homology set: Mutant domain Functional? Cbh-hSpCas9(D10A)-NLS RuvCI nickase activity Cbh-hSpCas9(E762A)-NLS RuvCII Cbh-hSpCas9(H840A)-NLS HNH no activity Cbh-hSpCas9(N854A)-NLS HNH wt nuclease activity Cbh-hSpCas9(N863A)-NLS HNH nickase activity Cbh-hSpCas9(D986A)-NLS RuvCIII Crystal set set: Mutant domain Functional? NLS-S15A-NLS RuvCI wt nuclease activity NLS-E762A-NLS RuvCII catalytically dead NLS-H982A-NLS RuvCIII wt nuclease activity NLS-H983A-NLS RuvCIII nickase activity NLS-D986A-NLS RuvCIII nickase activity >NLS-S15A-NLS ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACgccGTGGGCTGGGCCGTGAT CACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACC GGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAACA GCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGA ACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGAC AGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACGA GCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACC CCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCTG CGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATC GAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGT GCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGACG CCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGATC GCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGATTGCCCTGAG CCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAAC TGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATC GGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTG CTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTC TATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCG TGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAAC GGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCAT CAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACA GAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAG ATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTC CTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTA CGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCG AGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCC CAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGT GCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAA AGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGA AAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAG CTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGG CGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTAT CAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCG TGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACC TATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACAC CGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCG GCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGC AGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTG TCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGC CATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGA TGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGAC CACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGC ATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCT GCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGG ACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTC AGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAG AACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGA ACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAAT CTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAA GAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACT CCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTG ATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAA GTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGT GGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCG ACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGC AAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAG ATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGA AACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGC TGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTC AGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAA GGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGT GCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAA GAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGA CTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGC CTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCC GGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCT GTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGA AACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATC AGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCC GCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCA CCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCAC CATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCC ACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGC GACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa (SEQ ID NO: 71) >NLS-E762A-NLS ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGG TGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGAC GCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGAT CGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGATTGCCCTGA GCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAA CTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGAT CGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCT GCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCT CTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTC GTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAA CGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCA TCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAAC AGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCA GATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATT CCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACT ACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGC GAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGC CCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGG TGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCA AAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAG AAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCA GCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCG GCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTA TCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATC GTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAAC CTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACA CCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCC GGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATG CAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGT GTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCG CCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTG ATGGGCCGGCACAAGCCCGAGAACATCGTGATCGccATGGCCAGAGAGAACCAGAC CACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGC ATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCT GCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGG ACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTC AGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAG AACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGA ACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAAT CTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAA GAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACT CCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTG ATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAA GTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGT GGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCG ACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGC AAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAG ATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGA AACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGC TGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTC AGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAA GGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGT GCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAA GAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGA CTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGC CTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCC GGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCT GTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGA AACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATC AGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCC GCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCA CCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCAC CATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCC ACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGC GACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa (SEQ ID NO: 72) >NLS-H982A-NLS ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGG TGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGAC GCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGAT CGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGATTGCCCTGA GCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAA CTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGAT CGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCT GCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCT CTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTC GTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAA CGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCA TCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAAC AGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCA GATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATT CCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACT ACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGC GAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGC CCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGG TGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCA AAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAG AAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCA GCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCG GCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTA TCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATC GTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAAC CTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACA CCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCC GGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATG CAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGT GTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCG CCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTG ATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGA CCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGG CATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGC TGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTG GACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCC TCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACA AGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAA GAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACA ATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATC AAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGG ACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAA GTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTAC AAAGTGCGCGAGATCAACAACTACgccCACGCCCACGACGCCTACCTGAACGCCGTC GTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGG CGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCG GCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCG AGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGC GAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGT GCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCT TCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAG AAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTC TGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGA AAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATC GACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCT GCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTG

CCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTC CTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCA GAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGA TCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGT CCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATC CACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACC ACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGAT CCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAG GCGACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa (SEQ ID NO: 73) >NLS-H983A-NLS ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGG TGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGAC GCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGAT CGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGATTGCCCTGA GCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAA CTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGAT CGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCT GCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCT CTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTC GTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAA CGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCA TCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAAC AGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCA GATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATT CCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACT ACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGC GAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGC CCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGG TGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCA AAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAG AAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCA GCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCG GCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTA TCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATC GTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAAC CTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACA CCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCC GGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATG CAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGT GTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCG CCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTG ATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGA CCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGG CATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGC TGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTG GACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCC TCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACA AGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAA GAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACA ATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATC AAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGG ACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAA GTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTAC AAAGTGCGCGAGATCAACAACTACCACgccGCCCACGACGCCTACCTGAACGCCGTC GTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGG CGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCG GCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCG AGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGC GAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGT GCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCT TCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAG AAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTC TGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGA AAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATC GACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCT GCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTG CCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTC CTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCA GAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGA TCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGT CCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATC CACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACC ACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGAT CCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAG GCGACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGtaa (SEQ ID NO: 74) >NLS-D986A-NLS ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGA CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGA TCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAAC AGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAG AACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGA CAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACG AGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTAC CCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCT GCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGAT CGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGG TGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGAC GCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGAT CGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGATTGCCCTGA GCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAA CTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGAT CGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCT GCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCT CTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTC GTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAA CGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCA TCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAAC AGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCA GATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATT CCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACT ACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGC GAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGC CCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGG TGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCA AAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAG AAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCA GCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCG GCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTA TCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATC GTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAAC CTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACA CCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCC GGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATG CAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGT GTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCG CCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTG ATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGA CCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGG CATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGC TGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTG GACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCC TCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACA AGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAA GAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACA ATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATC AAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGG ACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAA GTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTAC AAAGTGCGCGAGATCAACAACTACCACCACGCCCACGcCGCCTACCTGAACGCCGTC GTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGG CGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCG GCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCG AGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGC GAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGT GCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCT TCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAG AAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTC TGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGA AAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATC GACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCT GCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTG CCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTC CTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCA GAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGA TCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGT CCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATC CACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACC ACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGAT CCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAG GCGACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAG (SEQ ID NO: 75)

Example 4

Truncating and Creating Chimeric Cas9s Based on S. pyogenes Cas9 Crystral Structure Herein

[0150] FIGS. 5A-C pertain to truncating and creating chimeric Cas9s based on the herein crystal structure. These figures provide schematics illustrating A. SpCas9 mutants designed for mapping out essential functional domains of Cas9 for truncation of protein. B. chimeric Cas9s that contain sequences (regions in pink) from Cas9 from S. thermophilus CRISPR 1, S. thermophilus CRISPR 3, Staphylococcus aureus, Neisseria meningiditis, or other Cas9 orthologs. C. Designs for creating chemically inducible dimerization of SpCas9. The chemically inducible SpCas9 functions.

[0151] DNA sequences for chimeric Cas9s are optimized for human expression by GenScript and synthesized de novo. Chimeric Cas9 proteins can be constructed by cloning and ligating individual functional domains from Cas9 orthologs (i.e. by PCR-amplifying individual functional domains from a desired Cas9 ortholog, then assemblying the pieces together by either Gibson or Golden Gate-cloning). Additionallly, a set of chemically-inducible Cas9s were constructed as two-component systems, where one portion of the Cas9 protein is fused to FKBP, and the remainder fused to FRB (e.g. FKBP-Cas9(amino acids 1-1098), FRB-Cas(1099-1368)). In absence of chemical induction, co-transfection of the two inducible Cas9 components have no catalytic activity, but the functional assembly of the components may be induced using Rapamycin [5 nM to 10 .mu.M].

Example 5

Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA

[0152] Cas9 is an RNA-guided nuclease from the microbial CRISPR-Cas system that can be targeted to specific genomic loci by single guide RNAs (sgRNAs). Applicants report the crystal structure of Streptococcus pyogenes Cas9 in complex with sgRNA and its target DNA at 2.4 .ANG. resolution. The structure revealed a bilobed architecture composed of target recognition and nuclease lobes, accommodating a sgRNA:DNA duplex in a positively-charged groove at their interface. Whereas the recognition lobe is essential for sgRNA and DNA binding, the nuclease lobe contains the HNH and RuvC nuclease domains, which are properly positioned for the cleavage of complementary and non-complementary strands of the target DNA, respectively. This high-resolution structure and accompanying functional analyses elucidate the molecular mechanism of RNA-guided DNA targeting by Cas9, paving the way for rational design of new and versatile genome-editing technologies.

[0153] The CRISPR (clustered regularly interspaced palindromic repeat)-Cas system is a naturally occurring microbial adaptive immune system for defense against invading phages and other mobile genetic elements (Deveau et al., 2010; Horvath and Barrangou, 2010; Marraffini and Sontheimer, 2010; Terns and Terns, 2011). Three types (I-III) of CRISPR-Cas systems have been functionally identified across a wide range of microbial species (Barrangou et al., 2007; Brouns et al., 2008; Marraffini and Sontheimer, 2008), each containing a cluster of CRISPR-associated (Cas) genes and its corresponding CRISPR array. These characteristic CRISPR arrays consist of repetitive sequences (direct repeats, referred to as repeats) interspaced by short stretches of non-repetitive sequences (spacers) derived from short segments of foreign genetic material (protospacers). The CRISPR array is transcribed and processed into short CRISPR RNAs (crRNAs), which direct Cas proteins to the target nucleic acids, DNA or RNA, via Watson-Crick base pairing to facilitate the nucleic acid destruction.

[0154] Type I and III CRISPR systems utilize ensembles of Cas proteins in complex with crRNA to mediate recognition and subsequent degradation of target nucleic acids (Spilman et al., 2013; Wiedenheft et al., 2011). In contrast, the Type II CRISPR system achieves recognition and cleavage of the target DNA (Garneau et al., 2010) via a single enzyme called Cas9 (Sapranauskas et al., 2011) along with two non-coding RNAs, the crRNA and a trans-activating crRNA (tracrRNA) (Deltcheva et al., 2011). The crRNA hybridizes with the tracrRNA to form a crRNA:tracrRNA duplex, which is then loaded onto Cas9 to direct cleavage of cognate DNA sequences bearing appropriate protospacer adjacent motifs (PAM) (Mojica et al., 2009).

[0155] The Type II CRISPR system was the first to be adapted for facilitating genome editing in eukaryotic cells (Cong et al., 2013; Mali et al., 2013b). The Cas9 protein from Streptococcus pyogenes, along with a single guide RNA (sgRNA), a synthetic fusion of crRNA and minimal tracrRNA (Jinek et al., 2012), could be programmed to instruct cleavage of virtually any sequence preceding a 5'-NGG PAM sequence in mammalian cells (Cong et al., 2013; Mali et al., 2013b). This unprecedented flexibility has enabled a broad range of applications including rapid generation of genetically modified cells and animal models (Gratz et al., 2013; Hwang et al., 2013; Wang et al., 2013; Yang et al., 2013), and genome-scale genetic screening (Qi et al., 2013; Shalem et al., 2014; Wang et al., 2014).

[0156] However, despite brisk progress in the development of the Cas9 technology, the mechanism of how the Cas9-sgRNA complex recognizes and cleaves its target DNA remains to be elucidated. Up to date, biochemical analyses at the domain levels have enabled site-specific engineering to convert the native Cas9 into a DNA nicking enzyme (Gasiunas et al., 2012; Jinek et al., 2012; Sapranauskas et al., 2011) that facilitates homology-directed repair in eukaryotic cells (Cong et al., 2013; Mali et al., 2013b) and further cleaves DNA with improved specificity given appropriately paired sgRNAs (Mali et al., 2013a; Ran et al., 2013). Moreover, a catalytically inactive Cas9 can serve as a RNA-guided DNA-binding platform to target effector domains and modulate endogenous transcription (Gilbert et al., 2013; Konermann et al., 2013; Maeder et al., 2013; Perez-Pinera et al., 2013; Qi et al., 2013). These Cas9 engineering advances represent just the first steps of what is possible in fully realizing the potential of this flexible RNA-guided genome positioning system. A precise structural information on Cas9 will thus not only enhance the understanding of how this elegant RNA-guided microbial adaptive immune system functions, but also inform further improvements of Cas9 targeting specificity, simplification of in vitro and in vivo delivery, and engineering of Cas9 for novel functions and optimized features.

[0157] In this example, Applicants report the crystal structure of S. pyogenes Cas9 in complex with sgRNA and its target DNA at 2.4 .ANG. resolution. This high-resolution structure along with functional analysis reveals the key functional interactions that integrate the guide RNA, target DNA, and Cas9 protein, paving the way towards enhancing Cas9 function as well as engineering novel applications.

[0158] Overall structure of the Cas9-sgRNA-DNA ternary complex: Applicants solved the crystal structure of full-length S. pyogenes Cas9 (residues 1-1368; D10A/C80L/C574E/H840A) in complex with a 98-nucleotide (nt) sgRNA and a 23-nt target DNA, at 2.4 .ANG. resolution, by the SAD (single-wavelength anomalous dispersion) method using a SeMet-labeled protein (FIG. 15 and Table 1). To improve the solution behavior of Cas9, Applicants replaced two less conserved cysteine residues (Cys80 and Cys574) with leucine and glutamic acid, respectively. This C80L/C574E mutant retained the ability to efficiently cleave genomic DNA in human embryonic kidney 293FT (HEK293FT) cells, confirming that these mutations have no effects on Cas9 nuclease function (FIG. 16). Additionally, to prevent cleavage of the target DNA during crystallization, Applicants replaced the two catalytic residues, Asp10 from the RuvC domain and His840 from the HNH domain, with alanine.

TABLE-US-00005 TABLE 1 Data collection and refinement statistics Native Cas9 SeMet Cas9 Data collection Beamline SPring-8 BL32XU SPring-8 BL41XU Wavelength (.ANG.) 1.000 0.9791 Space group P1 P1 Cell dimensions a, b, c (.ANG.) 76.7, 105.7, 126.8 76.2, 104.5, 125.5 .alpha., .beta., .gamma. (.degree.) 97.7, 98.4, 100.3 97.0, 98.2, 101.1 Resolution (.ANG.) 50-2.4 (2.54-2.4) 50-2.6 (2.67-2.6) R.sub.sym 0.07 (1.53) 0.167 (1.96) I/.sigma.I 22.53 (1.45) 12.62 (1.44) Completeness (%) 98.2 (96.3) 99.9 (99.9) Redundancy 7.93 (7.88) 19.1 (15.9) CC(1/2) 0.999 (0.671) 0.999 (0.736) Refinement Resolution (.ANG.) 50-2.4 No. reflections 146,862 R.sub.work/R.sub.free 0.241/0.276 No. atoms Protein 19,021 Nucleic acid 5,013 Solvent 200 B-factors Protein 72.6 Nucleic acid 72.6 Solvent 53.3 R.m.s deviations Bond lengths (.ANG.) 0.002 Bond angles (.degree.) 0.454 Ramachandran plot Favored region 96.8% Allowed region 3.2% Outlier region 0.0% *Highest resolution shell is shown in parenthesis.

[0159] The crystallographic asymmetric unit contained two Cas9-sgRNA-DNA ternary complexes (Mol A and Mol B). Although there are conformational differences between the two complexes, sgRNA and DNA are recognized by Cas9 in a similar manner. Most notably, while the HNH domain in Mol A is connected with the RuvC domain by a disordered linker, the HNH domain in Mol B is not visible in the electron density map, indicating the flexible nature of the HNH domain. Thus, Applicants first describe the structural features of Mol A unless otherwise stated, and then discuss the structural differences between the two complexes, which suggest the conformational flexibility of Cas9.

[0160] The crystal structure revealed that Cas9 consists of two lobes, a recognition (REC) lobe and a nuclease (NUC) lobe (FIG. 8A-C). The REC lobe can be divided into three regions, a long .alpha.-helix referred to as Bridge helix (BH) (residues 60-93), the REC1 (residues 94-179 and 308-713), and REC2 (residues 180-307) domains (FIG. 8A-C). The NUC lobe consists of the RuvC (residues 1-59,718-769, and 909-1098), HNH (residues 775-908), and PAM-interacting (PI) (residues 1099-1368) domains (FIG. 8A-C). The negatively-charged sgRNA:DNA hybrid duplex is accommodated in a positively-charged groove at the interface between the REC and NUC lobes (FIG. 8D). In the NUC lobe, the RuvC domain is assembled from the three split RuvC motifs (RuvC I-III), which interfaces with the PI domain to form a positively-charged surface that interacts with the 3' tail of the sgRNA (FIG. 8D). The HNH domain lies in between the RuvC II-III motifs and forms only a few contacts with the rest of the protein.

[0161] The REC lobe of Cas9 interacted with the repeat:anti-repeat duplex: The REC lobe comprises the REC1 and REC2 domains. REC1 adopted an elongated, .alpha.-helical structure comprising 26 .alpha.-helices (.alpha.2-.alpha.5 and .alpha.12-.alpha.33) and two .beta.-sheets (.beta.6/.beta.10 and .beta.7-.beta.9), whereas REC2 adopted a six-helix bundle structure (.alpha.6-.alpha.11) (FIGS. 9A and 17). A Dali search (Holm and Rosenstrom, 2010) revealed that the REC lobe did not share structural similarity with other known proteins, indicating that it is a Cas9-specific functional domain.

[0162] The REC lobe is one of the least conserved regions across the three families of Cas9 within the Type II CRISPR system (IIA, IIB and IIC) and many Cas9s contain significantly shorter REC lobes (FIGS. 18, 19). Applicants hypothesized that truncations in the REC lobe could be tolerated. As expected, and consistent with the observation that the REC2 domain does not contact the bound sgRNA:DNA hybrid duplex, a Cas9 mutant lacking the REC2 domain (4175-307) showed .about.50% of the wild-type Cas9 activity (FIG. 9B), indicating that the REC2 domain is not critical for DNA cleavage. The lower cleavage efficiency may be attributed in part to the reduced levels of Cas9 (4175-307) expression relative to that of the wild-type protein (FIG. 9C). In striking contrast, deletion of the crRNA repeat-interacting region (497-150) or tracrRNA anti-repeat-interacting region (4312-409) of the REC1 domain abolished DNA cleavage activity (FIG. 9B), indicating that the recognition of the repeat:anti-repeat duplex by the REC1 domain is critical for Cas9 function.

[0163] The PAM-interacting (PI) domain confers PAM specificity: The NUC lobe contains the PI domain, which adopts an elongated structure comprising seven .alpha.-helices (.alpha.47-.alpha.53), a three-stranded antiparallel .beta.-sheet (.beta.18-.beta.20), a five-stranded antiparallel .beta.-sheet (.beta.21-.beta.23, .beta.26 and .beta.27), and two-stranded antiparallel .beta.-sheet (.beta.24 and .beta.25) (FIGS. 9D and 17). Similar to the REC lobe, the PI domain also represents a novel protein fold unique to the Cas9 family.

[0164] The locations of the bound complementary strand DNA and the active site of the RuvC domain in the present structure suggest that the PI domain is positioned to recognize the PAM sequence on the non-complementary strand of the target DNA. Applicants tested whether replacement of the S. pyogenes Cas9 (SpCas9; Cas9 in this study) PI domain with that of an orthologous Cas9 protein recognizing a different PAM would be sufficient to alter SpCas9 PAM specificity. The Streptococcus thermophilus CRISPR-3 Cas9 (St3Cas9) shares .about.60% sequence identity with SpCas9; furthermore, their crRNA repeats and tracrRNAs are interchangeable (Fonfara et al., 2013). However, SpCas9 and St3Cas9 require different PAM sequences (5'-NGG for Cas9 and 5'-NGGNG for St3Cas9) for target DNA cleavage (Fonfara et al., 2013).

[0165] Applicants swapped the two PI domains to generate two chimeras, Sp-St3Cas9 (SpCas9 with the PI domain of St3Cas9) and St3-SpCas9 (St3Cas9 with the PI domain of SpCas9), and examined their cleavage activities for target DNA sequences bearing 5'-NGG PAM (5'-GGGCT) or 5'-NGGNG PAM (5'-GGGCG) (FIG. 9E). SpCas9 and St3-SpCas9, but not St3Cas9, cleaved the target DNA with 5'-NGG PAM (FIG. 9E), indicating that the PI domain of SpCas9 is required for the recognition of 5'-NGG PAM and is sufficient to alter the PAM recognition of St3Cas9. Sp-St3Cas9 retained cleavage activity for the target DNA with 5'-NGG PAM, albeit at a lower level than that of SpCas9 (FIG. 9E). Additionally, deletion of the PI domain (.DELTA.1099-1368) abolished the cleavage activity (FIG. 9E), indicating that the PI domain is critical for Cas9 function. These results reveal that the PI domain is a major determinant of PAM specificity.

[0166] The RuvC domain targets the non-complementary strand DNA: The RuvC domain consists of a six-stranded mixed .beta.-sheet (.beta.1, .beta.2, .beta.5, .beta.11, .beta.14 and .beta.17) flanked by .alpha.-helices (.alpha.34, .alpha.35 and .alpha.40-.alpha.46) and two additional two-stranded antiparallel .beta.-sheets (.beta.3/.beta.4 and .beta.15/.beta.16) (FIGS. 10A and 17). It shares structural similarity with retroviral integrase superfamily members characterized by an RNase H fold, such as Escherichia coli RuvC (PDB code 1HJR, 13% identity, root-mean-square deviation (rmsd) of 3.4 .ANG. for 123 equivalent C.alpha. atoms) (Ariyoshi et al., 1994) and Thermus thermophilus RuvC (PDB code 4LD0, 17% identity, rmsd of 3.4 .ANG. for 129 equivalent C.alpha. atoms) (Ariyoshi et al., 1994) and Thermus thermophilus RuvC (PDB code 4LD0, 17% identity, rmsd of 3.4 .ANG. for 129 equivalent C.alpha. atoms) (Gorecka et al., 2013) (FIG. 10B). RuvC nucleases have four catalytic residues (e.g., Asp7, Glu70, His143 and Asp146 in T. thermophilus RuvC), and cleave Holliday junctions through a two-metal mechanism (Ariyoshi et al., 1994; Chen et al., 2013; Gorecka et al., 2013). Asp10 (Ala), Glu762, His983 and Asp986 of the Cas9 RuvC domain are located at positions similar to those of the catalytic residues of T. thermophilus RuvC (FIG. 10A, B), consistent with the previous results that the D10A mutation abolished cleavage of the non-complementary DNA strand and that Cas9 requires Mg2+ ions for cleavage activity (Gasiunas et al., 2012; Jinek et al., 2012). Moreover, alanine substitution of Glu762, His983 or Asp986 also converted Cas9 into nickases (FIG. 10C, D). Each nickase mutant was able to facilitate targeted double strand breaks using pairs of juxtaposed sgRNAs (FIG. 10C, D), as demonstrated with the D10A nickase previously (Ran et al., 2013). This combination of structural observations and mutational analysis suggest that the Cas9 RuvC domain cleaves the non-complementary strand of the target DNA through the two-metal mechanism previously observed for other retroviral integrase superfamily nucleases.

[0167] It is important to note that there are key structural dissimilarities between the Cas9 RuvC domain and RuvC nucleases, explaining their functional differences. Unlike the Cas9 RuvC domain, RuvC nucleases forms a dimer and recognize a Holliday junction (Gorecka et al., 2013) (FIG. 10B). In addition to the conserved RNase H fold, the RuvC domain of Cas9 has additional structural elements involved in the interactions with the guide:DNA duplex (an end-capping loop between .alpha.43 and .alpha.44), and the PI domain/stem loop 3 (.beta.-hairpin formed by .beta.3 and .beta.4) (FIG. 10A).

[0168] The HNH domain targets the complementary strand DNA: The HNH domain comprises a two-stranded antiparallel .beta.-sheet (.beta.12 and .beta.13) flanked by four .alpha.-helices (.alpha.36-.alpha.42) (FIG. 10E). Likewise, it shares structural similarity with HNH endonucleases characterized by a .beta..beta..alpha.-metal fold, such as the phage T4 endonuclease VII (Endo VII) (Biertumpfel et al., 2007) (PDB code 2QNC, 8% identity, rmsd of 2.6 .ANG. for 60 equivalent C.alpha. atoms) (FIG. 10F) and Vibrio vulnificus nuclease (Li et al., 2003) (PDB code 1OUP, 8% identity, rmsd of 2.9 .ANG. for 78 equivalent C.alpha. atoms). HNH nucleases have three catalytic residues (e.g., Asp40, His41, and Asn62 in Endo VII), and cleave nucleic acid substrates through a single-metal mechanism (Biertumpfel et al., 2007; Li et al., 2003). In the structure of the Endo VII N62D mutant in complex with a Holliday junction, a Mg2+ ion is coordinated by Asp40, Asp62, and oxygen atoms of the scissile phosphate group of the substrate, while His41 acts as a general base to activate a water molecule for catalysis (FIG. 10F). Asp839, His840, and Asn863 of the Cas9 HNH domain correspond to Asp40, His41, and Asn62 of Endo VII, respectively (FIG. 10E), consistent with the observation that His840 is critical for the cleavage of the complementary DNA strand (Gasiunas et al., 2012; Jinek et al., 2012). The N863A mutant functions as a nickase (FIG. 10C, D), indicating that Asn863 participates in catalysis. These observations suggest that the Cas9 HNH domain may cleave the complementary strand of the target DNA through a single-metal mechanism as observed for other HNH superfamily nucleases. However, in the present structure, Asn863 of Cas9 is located at a position different from that of Asn62 in Endo VII (Biertumpfel et al., 2007), whereas Asp839 and His840 (Ala) of Cas9 are located at positions similar to those of Asp40 and His41 of Endo VII, respectively (FIG. 10E, F). This might be due to the absence of divalent ions, such as Mg2+, in Applicants' crystallization solution, suggesting that Asn863 can point towards the active site and participate in catalysis. Whereas the HNH domain shares a .beta..beta..alpha.-metal fold with other HNN endonuclease, their overall structures are different (FIG. 10E, F), consistent with the differences in their substrate specificities.

[0169] sgRNA recognizes target DNA via Watson-Crick base pairing: The sgRNA consists of crRNA- and tracrRNA-derived sequences connected by an artificial tetraloop (FIG. 11A). The crRNA sequence can be subdivided into guide (20-nt) and repeat (12-nt) regions, and the tracrRNA sequence likewise into anti-repeat (14-nt) and three tracrRNA stem loops (FIG. 11A). The crystal structure reveals that the sgRNA binds the target DNA to form a T-shaped architecture comprising a guide:DNA duplex, repeat:anti-repeat duplex and stem loops 1-3 (FIG. 11A, B). The repeat:anti-repeat duplex and stem loop 1 are connected by a single nucleotide (A51), and stem loops 1 and 2 are connected by a 5-nt single-stranded linker (nucleotides 63-67).

[0170] The guide (nucleotides 1-20) and target DNA (nucleotides 3'-23') form the guide:DNA hybrid duplex via 20 Watson-Crick base pairs, with the conformation of the duplex distorted from a canonical A-form RNA duplex (FIGS. 11B and 20). The crRNA repeat (nucleotides 21-32) and tracrRNA anti-repeat (nucleotides 37-50) form the repeat:anti-repeat duplex via nine Watson-Crick base pairs (U22:A49-A26:U45 and G29:C40-A32:U37) (FIG. 11A, B). Within this region, G27, A28, A41, A42, G43, and U44 are unpaired, with A28 and U44 flipped out from the duplex (FIG. 11C). The nucleobases of G27 and A41 stack with the A26:U45 and G29:C40 pairs, respectively, and the 2-amino group of G27 interacts with the backbone phosphate group between G43 and U44, stabilizing the duplex structure (FIG. 11C). G21 and U50 form a wobble base pair at the three-way junction between the guide:DNA/repeat:anti-repeat duplexes and stem loop 1, stabilizing the T-shaped architecture (FIG. 11C).

[0171] As expected from the RNA-fold predictions of the nucleotide sequence, the tracrRNA 3' tail (nucleotides 68-81 and 82-96) form stem loops 2 and 3 via four and six Watson-Crick base pairs (A69:U80-U72:A77 and G82:C96-G87:C91), respectively (FIG. 11A, B). Previously unappreciated, nucleotides 52-62 also form a stem loop (stem loop 1) via three Watson-Crick base pairs (G53:C61, G54:C60 and C55:G58), with U59 flipped out from the stem (FIG. 11A, B). Stem loop 1 is stabilized by the G62-G53:C61 stacking interaction and the G62-A51/A52 polar interactions (FIG. 11C).

[0172] The guide:DNA and repeat:anti-repeat duplexes are accommodated and deeply buried in a positively-charged groove at the interface of the two lobes, while the rest of the sgRNA extensively interacts with the positively-charged surface on the back side of the protein (FIG. 8D). In Mol A, the 3'-terminal bases of the target DNA (3'-ACC complementary to the PAM) are not visible in the electron density map. In contrast, the two adjacent bases (3'-AC) in Mol B are not recognized by Cas9, although they are structurally ordered due to the crystal packing interactions and are visible in the electron density map. These observations suggest that the 3'-ACC sequence complementary to the PAM (5'-TGG) is not recognized by Cas9, consistent with the previous biochemical data demonstrating that Cas9-catalyzed DNA cleavage requires the 5'-NGG PAM on the non-complementary strand, but not the 3'-NCC sequence on the complementary strand (Jinek et al., 2012).

[0173] Previous studies showed that although sgRNA with a 48-nt tracrRNA tail (referred to as sgRNA(+48)) is a minimal region for the Cas9-catalyzed DNA cleavage in vitro (Jinek et al., 2012), sgRNAs with extended tracrRNA tails, sgRNA(+67) and sgRNA(+85), dramatically improved Cas9 cleavage activity in vivo (Hsu et al., 2013). The present structure revealed that sgRNA(+48), sgRNA(+67) and sgRNA(+85) contain stem loop 1, stem loops 1-2 and stem loops 1-3, respectively (FIG. 11A, B). These observations indicated that, whereas stem loop 1 is essential for the formation of the functional Cas9-sgRNA complex, stem loops 2 and 3 further support the stable complex formation as well as enhance sgRNA stability, thus improving the in vivo activity.

[0174] To confirm the significance of each sgRNA structural component on Cas9 function, Applicants tested a number of sgRNAs with mutations in the repeat:anti-repeat duplex, stem loops 1-3, and the linker between stem loops 1 and 2. Applicants' results revealed that, whereas stem loops 2 and 3 as well as the linker region can tolerate a large number of mutations, the repeat:anti-repeat duplex and stem loop 1 are critical for Cas9 function (FIG. 11D). Moreover, the sgRNA sequence can tolerate a large number of mutations (FIG. 11D, reconstructed sgRNA). These results highlight the functional significance of the structure-dependent recognition of the repeat:anti-repeat duplex by Cas9.

[0175] Conserved arginine cluster on Bridge helix play a critical role in sgRNA:DNA interaction: The crRNA guide region is primarily recognized by the REC lobe (FIG. 12A). The backbone phosphate groups of the crRNA guide region (nucleotides 4-6 and 13-20) interact with the REC1 domain (Arg165, Gly166, Arg403, Asn407, Lys510, Tyr515 and Arg661) and Bridge helix (Ala59, Arg63, Arg66, Arg70, Arg71, Arg74 and Arg78) (FIG. 12B), and the 2'-hydroxyl groups of C15, U16 and G19 hydrogen bond with Tyr450, Arg447/Ile448 and Thr404 in the REC1 domain (FIG. 12B), respectively. These observations suggested that the Watson-Crick faces of eight PAM-proximal nucleotides of the Cas9-bound sgRNA are exposed to the solvent, thus serving as a nucleation site for pairing with the target complementary strand. This is consistent with previous reports that the 10-12 bp PAM-proximal "seed" region is critical for Cas9-catalyzed DNA cleavage (Cong et al., 2013; Fu et al., 2013; Hsu et al., 2013; Jinek et al., 2012; Mali et al., 2013a; Pattanayak et al., 2013).

[0176] Mutational analysis demonstrated that the R66A, R70A and R74A mutations on Bridge helix markedly reduced DNA cleavage activities (FIG. 12C), highlighting the functional significance of the recognition of the sgRNA "seed" region by the Bridge helix. Although Arg78 and Arg165 also interact with the "seed" region, the R78A and R165A mutants showed only moderately decreased activities (FIG. 12C). These results may reflect that, whereas Arg66, Arg70 and Arg74 form bifurcated salt bridges with the sgRNA backbone, Arg78 and Arg165 form a single salt bridge with the sgRNA backbone. A cluster of arginine residues on the Bridge helix are highly conserved among Cas9 proteins in the Type II-A-C systems (FIGS. 18, 19), suggesting that the Bridge helix is a universal structural feature of Cas9 proteins involved in recognition of the sgRNA and target DNA. This notion is supported by a previous observation that a strictly conserved arginine residue, equivalent to Arg70 of S. pyogenes Cas9, is essential for the function of Francisella novicida Cas9 in the Type II-B system (Sampson et al., 2013). Moreover, the alanine mutation of the repeat:anti-repeat duplex-interacting residues (Arg75 and Lys163) and stem loop 1-interacting residue (Arg69) resulted in decreased DNA cleavage activity (FIG. 12C), confirming the functional importance of the recognition of the repeat:anti-repeat duplex and stem loop 1 by Cas9.

[0177] The crRNA guide region is recognized by Cas9 in a sequence-independent manner except for the U16-Arg447 and G18-Arg71 interactions (FIG. 12A, B). This base-specific G18-Arg71 interaction may partly explain the observed preference of Cas9 for sgRNAs having guanines in the four PAM-proximal guide sequences (Wang et al., 2014).

[0178] The REC1 and RuvC domains facilitate RNA-guided DNA targeting: Cas9 recognizes the 20-bp DNA target site in a sequence-independent manner (FIG. 12A). The backbone phosphate groups of the target DNA (nucleotides 1', 9'-11', 13', and 20') interact with the REC1 (Asn497, Trp659, Arg661 and Gln695), RuvC (Gln926), and PI (Glu1108) domains. The C2' atoms of the target DNA (nucleotides 5', 7', 8', 11', 19', and 20') form van der Waals interactions with the REC1 domain (Leu169, Tyr450, Met495, Met694 and His698) and RuvC domain (Ala728) (FIG. 12D). These interactions are likely to contribute towards discriminating between DNA vs. RNA targets by Cas9. The terminal base pair of the guide:DNA duplex (G1:C20') is recognized by the RuvC domain via end-capping interactions (FIG. 12D); the nucleobases of sgRNA G1 and target DNA C20' interact with the side chains of Tyr1013 and Val1015, respectively, whereas the 2'-hydroxyl and phosphate groups of sgRNA G1 interact with Val1009 and Gln926, respectively. These end-capping interactions are consistent with the previous observation that Cas9 recognizes a 17-20-bp guide:DNA duplex, and that extended guide sequences are degraded in cells and do not contribute to improving sequence specificity (Mali et al., 2013a; Ran et al., 2013). Taken together, these structural findings explain the RNA-guided DNA targeting mechanism of Cas9.

[0179] The repeat:anti-repeat duplex is recognized by the REC and NUC lobes in a sequence-dependent manner: The repeat:anti-repeat duplex is extensively recognized by the REC and NUC lobes (FIG. 12A). The backbone phosphate groups of the crRNA repeat (nucleotides 24, 26, and 27) and anti-repeat (nucleotides 41, 45, 46, and 48-50) interact with the REC1 domain (Arg115, His116, His160, Lys163, Arg340, and Arg403), PI domain (Lys1113), and Bridge helix (Lys76) (FIG. 12E, F). The 2'-hydroxyl groups of the crRNA repeat (nucleotides 22-24) and anti-repeat (nucleotides 43-45 and 47) hydrogen bond with the REC1 domain (Leu101, Ser104, Phe105, Ile135, Tyr359, and Gln402) and the PI domain (Ile1110 and Tyr1131).

[0180] In contrast to the sequence-independent recognition of the guide region, there are sequence-dependent interactions between Cas9 and the repeat:anti-repeat duplex. The nucleobase of the flipped U44 is sandwiched between the side chains of Tyr325 and His328, with its N3 atom hydrogen bonded with the carbonyl group of Tyr325, while that of unpaired G43 stacks with the side chain of Tyr359 and hydrogen bonds with the side chain of Asp364 (FIG. 12A, F). Finally, the nucleobases of U23/A49 and A42/G43 hydrogen bond with the side chain of Arg1122 and the main-chain carbonyl group of Phe351, respectively.

[0181] In the present structure, the repeat:anti-repeat duplex is recognized primarily by the REC lobe, which is divergent in sequence and length among Cas9 orthologs within the Type II-A-C systems (FIGS. 18, 19), consistent with the previous observation that Cas9 and sgRNA are interchangeable only between closely related Type II systems (Fonfara et al., 2013). The three PAM-distal base pairs (C30:G39-A32:U37) are not recognized by Cas9 and protrude from the complex (FIG. 12A), consistent with a proposed model in which a Cas9-bound repeat:anti-repeat duplex is processed by the host RNase III enzyme (Deltcheva et al., 2011).

[0182] The nucleobases of G21 and U50 in the G21:U50 wobble pair stack with the terminal C20:G1' pair in the guide:DNA duplex and the side chain of Tyr72 on Bridge helix, respectively, with the U50 04 atom hydrogen bonded with the side chain of Arg75 (FIG. 12E). Notably, A51 adopts the syn-conformation, and is oriented in the direction opposite to U50 (FIGS. 11C and 12G). The nucleobase of A51 is sandwiched between the Phe1105 side chain in the PI domain and the U63 nucleobase in the linker, with its N7 and N1 atoms hydrogen bonded with the main-chain amide group of Phe1105 and the G62 2'-hydroxyl group in stem loop 1, respectively (FIG. 12G). Whereas a repeat:anti-repeat duplex is diverse in sequence and length among the Type II-A-C systems, the G21:U50 base pair is highly conserved among Cas9s (Fonfara et al., 2013), suggesting that this wobble pairing is a universal structural feature involved in the three-way junction formation.

[0183] To verify the sequence-dependent recognition of the repeat:anti-repeat duplex, Applicants evaluated the effect of repeat:anti-repeat mutations on Cas9-meditated DNA cleavage, and found multiple mutations that significantly reduce Cas9 activity (FIG. 12C). Notably, replacement of G43, which forms a base-specific hydrogen bond with Asp364, with adenine reduced Cas9 activity by over 3-fold. In addition, replacement of the flipped U44 in the repeat:anti-repeat duplex with adenine resulted in over a 5-fold drop in cleavage activity, whereas replacement of U44 with another pyrimidine base (cytosine) did not significantly affect cleavage activity (FIG. 12C). These results suggest that base-specific recognition of G43 and U44 could play an important role in sgRNA recognition by Cas9.

[0184] sgRNA stem loops 1-3 interact with Cas9: Stem loop 1 is primarily recognized by the REC lobe together with the PI domain (FIG. 12A). The backbone phosphate groups of stem loop 1 (nucleotides 52, 53, and 59-61) interact with the REC1 domain (Leu455, Ser460, Arg467, Thr472, and Ile473), PI domain (Lys1123 and Lys1124), and Bridge helix (Arg70 and Arg74), with the 2'-hydroxyl group of G58 hydrogen bonded with Leu455 in the REC1 domain. A52 interacts with Phe1105 through a face-to-edge .pi.-.pi. stacking interaction (FIG. 12G), and the flipped U59 nucleobase hydrogen bonds with the side chain of Asn77 (FIG. 12H).

[0185] Stem loops 2 and 3, and the single-stranded linker are primarily recognized by the NUC lobe (FIG. 12A); this contrasts with stem loop 1 and the guide:DNA/repeat:anti-repeat duplexes, which are recognized by both of the NUC and REC lobes. The backbone phosphate groups of the linker (nucleotides 63-65 and 67) interact with the RuvC domain (G1u57, Lys742, and Lys1097), PI domain (Thr1102), and Bridge helix (Arg69), with the 2'-hydroxyl groups of U64 and A65 hydrogen bonded with Glu57 and His721, respectively (FIG. 12I). The nucleobase of C67 hydrogen bonds with the main-chain amide group of Val1100 (FIG. 12I).

[0186] Stem loop 2 is recognized by Cas9 via the interactions between the NUC lobe and the non-Watson-Crick A68:G81 pair, which is formed by direct (between the A68 N6 and G81 O6 atoms) and water-mediated (between the A68 N1 and G81 N1 atoms) hydrogen-bonding interactions (FIG. 12J). The nucleobases of A68 and G81 contact the side chains of Ser1351 and Tyr1356, respectively, with the A68:G81 pair recognized by Thr1358 via a water-mediated hydrogen bond (FIG. 12J). The 2'-hydroxyl group of A68 hydrogen bonds with the side chain of His1349, and the 2-amino group of G81 hydrogen bonds with the main-chain carbonyl group of Lys33 (FIG. 12J).

[0187] Stem loop 3 interacts with the NUC lobe more extensively relative to stem loop 2 (FIG. 12K). The backbone phosphate groups of C91 and G92 interact with the RuvC domain (Arg40 and Lys44) (FIG. 12K), while the nucleobases of G89 and U90 hydrogen bond with Gln1272 and Glu1225/Ala1227, respectively (FIG. 12K). The nucleobases of A88 and C91 are recognized by the side chain of Asn46 via multiple hydrogen-bonding interactions (FIG. 12K).

[0188] Structural flexibility of Cas9 and sgRNA: Although the HNH domain cleaves the complementary strand of the target DNA at a position three nucleotides upstream of the PAM sequence (Gasiunas et al., 2012; Jinek et al., 2012), in the present structure the HNH domain is positioned away from the scissile phosphate group of the bound complementary strand (FIG. 13A). A structural comparison of Mol A and Mol B provided mechanistic insights into the complementary strand cleavage by the HNH domain. In Mol A, the HNH domain is followed by the .alpha.40 helix of the RuvC domain, which is connected with the .alpha.41 helix by an .alpha.40-.alpha.41 linker (residues 919-925) (FIG. 13A). Whereas in Mol A residues 913-925 form the C-terminal portion of the .alpha.43 helix and .alpha.43-.alpha.44 linker, in Mol B these residues form an extended .alpha.-helix, which is directed toward the cleavage site of the complementary strand (FIG. 13A). These observations suggest that the HNH domain can approach and cleave the target DNA through conformational changes in the segment connecting the HNH and RuvC domains.

[0189] Moreover, the structural comparison revealed a conformational flexibility between the REC and NUC lobes (FIG. 13B). Compared to Mol A, Mol B adopts a more open conformation, in which the two lobes are rotated by 15.degree. at a hinge loop between Bridge helix and the strand .beta.5 in the RuvC domain (FIG. 13B). The bound sgRNA also undergoes an accompanying conformational change at the single-stranded linker, which interacts with the hinge loop (FIG. 13C). Applicants also observed an accompanying displacement of the .beta.17-.beta.18 loop of the PI domain, which interacts with the repeat:anti-repeat duplex and the .alpha.2-.alpha.3 loop of the REC1 domain (FIG. 13B). Notably, there is no direct contact between the two lobes in the present structure, except for the interactions between the .alpha.2-.alpha.3 and .beta.17-.beta.18 loops (FIG. 13D), suggesting that Cas9 is highly flexible in the absence of the sgRNA. The flexible nature of Cas9 is likely to play a role in the assembly of the Cas9-sgRNA-DNA ternary complex.

[0190] The crystal structure of Cas9 in complex with guide RNA and target DNA reveals that the 20-bp heteroduplex formed by the crRNA guide region and the complementary strand of the target DNA is accommodated in the positively-charged groove at the interface between the REC and NUC lobes of Cas9, with the scissile phosphate group of the target properly positioned for cleavage by the HNH domain. Although the present structure does not contain the non-complementary DNA strand, the position of the bound complementary strand suggests that the scissile phosphate of the non-complementary strand is located in the vicinity of the active site of the RuvC domain, consistent with previous biochemical data (Gasiunas et al., 2012; Jinek et al., 2012). Furthermore, Applicants' structural and functional analyses indicate that the PI domain participates in the recognition of the PAM sequence of the non-complementary strand.

[0191] Based on these observations, Applicants propose a model for the Cas9-catalyzed RNA-guided DNA cleavage (FIG. 14). Cas9 recognizes the PAM-proximal guide region and repeat:anti-repeat duplex of sgRNA to form a Cas9-sgRNA binary complex. The binary complex subsequently recognizes the DNA sequence complementary to the 20-nt guide region of the bound sgRNA, forming the final Cas9-sgRNA-target DNA ternary complex. During the ternary complex formation, the PI domain recognizes the PAM sequence of the non-complementary strand, facilitating the R-loop formation. Upon assembly of the ternary complex, the mobile HNH domain approaches and cleaves the complementary strand in the guide:DNA duplex, whereas the RuvC domain cleaves the single-stranded, non-complementary strand.

[0192] Applicants' crystal structure provides a critical step towards understanding the molecular mechanism of RNA-guided DNA targeting by Cas9. Further structural and functional studies with S. pyogenes Cas9 or related orthologs, including the structural determination of the Cas9-sgRNA-DNA ternary complex containing the non-complementary strand, may be important for illuminating details such as Cas9-mediated recognition of PAM sequences on the target DNA or mismatch tolerance between the sgRNA:DNA duplex. However, the present structural and functional analyses already provide a useful scaffold for rational engineering of Cas9-based genome modulating technologies. Applicants reported, for example, an S. pyogenes Cas9 truncation mutant (FIG. 9B) that will facilitate packaging of Cas9 into size-constrained viral vectors for in vivo and therapeutic applications. Similarly, future engineering of the PI domain allows for programming of PAM specificity, improving target site recognition fidelity, and increasing the versatility of the Cas9 genome engineering platform.

[0193] Experimental Procedures

[0194] Protein preparation: The gene encoding full-length S. pyogenes Cas9 (residues 1-1368) was cloned between the NdeI and XhoI sites of the modified pCold-GST vector (TaKaRa). The protein was expressed at 20.degree. C. in Escherichia coli Rosetta 2 (DE3) (Novagen), and was purified by Ni-NTA Superflow resin (QIAGEN). The eluted protein was incubated overnight at 4.degree. C. with TEV protease to remove the GST-tag, and further purified by chromatography on Ni-NTA, Mono S (GE Healthcare) and HiLoad Superdex 200 16/60 (GE Healthcare) columns. The SeMet-labeled protein was prepared using a similar protocol for the native protein. The sgRNA was in vitro transcribed by T7 polymerase using a PCR-amplified template, and was purified on 10% denaturing polyacrylamide gel electrophoresis. The target DNA was purchased from Sigma-Aldrich. The purified Cas9 protein was mixed with sgRNA and DNA (molar ratio 1:1.5:2), and then the complex was purified using a Superdex 200 Increase column (GE Healthcare) in a buffer containing 10 mM Tris-HCl, pH 8.0, 150 mM NaCl and 1 mM DTT.

[0195] Crystallography: The purified Cas9-sgRNA-DNA complex was crystallized at 20.degree. C. by the hanging-drop vapor diffusion method. Crystals were obtained by mixing 1 .mu.l of complex solution (A.sub.260 nm=15) and 1 .mu.l of reservoir solution (12% PEG 3,350, 100 mM Tris-HCl, pH 8.0, 200 mM ammonium acetate, 150 mM NaCl and 100 mM NDSB-256).The SeMet-labeled protein was crystallized under conditions similar to those for the native protein. X-ray diffraction data were collected at 100 K on the beamlines BL32XU and BL41XU at SPring-8 (Hyogo, Japan). The crystals were cryoprotected in reservoir solution supplemented with 25% ethylene glycol. X-ray diffraction data were processed using XDS (Kabsch, 2010). The structure was determined by the SAD method, using the 2.8 .ANG. resolution data from the SeMet-labeled crystal. Forty of the potential 44 Se atoms were located using SHELXD (Sheldrick, 2008) and autoSHARP (delaFortelle and Bricogne, 1997). The initial phases were calculated using autoSHARP, and further improved by 2-fold NCS averaging using DM (Winn et al., 2011). The model was automatically built using PHENIX AutoSol (Adams et al., 2002), followed by manual model building using COOT (Emsley and Cowtan, 2004) and refinement using PHENIX (Adams et al., 2002). The resulting model was further refined using for native 2.4 .ANG. resolution data.

[0196] Cell culture and transfection: Human embryonic kidney (HEK) cell line 293FT (Life Technologies) or mouse Neuro 2a (Sigma-Aldrich) cell line was maintained in Dulbecco's modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (HyClone), 2 mM GlutaMAX (Life Technologies), 100 U/ml penicillin, and 100 .mu.g/ml streptomycin at 37.degree. C. with 5% CO.sub.2 incubation. Cells were seeded onto 24-well plates (Corning) at a density of 120,000 cells/well, 24 h prior to transfection. Cells were transfected using Lipofectamine 2000 (Life Technologies) at 70-80% confluency following the manufacturer's recommended protocol. A total of 400 ng Cas9 plasmid and 100 ng of U6::sgRNA PCR product was transfected.

[0197] SURVEYOR nuclease assay for genome modification: 293FT cells were transfected with DNA as described above. Cells were incubated at 37.degree. C. for 72 h post-transfection prior to genomic DNA extraction. Genomic DNA was extracted using the QuickExtract DNA Extraction Solution (Epicentre) following the manufacturer's protocol. Briefly, pelleted cells were resuspended in QuickExtract solution and incubated at 65.degree. C. for 15 min, 68.degree. C. for 15 min, and 98.degree. C. for 10 min.

[0198] The genomic region flanking the CRISPR target site for each gene was PCR amplified, and products were purified using QiaQuick Spin Column (Qiagen) following the manufacturer's protocol. 400 ng total of the purified PCR products were mixed with 2 .mu.l 10.times. Taq DNA Polymerase PCR buffer (Enzymatics) and ultrapure water to a final volume of 20 .mu.l, and subjected to a re-annealing process to enable heteroduplex formation: 95.degree. C. for 10 min, 95.degree. C. to 85.degree. C. ramping at -2.degree. C./s, 85.degree. C. to 25.degree. C. at -0.25.degree. C./s, and 25.degree. C. hold for 1 min. After re-annealing, products were treated with SURVEYOR nuclease and SURVEYOR enhancer S (Transgenomics) following the manufacturer's recommended protocol, and analyzed on 4-20% Novex TBE poly-acrylamide gels (Life Technologies). Gels were stained with SYBR Gold DNA stain (Life Technologies) for 30 min and imaged with a Gel Doc gel imaging system (Bio-rad). Quantification was based on relative band intensities. Indel percentage was determined by the formula, 100.times.(1-(1-(b+c)/(a+b+c)).sup.1/2), where a is the integrated intensity of the undigested PCR product, and b and c are the integrated intensities of each cleavage product.

[0199] Western blot: HEK 293FT cells were transfected and lysed in 1.times. RIPA buffer (Sigma-Aldrich) supplemented with Protease Inhibitor (Roche). Lysates were loaded onto Bolt 4-12% Bis-Tris Plus Gel (Invitrogen) and transferred to nitrocellulose membranes. Membranes were blocked in Tris-buffered saline containing 0.1% Tween-20 and 5% blocking agent (G-Biosciences). Membrane was probed with rabbit anti-FLAG (1:5000, Abcam), HRP-conjugated anti-GAPDH (1:5,000 Cell Signaling Technology), and HRP-conjugated anti-rabbit (1:1000). Blots were visualized on Gel Doc XR+ System (Bio-rad).

[0200] Sequence Information:

TABLE-US-00006 Italic: 3XFLAG sequence Underlined: NLS sequences Wildtype SpCas9 ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAAAGACGATGACGATAAGATGGC- CCCAAAGAAGAAGCGGAAG GTCGGTATCCACGGAGTCCCAGCAGCCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGG- CTGGGCCGTGATCACCGAC GAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGAT- CGGAGCCCTGCTGTTCGAC AGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGAT- CTGCTATCTGCAAGAGATC TTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGA- TAAGAAGCACGAGCGGCAC CCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAA- ACTGGTGGACAGCACCGAC AAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGG- CGACCTGAACCCCGACAAC AGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGC- CAGCGGCGTGGACGCCAAG GCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAA- GAATGGCCTGTTCGGCAAC CTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCA- GCTGAGCAAGGACACCTAC GACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCT- GTCCGACGCCATCCTGCTG AGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGA- GCACCACCAGGACCTGACC CTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGG- CTACGCCGGCTACATTGAC GGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACT- GCTCGTGAAGCTGAACAGA GAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCA- CGCCATTCTGCGGCGGCAG GAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTA- CGTGGGCCCTCTGGCCAGG GGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGT- GGACAAGGGCGCTTCCGCC CAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCT- GCTGTACGAGTACTTCACC GTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCA- GAAAAAGGCCATCGTGGAC CTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTT- CGACTCCGTGGAAATCTCC GGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTT- CCTGGACAATGAGGAAAAC GAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAA- AACCTATGCCCACCTGTTC GACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAA- CGGCATCCGGGACAAGCAG TCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGA- CGACAGCCTGACCTTTAAA GAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAG- CCCCGCCATTAAGAAGGGC ATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGAT- CGAAATGGCCAGAGAGAAC CAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGG- CAGCCAGATCCTGAAAGAA CACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTA- CGTGGACCAGGAACTGGAC ATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAA- CAAGGTGCTGACCAGAAGC GACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCA- GCTGCTGAACGCCAAGCTG ATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTT- CATCAAGAGACAGCTGGTG GAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGA- CAAGCTGATCCGGGAAGTG AAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGAT- CAACAACTACCACCACGCC CACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGT- GTACGGCGACTACAAGGTG TACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAG- CAACATCATGAACTTTTTC AAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGA- GATCGTGTGGGATAAGGGC CGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGAC- AGGCGGCTTCAGCAAAGAG TCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGG- CTTCGACAGCCCCACCGTG GCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCT- GGGGATCACCATCATGGAA AGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGAT- CATCAAGCTGCCTAAGTAC TCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACT- GGCCCTGCCCTCCAAATAT GTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCT- GTTTGTGGAACAGCACAAG CACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGA- CAAAGTGCTGTCCGCCTAC AACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGG- AGCCCCTGCCGCCTTCAAG TACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCA- GAGCATCACCGGCCTGTAC GAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAA- AAAGAAAAAG (SEQ ID NO: 76) Sp_del(97-150) ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAAAGACGATGACGATAAGATGGC- CCCAAAGAAGAAGCGGAAG GTCGGTATCCACGGAGTCCCAGCAGCCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGG- CTGGGCCGTGATCACCGAC GAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGAT- CGGAGCCCTGCTGTTCGAC AGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGAT- CTGCTATCTGCAAGAGATC TTCAGCAACGAGATGGCCAAGGTGGACGACAGCCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTT- CCGGGGCCACTTCCTGATC GAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCT- GTTCGAGGAAAACCCCATC AACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGAT- CGCCCAGCTGCCCGGCGAG AAGAAGAATGGCCTGTTCGGAAACCTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGA- CCTGGCCGAGGATGCCAAA CTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGA- CCTGTTTCTGGCCGCCAAG AACCTGTCCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGC- CTCTATGATCAAGAGATAC GACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGAT- TTTCTTCGACCAGAGCAAG AACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGA- AAAGATGGACGGCACCGAG GAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCA- CCAGATCCACCTGGGAGAG CTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGAT- CCTGACCTTCCGCATCCCC TACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCAC- CCCCTGGAACTTCGAGGAA GTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGA- GAAGGTGCTGCCCAAGCAC AGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAA- GCCCGCCTTCCTGAGCGGC GAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGA- CTACTTCAAGAAAATCGAG TGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCT- GAAAATTATCAAGGACAAG GACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAG- AGAGATGATCGAGGAACGG CTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGG- CAGGCTGAGCCGGAAGCTG ATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAG- AAACTTCATGCAGCTGATC CACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGA- GCACATTGCCAATCTGGCC GGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCG- GCACAAGCCCGAGAACATC GTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGAT- CGAAGAGGGCATCAAAGAG CTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTA- CCTGCAGAATGGGCGGGAT ATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTT- TCTGAAGGACGACTCCATC GACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAA- GAAGATGAAGAACTACTGG CGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCT- GAGCGAACTGGATAAGGCC GGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGAT- GAACACTAAGTACGACGAG AATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTT- CCAGTTTTACAAAGTGCGC GAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTA- CCCTAAGCTGGAAAGCGAG TTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGC- TACCGCCAAGTACTTCTTC TACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGAT- CGAGACAAACGGCGAAACC GGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATAT- CGTGAAAAAGACCGAGGTG CAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGA- CTGGGACCCTAAGAAGTAC GGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAA- ACTGAAGAGTGTGAAAGAG CTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTA- CAAAGAAGTGAAAAAGGAC CTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGG- CGAACTGCAGAAGGGAAAC GAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCC- CGAGGATAATGAGCAGAAA CAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGT- GATCCTGGCCGACGCTAAT CTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCA- CCTGTTTACCCTGACCAAT CTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGT- GCTGGACGCCACCCTGATC CACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAAAAGGCCGGCGGC- CACGAAAAAGGCCGGCCAG GCAAAAAAGAAAAAG (SEQ ID NO: 77) Sp_del(175-307) ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAAAGACGATGACGATAAGATGGC- CCCAAAGAAGAAGCGGAAG GTCGGTATCCACGGAGTCCCAGCAGCCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGG- CTGGGCCGTGATCACCGAC GAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGAT- CGGAGCCCTGCTGTTCGAC AGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGAT- CTGCTATCTGCAAGAGATC TTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGA- TAAGAAGCACGAGCGGCAC CCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAA- ACTGGTGGACAGCACCGAC AAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGG- CGACCTGGTGAACACCGAG ATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAA- AGCTCTCGTGCGGCAGCAG CTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGC- CAGCCAGGAAGAGTTCTAC AAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCT- GCTGCGGAAGCAGCGGACC TTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTT- TTACCCATTCCTGAAGGAC AACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAG- CAGATTCGCCTGGATGACC AGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTT- CATCGAGCGGATGACCAAC TTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAA- CGAGCTGACCAAAGTGAAA TACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTT- CAAGACCAACCGGAAAGTG ACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGA- AGATCGGTTCAACGCCTCC CTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACAT- TCTGGAAGATATCGTGCTG ACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAA- AGTGATGAAGCAGCTGAAG CGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAA- GACAATCCTGGATTTCCTG AAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACAT- CCAGAAAGCCCAGGTGTCC GGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCA- GACAGTGAAGGTGGTGGAC GAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCAC- CCAGAAGGGACAGAAGAAC AGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGT- GGAAAACACCCAGCTGCAG AACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCG- GCTGTCCGACTACGATGTG GACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAA- CCGGGGCAAGAGCGACAAC GTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCA- GAGAAAGTTCGACAATCTG ACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCG- GCAGATCACAAAGCACGTG GCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGAT- CACCCTGAAGTCCAAGCTG GTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGC- CTACCTGAACGCCGTCGTG

GGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGT- GCGGAAGATGATCGCCAAG AGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGA- GATTACCCTGGCCAACGGC GAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTT- TGCCACCGTGCGGAAAGTG CTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCT- GCCCAAGAGGAACAGCGAT AAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTC- TGTGCTGGTGGTGGCCAAA GTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAG- CTTCGAGAAGAATCCCATC GACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTT- CGAGCTGGAAAACGGCCGG AAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTT- CCTGTACCTGGCCAGCCAC TATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCT- GGACGAGATCATCGAGCAG ATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCA- CCGGGATAAGCCCATCAGA GAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGA- CACCACCATCGACCGGAAG AGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACG- GATCGACCTGTCTCAGCTG GGAGGCGACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAG (SEQ ID NO: 78) Sp_del(312-409) ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAAAGACGATGACGATAAGATGGC- CCCAAAGAAGAAGCGGAAG GTCGGTATCCACGGAGTCCCAGCAGCCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGG- CTGGGCCGTGATCACCGAC GAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGAT- CGGAGCCCTGCTGTTCGAC AGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGAT- CTGCTATCTGCAAGAGATC TTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGA- TAAGAAGCACGAGCGGCAC CCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAA- ACTGGTGGACAGCACCGAC AAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGG- CGACCTGAACCCCGACAAC AGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGC- CAGCGGCGTGGACGCCAAG GCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAA- GAATGGCCTGTTCGGAAAC CTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCA- GCTGAGCAAGGACACCTAC GACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCT- GTCCGACGCCATCCTGCTG AGCGACATCCTGAGAGTGAACACCGAGATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCG- GCAGGAAGATTTTTACCCA TTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGC- CAGGGGAAACAGCAGATTC GCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTC- CGCCCAGAGCTTCATCGAG CGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTT- CACCGTGTATAACGAGCTG ACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGT- GGACCTGCTGTTCAAGACC AACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAAT- CTCCGGCGTGGAAGATCGG TTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGA- AAACGAGGACATTCTGGAA GATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCT- GTTCGACGACAAAGTGATG AAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAA- GCAGTCCGGCAAGACAATC CTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTT- TAAAGAGGACATCCAGAAA GCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAA- GGGCATCCTGCAGACAGTG AAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGA- GAACCAGACCACCCAGAAG GGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAA- AGAACACCCCGTGGAAAAC ACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACT- GGACATCAACCGGCTGTCC GACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAG- AAGCGACAAGAACCGGGGC AAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAA- GCTGATTACCCAGAGAAAG TTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCT- GGTGGAAACCCGGCAGATC ACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGA- AGTGAAAGTGATCACCCTG AAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCA- CGCCCACGACGCCTACCTG AACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAA- GGTGTACGACGTGCGGAAG ATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTT- TTTCAAGACCGAGATTACC CTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAA- GGGCCGGGATTTTGCCACC GTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAA- AGAGTCTATCCTGCCCAAG AGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCAC- CGTGGCCTATTCTGTGCTG GTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCAT- GGAAAGAAGCAGCTTCGAG AAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAA- GTACTCCCTGTTCGAGCTG GAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAA- ATATGTGAACTTCCTGTAC CTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCA- CAAGCACTACCTGGACGAG ATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGC- CTACAACAAGCACCGGGAT AAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTT- CAAGTACTTTGACACCACC ATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCT- GTACGAGACACGGATCGAC CTGTCTCAGCTGGGAGGCGACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAG (SEQ ID NO: 79) Sp_del(1098-end) ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAAAGACGATGACGATAAGATGGC- CCCAAAGAAGAAGCGGAAG GTCGGTATCCACGGAGTCCCAGCAGCCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGG- CTGGGCCGTGATCACCGAC GAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGAT- CGGAGCCCTGCTGTTCGAC AGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGAT- CTGCTATCTGCAAGAGATC TTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGA- TAAGAAGCACGAGCGGCAC CCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAA- ACTGGTGGACAGCACCGAC AAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGG- CGACCTGAACCCCGACAAC AGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGC- CAGCGGCGTGGACGCCAAG GCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAA- GAATGGCCTGTTCGGAAAC CTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCA- GCTGAGCAAGGACACCTAC GACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCT- GTCCGACGCCATCCTGCTG AGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGA- GCACCACCAGGACCTGACC CTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGG- CTACGCCGGCTACATTGAC GGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACT- GCTCGTGAAGCTGAACAGA GAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCA- CGCCATTCTGCGGCGGCAG GAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTA- CGTGGGCCCTCTGGCCAGG GGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGT- GGACAAGGGCGCTTCCGCC CAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCT- GCTGTACGAGTACTTCACC GTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCA- GAAAAAGGCCATCGTGGAC CTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTT- CGACTCCGTGGAAATCTCC GGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTT- CCTGGACAATGAGGAAAAC GAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAA- AACCTATGCCCACCTGTTC GACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAA- CGGCATCCGGGACAAGCAG TCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGA- CGACAGCCTGACCTTTAAA GAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAG- CCCCGCCATTAAGAAGGGC ATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGAT- CGAAATGGCCAGAGAGAAC CAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGG- CAGCCAGATCCTGAAAGAA CACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTA- CGTGGACCAGGAACTGGAC ATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAA- CAAGGTGCTGACCAGAAGC GACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCA- GCTGCTGAACGCCAAGCTG ATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTT- CATCAAGAGACAGCTGGTG GAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGA- CAAGCTGATCCGGGAAGTG AAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGAT- CAACAACTACCACCACGCC CACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGT- GTACGGCGACTACAAGGTG TACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAG- CAACATCATGAACTTTTTC AAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGA- GATCGTGTGGGATAAGGGC CGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCAAAAGGCCGGC- GGCCACGAAAAAGGCCGGC CAGGCAAAAAAGAAAAAG (SEQ ID NO: 80) St3Cas9 ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAAAGACGATGACGATAAGATGGC- CCCAAAGAAGAAGCGGAAG GTCGGTATCCACGGAGTCCCAGCAGCCACCAAGCCCTACAGCATCGGCCTGGACATCGGCACCAATAGCGTGGG- CTGGGCCGTGACCACCGAC AACTACAAGGTGCCCAGCAAGAAAATGAAGGTGCTGGGCAACACCTCCAAGAAGTACATCAAGAAAAACCTGCT- GGGCGTGCTGCTGTTCGAC AGCGGCATTACAGCCGAGGGCAGACGGCTGAAGAGAACCGCCAGACGGCGGTACACCCGGCGGAGAAACAGAAT- CCTGTATCTGCAAGAGATC TTCAGCACCGAGATGGCTACCCTGGACGACGCCTTCTTCCAGCGGCTGGACGACAGCTTCCTGGTGCCCGACGA- CAAGCGGGACAGCAAGTAC CCCATCTTCGGCAACCTGGTGGAAGAGAAGGCCTACCACGACGAGTTCCCCACCATCTACCACCTGAGAAAGTA- CCTGGCCGACAGCACCAAG AAGGCCGACCTGAGACTGGTGTATCTGGCCCTGGCCCACATGATCAAGTACCGGGGCCACTTCCTGATCGAGGG- CGAGTTCAACAGCAAGAAC AACGACATCCAGAAGAACTTCCAGGACTTCCTGGACACCTACAACGCCATCTTCGAGAGCGACCTGTCCCTGGA- AAACAGCAAGCAGCTGGAA GAGATCGTGAAGGACAAGATCAGCAAGCTGGAAAAGAAGGACCGCATCCTGAAGCTGTTCCCCGGCGAGAAGAA- CAGCGGAATCTTCAGCGAG TTTCTGAAGCTGATCGTGGGCAACCAGGCCGACTTCAGAAAGTGCTTCAACCTGGACGAGAAAGCCAGCCTGCA- CTTCAGCAAAGAGAGCTAC GACGAGGACCTGGAAACCCTGCTGGGATATATCGGCGACGACTACAGCGACGTGTTCCTGAAGGCCAAGAAGCT- GTACGACGCTATCCTGCTG AGCGGCTTCCTGACCGTGACCGACAACGAGACAGAGGCCCCACTGAGCAGCGCCATGATTAAGCGGTACAACGA- GCACAAAGAGGATCTGGCT CTGCTGAAAGAGTACATCCGGAACATCAGCCTGAAAACCTACAATGAGGTGTTCAAGGACGACACCAAGAACGG- CTACGCCGGCTACATCGAC GGCAAGACCAACCAGGAAGAGGAAGATTTCTATGTGTACCTGAAGAAGCTGCTGGCCGAGTTCGAGGGGGCCGA- CTACTTTCTGGAAAAAATC GACCGCGAGGATTTCCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCTACCAGATCCATCTGCAGGA- AATGCGGGCCATCCTGGAC AAGCAGGCCAAGTTCTACCCATTCCTGGCCAAGAACAAAGAGCGGATCGAGAAGATCCTGACCTTCCGCATCCC- TTACTACGTGGGCCCCCTG GCCAGAGGCAACAGCGATTTTGCCTGGTCCATCCGGAAGCGCAATGAGAAGATCACCCCCTGGAACTTCGAGGA- CGTGATCGACAAAGAGTCC AGCGCCGAGGCCTTCATCAACCGGATGACCAGCTTCGACCTGTACCTGCCCGAGGAAAAGGTGCTGCCCAAGCA- CAGCCTGCTGTACGAGACA TTCAATGTGTATAACGAGCTGACCAAAGTGCGGTTTATCGCCGAGTCTATGCGGGACTACCAGTTCCTGGACTC- CAAGCAGAAAAAGGACATC GTGCGGCTGTACTTCAAGGACAAGCGGAAAGTGACCGATAAGGACATCATCGAGTACCTGCACGCCATCTACGG- CTACGATGGCATCGAGCTG AAGGGCATCGAGAAGCAGTTCAACTCCAGCCTGAGCACATACCACGACCTGCTGAACATTATCAACGACAAAGA- ATTTCTGGACGACTCCAGC AACGAGGCCATCATCGAAGAGATCATCCACACCCTGACCATCTTTGAGGACCGCGAGATGATCAAGCAGCGGCT- GAGCAAGTTCGAGAACATC TTCGACAAGAGCGTGCTGAAAAAGCTGAGCAGACGGCACTACACCGGCTGGGGCAAGCTGAGCGCCAAGCTGAT- CAACGGCATCCGGGACGAG AAGTCCGGCAACACAATCCTGGACTACCTGATCGACGACGGCATCAGCAACCGGAACTTCATGCAGCTGATCCA- CGACGACGCCCTGAGCTTC AAGAAGAAGATCCAGAAGGCCCAGATCATCGGGGACGAGGACAAGGGCAACATCAAAGAAGTCGTGAAGTCCCT- GCCCGGCAGCCCCGCCATC AAGAAGGGAATCCTGCAGAGCATCAAGATCGTGGACGAGCTCGTGAAAGTGATGGGCGGCAGAAAGCCCGAGAG- CATCGTGGTGGTGGTGGAA ATGGCTAGAGAGAACCAGTACACCAATCAGGGCAAGAGCAACAGCCAGCAGAGACTGAAGAGACTGGAAAAGTC- CCTGAAAGAGCTGGGCAGC AAGATTCTGAAAGAGAATATCCCTGCCAAGCTGTCCAAGATCGACAACAACGCCCTGCAGAACGACCGGCTGTA- CCTGTACTACCTGCAGAAT GGCAAGGACATGTATACAGGCGACGACCTGGATATCGACCGCCTGAGCAACTACGACATCGACCATATTATCCC- CCAGGCCTTCCTGAAAGAC AACAGCATTGACAACAAAGTGCTGGTGTCCTCCGCCAGCAACCGCGGCAAGTCCGATGATGTGCCCAGCCTGGA-

AGTCGTGAAAAAGAGAAAG ACCTTCTGGTATCAGCTGCTGAAAAGCAAGCTGATTAGCCAGAGGAAGTTCGACAACCTGACCAAGGCCGAGAG- AGGCGGCCTGAGCCCTGAA GATAAGGCCGGCTTCATCCAGAGACAGCTGGTGGAAACCCGGCAGATCACCAAGCACGTGGCCAGACTGCTGGA- TGAGAAGTTTAACAACAAG AAGGACGAGAACAACCGGGCCGTGCGGACCGTGAAGATCATCACCCTGAAGTCCACCCTGGTGTCCCAGTTCCG- GAAGGACTTCGAGCTGTAT AAAGTGCGCGAGATCAATGACTTTCACCACGCCCACGACGCCTACCTGAATGCCGTGGTGGCTTCCGCCCTGCT- GAAGAAGTACCCTAAGCTG GAACCCGAGTTCGTGTACGGCGACTACCCCAAGTACAACTCCTTCAGAGAGCGGAAGTCCGCCACCGAGAAGGT- GTACTTCTACTCCAACATC ATGAATATCTTTAAGAAGTCCATCTCCCTGGCCGATGGCAGAGTGATCGAGCGGCCCCTGATCGAAGTGAACGA- AGAGACAGGCGAGAGCGTG TGGAACAAAGAAAGCGACCTGGCCACCGTGCGGCGGGTGCTGAGTTATCCTCAAGTGAATGTCGTGAAGAAGGT- GGAAGAACAGAACCACGGC CTGGATCGGGGCAAGCCCAAGGGCCTGTTCAACGCCAACCTGTCCAGCAAGCCTAAGCCCAACTCCAACGAGAA- TCTCGTGGGGGCCAAAGAG TACCTGGACCCTAAGAAGTACGGGTACGGCGGATACGCCGGCATCTCCAATAGCTTCACCGTGCTCGTGAAGGG- CACAATCGAGAAGGGCGCT AAGAAAAAGATCACAAACGTGCTGGAATTTCAGGGGATCTCTATCCTGGACCGGATCAACTACCGGAAGGATAA- GCTGAACTTTCTGCTGGAA AAAGGCTACAAGGACATTGAGCTGATTATCGAGCTGCCTAAGTACTCCCTGTTCGAACTGAGCGACGGCTCCAG- ACGGATGCTGGCCTCCATC CTGTCCACCAACAACAAGCGGGGCGAGATCCACAAGGGAAACCAGATCTTCCTGAGCCAGAAATTTGTGAAACT- GCTGTACCACGCCAAGCGG ATCTCCAACACCATCAATGAGAACCACCGGAAATACGTGGAAAACCACAAGAAAGAGTTTGAGGAACTGTTCTA- CTACATCCTGGAGTTCAAC GAGAACTATGTGGGAGCCAAGAAGAACGGCAAACTGCTGAACTCCGCCTTCCAGAGCTGGCAGAACCACAGCAT- CGACGAGCTGTGCAGCTCC TTCATCGGCCCTACCGGCAGCGAGCGGAAGGGACTGTTTGAGCTGACCTCCAGAGGCTCTGCCGCCGACTTTGA- GTTCCTGGGAGTGAAGATC CCCCGGTACAGAGACTACACCCCCTCTAGTCTGCTGAAGGACGCCACCCTGATCCACCAGAGCGTGACCGGCCT- GTACGAAACCCGGATCGAC CTGGCTAAGCTGGGCGAGGGAAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAG (SEQ ID NO: 81) SpCas9(C80L, C574A) ATGGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCGACGAGTA- CAAGGTGCCCAGCAAGAAA TTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGG- CGAAACAGCCGAGGCCACC CGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGATCctgTATCTGCAAGAGATCTTCAG- CAACGAGATGGCCAAGGTG GACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCAT- CTTCGGCAACATCGTGGAC GAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGC- CGACCTGCGGCTGATCTAT CTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGA- CGTGGACAAGCTGTTCATC CAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCAT- CCTGTCTGCCAGACTGAGC AAGAGCAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAAACCTGAT- TGCCCTGAGCCTGGGCCTG ACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGA- CGACCTGGACAACCTGCTG GCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGA- CATCCTGAGAGTGAACACC GAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCT- GAAAGCTCTCGTGCGGCAG CAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGG- AGCCAGCCAGGAAGAGTTC TACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGA- CCTGCTGCGGAAGCAGCGG ACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGA- TTTTTACCCATTCCTGAAG GACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAA- CAGCAGATTCGCCTGGATG ACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAG- CTTCATCGAGCGGATGACC AACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTA- TAACGAGCTGACCAAAGTG AAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCT- GTTCAAGACCAACCGGAAA GTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGgagTTCGACTCCGTGGAAATCTCCGGCGT- GGAAGATCGGTTCAACGCC TCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGA- CATTCTGGAAGATATCGTG CTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGA- CAAAGTGATGAAGCAGCTG AAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGG- CAAGACAATCCTGGATTTC CTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGA- CATCCAGAAAGCCCAGGTG TCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCT- GCAGACAGTGAAGGTGGTG GACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGAC- CACCCAGAAGGGACAGAAG AACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCC- CGTGGAAAACACCCAGCTG CAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAA- CCGGCTGTCCGACTACGAT GTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAA- GAACCGGGGCAAGAGCGAC AACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTAC- CCAGAGAAAGTTCGACAAT CTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAAC- CCGGCAGATCACAAAGCAC GTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGT- GATCACCCTGAAGTCCAAG CTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGA- CGCCTACCTGAACGCCGTC GTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGA- CGTGCGGAAGATGATCGCC AAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGAC- CGAGATTACCCTGGCCAAC GGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGA- TTTTGCCACCGTGCGGAAA GTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTAT- CCTGCCCAAGAGGAACAGC GATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTA- TTCTGTGCTGGTGGTGGCC AAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAG- CAGCTTCGAGAAGAATCCC ATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCT- GTTCGAGCTGGAAAACGGC CGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAA- CTTCCTGTACCTGGCCAGC CACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTA- CCTGGACGAGATCATCGAG CAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAA- GCACCGGGATAAGCCCATC AGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTT- TGACACCACCATCGACCGG AAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGAC- ACGGATCGACCTGTCTCAG CTGGGAGGCGAC (SEQ ID NO: 82) Sp_St3 Cas9 chimera (St3 in bold) ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAAAGACGATGACGATAAGATGGC- CCCAAAGAAGAAGCGGAAG GTCGGTATCCACGGAGTCCCAGCAGCCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGG- CTGGGCCGTGATCACCGAC GAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGAT- CGGAGCCCTGCTGTTCGAC AGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGAT- CTGCTATCTGCAAGAGATC TTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGA- TAAGAAGCACGAGCGGCAC CCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAA- ACTGGTGGACAGCACCGAC AAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGG- CGACCTGAACCCCGACAAC AGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGC- CAGCGGCGTGGACGCCAAG GCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAA- GAATGGCCTGTTCGGAAAC CTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCA- GCTGAGCAAGGACACCTAC GACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCT- GTCCGACGCCATCCTGCTG AGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGA- GCACCACCAGGACCTGACC CTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGG- CTACGCCGGCTACATTGAC GGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACT- GCTCGTGAAGCTGAACAGA GAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCA- CGCCATTCTGCGGCGGCAG GAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTA- CGTGGGCCCTCTGGCCAGG GGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGT- GGACAAGGGCGCTTCCGCC CAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCT- GCTGTACGAGTACTTCACC GTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCA- GAAAAAGGCCATCGTGGAC CTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTT- CGACTCCGTGGAAATCTCC GGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTT- CCTGGACAATGAGGAAAAC GAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAA- AACCTATGCCCACCTGTTC GACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAA- CGGCATCCGGGACAAGCAG TCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGA- CGACAGCCTGACCTTTAAA GAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAG- CCCCGCCATTAAGAAGGGC ATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGAT- CGAAATGGCCAGAGAGAAC CAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGG- CAGCCAGATCCTGAAAGAA CACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTA- CGTGGACCAGGAACTGGAC ATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAA- CAAGGTGCTGACCAGAAGC GACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCA- GCTGCTGAACGCCAAGCTG ATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTT- CATCAAGAGACAGCTGGTG GAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGA- CAAGCTGATCCGGGAAGTG AAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGAT- CAACAACTACCACCACGCC CACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGT- GTACGGCGACTACAAGGTG TACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAG- CAACATCATGAACTTTTTC AAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGA- GATCGTGTGGGATAAGGGC CGGGATTTTGCCACCGTGGGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGTGGAAGAACA- GAACCACGGCCTGGATCGG GGCAAGCCCAAGGGCCTGTTCAACGCCAACCTGTCCAGCAAGCCTAAGCCCAACTCCAACGAGAATCTCGTGGG- GGCCAAAGAGTACCTGGA CCCTAAGAAGTACGGGTACGGCGGATACGCCGGCATCTCCAATAGCTTCACCGTGCTCGTGAAGGGCACAATCG- AGAAGGGCGCTAAGAAAA AGATCACAAACGTGCTGGAATTTCAGGGGATCTCTATCCTGGACCGGATCAACTACCGGAAGGATAAGCTGAAC- TTTCTGCTGGAAAAAGGC TACAAGGACATTGAGCTGATTATCGAGCTGCCTAAGTACTCCCTGTTCGAACTGAGCGACGGCTCCAGACGGAT- GCTGGCCTCCATCCTGTC CACCAACAACAAGCGGGGCGAGATCCACAAGGGAAACCAGATCTTCCTGAGCCAGAAATTTGTGAAACTGCTGT- ACCACGCCAAGCGGATCT CCAACACCATCAATGAGAACCACCGGAAATACGTGGAAAACCACAAGAAAGAGTTTGAGGAACTGTTCTACTAC- ATCCTGGAGTTCAACGAG AACTATGTGGGAGCCAAGAAGAACGGCAAACTGCTGAACTCCGCCTTCCAGAGCTGGCAGAACCACAGCATCGA- CGAGCTGTGCAGCTCCTT CATCGGCCCTACCGGCAGCGAGCGGAAGGGACTGTTTGAGCTGACCTCCAGAGGCTCTGCCGCCGACTTTGAGT- TCCTGGGAGTGAAGATCC CCCGGTACAGAGACTACACCCCCTCTAGTCTGCTGAAGGACGCCACCCTGATCCACCAGAGCGTGACCGGCCTG- TACGAAACCCGGATCGAC CTGGCTAAGCTGGGCGAGGGAAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAG (SEQ ID NO: 83) St3_Sp Cas9 chimera (St3 in bold) ATGGCCCCAAAGAAGAAGGGGAAGGTGGGTATCCACGGAGTGCCAGCAGCCatgACCAGGCCTACAGCATGGGC- CTGGACATGGGCACCAAT AGGGTGGGCTGGGCCGTGACCACCGACAACTACAAGGTGCCCAGCAAGAAAATGAAGGTGCTGGGCAACACCTC- CAAGAAGTACATCAAGAA AAACCTGCTGGGCGTGCTGCTGTTCGACAGGGGCATTACAGCCGAGGGCAGACGGCTGAAGAGAACCGCCAGAC- GGCGGTACACCCGGCGGA GAAACAGAATGCTGTATCTGCAAGAGATCTTCAGCACCGAGATGGCTACCCTGGACGACGCCTTCTTCCAGCGG- CTGGACGACAGCTTCCTG GTGGCCGACGACAAGGGGGACAGCAAGTACCGCATCTTCGGCAACCTGGTGGAAGAGAAGGCCTACCACGACGA- GTTCCGCACCATCTACCA CGTGAGAAAGTACCTGGCCGACAGCACCAAGAAGGCCGACCTGAGACTGGTGTATCTGGCCGTGGCCCACATGA- TCAAGTACCGGGGCCACT TGCTGATCGAGGGCGAGTTCAACAGCAAGAACAACGACATCCAGAAGAACTTCCAGGACTTCCTGGACACCTAC- AACGCCATCTTCGAGAGC GACCTGTGCCTGGAAAACAGCAAGCAGCTGGAAGAGATCGTGAAGGACAAGATCAGCAAGCTGGAAAAGAAGGA- CCGCATCCTGAAGCTGTT GCCGGGCGAGAAGAACAGGGGAATCTTCAGCGAGTTTCTGAAGCTGATCGTGGGCAACCAGGCCGACTTCAGAA- AGTGCTTCAACCTGGACG AGAAAGGCAGGCTGCACTTCAGCAAAGAGAGCTACGACGAGGACCTGGAAACCCTGCTGGGATATATCGGCGAC- GACTACAGCGACGTGTTC CTGAAGGCCAAGAAGCTGTACGACGCTATCCTGCTGAGCGGCTTCCTGACCGTGACCGACAACGAGACAGAGGC- CCCACTGAGCAGCGCCAT GATTAAGCGGTACAACGAGCACAAAGAGGATCTGGCTCTGCTGAAAGAGTACATCCGGAACATCAGCCTGAAAA- CCTACAATGAGGTGTTCA AGGACGACACCAAGAACGGCTACGCCGGCTACATCGACGGCAAGACCAACCAGGAAGAGGAAGATTTCTATGTG- TACCTGAAGAAGCTGCTG GCCGAGTTCGAGGGGGCCGACTACTTTCTGGAAAAAATCGACCGCGAGGATTTCCTGCGGAAGCAGCGGACCTT-

CGACAACGGCAGCATCCC CTACCAGATCCATCTGCAGGAAATGCGGGCCATCCTGGACAAGCAGGCCAAGTTCTACCCATTCCTGGCCAAGA- ACAAAGAGCGGATCGAGA AGATCCTGACCTTCCGCATCCCTTACTACGTGGGCCCCCTGGCCAGAGGCAACAGCGATTTTGCCTGGTCCATC- CGGAAGCGCAATGAGAAG ATCACCCCCTGGAACTTCGAGGACGTGATCGACAAAGAGTCCAGCGCCGAGGCCTTCATCAACCGGATGACCAG- CTTCGACCTGTACCTGCC CGAGGAAAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGACATTCAATGTGTATAACGAGCTGACCAAAGTGC- GGTTTATCGCCGAGTCTA TGCGGGACTACCAGTTCCTGGACTCCAAGCAGAAAAAGGACATCGTGCGGCTGTACTTCAAGGACAAGCGGAAA- GTGACCGATAAGGACATC ATCGAGTACCTGCACGCCATCTACGGCTACGATGGCATCGAGCTGAAGGGCATCGAGAAGCAGTTCAACTCCAG- CCTGAGCACATACCACGA CCTGCTGAACATTATCAACGACAAAGAATTTCTGGACGACTCCAGCAACGAGGCCATCATCGAAGAGATCATCC- ACACCCTGACCATCTTTG AGGACCGCGAGATGATCAAGCAGCGGCTGAGCAAGTTCGAGAACATCTTCGACAAGAGCGTGCTGAAAAAGCTG- AGCAGACGGCACTACACC GGCTGGGGCAAGCTGAGCGCCAAGCTGATCAACGGCATCCGGGACGAGAAGTCCGGCAACACAATCCTGGACTA- CCTGATCGACGACGGCAT CAGGAACCGGAACTTCATGCAGCTGATCCACGACGACGCCGTGAGCTTCAAGAAGAAGATCCAGAAGGCCCAGA- TCATCGGGGACGAGGACA AGGGCAACATCAAAGAAGTGGTGAAGTGCCTGCCGGGCAGCCGCGCCATCAAGAAGGGAATCCTGCAGAGCATC- AAGATCGTGGACGAGCTC GTGAAAGTGATGGGCGGCAGAAAGCCCGAGAGCATCGTGGTGGTGGTGGAAATGGCTAGAGAGAACCAGTACAC- CAATCAGGGCAAGAGCAA CAGGCAGGAGAGACTGAAGAGACTGGAAAAGTGCCTGAAAGAGCTGGGCAGCAAGATTCTGAAAGAGAATATCC- CTGCCAAGGTGTGCAAGA TGGACAACAACGGCCTGCAGAACGACCGGCTGTACCTGTACTACCTGCAGAATGGCAAGGACATGTATACAGGC- GACGACCTGGATATCGAC CGGCTGAGGAACTACGACATCGACCATATTATCCGCCAGGCCTTCCTGAAAGACAACAGCATTGACAACAAAGT- GCTGGTGTCCTCCGCCAG CAACCGGGGCAAGTCCGATGATGTGCCCAGCCTGGAAGTGGTGAAAAAGAGAAAGACCTTCTGGTATCAGGTGG- TGAAAAGCAAGCTGATTA GCCAGAGGAAGTTCGACAACCTGACCAAGGCCGAGAGAGGCGGCCTGAGCCCTGAAGATAAGGCCGGCTTCATC- CAGAGACAGCTGGTGGAA ACCGGGCAGATCACCAAGCACGTGGCCAGACTGCTGGATGAGAAGTTTAACAACAAGAAGGACGAGAACAACCG- GGCCGTGCGGACCGTGAA GATCATCACCCTGAAGTCCACCCTGGTGTCCCAGTTCCGGAAGGACTTCGAGCTGTATAAAGTGCGCGAGATCA- ATGACTTTCACCACGCCC ACGACGGCTACCTGAATGCCGTGGTGGCTTCCGCCCTGCTGAAGAAGTACCCTAAGCTGGAACCCGAGTTCGTG- TACGGCGACTACCCCAAG TACAACTGGTTCAGAGAGGGGAAGTCCGCCACCGAGAAGGTGTACTTCTACTCCAACATCATGAATATCTTTAA- GAAGTCCATCTCCCTGGC CGATGGCAGAGTGATCGAGGGGCCGCTGATCGAAGTGAACGAAGAGACAGGCGAGAGCGTGTGGAACAAAGAAA- GCGACCTGGCCACCGTGC GGGGGGTGGTGAGTTATGGTGAAGTGAATGTGGTGAAGAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAG- TCTATCCTGCCCAAGAGGA ACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTG- GCCTATTCTGTGCTGGTGG TGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAA- AGAAGCAGCTTCGAGAAGA ATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTAC- TCCCTGTTCGAGCTGGAAA ACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATAT- GTGAACTTCCTGTACCTGG CCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAG- CACTACCTGGACGAGATCA TCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTAC- AACAAGCACCGGGATAAGC CCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAG- TACTTTGACACCACCATCG ACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTAC- GAGACACGGATCGACCTGT CTCAGCTGGGAGGCGACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAG (SEQ ID NO: 84) SpCas9 nickases Mutated residues (changed to GCC) bolded in order: D10, E762, N863, H983, D986 ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAAAGACGATGACGATAAGATGGC- CCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCA GCCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCGACGAGTA- CAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAACAGCCGAGGCCACCCGGC- TGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCG GATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAG- AGTCCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCC CATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAAC- TGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTATCT GGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGACG- TGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCT GTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCA- GACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAA GAATGGCCTGTTCGGCAACCTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGG- CCGAGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGA CGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCG- ACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGAT CACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAG- CTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTT CTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCA- TCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCT CGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCC- ACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTT TTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCC- CTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAA GAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCG- AGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGT GCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCG- AGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAA GGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGA- AAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGA TCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATG- AGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGAC ACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGA- AGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAG CCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCT- TCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCT GACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATC- TGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGT GAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAG- AGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGA GAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACC- CAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATG GGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCT- CAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGA CCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTAC- TGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAG TTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCT- GGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTG GACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTC- CAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAA GTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAA- AAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTA CAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCT- TCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCT GGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGG- GCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCA AGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACA- GCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAA GTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCA- AGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCAT GGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACC- TGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAA CGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATG- TGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGG CTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGC- AGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAA TCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCC- ACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAA GTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACC- AGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCA GCTGGGAGGCGACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAG (SEQ ID NO: 85) SpCas9 point mutants Mutated residues (changed to GCC) bolded in order: R63A, R66A, R69A, R70A, R74A, R75A, R78A, K163A, R165A, K510A ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAAAGACGATGACGATAAGATGGC- CCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCA GCCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCGACGAGTA- CAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGAC CGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAACAGCCGAGGCCACCCGGCT- GAAGAGAACCGCCAAGAAGAGATACACCAGACGGAAGAACCG GATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAG- AGTCCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACC CCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAA- CTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTATC TGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGAC- GTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAG CTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAG- CAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAG AAGAATGGCCTGTTCGGCAACCTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCT- GGCCGAGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGAC GACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTC- CGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAG ATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAA- AGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATT TTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTT- CATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTG CTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGAT- CCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGAT TTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGG- CCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGA AAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCAT- CGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAG GTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGAC- CGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAA AAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCA- AGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGA AGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACA- ATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCT GACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGA- TGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCT GAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACG- GCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAG CCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCA- ATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGAC AGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCA- GAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGA GAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACA- CCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAA TGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGC- CTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCT GACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACT- ACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAA GTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGC- TGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCT GGACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGT- CCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAA AGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCA- AAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTA CAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCT- TCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCT GGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGG- GCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCA AGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACA- GCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAA GTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCA- AGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCAT GGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACC- TGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAA CGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATG- TGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGG CTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGC- AGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAA TCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCC- ACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAA GTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACC- AGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCA GCTGGGAGGCGACAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAG (SEQ ID NO: 86) sgRNA sequences: guide sequence underlined +83 GAGUCCGAGCAGAAGAAGAAGCCCCAGAGCUAGAAAUAGCAAGUUGGGGUAAGGCUAGUCCGUUAUCAACUUGA- AAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 87) +47 GAGUCCGAGCAGAAGAAGAAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUUU (SEQ ID NO: 88) +67 GAGUCCGAGCAGAAGAAGAAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGA- AAAGUGUUUU (SEQ ID NO: 89) mutate proximal crRNA: tracrRNA duplex GAGUCCGAGCAGAAGAAGAAGCCCCAGAGCUAGAAAUAGCAAGUUGGGGUAAGGCUAGUCCGUUAUCAACUUGA- AAAAGUGGCACCGAGUCGGUGCUUU (SEQ ID NO: 90) truncate distal crRNA: tracrRNA duplex GAGUCCGAGCAGAAGAAGAAGUUUUAGAGACAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGC- ACCGAGUCGGUGCUUUU (SEQ ID NO: 91) remove crRNA: tracrRNA duplex bulge GAGUCCGAGCAGAAGAAGAAGUUUUAGAGCUAGAAAUAGCUUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAA- AAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 92)

abolish stemloop 1 GAGUCCGAGCAGAAGAAGAAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAUUCUAGUAAGUUAUCAACUUGA- AAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 93) mutate stemloop 1 GAGUCCGAGCAGAAGAAGAAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGCCAUGUGCGUUAUCAACUUGA- AAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 94) truncate linker GAGUCCGAGCAGAAGAAGAAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUAACUUGAAAAA- GUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 95) replace stempllo 2 GAGUCCGAGCAGAAGAAGAAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCACGCCGA- AAGGCGGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 96) lengthen stemloop 2 GAGUCCGAGCAGAAGAAGAAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGA- GAAAUCAAGUGGCACCGAGUCGGUGCUUU (SEQ ID NO: 97) mutate stemloop 3 GAGUCCGAGCAGAAGAAGAAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGA- AAAAGUGGCCCGCGGCGGGGCUUUU (SEQ ID NO: 98) lengthen stemloop 3 GAGUCCGAGCAGAAGAAGAAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGA- AAAAGUGGCACCGAAAGUUUCGGUGCUUUU (SEQ ID NO: 99) reconstructed sgRNA GAGUCCGAGCAGAAGAAGAAGCCCAGAGCAUUAGCAAGUUGGGGUAAGCCAUGUGCGUUAUCAGGGCACCAGCC- CGGCACCGAGUCGGUGCUUUU (SEQ IDD NO: 100) G43A GAGUCCGAGCAGAAGAAGAAGUUUUAGAGCUAGAAAUAGCAACUUAAAAUAAGGCUAGUCCGUUAUCAACUUGA- AAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 101) U44G GAGUCCGAGCAGAAGAAGAAGUUUUAGAGCUAGAAAUAGCAAGGUAAAAUAAGGCUAGUCCGUUAUCAACUUGA- AAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 102) U44C GAGUCCGAGCAGAAGAAGAAGUUUUAGAGCUAGAAAUAGCAAGCUAAAAUAAGGCUAGUCCGUUAUCAACUUGA- AAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 103) Primers (SEQ ID NOS 104-107, respectively, in order of appearance) Cas9 Target PAM SURVEYOR primer F SURVERYOR R Sp GAGTCCGAGCAGAAGAAGAA GGG CCATCCCCTTCTGTGAATGT GGAGATTGGAGACACGGAGA St3 GCTCCCATCACATCAACCGG TGGCG same same

[0201] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

REFERENCES

[0202] 1. Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S. & Gregory, P. D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 11, 636-646 (2010).

[0203] 2. Bogdanove, A. J. & Voytas, D. F. TAL effectors: customizable proteins for DNA targeting. Science 333, 1843-1846 (2011).

[0204] 3. Stoddard, B. L. Homing endonuclease structure and function. Q. Rev. Biophys. 38, 49-95 (2005).

[0205] 4. Bae, T. & Schneewind, O. Allelic replacement in Staphylococcus aureus with inducible counter-selection. Plasmid 55, 58-63 (2006).

[0206] 5. Sung, C. K., Li, H., Claverys, J. P. & Morrison, D. A. An rpsL cassette, janus, for gene replacement through negative selection in Streptococcus pneumoniae. Appl. Environ. Microbiol. 67, 5190-5196 (2001).

[0207] 6. Sharan, S. K., Thomason, L. C., Kuznetsov, S. G. & Court, D. L. Recombineering: a homologous recombination-based method of genetic engineering. Nat. Protoc. 4, 206-223 (2009).

[0208] 7. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012).

[0209] 8. Deveau, H., Garneau, J. E. & Moineau, S. CRISPR/Cas system and its role in phage-bacteria interactions. Annu. Rev. Microbiol. 64, 475-493 (2010).

[0210] 9. Horvath, P. & Barrangou, R. CRISPR/Cas, the immune system of bacteria and archaea. Science 327, 167-170 (2010).

[0211] 10. Terns, M. P. & Terns, R. M. CRISPR-based adaptive immune systems. Curr. Opin. Microbiol. 14, 321-327 (2011).

[0212] 11. van der Oost, J., Jore, M. M., Westra, E. R., Lundgren, M. & Brouns, S. J. CRISPR-based adaptive and heritable immunity in prokaryotes. Trends. Biochem. Sci. 34, 401-407 (2009).

[0213] 12. Brouns, S. J. et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321, 960-964 (2008).

[0214] 13. Carte, J., Wang, R., Li, H., Terns, R. M. & Terns, M. P. Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes. Genes Dev. 22, 3489-3496 (2008).

[0215] 14. Deltcheva, E. et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602-607 (2011).

[0216] 15. Hatoum-Aslan, A., Maniv, I. & Marraffini, L. A. Mature clustered, regularly interspaced, short palindromic repeats RNA (crRNA) length is measured by a ruler mechanism anchored at the precursor processing site. Proc. Natl. Acad. Sci. U.S.A. 108, 21218-21222 (2011).

[0217] 16. Haurwitz, R. E., Jinek, M., Wiedenheft, B., Zhou, K. & Doudna, J. A. Sequence- and structure-specific RNA processing by a CRISPR endonuclease. Science 329, 1355-1358 (2010).

[0218] 17. Deveau, H. et al. Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J. Bacteriol. 190, 1390-1400 (2008).

[0219] 18. Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc. Natl. Acad. Sci. U.S.A. (2012).

[0220] 19. Makarova, K. S., Aravind, L., Wolf, Y. I. & Koonin, E. V. Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems. Biol. Direct. 6, 38 (2011).

[0221] 20. Barrangou, R. RNA-mediated programmable DNA cleavage. Nat. Biotechnol. 30, 836-838 (2012).

[0222] 21. Brouns, S. J. Molecular biology. A Swiss army knife of immunity. Science 337, 808-809 (2012).

[0223] 22. Carroll, D. A CRISPR Approach to Gene Targeting. Mol. Ther. 20, 1658-1660 (2012).

[0224] 23. Bikard, D., Hatoum-Aslan, A., Mucida, D. & Marraffini, L. A. CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection. Cell Host Microbe 12, 177-186 (2012).

[0225] 24. Sapranauskas, R. et al. The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res. (2011).

[0226] 25. Semenova, E. et al. Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc. Natl. Acad. Sci. U.S.A. (2011).

[0227] 26. Wiedenheft, B. et al. RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions. Proc. Natl. Acad. Sci. U.S.A. (2011).

[0228] 27. Zahner, D. & Hakenbeck, R. The Streptococcus pneumoniae beta-galactosidase is a surface protein. J. Bacteriol. 182, 5919-5921 (2000).

[0229] 28. Marraffini, L. A., Dedent, A. C. & Schneewind, O. Sortases and the art of anchoring proteins to the envelopes of gram-positive bacteria. Microbiol. Mol. Biol. Rev. 70, 192-221 (2006).

[0230] 29. Motamedi, M. R., Szigety, S. K. & Rosenberg, S. M. Double-strand-break repair recombination in Escherichia coli: physical evidence for a DNA replication mechanism in vivo. Genes Dev. 13, 2889-2903 (1999).

[0231] 30. Hosaka, T. et al. The novel mutation K87E in ribosomal protein S12 enhances protein synthesis activity during the late growth phase in Escherichia coli. Mol. Genet. Genomics 271, 317-324 (2004).

[0232] 31. Costantino, N. & Court, D. L. Enhanced levels of lambda Red-mediated recombinants in mismatch repair mutants. Proc. Natl. Acad. Sci. U.S.A. 100, 15748-15753 (2003).

[0233] 32. Edgar, R. & Qimron, U. The Escherichia coli CRISPR system protects from lambda lysogenization, lysogens, and prophage induction. J. Bacteriol. 192, 6291-6294 (2010).

[0234] 33. Marraffini, L. A. & Sontheimer, E. J. Self versus non-self discrimination during CRISPR RNA-directed immunity. Nature 463, 568-571 (2010).

[0235] 34. Fischer, S. et al. An archaeal immune system can detect multiple Protospacer Adjacent Motifs (PAMs) to target invader DNA. J. Biol. Chem. 287, 33351-33363 (2012).

[0236] 35. Gudbergsdottir, S. et al. Dynamic properties of the Sulfolobus CRISPR/Cas and CRISPR/Cmr systems when challenged with vector-borne viral and plasmid genes and protospacers. Mol. Microbiol. 79, 35-49 (2011).

[0237] 36. Wang, H. H. et al. Genome-scale promoter engineering by coselection MAGE. Nat Methods 9, 591-593 (2012).

[0238] 37. Cong L, Ran F A, Cox D, Lin S, Barretto R, Habib N, Hsu P D, Wu X, Jiang W, Marraffini L A, Zhang F. Multiplex Genome Engineering Using CRISPR/Cas Systems. Science. 2013 Feb. 15; 339(6121):819-23.

[0239] 38. Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., and Church, G M. (2013b). RNA-guided human genome engineering via Cas9. Science 339, 823-826.

[0240] 39. Hoskins, J. et al. Genome of the bacterium Streptococcus pneumoniae strain R6. J. Bacteriol. 183, 5709-5717 (2001).

[0241] 40. Havarstein, L. S., Coomaraswamy, G. & Morrison, D. A. An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae. Proc. Natl. Acad. Sci. U.S.A. 92, 11140-11144 (1995).

[0242] 41. Horinouchi, S. & Weisblum, B. Nucleotide sequence and functional map of pC194, a plasmid that specifies inducible chloramphenicol resistance. J. Bacteriol. 150, 815-825 (1982).

[0243] 42. Horton, R. M. In Vitro Recombination and Mutagenesis of DNA: SOEing Together Tailor-Made Genes. Methods Mol. Biol. 15, 251-261 (1993).

[0244] 43. Podbielski, A., Spellerberg, B., Woischnik, M., Pohl, B. & Lutticken, R. Novel series of plasmid vectors for gene inactivation and expression analysis in group A streptococci (GAS). Gene 177, 137-147 (1996).

[0245] 44. Husmann, L. K., Scott, J. R., Lindahl, G. & Stenberg, L. Expression of the Arp protein, a member of the M protein family, is not sufficient to inhibit phagocytosis of Streptococcus pyogenes. Infection and immunity 63, 345-348 (1995).

[0246] 45. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6, 343-345 (2009).

[0247] 46. Garneau J. E. et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468,67-71(04 November 2010)

[0248] 47. Barrangou R. et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007 Mar. 23; 315(5819):1709-12.

[0249] 48. Ishino Y. et al. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 1987 December; 169(12):5429-33.

[0250] 49. Mojica F. J. M et al. Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. Molecular Microbiology (2000) 36(1), 244-246.

[0251] 50. Jansen R. et al. Identification of genes that are associated with DNA repeats in prokaryotes. Molecular Microbiology (2002) 43(6), 1565-1575.

[0252] 51. Gouet, P., Courcelle, E., Stuart, D. I., and Metoz, F. (1999). ESPript: analysis of multiple sequence alignments in PostScript. Bioinformatics 15, 305-308.

[0253] 52. Notredame, C., Higgins, D. G., and Heringa, J. (2000). T-Coffee: A novel method for fast and accurate multiple sequence alignment. J Mol Biol 302, 205-217.

[0254] 53. Adams, P. D., Grosse-Kunstleve, R. W., Hung, L. W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., and Terwilliger, T. C. (2002). PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58, 1948-1954.

[0255] 54. Ariyoshi, M., Vassylyev, D. G., Iwasaki, H., Nakamura, H., Shinagawa, H., and Morikawa, K. (1994). Atomic structure of the RuvC resolvase: a holliday junction-specific endonuclease from E. coli. Cell 78, 1063-1072.

[0256] 55. Biertumpfel, C., Yang, W., and Suck, D. (2007). Crystal structure of T4 endonuclease VII resolving a Holliday junction. Nature 449, 616-620.

[0257] 56. Chen, L., Shi, K., Yin, Z., and Aihara, H. (2013). Structural asymmetry in the Thermus thermophilus RuvC dimer suggests a basis for sequential strand cleavages during Holliday junction resolution. Nucleic acids research 41, 648-656.

[0258] 57. delaFortelle, E., and Bricogne, G. (1997). Maximum-likelihood heavy-atom parameter refinement for multiple isomorphous replacement and multiwavelength anomalous diffraction methods. Methods Enzymol 276, 472-494.

[0259] 58. Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60, 2126-2132.

[0260] 59. Fonfara, I., Le Rhun, A., Chylinski, K., Makarova, K. S., Lecrivain, A. L., Bzdrenga, J., Koonin, E. V., and Charpentier, E. (2013). Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. Nucleic acids research.

[0261] 60. Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., and Sander, J. D. (2013). High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature biotechnology 31, 822-826.

[0262] 61. Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442-451.

[0263] 62. Gorecka, K. M., Komorowska, W., and Nowotny, M. (2013). Crystal structure of RuvC resolvase in complex with Holliday junction substrate. Nucleic Acids Res 41, 9945-9955.

[0264] 63. Gratz, S. J., Cummings, A. M., Nguyen, J. N., Hamm, D. C., Donohue, L. K., Harrison, M. M., Wildonger, J., and O'Connor-Giles, K. M. (2013). Genome engineering of Drosophila with the CRISPR RNA-guided Cas9 nuclease. Genetics 194, 1029-1035.

[0265] 64. Holm, L., and Rosenstrom, P. (2010). Dali server: conservation mapping in 3D. Nucleic acids research 38, W545-549.

[0266] 65. Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. Nature biotechnology 31, 827-832.

[0267] 66. Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., Peterson, R. T., Yeh, J. R., and Joung, J. K. (2013). Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature biotechnology 31, 227-229.

[0268] 67. Kabsch, W. (2010). Xds. Acta crystallographica Section D, Biological crystallography 66, 125-132.

[0269] 68. Konermann, S., Brigham, M. D., Trevino, A. E., Hsu, P. D., Heidenreich, M., Cong, L., Platt, R. J., Scott, D. A., Church, G. M., and Zhang, F. (2013). Optical control of mammalian endogenous transcription and epigenetic states. Nature 500, 472-476.

[0270] 69. Li, C. L., Hor, L. I., Chang, Z. F., Tsai, L. C., Yang, W. Z., and Yuan, H. S. (2003). DNA binding and cleavage by the periplasmic nuclease Vvn: a novel structure with a known active site. The EMBO journal 22, 4014-4025.

[0271] 70. Maeder, M. L., Linder, S. J., Cascio, V. M., Fu, Y., Ho, Q. H., and Joung, J. K. (2013). CRISPR RNA-guided activation of endogenous human genes. Nature methods 10, 977-979.

[0272] 71. Mali, P., Aach, J., Stranges, P. B., Esvelt, K. M., Moosburner, M., Kosuri, S., Yang, L., and Church, G. M. (2013a). CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature biotechnology 31, 833-838.

[0273] 72. Marraffini, L. A., and Sontheimer, E. J. (2008). CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science 322, 1843-1845.

[0274] 73. Marraffini, L. A., and Sontheimer, E. J. (2010). CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. Nat Rev Genet 11, 181-190.

[0275] 74. Mojica, F. J., Diez-Villasenor, C., Garcia-Martinez, J., and Almendros, C. (2009). Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 155, 733-740.

[0276] 75. Pattanayak, V., Lin, S., Guilinger, J. P., Ma, E., Doudna, J. A., and Liu, D. R. (2013). High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nature biotechnology 31, 839-843.

[0277] 76. Perez-Pinera, P., Kocak, D. D., Vockley, C. M., Adler, A. F., Kabadi, A. M., Polstein, L. R., Thakore, P. I., Glass, K. A., Ousterout, D. G., Leong, K. W., et al. (2013). RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nature methods 10, 973-976.

[0278] 77. Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., and Lim, W. A. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173-1183.

[0279] 78. Ran, F. A., Hsu, P. D., Lin, C. Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013). Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380-1389.

[0280] 79. Sampson, T. R., Saroj, S. D., Llewellyn, A. C., Tzeng, Y. L., and Weiss, D. S. (2013). A CRISPR/Cas system mediates bacterial innate immune evasion and virulence. Nature 497, 254-257.

[0281] 80. Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014). Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87.



[0282] 81. Sheldrick, G. M. (2008). A short history of SHELX. Acta crystallographica Section A, Foundations of crystallography 64, 112-122.

[0283] 82. Spilman, M., Cocozaki, A., Hale, C., Shao, Y., Ramia, N., Terns, R., Terns, M., Li, H., and Stagg, S. (2013). Structure of an RNA silencing complex of the CRISPR-Cas immune system. Molecular cell 52, 146-152.

[0284] 83. Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., and Jaenisch, R. (2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910-918.

[0285] 84. Wang, T., Wei, J. J., Sabatini, D. M., and Lander, E. S. (2014). Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84.

[0286] 85. Wiedenheft, B., Lander, G. C., Zhou, K., Jore, M. M., Brouns, S. J., van der Oost, J., Doudna, J. A., and Nogales, E. (2011). Structures of the RNA-guided surveillance complex from a bacterial immune system. Nature 477, 486-489.

[0287] 86. Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G., McCoy, A., et al. (2011). Overview of the CCP4 suite and current developments. Acta crystallographica Section D, Biological crystallography 67, 235-242.

[0288] 87. Yang, H., Wang, H., Shivalila, C. S., Cheng, A. W., Shi, L., and Jaenisch, R. (2013). One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154, 1370-1379.

TABLE-US-LTS-00001

[0288] LENGTHY TABLES The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20200080067A1). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

Sequence CWU 1

1

20214PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic peptide" 1Gly Gly Gly Ser126PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic peptide" 2Ala Glu Ala Ala Ala Lys1 53137DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide"modified_base(1)..(20)a, c, t, g, unknown or other 3nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcaagatt tagaaataaa tcttgcagaa 60gctacaaaga taaggcttca tgccgaaatc aacaccctgt cattttatgg cagggtgttt 120tcgttattta atttttt 1374123DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide"modified_base(1)..(20)a, c, t, g, unknown or other 4nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcagaaat gcagaagcta caaagataag 60gcttcatgcc gaaatcaaca ccctgtcatt ttatggcagg gtgttttcgt tatttaattt 120ttt 1235110DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide"modified_base(1)..(20)a, c, t, g, unknown or other 5nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcagaaat gcagaagcta caaagataag 60gcttcatgcc gaaatcaaca ccctgtcatt ttatggcagg gtgttttttt 1106102DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide"modified_base(1)..(20)a, c, t, g, unknown or other 6nnnnnnnnnn nnnnnnnnnn gttttagagc tagaaatagc aagttaaaat aaggctagtc 60cgttatcaac ttgaaaaagt ggcaccgagt cggtgctttt tt 102788DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide"modified_base(1)..(20)a, c, t, g, unknown or other 7nnnnnnnnnn nnnnnnnnnn gttttagagc tagaaatagc aagttaaaat aaggctagtc 60cgttatcaac ttgaaaaagt gttttttt 88876DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide"modified_base(1)..(20)a, c, t, g, unknown or other 8nnnnnnnnnn nnnnnnnnnn gttttagagc tagaaatagc aagttaaaat aaggctagtc 60cgttatcatt tttttt 76920DNAHomo sapiens 9gagtccgagc agaagaagaa 201020DNAHomo sapiens 10gagtcctagc aggagaagaa 201120DNAHomo sapiens 11gagtctaagc agaagaagaa 20127PRTSimian virus 40 12Pro Lys Lys Lys Arg Lys Val1 51316PRTUnknownsource/note="Description of Unknown Nucleoplasmin bipartite NLS sequence" 13Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys1 5 10 15149PRTUnknownsource/note="Description of Unknown C-myc NLS sequence" 14Pro Ala Ala Lys Arg Val Lys Leu Asp1 51511PRTUnknownsource/note="Description of Unknown C-myc NLS sequence" 15Arg Gln Arg Arg Asn Glu Leu Lys Arg Ser Pro1 5 101638PRTHomo sapiens 16Asn Gln Ser Ser Asn Phe Gly Pro Met Lys Gly Gly Asn Phe Gly Gly1 5 10 15Arg Ser Ser Gly Pro Tyr Gly Gly Gly Gly Gln Tyr Phe Ala Lys Pro 20 25 30Arg Asn Gln Gly Gly Tyr 351742PRTUnknownsource/note="Description of Unknown IBB domain from importin-alpha sequence" 17Arg Met Arg Ile Glx Phe Lys Asn Lys Gly Lys Asp Thr Ala Glu Leu1 5 10 15Arg Arg Arg Arg Val Glu Val Ser Val Glu Leu Arg Lys Ala Lys Lys 20 25 30Asp Glu Gln Ile Leu Lys Arg Arg Asn Val 35 40188PRTUnknownsource/note="Description of Unknown Myoma T Protein sequence" 18Val Ser Arg Lys Arg Pro Arg Pro1 5198PRTUnknownsource/note="Description of Unknown Myoma T Protein sequence" 19Pro Pro Lys Lys Ala Arg Glu Asp1 5208PRTHomo sapiens 20Pro Gln Pro Lys Lys Lys Pro Leu1 52112PRTMus musculus 21Ser Ala Leu Ile Lys Lys Lys Lys Lys Met Ala Pro1 5 10225PRTInfluenza virus 22Asp Arg Leu Arg Arg1 5237PRTInfluenza virus 23Pro Lys Gln Lys Lys Arg Lys1 52410PRTHepatitis delta virus 24Arg Lys Leu Lys Lys Lys Ile Lys Lys Leu1 5 102510PRTMus musculus 25Arg Glu Lys Lys Lys Phe Leu Lys Arg Arg1 5 102620PRTHomo sapiens 26Lys Arg Lys Gly Asp Glu Val Asp Gly Val Asp Glu Val Ala Lys Lys1 5 10 15Lys Ser Lys Lys 202717PRTHomo sapiens 27Arg Lys Cys Leu Gln Ala Gly Met Asn Leu Glu Ala Arg Lys Thr Lys1 5 10 15Lys2812PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic peptide" 28Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser1 5 10297PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic peptide" 29Ala Glu Ala Ala Ala Lys Ala1 53012RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 30guuuuagagc ua 12314203DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 31atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg aaccccgaca acagcgacgt ggacaagctg 600ttcatccagc tggtgcagac ctacaaccag ctgttcgagg aaaaccccat caacgccagc 660ggcgtggacg ccaaggccat cctgtctgcc agactgagca agagcagacg gctggaaaat 720ctgatcgccc agctgcccgg cgagaagaag aatggcctgt tcggaaacct gattgccctg 780agcctgggcc tgacccccaa cttcaagagc aacttcgacc tggccgagga tgccaaactg 840cagctgagca aggacaccta cgacgacgac ctggacaacc tgctggccca gatcggcgac 900cagtacgccg acctgtttct ggccgccaag aacctgtccg acgccatcct gctgagcgac 960atcctgagag tgaacaccga gatcaccaag gcccccctga gcgcctctat gatcaagaga 1020tacgacgagc accaccagga cctgaccctg ctgaaagctc tcgtgcggca gcagctgcct 1080gagaagtaca aagagatttt cttcgaccag agcaagaacg gctacgccgg ctacattgac 1140ggcggagcca gccaggaaga gttctacaag ttcatcaagc ccatcctgga aaagatggac 1200ggcaccgagg aactgctcgt gaagctgaac agagaggacc tgctgcggaa gcagcggacc 1260ttcgacaacg gcagcatccc ccaccagatc cacctgggag agctgcacgc cattctgcgg 1320cggcaggaag atttttaccc attcctgaag gacaaccggg aaaagatcga gaagatcctg 1380accttccgca tcccctacta cgtgggccct ctggccaggg gaaacagcag attcgcctgg 1440atgaccagaa agagcgagga aaccatcacc ccctggaact tcgaggaagt ggtggacaag 1500ggcgcttccg cccagagctt catcgagcgg atgaccaact tcgataagaa cctgcccaac 1560gagaaggtgc tgcccaagca cagcctgctg tacgagtact tcaccgtgta taacgagctg 1620accaaagtga aatacgtgac cgagggaatg agaaagcccg ccttcctgag cggcgagcag 1680aaaaaggcca tcgtggacct gctgttcaag accaaccgga aagtgaccgt gaagcagctg 1740aaagaggact acttcaagaa aatcgagtgc ttcgactccg tggaaatctc cggcgtggaa 1800gatcggttca acgcctccct gggcacatac cacgatctgc tgaaaattat caaggacaag 1860gacttcctgg acaatgagga aaacgaggac attctggaag atatcgtgct gaccctgaca 1920ctgtttgagg acagagagat gatcgaggaa cggctgaaaa cctatgccca cctgttcgac 1980gacaaagtga tgaagcagct gaagcggcgg agatacaccg gctggggcag gctgagccgg 2040aagctgatca acggcatccg ggacaagcag tccggcaaga caatcctgga tttcctgaag 2100tccgacggct tcgccaacag aaacttcatg cagctgatcc acgacgacag cctgaccttt 2160aaagaggaca tccagaaagc ccaggtgtcc ggccagggcg atagcctgca cgagcacatt 2220gccaatctgg ccggcagccc cgccattaag aagggcatcc tgcagacagt gaaggtggtg 2280gacgagctcg tgaaagtgat gggccggcac aagcccgaga acatcgtgat cgaaatggcc 2340agagagaacc agaccaccca gaagggacag aagaacagcc gcgagagaat gaagcggatc 2400gaagagggca tcaaagagct gggcagccag atcctgaaag aacaccccgt ggaaaacacc 2460cagctgcaga acgagaagct gtacctgtac tacctgcaga atgggcggga tatgtacgtg 2520gaccaggaac tggacatcaa ccggctgtcc gactacgatg tggaccatat cgtgcctcag 2580agctttctga aggacgactc catcgacaac aaggtgctga ccagaagcga caagaaccgg 2640ggcaagagcg acaacgtgcc ctccgaagag gtcgtgaaga agatgaagaa ctactggcgg 2700cagctgctga acgccaagct gattacccag agaaagttcg acaatctgac caaggccgag 2760agaggcggcc tgagcgaact ggataaggcc ggcttcatca agagacagct ggtggaaacc 2820cggcagatca caaagcacgt ggcacagatc ctggactccc ggatgaacac taagtacgac 2880gagaatgaca agctgatccg ggaagtgaaa gtgatcaccc tgaagtccaa gctggtgtcc 2940gatttccgga aggatttcca gttttacaaa gtgcgcgaga tcaacaacta ccaccacgcc 3000cacgacgcct acctgaacgc cgtcgtggga accgccctga tcaaaaagta ccctaagctg 3060gaaagcgagt tcgtgtacgg cgactacaag gtgtacgacg tgcggaagat gatcgccaag 3120agcgagcagg aaatcggcaa ggctaccgcc aagtacttct tctacagcaa catcatgaac 3180tttttcaaga ccgagattac cctggccaac ggcgagatcc ggaagcggcc tctgatcgag 3240acaaacggcg aaaccgggga gatcgtgtgg gataagggcc gggattttgc caccgtgcgg 3300aaagtgctga gcatgcccca agtgaatatc gtgaaaaaga ccgaggtgca gacaggcggc 3360ttcagcaaag agtctatcct gcccaagagg aacagcgata agctgatcgc cagaaagaag 3420gactgggacc ctaagaagta cggcggcttc gacagcccca ccgtggccta ttctgtgctg 3480gtggtggcca aagtggaaaa gggcaagtcc aagaaactga agagtgtgaa agagctgctg 3540gggatcacca tcatggaaag aagcagcttc gagaagaatc ccatcgactt tctggaagcc 3600aagggctaca aagaagtgaa aaaggacctg atcatcaagc tgcctaagta ctccctgttc 3660gagctggaaa acggccggaa gagaatgctg gcctctgccg gcgaactgca gaagggaaac 3720gaactggccc tgccctccaa atatgtgaac ttcctgtacc tggccagcca ctatgagaag 3780ctgaagggct cccccgagga taatgagcag aaacagctgt ttgtggaaca gcacaagcac 3840tacctggacg agatcatcga gcagatcagc gagttctcca agagagtgat cctggccgac 3900gctaatctgg acaaagtgct gtccgcctac aacaagcacc gggataagcc catcagagag 3960caggccgaga atatcatcca cctgtttacc ctgaccaatc tgggagcccc tgccgccttc 4020aagtactttg acaccaccat cgaccggaag aggtacacca gcaccaaaga ggtgctggac 4080gccaccctga tccaccagag catcaccggc ctgtacgaga cacggatcga cctgtctcag 4140ctgggaggcg acaaaaggcc ggcggccacg aaaaaggccg gccaggcaaa aaagaaaaag 4200taa 42033251DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 32atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc c 5133171DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 33gacaagaagt acagcatcgg cctggacatc ggcaccaact ctgtgggctg ggccgtgatc 60accgacgagt acaaggtgcc cagcaagaaa ttcaaggtgc tgggcaacac cgaccggcac 120agcatcaaga agaacctgat cggagccctg ctgttcgaca gcggcgaaac a 1713484DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 34gccgaggcca cccggctgaa gagaaccgcc agaagaagat acaccagacg gaagaaccgg 60atctgctatc tgcaagagat cttc 8435261DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 35agcaacgaga tggccaaggt ggacgacagc ttcttccaca gactggaaga gtccttcctg 60gtggaagagg ataagaagca cgagcggcac cccatcttcg gcaacatcgt ggacgaggtg 120gcctaccacg agaagtaccc caccatctac cacctgagaa agaaactggt ggacagcacc 180gacaaggccg acctgcggct gatctatctg gccctggccc acatgatcaa gttccggggc 240cacttcctga tcgagggcga c 26136414DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 36ctgaaccccg acaacagcga cgtggacaag ctgttcatcc agctggtgca gacctacaac 60cagctgttcg aggaaaaccc catcaacgcc agcggcgtgg acgccaaggc catcctgtct 120gccagactga gcaagagcag acggctggaa aatctgatcg cccagctgcc cggcgagaag 180aagaatggcc tgttcggaaa cctgattgcc ctgagcctgg gcctgacccc caacttcaag 240agcaacttcg acctggccga ggatgccaaa ctgcagctga gcaaggacac ctacgacgac 300gacctggaca acctgctggc ccagatcggc gaccagtacg ccgacctgtt tctggccgcc 360aagaacctgt ccgacgccat cctgctgagc gacatcctga gagtgaacac cgag 414371200DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 37atcaccaagg cccccctgag cgcctctatg atcaagagat acgacgagca ccaccaggac 60ctgaccctgc tgaaagctct cgtgcggcag cagctgcctg agaagtacaa agagattttc 120ttcgaccaga gcaagaacgg ctacgccggc tacattgacg gcggagccag ccaggaagag 180ttctacaagt tcatcaagcc catcctggaa aagatggacg gcaccgagga actgctcgtg 240aagctgaaca gagaggacct gctgcggaag cagcggacct tcgacaacgg cagcatcccc 300caccagatcc acctgggaga gctgcacgcc attctgcggc ggcaggaaga tttttaccca 360ttcctgaagg acaaccggga aaagatcgag aagatcctga ccttccgcat cccctactac 420gtgggccctc tggccagggg aaacagcaga ttcgcctgga tgaccagaaa gagcgaggaa 480accatcaccc cctggaactt cgaggaagtg gtggacaagg gcgcttccgc ccagagcttc 540atcgagcgga tgaccaactt cgataagaac ctgcccaacg agaaggtgct gcccaagcac 600agcctgctgt acgagtactt caccgtgtat aacgagctga ccaaagtgaa atacgtgacc 660gagggaatga gaaagcccgc cttcctgagc ggcgagcaga aaaaggccat cgtggacctg 720ctgttcaaga ccaaccggaa agtgaccgtg aagcagctga aagaggacta cttcaagaaa 780atcgagtgct tcgactccgt ggaaatctcc ggcgtggaag atcggttcaa cgcctccctg 840ggcacatacc acgatctgct gaaaattatc aaggacaagg acttcctgga caatgaggaa 900aacgaggaca ttctggaaga tatcgtgctg accctgacac tgtttgagga cagagagatg 960atcgaggaac ggctgaaaac ctatgcccac ctgttcgacg acaaagtgat gaagcagctg 1020aagcggcgga gatacaccgg ctggggcagg ctgagccgga agctgatcaa cggcatccgg 1080gacaagcagt ccggcaagac aatcctggat ttcctgaagt ccgacggctt cgccaacaga 1140aacttcatgc agctgatcca cgacgacagc ctgaccttta aagaggacat ccagaaagcc 12003821DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 38caggtgtccg gccagggcga t 213924DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 39atcgtgatcg aaatggccag agag 244087DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 40gactacgatg tggaccatat cgtgcctcag agctttctga aggacgactc catcgacaac 60aaggtgctga ccagaagcga caagaac 874124DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 41caccacgccc acgacgccta cctg 2442813DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 42accgaggtgc agacaggcgg cttcagcaaa gagtctatcc tgcccaagag gaacagcgat 60aagctgatcg ccagaaagaa ggactgggac cctaagaagt acggcggctt cgacagcccc 120accgtggcct attctgtgct ggtggtggcc aaagtggaaa agggcaagtc caagaaactg 180aagagtgtga aagagctgct ggggatcacc atcatggaaa gaagcagctt cgagaagaat 240cccatcgact ttctggaagc caagggctac aaagaagtga aaaaggacct gatcatcaag 300ctgcctaagt actccctgtt cgagctggaa aacggccgga agagaatgct ggcctctgcc 360ggcgaactgc agaagggaaa cgaactggcc ctgccctcca aatatgtgaa cttcctgtac 420ctggccagcc actatgagaa gctgaagggc tcccccgagg ataatgagca gaaacagctg 480tttgtggaac agcacaagca ctacctggac gagatcatcg agcagatcag cgagttctcc 540aagagagtga tcctggccga cgctaatctg gacaaagtgc tgtccgccta caacaagcac 600cgggataagc ccatcagaga gcaggccgag aatatcatcc acctgtttac cctgaccaat 660ctgggagccc ctgccgcctt caagtacttt gacaccacca tcgaccggaa gaggtacacc 720agcaccaaag aggtgctgga cgccaccctg atccaccaga gcatcaccgg cctgtacgag 780acacggatcg acctgtctca gctgggaggc gac 8134348DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 43aaaaggccgg cggccacgaa aaaggccggc caggcaaaaa agaaaaag 48443789DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 44atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacatc accaaggcac cactgagcgc ctctatgatc 600aagagatacg acgagcacca ccaggacctg accctgctga aagctctcgt gcggcagcag 660ctgcctgaga agtacaaaga gattttcttc gaccagagca agaacggcta cgccggctac 720attgacggcg gagccagcca ggaagagttc tacaagttca tcaagcccat cctggaaaag 780atggacggca ccgaggaact gctcgtgaag ctgaacagag aggacctgct gcggaagcag 840cggaccttcg acaacggcag catcccccac cagatccacc tgggagagct gcacgccatt 900ctgcggcggc aggaagattt ttacccattc ctgaaggaca accgggaaaa gatcgagaag 960atcctgacct tccgcatccc ctactacgtg ggccctctgg ccaggggaaa cagcagattc 1020gcctggatga ccagaaagag cgaggaaacc atcaccccct ggaacttcga ggaagtggtg 1080gacaagggcg cttccgccca gagcttcatc gagcggatga ccaacttcga taagaacctg 1140cccaacgaga aggtgctgcc caagcacagc ctgctgtacg agtacttcac cgtgtataac 1200gagctgacca aagtgaaata cgtgaccgag ggaatgagaa agcccgcctt cctgagcggc 1260gagcagaaaa aggccatcgt ggacctgctg ttcaagacca accggaaagt gaccgtgaag 1320cagctgaaag aggactactt

caagaaaatc gagtgcttcg actccgtgga aatctccggc 1380gtggaagatc ggttcaacgc ctccctgggc acataccacg atctgctgaa aattatcaag 1440gacaaggact tcctggacaa tgaggaaaac gaggacattc tggaagatat cgtgctgacc 1500ctgacactgt ttgaggacag agagatgatc gaggaacggc tgaaaaccta tgcccacctg 1560ttcgacgaca aagtgatgaa gcagctgaag cggcggagat acaccggctg gggcaggctg 1620agccggaagc tgatcaacgg catccgggac aagcagtccg gcaagacaat cctggatttc 1680ctgaagtccg acggcttcgc caacagaaac ttcatgcagc tgatccacga cgacagcctg 1740acctttaaag aggacatcca gaaagcccag gtgtccggcc agggcgatag cctgcacgag 1800cacattgcca atctggccgg cagccccgcc attaagaagg gcatcctgca gacagtgaag 1860gtggtggacg agctcgtgaa agtgatgggc cggcacaagc ccgagaacat cgtgatcgaa 1920atggccagag agaaccagac cacccagaag ggacagaaga acagccgcga gagaatgaag 1980cggatcgaag agggcatcaa agagctgggc agccagatcc tgaaagaaca ccccgtggaa 2040aacacccagc tgcagaacga gaagctgtac ctgtactacc tgcagaatgg gcgggatatg 2100tacgtggacc aggaactgga catcaaccgg ctgtccgact acgatgtgga ccatatcgtg 2160cctcagagct ttctgaagga cgactccatc gacaacaagg tgctgaccag aagcgacaag 2220aaccggggca agagcgacaa cgtgccctcc gaagaggtcg tgaagaagat gaagaactac 2280tggcggcagc tgctgaacgc caagctgatt acccagagaa agttcgacaa tctgaccaag 2340gccgagagag gcggcctgag cgaactggat aaggccggct tcatcaagag acagctggtg 2400gaaacccggc agatcacaaa gcacgtggca cagatcctgg actcccggat gaacactaag 2460tacgacgaga atgacaagct gatccgggaa gtgaaagtga tcaccctgaa gtccaagctg 2520gtgtccgatt tccggaagga tttccagttt tacaaagtgc gcgagatcaa caactaccac 2580cacgcccacg acgcctacct gaacgccgtc gtgggaaccg ccctgatcaa aaagtaccct 2640aagctggaaa gcgagttcgt gtacggcgac tacaaggtgt acgacgtgcg gaagatgatc 2700gccaagagcg agcaggaaat cggcaaggct accgccaagt acttcttcta cagcaacatc 2760atgaactttt tcaagaccga gattaccctg gccaacggcg agatccggaa gcggcctctg 2820atcgagacaa acggcgaaac cggggagatc gtgtgggata agggccggga ttttgccacc 2880gtgcggaaag tgctgagcat gccccaagtg aatatcgtga aaaagaccga ggtgcagaca 2940ggcggcttca gcaaagagtc tatcctgccc aagaggaaca gcgataagct gatcgccaga 3000aagaaggact gggaccctaa gaagtacggc ggcttcgaca gccccaccgt ggcctattct 3060gtgctggtgg tggccaaagt ggaaaagggc aagtccaaga aactgaagag tgtgaaagag 3120ctgctgggga tcaccatcat ggaaagaagc agcttcgaga agaatcccat cgactttctg 3180gaagccaagg gctacaaaga agtgaaaaag gacctgatca tcaagctgcc taagtactcc 3240ctgttcgagc tggaaaacgg ccggaagaga atgctggcct ctgccggcga actgcagaag 3300ggaaacgaac tggccctgcc ctccaaatat gtgaacttcc tgtacctggc cagccactat 3360gagaagctga agggctcccc cgaggataat gagcagaaac agctgtttgt ggaacagcac 3420aagcactacc tggacgagat catcgagcag atcagcgagt tctccaagag agtgatcctg 3480gccgacgcta atctggacaa agtgctgtcc gcctacaaca agcaccggga taagcccatc 3540agagagcagg ccgagaatat catccacctg tttaccctga ccaatctggg agcccctgcc 3600gccttcaagt actttgacac caccatcgac cggaagaggt acaccagcac caaagaggtg 3660ctggacgcca ccctgatcca ccagagcatc accggcctgt acgagacacg gatcgacctg 3720tctcagctgg gaggcgacaa aaggccggcg gccacgaaaa aggccggcca ggcaaaaaag 3780aaaaagtaa 37894515PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic peptide" 45Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser1 5 10 15463834DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 46atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacggt ggcggtggct cgggtggcgg tggctcgggt 600ggcggtggct cgatcaccaa ggcccccctg agcgcctcta tgatcaagag atacgacgag 660caccaccagg acctgaccct gctgaaagct ctcgtgcggc agcagctgcc tgagaagtac 720aaagagattt tcttcgacca gagcaagaac ggctacgccg gctacattga cggcggagcc 780agccaggaag agttctacaa gttcatcaag cccatcctgg aaaagatgga cggcaccgag 840gaactgctcg tgaagctgaa cagagaggac ctgctgcgga agcagcggac cttcgacaac 900ggcagcatcc cccaccagat ccacctggga gagctgcacg ccattctgcg gcggcaggaa 960gatttttacc cattcctgaa ggacaaccgg gaaaagatcg agaagatcct gaccttccgc 1020atcccctact acgtgggccc tctggccagg ggaaacagca gattcgcctg gatgaccaga 1080aagagcgagg aaaccatcac cccctggaac ttcgaggaag tggtggacaa gggcgcttcc 1140gcccagagct tcatcgagcg gatgaccaac ttcgataaga acctgcccaa cgagaaggtg 1200ctgcccaagc acagcctgct gtacgagtac ttcaccgtgt ataacgagct gaccaaagtg 1260aaatacgtga ccgagggaat gagaaagccc gccttcctga gcggcgagca gaaaaaggcc 1320atcgtggacc tgctgttcaa gaccaaccgg aaagtgaccg tgaagcagct gaaagaggac 1380tacttcaaga aaatcgagtg cttcgactcc gtggaaatct ccggcgtgga agatcggttc 1440aacgcctccc tgggcacata ccacgatctg ctgaaaatta tcaaggacaa ggacttcctg 1500gacaatgagg aaaacgagga cattctggaa gatatcgtgc tgaccctgac actgtttgag 1560gacagagaga tgatcgagga acggctgaaa acctatgccc acctgttcga cgacaaagtg 1620atgaagcagc tgaagcggcg gagatacacc ggctggggca ggctgagccg gaagctgatc 1680aacggcatcc gggacaagca gtccggcaag acaatcctgg atttcctgaa gtccgacggc 1740ttcgccaaca gaaacttcat gcagctgatc cacgacgaca gcctgacctt taaagaggac 1800atccagaaag cccaggtgtc cggccagggc gatagcctgc acgagcacat tgccaatctg 1860gccggcagcc ccgccattaa gaagggcatc ctgcagacag tgaaggtggt ggacgagctc 1920gtgaaagtga tgggccggca caagcccgag aacatcgtga tcgaaatggc cagagagaac 1980cagaccaccc agaagggaca gaagaacagc cgcgagagaa tgaagcggat cgaagagggc 2040atcaaagagc tgggcagcca gatcctgaaa gaacaccccg tggaaaacac ccagctgcag 2100aacgagaagc tgtacctgta ctacctgcag aatgggcggg atatgtacgt ggaccaggaa 2160ctggacatca accggctgtc cgactacgat gtggaccata tcgtgcctca gagctttctg 2220aaggacgact ccatcgacaa caaggtgctg accagaagcg acaagaaccg gggcaagagc 2280gacaacgtgc cctccgaaga ggtcgtgaag aagatgaaga actactggcg gcagctgctg 2340aacgccaagc tgattaccca gagaaagttc gacaatctga ccaaggccga gagaggcggc 2400ctgagcgaac tggataaggc cggcttcatc aagagacagc tggtggaaac ccggcagatc 2460acaaagcacg tggcacagat cctggactcc cggatgaaca ctaagtacga cgagaatgac 2520aagctgatcc gggaagtgaa agtgatcacc ctgaagtcca agctggtgtc cgatttccgg 2580aaggatttcc agttttacaa agtgcgcgag atcaacaact accaccacgc ccacgacgcc 2640tacctgaacg ccgtcgtggg aaccgccctg atcaaaaagt accctaagct ggaaagcgag 2700ttcgtgtacg gcgactacaa ggtgtacgac gtgcggaaga tgatcgccaa gagcgagcag 2760gaaatcggca aggctaccgc caagtacttc ttctacagca acatcatgaa ctttttcaag 2820accgagatta ccctggccaa cggcgagatc cggaagcggc ctctgatcga gacaaacggc 2880gaaaccgggg agatcgtgtg ggataagggc cgggattttg ccaccgtgcg gaaagtgctg 2940agcatgcccc aagtgaatat cgtgaaaaag accgaggtgc agacaggcgg cttcagcaaa 3000gagtctatcc tgcccaagag gaacagcgat aagctgatcg ccagaaagaa ggactgggac 3060cctaagaagt acggcggctt cgacagcccc accgtggcct attctgtgct ggtggtggcc 3120aaagtggaaa agggcaagtc caagaaactg aagagtgtga aagagctgct ggggatcacc 3180atcatggaaa gaagcagctt cgagaagaat cccatcgact ttctggaagc caagggctac 3240aaagaagtga aaaaggacct gatcatcaag ctgcctaagt actccctgtt cgagctggaa 3300aacggccgga agagaatgct ggcctctgcc ggcgaactgc agaagggaaa cgaactggcc 3360ctgccctcca aatatgtgaa cttcctgtac ctggccagcc actatgagaa gctgaagggc 3420tcccccgagg ataatgagca gaaacagctg tttgtggaac agcacaagca ctacctggac 3480gagatcatcg agcagatcag cgagttctcc aagagagtga tcctggccga cgctaatctg 3540gacaaagtgc tgtccgccta caacaagcac cgggataagc ccatcagaga gcaggccgag 3600aatatcatcc acctgtttac cctgaccaat ctgggagccc ctgccgcctt caagtacttt 3660gacaccacca tcgaccggaa gaggtacacc agcaccaaag aggtgctgga cgccaccctg 3720atccaccaga gcatcaccgg cctgtacgag acacggatcg acctgtctca gctgggaggc 3780gacaaaaggc cggcggccac gaaaaaggcc ggccaggcaa aaaagaaaaa gtaa 38344730PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 47Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1 5 10 15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 20 25 30483879DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 48atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacggt ggcggtggct cgggtggcgg tggctcgggt 600ggcggtggct cgggtggcgg tggctcgggt ggcggtggct cgggtggcgg tggctcgatc 660accaaggccc ccctgagcgc ctctatgatc aagagatacg acgagcacca ccaggacctg 720accctgctga aagctctcgt gcggcagcag ctgcctgaga agtacaaaga gattttcttc 780gaccagagca agaacggcta cgccggctac attgacggcg gagccagcca ggaagagttc 840tacaagttca tcaagcccat cctggaaaag atggacggca ccgaggaact gctcgtgaag 900ctgaacagag aggacctgct gcggaagcag cggaccttcg acaacggcag catcccccac 960cagatccacc tgggagagct gcacgccatt ctgcggcggc aggaagattt ttacccattc 1020ctgaaggaca accgggaaaa gatcgagaag atcctgacct tccgcatccc ctactacgtg 1080ggccctctgg ccaggggaaa cagcagattc gcctggatga ccagaaagag cgaggaaacc 1140atcaccccct ggaacttcga ggaagtggtg gacaagggcg cttccgccca gagcttcatc 1200gagcggatga ccaacttcga taagaacctg cccaacgaga aggtgctgcc caagcacagc 1260ctgctgtacg agtacttcac cgtgtataac gagctgacca aagtgaaata cgtgaccgag 1320ggaatgagaa agcccgcctt cctgagcggc gagcagaaaa aggccatcgt ggacctgctg 1380ttcaagacca accggaaagt gaccgtgaag cagctgaaag aggactactt caagaaaatc 1440gagtgcttcg actccgtgga aatctccggc gtggaagatc ggttcaacgc ctccctgggc 1500acataccacg atctgctgaa aattatcaag gacaaggact tcctggacaa tgaggaaaac 1560gaggacattc tggaagatat cgtgctgacc ctgacactgt ttgaggacag agagatgatc 1620gaggaacggc tgaaaaccta tgcccacctg ttcgacgaca aagtgatgaa gcagctgaag 1680cggcggagat acaccggctg gggcaggctg agccggaagc tgatcaacgg catccgggac 1740aagcagtccg gcaagacaat cctggatttc ctgaagtccg acggcttcgc caacagaaac 1800ttcatgcagc tgatccacga cgacagcctg acctttaaag aggacatcca gaaagcccag 1860gtgtccggcc agggcgatag cctgcacgag cacattgcca atctggccgg cagccccgcc 1920attaagaagg gcatcctgca gacagtgaag gtggtggacg agctcgtgaa agtgatgggc 1980cggcacaagc ccgagaacat cgtgatcgaa atggccagag agaaccagac cacccagaag 2040ggacagaaga acagccgcga gagaatgaag cggatcgaag agggcatcaa agagctgggc 2100agccagatcc tgaaagaaca ccccgtggaa aacacccagc tgcagaacga gaagctgtac 2160ctgtactacc tgcagaatgg gcgggatatg tacgtggacc aggaactgga catcaaccgg 2220ctgtccgact acgatgtgga ccatatcgtg cctcagagct ttctgaagga cgactccatc 2280gacaacaagg tgctgaccag aagcgacaag aaccggggca agagcgacaa cgtgccctcc 2340gaagaggtcg tgaagaagat gaagaactac tggcggcagc tgctgaacgc caagctgatt 2400acccagagaa agttcgacaa tctgaccaag gccgagagag gcggcctgag cgaactggat 2460aaggccggct tcatcaagag acagctggtg gaaacccggc agatcacaaa gcacgtggca 2520cagatcctgg actcccggat gaacactaag tacgacgaga atgacaagct gatccgggaa 2580gtgaaagtga tcaccctgaa gtccaagctg gtgtccgatt tccggaagga tttccagttt 2640tacaaagtgc gcgagatcaa caactaccac cacgcccacg acgcctacct gaacgccgtc 2700gtgggaaccg ccctgatcaa aaagtaccct aagctggaaa gcgagttcgt gtacggcgac 2760tacaaggtgt acgacgtgcg gaagatgatc gccaagagcg agcaggaaat cggcaaggct 2820accgccaagt acttcttcta cagcaacatc atgaactttt tcaagaccga gattaccctg 2880gccaacggcg agatccggaa gcggcctctg atcgagacaa acggcgaaac cggggagatc 2940gtgtgggata agggccggga ttttgccacc gtgcggaaag tgctgagcat gccccaagtg 3000aatatcgtga aaaagaccga ggtgcagaca ggcggcttca gcaaagagtc tatcctgccc 3060aagaggaaca gcgataagct gatcgccaga aagaaggact gggaccctaa gaagtacggc 3120ggcttcgaca gccccaccgt ggcctattct gtgctggtgg tggccaaagt ggaaaagggc 3180aagtccaaga aactgaagag tgtgaaagag ctgctgggga tcaccatcat ggaaagaagc 3240agcttcgaga agaatcccat cgactttctg gaagccaagg gctacaaaga agtgaaaaag 3300gacctgatca tcaagctgcc taagtactcc ctgttcgagc tggaaaacgg ccggaagaga 3360atgctggcct ctgccggcga actgcagaag ggaaacgaac tggccctgcc ctccaaatat 3420gtgaacttcc tgtacctggc cagccactat gagaagctga agggctcccc cgaggataat 3480gagcagaaac agctgtttgt ggaacagcac aagcactacc tggacgagat catcgagcag 3540atcagcgagt tctccaagag agtgatcctg gccgacgcta atctggacaa agtgctgtcc 3600gcctacaaca agcaccggga taagcccatc agagagcagg ccgagaatat catccacctg 3660tttaccctga ccaatctggg agcccctgcc gccttcaagt actttgacac caccatcgac 3720cggaagaggt acaccagcac caaagaggtg ctggacgcca ccctgatcca ccagagcatc 3780accggcctgt acgagacacg gatcgacctg tctcagctgg gaggcgacaa aaggccggcg 3840gccacgaaaa aggccggcca ggcaaaaaag aaaaagtaa 38794945PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 49Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1 5 10 15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 20 25 30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 35 40 45503924DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 50atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacggt ggcggtggct cgggtggcgg tggctcgggt 600ggcggtggct cgggtggcgg tggctcgggt ggcggtggct cgggtggcgg tggctcgggt 660ggcggtggct cgggtggcgg tggctcgggt ggcggtggct cgatcaccaa ggcccccctg 720agcgcctcta tgatcaagag atacgacgag caccaccagg acctgaccct gctgaaagct 780ctcgtgcggc agcagctgcc tgagaagtac aaagagattt tcttcgacca gagcaagaac 840ggctacgccg gctacattga cggcggagcc agccaggaag agttctacaa gttcatcaag 900cccatcctgg aaaagatgga cggcaccgag gaactgctcg tgaagctgaa cagagaggac 960ctgctgcgga agcagcggac cttcgacaac ggcagcatcc cccaccagat ccacctggga 1020gagctgcacg ccattctgcg gcggcaggaa gatttttacc cattcctgaa ggacaaccgg 1080gaaaagatcg agaagatcct gaccttccgc atcccctact acgtgggccc tctggccagg 1140ggaaacagca gattcgcctg gatgaccaga aagagcgagg aaaccatcac cccctggaac 1200ttcgaggaag tggtggacaa gggcgcttcc gcccagagct tcatcgagcg gatgaccaac 1260ttcgataaga acctgcccaa cgagaaggtg ctgcccaagc acagcctgct gtacgagtac 1320ttcaccgtgt ataacgagct gaccaaagtg aaatacgtga ccgagggaat gagaaagccc 1380gccttcctga gcggcgagca gaaaaaggcc atcgtggacc tgctgttcaa gaccaaccgg 1440aaagtgaccg tgaagcagct gaaagaggac tacttcaaga aaatcgagtg cttcgactcc 1500gtggaaatct ccggcgtgga agatcggttc aacgcctccc tgggcacata ccacgatctg 1560ctgaaaatta tcaaggacaa ggacttcctg gacaatgagg aaaacgagga cattctggaa 1620gatatcgtgc tgaccctgac actgtttgag gacagagaga tgatcgagga acggctgaaa 1680acctatgccc acctgttcga cgacaaagtg atgaagcagc tgaagcggcg gagatacacc 1740ggctggggca ggctgagccg gaagctgatc aacggcatcc gggacaagca gtccggcaag 1800acaatcctgg atttcctgaa gtccgacggc ttcgccaaca gaaacttcat gcagctgatc 1860cacgacgaca gcctgacctt taaagaggac atccagaaag cccaggtgtc cggccagggc 1920gatagcctgc acgagcacat tgccaatctg gccggcagcc ccgccattaa gaagggcatc 1980ctgcagacag tgaaggtggt ggacgagctc gtgaaagtga tgggccggca caagcccgag 2040aacatcgtga tcgaaatggc cagagagaac cagaccaccc agaagggaca gaagaacagc 2100cgcgagagaa tgaagcggat cgaagagggc atcaaagagc tgggcagcca gatcctgaaa 2160gaacaccccg tggaaaacac ccagctgcag aacgagaagc tgtacctgta ctacctgcag 2220aatgggcggg atatgtacgt ggaccaggaa ctggacatca accggctgtc cgactacgat 2280gtggaccata tcgtgcctca gagctttctg aaggacgact ccatcgacaa caaggtgctg 2340accagaagcg acaagaaccg gggcaagagc gacaacgtgc cctccgaaga ggtcgtgaag 2400aagatgaaga actactggcg gcagctgctg aacgccaagc tgattaccca gagaaagttc 2460gacaatctga ccaaggccga gagaggcggc ctgagcgaac tggataaggc cggcttcatc 2520aagagacagc tggtggaaac ccggcagatc acaaagcacg tggcacagat cctggactcc 2580cggatgaaca ctaagtacga cgagaatgac aagctgatcc gggaagtgaa agtgatcacc 2640ctgaagtcca agctggtgtc cgatttccgg aaggatttcc agttttacaa agtgcgcgag 2700atcaacaact accaccacgc ccacgacgcc tacctgaacg ccgtcgtggg aaccgccctg 2760atcaaaaagt accctaagct ggaaagcgag ttcgtgtacg gcgactacaa ggtgtacgac 2820gtgcggaaga tgatcgccaa gagcgagcag gaaatcggca aggctaccgc caagtacttc 2880ttctacagca acatcatgaa ctttttcaag accgagatta ccctggccaa cggcgagatc 2940cggaagcggc ctctgatcga gacaaacggc gaaaccgggg agatcgtgtg ggataagggc 3000cgggattttg ccaccgtgcg gaaagtgctg agcatgcccc aagtgaatat cgtgaaaaag 3060accgaggtgc agacaggcgg cttcagcaaa gagtctatcc tgcccaagag gaacagcgat 3120aagctgatcg ccagaaagaa ggactgggac cctaagaagt acggcggctt cgacagcccc 3180accgtggcct attctgtgct ggtggtggcc aaagtggaaa agggcaagtc caagaaactg 3240aagagtgtga aagagctgct ggggatcacc atcatggaaa gaagcagctt cgagaagaat 3300cccatcgact ttctggaagc caagggctac aaagaagtga aaaaggacct gatcatcaag 3360ctgcctaagt actccctgtt cgagctggaa aacggccgga agagaatgct ggcctctgcc 3420ggcgaactgc agaagggaaa cgaactggcc ctgccctcca aatatgtgaa cttcctgtac 3480ctggccagcc actatgagaa gctgaagggc tcccccgagg ataatgagca gaaacagctg 3540tttgtggaac agcacaagca ctacctggac gagatcatcg agcagatcag cgagttctcc 3600aagagagtga tcctggccga cgctaatctg gacaaagtgc tgtccgccta caacaagcac 3660cgggataagc ccatcagaga

gcaggccgag aatatcatcc acctgtttac cctgaccaat 3720ctgggagccc ctgccgcctt caagtacttt gacaccacca tcgaccggaa gaggtacacc 3780agcaccaaag aggtgctgga cgccaccctg atccaccaga gcatcaccgg cctgtacgag 3840acacggatcg acctgtctca gctgggaggc gacaaaaggc cggcggccac gaaaaaggcc 3900ggccaggcaa aaaagaaaaa gtaa 39245160PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 51Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1 5 10 15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 20 25 30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 35 40 45Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 50 55 60523969DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 52atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacggt ggcggtggct cgggtggcgg tggctcgggt 600ggcggtggct cgggtggcgg tggctcgggt ggcggtggct cgggtggcgg tggctcgggt 660ggcggtggct cgggtggcgg tggctcgggt ggcggtggct cgggtggcgg tggctcgggt 720ggcggtggct cgggtggcgg tggctcgatc accaaggccc ccctgagcgc ctctatgatc 780aagagatacg acgagcacca ccaggacctg accctgctga aagctctcgt gcggcagcag 840ctgcctgaga agtacaaaga gattttcttc gaccagagca agaacggcta cgccggctac 900attgacggcg gagccagcca ggaagagttc tacaagttca tcaagcccat cctggaaaag 960atggacggca ccgaggaact gctcgtgaag ctgaacagag aggacctgct gcggaagcag 1020cggaccttcg acaacggcag catcccccac cagatccacc tgggagagct gcacgccatt 1080ctgcggcggc aggaagattt ttacccattc ctgaaggaca accgggaaaa gatcgagaag 1140atcctgacct tccgcatccc ctactacgtg ggccctctgg ccaggggaaa cagcagattc 1200gcctggatga ccagaaagag cgaggaaacc atcaccccct ggaacttcga ggaagtggtg 1260gacaagggcg cttccgccca gagcttcatc gagcggatga ccaacttcga taagaacctg 1320cccaacgaga aggtgctgcc caagcacagc ctgctgtacg agtacttcac cgtgtataac 1380gagctgacca aagtgaaata cgtgaccgag ggaatgagaa agcccgcctt cctgagcggc 1440gagcagaaaa aggccatcgt ggacctgctg ttcaagacca accggaaagt gaccgtgaag 1500cagctgaaag aggactactt caagaaaatc gagtgcttcg actccgtgga aatctccggc 1560gtggaagatc ggttcaacgc ctccctgggc acataccacg atctgctgaa aattatcaag 1620gacaaggact tcctggacaa tgaggaaaac gaggacattc tggaagatat cgtgctgacc 1680ctgacactgt ttgaggacag agagatgatc gaggaacggc tgaaaaccta tgcccacctg 1740ttcgacgaca aagtgatgaa gcagctgaag cggcggagat acaccggctg gggcaggctg 1800agccggaagc tgatcaacgg catccgggac aagcagtccg gcaagacaat cctggatttc 1860ctgaagtccg acggcttcgc caacagaaac ttcatgcagc tgatccacga cgacagcctg 1920acctttaaag aggacatcca gaaagcccag gtgtccggcc agggcgatag cctgcacgag 1980cacattgcca atctggccgg cagccccgcc attaagaagg gcatcctgca gacagtgaag 2040gtggtggacg agctcgtgaa agtgatgggc cggcacaagc ccgagaacat cgtgatcgaa 2100atggccagag agaaccagac cacccagaag ggacagaaga acagccgcga gagaatgaag 2160cggatcgaag agggcatcaa agagctgggc agccagatcc tgaaagaaca ccccgtggaa 2220aacacccagc tgcagaacga gaagctgtac ctgtactacc tgcagaatgg gcgggatatg 2280tacgtggacc aggaactgga catcaaccgg ctgtccgact acgatgtgga ccatatcgtg 2340cctcagagct ttctgaagga cgactccatc gacaacaagg tgctgaccag aagcgacaag 2400aaccggggca agagcgacaa cgtgccctcc gaagaggtcg tgaagaagat gaagaactac 2460tggcggcagc tgctgaacgc caagctgatt acccagagaa agttcgacaa tctgaccaag 2520gccgagagag gcggcctgag cgaactggat aaggccggct tcatcaagag acagctggtg 2580gaaacccggc agatcacaaa gcacgtggca cagatcctgg actcccggat gaacactaag 2640tacgacgaga atgacaagct gatccgggaa gtgaaagtga tcaccctgaa gtccaagctg 2700gtgtccgatt tccggaagga tttccagttt tacaaagtgc gcgagatcaa caactaccac 2760cacgcccacg acgcctacct gaacgccgtc gtgggaaccg ccctgatcaa aaagtaccct 2820aagctggaaa gcgagttcgt gtacggcgac tacaaggtgt acgacgtgcg gaagatgatc 2880gccaagagcg agcaggaaat cggcaaggct accgccaagt acttcttcta cagcaacatc 2940atgaactttt tcaagaccga gattaccctg gccaacggcg agatccggaa gcggcctctg 3000atcgagacaa acggcgaaac cggggagatc gtgtgggata agggccggga ttttgccacc 3060gtgcggaaag tgctgagcat gccccaagtg aatatcgtga aaaagaccga ggtgcagaca 3120ggcggcttca gcaaagagtc tatcctgccc aagaggaaca gcgataagct gatcgccaga 3180aagaaggact gggaccctaa gaagtacggc ggcttcgaca gccccaccgt ggcctattct 3240gtgctggtgg tggccaaagt ggaaaagggc aagtccaaga aactgaagag tgtgaaagag 3300ctgctgggga tcaccatcat ggaaagaagc agcttcgaga agaatcccat cgactttctg 3360gaagccaagg gctacaaaga agtgaaaaag gacctgatca tcaagctgcc taagtactcc 3420ctgttcgagc tggaaaacgg ccggaagaga atgctggcct ctgccggcga actgcagaag 3480ggaaacgaac tggccctgcc ctccaaatat gtgaacttcc tgtacctggc cagccactat 3540gagaagctga agggctcccc cgaggataat gagcagaaac agctgtttgt ggaacagcac 3600aagcactacc tggacgagat catcgagcag atcagcgagt tctccaagag agtgatcctg 3660gccgacgcta atctggacaa agtgctgtcc gcctacaaca agcaccggga taagcccatc 3720agagagcagg ccgagaatat catccacctg tttaccctga ccaatctggg agcccctgcc 3780gccttcaagt actttgacac caccatcgac cggaagaggt acaccagcac caaagaggtg 3840ctggacgcca ccctgatcca ccagagcatc accggcctgt acgagacacg gatcgacctg 3900tctcagctgg gaggcgacaa aaggccggcg gccacgaaaa aggccggcca ggcaaaaaag 3960aaaaagtaa 39695317PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic peptide" 53Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1 5 10 15Ala543840DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 54atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacgct gaagctgctg ctaaagaagc tgctgctaaa 600gaagctgctg ctaaagctat caccaaggcc cccctgagcg cctctatgat caagagatac 660gacgagcacc accaggacct gaccctgctg aaagctctcg tgcggcagca gctgcctgag 720aagtacaaag agattttctt cgaccagagc aagaacggct acgccggcta cattgacggc 780ggagccagcc aggaagagtt ctacaagttc atcaagccca tcctggaaaa gatggacggc 840accgaggaac tgctcgtgaa gctgaacaga gaggacctgc tgcggaagca gcggaccttc 900gacaacggca gcatccccca ccagatccac ctgggagagc tgcacgccat tctgcggcgg 960caggaagatt tttacccatt cctgaaggac aaccgggaaa agatcgagaa gatcctgacc 1020ttccgcatcc cctactacgt gggccctctg gccaggggaa acagcagatt cgcctggatg 1080accagaaaga gcgaggaaac catcaccccc tggaacttcg aggaagtggt ggacaagggc 1140gcttccgccc agagcttcat cgagcggatg accaacttcg ataagaacct gcccaacgag 1200aaggtgctgc ccaagcacag cctgctgtac gagtacttca ccgtgtataa cgagctgacc 1260aaagtgaaat acgtgaccga gggaatgaga aagcccgcct tcctgagcgg cgagcagaaa 1320aaggccatcg tggacctgct gttcaagacc aaccggaaag tgaccgtgaa gcagctgaaa 1380gaggactact tcaagaaaat cgagtgcttc gactccgtgg aaatctccgg cgtggaagat 1440cggttcaacg cctccctggg cacataccac gatctgctga aaattatcaa ggacaaggac 1500ttcctggaca atgaggaaaa cgaggacatt ctggaagata tcgtgctgac cctgacactg 1560tttgaggaca gagagatgat cgaggaacgg ctgaaaacct atgcccacct gttcgacgac 1620aaagtgatga agcagctgaa gcggcggaga tacaccggct ggggcaggct gagccggaag 1680ctgatcaacg gcatccggga caagcagtcc ggcaagacaa tcctggattt cctgaagtcc 1740gacggcttcg ccaacagaaa cttcatgcag ctgatccacg acgacagcct gacctttaaa 1800gaggacatcc agaaagccca ggtgtccggc cagggcgata gcctgcacga gcacattgcc 1860aatctggccg gcagccccgc cattaagaag ggcatcctgc agacagtgaa ggtggtggac 1920gagctcgtga aagtgatggg ccggcacaag cccgagaaca tcgtgatcga aatggccaga 1980gagaaccaga ccacccagaa gggacagaag aacagccgcg agagaatgaa gcggatcgaa 2040gagggcatca aagagctggg cagccagatc ctgaaagaac accccgtgga aaacacccag 2100ctgcagaacg agaagctgta cctgtactac ctgcagaatg ggcgggatat gtacgtggac 2160caggaactgg acatcaaccg gctgtccgac tacgatgtgg accatatcgt gcctcagagc 2220tttctgaagg acgactccat cgacaacaag gtgctgacca gaagcgacaa gaaccggggc 2280aagagcgaca acgtgccctc cgaagaggtc gtgaagaaga tgaagaacta ctggcggcag 2340ctgctgaacg ccaagctgat tacccagaga aagttcgaca atctgaccaa ggccgagaga 2400ggcggcctga gcgaactgga taaggccggc ttcatcaaga gacagctggt ggaaacccgg 2460cagatcacaa agcacgtggc acagatcctg gactcccgga tgaacactaa gtacgacgag 2520aatgacaagc tgatccggga agtgaaagtg atcaccctga agtccaagct ggtgtccgat 2580ttccggaagg atttccagtt ttacaaagtg cgcgagatca acaactacca ccacgcccac 2640gacgcctacc tgaacgccgt cgtgggaacc gccctgatca aaaagtaccc taagctggaa 2700agcgagttcg tgtacggcga ctacaaggtg tacgacgtgc ggaagatgat cgccaagagc 2760gagcaggaaa tcggcaaggc taccgccaag tacttcttct acagcaacat catgaacttt 2820ttcaagaccg agattaccct ggccaacggc gagatccgga agcggcctct gatcgagaca 2880aacggcgaaa ccggggagat cgtgtgggat aagggccggg attttgccac cgtgcggaaa 2940gtgctgagca tgccccaagt gaatatcgtg aaaaagaccg aggtgcagac aggcggcttc 3000agcaaagagt ctatcctgcc caagaggaac agcgataagc tgatcgccag aaagaaggac 3060tgggacccta agaagtacgg cggcttcgac agccccaccg tggcctattc tgtgctggtg 3120gtggccaaag tggaaaaggg caagtccaag aaactgaaga gtgtgaaaga gctgctgggg 3180atcaccatca tggaaagaag cagcttcgag aagaatccca tcgactttct ggaagccaag 3240ggctacaaag aagtgaaaaa ggacctgatc atcaagctgc ctaagtactc cctgttcgag 3300ctggaaaacg gccggaagag aatgctggcc tctgccggcg aactgcagaa gggaaacgaa 3360ctggccctgc cctccaaata tgtgaacttc ctgtacctgg ccagccacta tgagaagctg 3420aagggctccc ccgaggataa tgagcagaaa cagctgtttg tggaacagca caagcactac 3480ctggacgaga tcatcgagca gatcagcgag ttctccaaga gagtgatcct ggccgacgct 3540aatctggaca aagtgctgtc cgcctacaac aagcaccggg ataagcccat cagagagcag 3600gccgagaata tcatccacct gtttaccctg accaatctgg gagcccctgc cgccttcaag 3660tactttgaca ccaccatcga ccggaagagg tacaccagca ccaaagaggt gctggacgcc 3720accctgatcc accagagcat caccggcctg tacgagacac ggatcgacct gtctcagctg 3780ggaggcgaca aaaggccggc ggccacgaaa aaggccggcc aggcaaaaaa gaaaaagtaa 38405536PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 55Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1 5 10 15Ala Leu Glu Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala 20 25 30Ala Ala Lys Ala 35563897DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 56atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacgct gaagccgctg ctaaagaagc cgctgctaaa 600gaagccgctg ctaaagccct ggaggctgaa gccgctgcta aagaagccgc tgctaaagaa 660gccgctgcta aagctatcac caaggccccc ctgagcgcct ctatgatcaa gagatacgac 720gagcaccacc aggacctgac cctgctgaaa gctctcgtgc ggcagcagct gcctgagaag 780tacaaagaga ttttcttcga ccagagcaag aacggctacg ccggctacat tgacggcgga 840gccagccagg aagagttcta caagttcatc aagcccatcc tggaaaagat ggacggcacc 900gaggaactgc tcgtgaagct gaacagagag gacctgctgc ggaagcagcg gaccttcgac 960aacggcagca tcccccacca gatccacctg ggagagctgc acgccattct gcggcggcag 1020gaagattttt acccattcct gaaggacaac cgggaaaaga tcgagaagat cctgaccttc 1080cgcatcccct actacgtggg ccctctggcc aggggaaaca gcagattcgc ctggatgacc 1140agaaagagcg aggaaaccat caccccctgg aacttcgagg aagtggtgga caagggcgct 1200tccgcccaga gcttcatcga gcggatgacc aacttcgata agaacctgcc caacgagaag 1260gtgctgccca agcacagcct gctgtacgag tacttcaccg tgtataacga gctgaccaaa 1320gtgaaatacg tgaccgaggg aatgagaaag cccgccttcc tgagcggcga gcagaaaaag 1380gccatcgtgg acctgctgtt caagaccaac cggaaagtga ccgtgaagca gctgaaagag 1440gactacttca agaaaatcga gtgcttcgac tccgtggaaa tctccggcgt ggaagatcgg 1500ttcaacgcct ccctgggcac ataccacgat ctgctgaaaa ttatcaagga caaggacttc 1560ctggacaatg aggaaaacga ggacattctg gaagatatcg tgctgaccct gacactgttt 1620gaggacagag agatgatcga ggaacggctg aaaacctatg cccacctgtt cgacgacaaa 1680gtgatgaagc agctgaagcg gcggagatac accggctggg gcaggctgag ccggaagctg 1740atcaacggca tccgggacaa gcagtccggc aagacaatcc tggatttcct gaagtccgac 1800ggcttcgcca acagaaactt catgcagctg atccacgacg acagcctgac ctttaaagag 1860gacatccaga aagcccaggt gtccggccag ggcgatagcc tgcacgagca cattgccaat 1920ctggccggca gccccgccat taagaagggc atcctgcaga cagtgaaggt ggtggacgag 1980ctcgtgaaag tgatgggccg gcacaagccc gagaacatcg tgatcgaaat ggccagagag 2040aaccagacca cccagaaggg acagaagaac agccgcgaga gaatgaagcg gatcgaagag 2100ggcatcaaag agctgggcag ccagatcctg aaagaacacc ccgtggaaaa cacccagctg 2160cagaacgaga agctgtacct gtactacctg cagaatgggc gggatatgta cgtggaccag 2220gaactggaca tcaaccggct gtccgactac gatgtggacc atatcgtgcc tcagagcttt 2280ctgaaggacg actccatcga caacaaggtg ctgaccagaa gcgacaagaa ccggggcaag 2340agcgacaacg tgccctccga agaggtcgtg aagaagatga agaactactg gcggcagctg 2400ctgaacgcca agctgattac ccagagaaag ttcgacaatc tgaccaaggc cgagagaggc 2460ggcctgagcg aactggataa ggccggcttc atcaagagac agctggtgga aacccggcag 2520atcacaaagc acgtggcaca gatcctggac tcccggatga acactaagta cgacgagaat 2580gacaagctga tccgggaagt gaaagtgatc accctgaagt ccaagctggt gtccgatttc 2640cggaaggatt tccagtttta caaagtgcgc gagatcaaca actaccacca cgcccacgac 2700gcctacctga acgccgtcgt gggaaccgcc ctgatcaaaa agtaccctaa gctggaaagc 2760gagttcgtgt acggcgacta caaggtgtac gacgtgcgga agatgatcgc caagagcgag 2820caggaaatcg gcaaggctac cgccaagtac ttcttctaca gcaacatcat gaactttttc 2880aagaccgaga ttaccctggc caacggcgag atccggaagc ggcctctgat cgagacaaac 2940ggcgaaaccg gggagatcgt gtgggataag ggccgggatt ttgccaccgt gcggaaagtg 3000ctgagcatgc cccaagtgaa tatcgtgaaa aagaccgagg tgcagacagg cggcttcagc 3060aaagagtcta tcctgcccaa gaggaacagc gataagctga tcgccagaaa gaaggactgg 3120gaccctaaga agtacggcgg cttcgacagc cccaccgtgg cctattctgt gctggtggtg 3180gccaaagtgg aaaagggcaa gtccaagaaa ctgaagagtg tgaaagagct gctggggatc 3240accatcatgg aaagaagcag cttcgagaag aatcccatcg actttctgga agccaagggc 3300tacaaagaag tgaaaaagga cctgatcatc aagctgccta agtactccct gttcgagctg 3360gaaaacggcc ggaagagaat gctggcctct gccggcgaac tgcagaaggg aaacgaactg 3420gccctgccct ccaaatatgt gaacttcctg tacctggcca gccactatga gaagctgaag 3480ggctcccccg aggataatga gcagaaacag ctgtttgtgg aacagcacaa gcactacctg 3540gacgagatca tcgagcagat cagcgagttc tccaagagag tgatcctggc cgacgctaat 3600ctggacaaag tgctgtccgc ctacaacaag caccgggata agcccatcag agagcaggcc 3660gagaatatca tccacctgtt taccctgacc aatctgggag cccctgccgc cttcaagtac 3720tttgacacca ccatcgaccg gaagaggtac accagcacca aagaggtgct ggacgccacc 3780ctgatccacc agagcatcac cggcctgtac gagacacgga tcgacctgtc tcagctggga 3840ggcgacaaaa ggccggcggc cacgaaaaag gccggccagg caaaaaagaa aaagtaa 38975755PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 57Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1 5 10 15Ala Leu Glu Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala 20 25 30Ala Ala Lys Ala Leu Glu Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala 35 40 45Lys Glu Ala Ala Ala Lys Ala 50 55583954DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 58atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacgct gaagctgctg ctaaagaagc tgctgctaaa 600gaagctgctg ctaaagccct ggaggctgaa gctgctgcta aagaagctgc tgctaaagaa 660gctgctgcta aagccctgga ggctgaagct gctgctaaag aagctgctgc taaagaagct 720gctgctaaag ctatcaccaa ggcccccctg agcgcctcta tgatcaagag atacgacgag 780caccaccagg acctgaccct gctgaaagct ctcgtgcggc agcagctgcc tgagaagtac 840aaagagattt tcttcgacca gagcaagaac ggctacgccg gctacattga cggcggagcc 900agccaggaag agttctacaa gttcatcaag cccatcctgg aaaagatgga cggcaccgag 960gaactgctcg tgaagctgaa cagagaggac ctgctgcgga agcagcggac cttcgacaac 1020ggcagcatcc cccaccagat ccacctggga gagctgcacg ccattctgcg gcggcaggaa 1080gatttttacc cattcctgaa ggacaaccgg gaaaagatcg agaagatcct gaccttccgc 1140atcccctact acgtgggccc tctggccagg ggaaacagca gattcgcctg gatgaccaga 1200aagagcgagg aaaccatcac

cccctggaac ttcgaggaag tggtggacaa gggcgcttcc 1260gcccagagct tcatcgagcg gatgaccaac ttcgataaga acctgcccaa cgagaaggtg 1320ctgcccaagc acagcctgct gtacgagtac ttcaccgtgt ataacgagct gaccaaagtg 1380aaatacgtga ccgagggaat gagaaagccc gccttcctga gcggcgagca gaaaaaggcc 1440atcgtggacc tgctgttcaa gaccaaccgg aaagtgaccg tgaagcagct gaaagaggac 1500tacttcaaga aaatcgagtg cttcgactcc gtggaaatct ccggcgtgga agatcggttc 1560aacgcctccc tgggcacata ccacgatctg ctgaaaatta tcaaggacaa ggacttcctg 1620gacaatgagg aaaacgagga cattctggaa gatatcgtgc tgaccctgac actgtttgag 1680gacagagaga tgatcgagga acggctgaaa acctatgccc acctgttcga cgacaaagtg 1740atgaagcagc tgaagcggcg gagatacacc ggctggggca ggctgagccg gaagctgatc 1800aacggcatcc gggacaagca gtccggcaag acaatcctgg atttcctgaa gtccgacggc 1860ttcgccaaca gaaacttcat gcagctgatc cacgacgaca gcctgacctt taaagaggac 1920atccagaaag cccaggtgtc cggccagggc gatagcctgc acgagcacat tgccaatctg 1980gccggcagcc ccgccattaa gaagggcatc ctgcagacag tgaaggtggt ggacgagctc 2040gtgaaagtga tgggccggca caagcccgag aacatcgtga tcgaaatggc cagagagaac 2100cagaccaccc agaagggaca gaagaacagc cgcgagagaa tgaagcggat cgaagagggc 2160atcaaagagc tgggcagcca gatcctgaaa gaacaccccg tggaaaacac ccagctgcag 2220aacgagaagc tgtacctgta ctacctgcag aatgggcggg atatgtacgt ggaccaggaa 2280ctggacatca accggctgtc cgactacgat gtggaccata tcgtgcctca gagctttctg 2340aaggacgact ccatcgacaa caaggtgctg accagaagcg acaagaaccg gggcaagagc 2400gacaacgtgc cctccgaaga ggtcgtgaag aagatgaaga actactggcg gcagctgctg 2460aacgccaagc tgattaccca gagaaagttc gacaatctga ccaaggccga gagaggcggc 2520ctgagcgaac tggataaggc cggcttcatc aagagacagc tggtggaaac ccggcagatc 2580acaaagcacg tggcacagat cctggactcc cggatgaaca ctaagtacga cgagaatgac 2640aagctgatcc gggaagtgaa agtgatcacc ctgaagtcca agctggtgtc cgatttccgg 2700aaggatttcc agttttacaa agtgcgcgag atcaacaact accaccacgc ccacgacgcc 2760tacctgaacg ccgtcgtggg aaccgccctg atcaaaaagt accctaagct ggaaagcgag 2820ttcgtgtacg gcgactacaa ggtgtacgac gtgcggaaga tgatcgccaa gagcgagcag 2880gaaatcggca aggctaccgc caagtacttc ttctacagca acatcatgaa ctttttcaag 2940accgagatta ccctggccaa cggcgagatc cggaagcggc ctctgatcga gacaaacggc 3000gaaaccgggg agatcgtgtg ggataagggc cgggattttg ccaccgtgcg gaaagtgctg 3060agcatgcccc aagtgaatat cgtgaaaaag accgaggtgc agacaggcgg cttcagcaaa 3120gagtctatcc tgcccaagag gaacagcgat aagctgatcg ccagaaagaa ggactgggac 3180cctaagaagt acggcggctt cgacagcccc accgtggcct attctgtgct ggtggtggcc 3240aaagtggaaa agggcaagtc caagaaactg aagagtgtga aagagctgct ggggatcacc 3300atcatggaaa gaagcagctt cgagaagaat cccatcgact ttctggaagc caagggctac 3360aaagaagtga aaaaggacct gatcatcaag ctgcctaagt actccctgtt cgagctggaa 3420aacggccgga agagaatgct ggcctctgcc ggcgaactgc agaagggaaa cgaactggcc 3480ctgccctcca aatatgtgaa cttcctgtac ctggccagcc actatgagaa gctgaagggc 3540tcccccgagg ataatgagca gaaacagctg tttgtggaac agcacaagca ctacctggac 3600gagatcatcg agcagatcag cgagttctcc aagagagtga tcctggccga cgctaatctg 3660gacaaagtgc tgtccgccta caacaagcac cgggataagc ccatcagaga gcaggccgag 3720aatatcatcc acctgtttac cctgaccaat ctgggagccc ctgccgcctt caagtacttt 3780gacaccacca tcgaccggaa gaggtacacc agcaccaaag aggtgctgga cgccaccctg 3840atccaccaga gcatcaccgg cctgtacgag acacggatcg acctgtctca gctgggaggc 3900gacaaaaggc cggcggccac gaaaaaggcc ggccaggcaa aaaagaaaaa gtaa 39545968PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 59Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1 5 10 15Leu Glu Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala 20 25 30Lys Leu Glu Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala 35 40 45Ala Lys Leu Glu Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala 50 55 60Ala Ala Lys Ala65604011DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 60atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacgct gaagctgctg ctaaagaagc tgctgctaaa 600gaagctgctg ctaaagccct ggaggctgaa gctgctgcta aagaagctgc tgctaaagaa 660gctgctgcta aagccctgga ggctgaagct gctgctaaag aagctgctgc taaagaagct 720gctgctaaag ccctggaggc tgaagctgct gctaaagaag ctgctgctaa agaagctgct 780gctaaagcta tcaccaaggc ccccctgagc gcctctatga tcaagagata cgacgagcac 840caccaggacc tgaccctgct gaaagctctc gtgcggcagc agctgcctga gaagtacaaa 900gagattttct tcgaccagag caagaacggc tacgccggct acattgacgg cggagccagc 960caggaagagt tctacaagtt catcaagccc atcctggaaa agatggacgg caccgaggaa 1020ctgctcgtga agctgaacag agaggacctg ctgcggaagc agcggacctt cgacaacggc 1080agcatccccc accagatcca cctgggagag ctgcacgcca ttctgcggcg gcaggaagat 1140ttttacccat tcctgaagga caaccgggaa aagatcgaga agatcctgac cttccgcatc 1200ccctactacg tgggccctct ggccagggga aacagcagat tcgcctggat gaccagaaag 1260agcgaggaaa ccatcacccc ctggaacttc gaggaagtgg tggacaaggg cgcttccgcc 1320cagagcttca tcgagcggat gaccaacttc gataagaacc tgcccaacga gaaggtgctg 1380cccaagcaca gcctgctgta cgagtacttc accgtgtata acgagctgac caaagtgaaa 1440tacgtgaccg agggaatgag aaagcccgcc ttcctgagcg gcgagcagaa aaaggccatc 1500gtggacctgc tgttcaagac caaccggaaa gtgaccgtga agcagctgaa agaggactac 1560ttcaagaaaa tcgagtgctt cgactccgtg gaaatctccg gcgtggaaga tcggttcaac 1620gcctccctgg gcacatacca cgatctgctg aaaattatca aggacaagga cttcctggac 1680aatgaggaaa acgaggacat tctggaagat atcgtgctga ccctgacact gtttgaggac 1740agagagatga tcgaggaacg gctgaaaacc tatgcccacc tgttcgacga caaagtgatg 1800aagcagctga agcggcggag atacaccggc tggggcaggc tgagccggaa gctgatcaac 1860ggcatccggg acaagcagtc cggcaagaca atcctggatt tcctgaagtc cgacggcttc 1920gccaacagaa acttcatgca gctgatccac gacgacagcc tgacctttaa agaggacatc 1980cagaaagccc aggtgtccgg ccagggcgat agcctgcacg agcacattgc caatctggcc 2040ggcagccccg ccattaagaa gggcatcctg cagacagtga aggtggtgga cgagctcgtg 2100aaagtgatgg gccggcacaa gcccgagaac atcgtgatcg aaatggccag agagaaccag 2160accacccaga agggacagaa gaacagccgc gagagaatga agcggatcga agagggcatc 2220aaagagctgg gcagccagat cctgaaagaa caccccgtgg aaaacaccca gctgcagaac 2280gagaagctgt acctgtacta cctgcagaat gggcgggata tgtacgtgga ccaggaactg 2340gacatcaacc ggctgtccga ctacgatgtg gaccatatcg tgcctcagag ctttctgaag 2400gacgactcca tcgacaacaa ggtgctgacc agaagcgaca agaaccgggg caagagcgac 2460aacgtgccct ccgaagaggt cgtgaagaag atgaagaact actggcggca gctgctgaac 2520gccaagctga ttacccagag aaagttcgac aatctgacca aggccgagag aggcggcctg 2580agcgaactgg ataaggccgg cttcatcaag agacagctgg tggaaacccg gcagatcaca 2640aagcacgtgg cacagatcct ggactcccgg atgaacacta agtacgacga gaatgacaag 2700ctgatccggg aagtgaaagt gatcaccctg aagtccaagc tggtgtccga tttccggaag 2760gatttccagt tttacaaagt gcgcgagatc aacaactacc accacgccca cgacgcctac 2820ctgaacgccg tcgtgggaac cgccctgatc aaaaagtacc ctaagctgga aagcgagttc 2880gtgtacggcg actacaaggt gtacgacgtg cggaagatga tcgccaagag cgagcaggaa 2940atcggcaagg ctaccgccaa gtacttcttc tacagcaaca tcatgaactt tttcaagacc 3000gagattaccc tggccaacgg cgagatccgg aagcggcctc tgatcgagac aaacggcgaa 3060accggggaga tcgtgtggga taagggccgg gattttgcca ccgtgcggaa agtgctgagc 3120atgccccaag tgaatatcgt gaaaaagacc gaggtgcaga caggcggctt cagcaaagag 3180tctatcctgc ccaagaggaa cagcgataag ctgatcgcca gaaagaagga ctgggaccct 3240aagaagtacg gcggcttcga cagccccacc gtggcctatt ctgtgctggt ggtggccaaa 3300gtggaaaagg gcaagtccaa gaaactgaag agtgtgaaag agctgctggg gatcaccatc 3360atggaaagaa gcagcttcga gaagaatccc atcgactttc tggaagccaa gggctacaaa 3420gaagtgaaaa aggacctgat catcaagctg cctaagtact ccctgttcga gctggaaaac 3480ggccggaaga gaatgctggc ctctgccggc gaactgcaga agggaaacga actggccctg 3540ccctccaaat atgtgaactt cctgtacctg gccagccact atgagaagct gaagggctcc 3600cccgaggata atgagcagaa acagctgttt gtggaacagc acaagcacta cctggacgag 3660atcatcgagc agatcagcga gttctccaag agagtgatcc tggccgacgc taatctggac 3720aaagtgctgt ccgcctacaa caagcaccgg gataagccca tcagagagca ggccgagaat 3780atcatccacc tgtttaccct gaccaatctg ggagcccctg ccgccttcaa gtactttgac 3840accaccatcg accggaagag gtacaccagc accaaagagg tgctggacgc caccctgatc 3900caccagagca tcaccggcct gtacgagaca cggatcgacc tgtctcagct gggaggcgac 3960aaaaggccgg cggccacgaa aaaggccggc caggcaaaaa agaaaaagta a 4011613804DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 61atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg gtgaacaccg agatcaccaa ggcccccctg 600agcgcctcta tgatcaagag atacgacgag caccaccagg acctgaccct gctgaaagct 660ctcgtgcggc agcagctgcc tgagaagtac aaagagattt tcttcgacca gagcaagaac 720ggctacgccg gctacattga cggcggagcc agccaggaag agttctacaa gttcatcaag 780cccatcctgg aaaagatgga cggcaccgag gaactgctcg tgaagctgaa cagagaggac 840ctgctgcgga agcagcggac cttcgacaac ggcagcatcc cccaccagat ccacctggga 900gagctgcacg ccattctgcg gcggcaggaa gatttttacc cattcctgaa ggacaaccgg 960gaaaagatcg agaagatcct gaccttccgc atcccctact acgtgggccc tctggccagg 1020ggaaacagca gattcgcctg gatgaccaga aagagcgagg aaaccatcac cccctggaac 1080ttcgaggaag tggtggacaa gggcgcttcc gcccagagct tcatcgagcg gatgaccaac 1140ttcgataaga acctgcccaa cgagaaggtg ctgcccaagc acagcctgct gtacgagtac 1200ttcaccgtgt ataacgagct gaccaaagtg aaatacgtga ccgagggaat gagaaagccc 1260gccttcctga gcggcgagca gaaaaaggcc atcgtggacc tgctgttcaa gaccaaccgg 1320aaagtgaccg tgaagcagct gaaagaggac tacttcaaga aaatcgagtg cttcgactcc 1380gtggaaatct ccggcgtgga agatcggttc aacgcctccc tgggcacata ccacgatctg 1440ctgaaaatta tcaaggacaa ggacttcctg gacaatgagg aaaacgagga cattctggaa 1500gatatcgtgc tgaccctgac actgtttgag gacagagaga tgatcgagga acggctgaaa 1560acctatgccc acctgttcga cgacaaagtg atgaagcagc tgaagcggcg gagatacacc 1620ggctggggca ggctgagccg gaagctgatc aacggcatcc gggacaagca gtccggcaag 1680acaatcctgg atttcctgaa gtccgacggc ttcgccaaca gaaacttcat gcagctgatc 1740cacgacgaca gcctgacctt taaagaggac atccagaaag cccaggtgtc cggccagggc 1800gatagcctgc acgagcacat tgccaatctg gccggcagcc ccgccattaa gaagggcatc 1860ctgcagacag tgaaggtggt ggacgagctc gtgaaagtga tgggccggca caagcccgag 1920aacatcgtga tcgaaatggc cagagagaac cagaccaccc agaagggaca gaagaacagc 1980cgcgagagaa tgaagcggat cgaagagggc atcaaagagc tgggcagcca gatcctgaaa 2040gaacaccccg tggaaaacac ccagctgcag aacgagaagc tgtacctgta ctacctgcag 2100aatgggcggg atatgtacgt ggaccaggaa ctggacatca accggctgtc cgactacgat 2160gtggaccata tcgtgcctca gagctttctg aaggacgact ccatcgacaa caaggtgctg 2220accagaagcg acaagaaccg gggcaagagc gacaacgtgc cctccgaaga ggtcgtgaag 2280aagatgaaga actactggcg gcagctgctg aacgccaagc tgattaccca gagaaagttc 2340gacaatctga ccaaggccga gagaggcggc ctgagcgaac tggataaggc cggcttcatc 2400aagagacagc tggtggaaac ccggcagatc acaaagcacg tggcacagat cctggactcc 2460cggatgaaca ctaagtacga cgagaatgac aagctgatcc gggaagtgaa agtgatcacc 2520ctgaagtcca agctggtgtc cgatttccgg aaggatttcc agttttacaa agtgcgcgag 2580atcaacaact accaccacgc ccacgacgcc tacctgaacg ccgtcgtggg aaccgccctg 2640atcaaaaagt accctaagct ggaaagcgag ttcgtgtacg gcgactacaa ggtgtacgac 2700gtgcggaaga tgatcgccaa gagcgagcag gaaatcggca aggctaccgc caagtacttc 2760ttctacagca acatcatgaa ctttttcaag accgagatta ccctggccaa cggcgagatc 2820cggaagcggc ctctgatcga gacaaacggc gaaaccgggg agatcgtgtg ggataagggc 2880cgggattttg ccaccgtgcg gaaagtgctg agcatgcccc aagtgaatat cgtgaaaaag 2940accgaggtgc agacaggcgg cttcagcaaa gagtctatcc tgcccaagag gaacagcgat 3000aagctgatcg ccagaaagaa ggactgggac cctaagaagt acggcggctt cgacagcccc 3060accgtggcct attctgtgct ggtggtggcc aaagtggaaa agggcaagtc caagaaactg 3120aagagtgtga aagagctgct ggggatcacc atcatggaaa gaagcagctt cgagaagaat 3180cccatcgact ttctggaagc caagggctac aaagaagtga aaaaggacct gatcatcaag 3240ctgcctaagt actccctgtt cgagctggaa aacggccgga agagaatgct ggcctctgcc 3300ggcgaactgc agaagggaaa cgaactggcc ctgccctcca aatatgtgaa cttcctgtac 3360ctggccagcc actatgagaa gctgaagggc tcccccgagg ataatgagca gaaacagctg 3420tttgtggaac agcacaagca ctacctggac gagatcatcg agcagatcag cgagttctcc 3480aagagagtga tcctggccga cgctaatctg gacaaagtgc tgtccgccta caacaagcac 3540cgggataagc ccatcagaga gcaggccgag aatatcatcc acctgtttac cctgaccaat 3600ctgggagccc ctgccgcctt caagtacttt gacaccacca tcgaccggaa gaggtacacc 3660agcaccaaag aggtgctgga cgccaccctg atccaccaga gcatcaccgg cctgtacgag 3720acacggatcg acctgtctca gctgggaggc gacaaaaggc cggcggccac gaaaaaggcc 3780ggccaggcaa aaaagaaaaa gtaa 3804623393DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 62atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg aaccccgaca acagcgacgt ggacaagctg 600ttcatccagc tggtgcagac ctacaaccag ctgttcgagg aaaaccccat caacgccagc 660ggcgtggacg ccaaggccat cctgtctgcc agactgagca agagcagacg gctggaaaat 720ctgatcgccc agctgcccgg cgagaagaag aatggcctgt tcggaaacct gattgccctg 780agcctgggcc tgacccccaa cttcaagagc aacttcgacc tggccgagga tgccaaactg 840cagctgagca aggacaccta cgacgacgac ctggacaacc tgctggccca gatcggcgac 900cagtacgccg acctgtttct ggccgccaag aacctgtccg acgccatcct gctgagcgac 960atcctgagag tgaacaccga gatcaccaag gcccccctga gcgcctctat gatcaagaga 1020tacgacgagc accaccagga cctgaccctg ctgaaagctc tcgtgcggca gcagctgcct 1080gagaagtaca aagagatttt cttcgaccag agcaagaacg gctacgccgg ctacattgac 1140ggcggagcca gccaggaaga gttctacaag ttcatcaagc ccatcctgga aaagatggac 1200ggcaccgagg aactgctcgt gaagctgaac agagaggacc tgctgcggaa gcagcggacc 1260ttcgacaacg gcagcatccc ccaccagatc cacctgggag agctgcacgc cattctgcgg 1320cggcaggaag atttttaccc attcctgaag gacaaccggg aaaagatcga gaagatcctg 1380accttccgca tcccctacta cgtgggccct ctggccaggg gaaacagcag attcgcctgg 1440atgaccagaa agagcgagga aaccatcacc ccctggaact tcgaggaagt ggtggacaag 1500ggcgcttccg cccagagctt catcgagcgg atgaccaact tcgataagaa cctgcccaac 1560gagaaggtgc tgcccaagca cagcctgctg tacgagtact tcaccgtgta taacgagctg 1620accaaagtga aatacgtgac cgagggaatg agaaagcccg ccttcctgag cggcgagcag 1680aaaaaggcca tcgtggacct gctgttcaag accaaccgga aagtgaccgt gaagcagctg 1740aaagaggact acttcaagaa aatcgagtgc ttcgactccg tggaaatctc cggcgtggaa 1800gatcggttca acgcctccct gggcacatac cacgatctgc tgaaaattat caaggacaag 1860gacttcctgg acaatgagga aaacgaggac attctggaag atatcgtgct gaccctgaca 1920ctgtttgagg acagagagat gatcgaggaa cggctgaaaa cctatgccca cctgttcgac 1980gacaaagtga tgaagcagct gaagcggcgg agatacaccg gctggggcag gctgagccgg 2040aagctgatca acggcatccg ggacaagcag tccggcaaga caatcctgga tttcctgaag 2100tccgacggct tcgccaacag aaacttcatg cagctgatcc acgacgacag cctgaccttt 2160aaagaggaca tccagaaagc ccaggtgtcc ggccagggcg atagcctgca cgagcacatt 2220gccaatctgg ccggcagccc cgccattaag aagggcatcc tgcagacagt gaaggtggtg 2280gacgagctcg tgaaagtgat gggccggcac aagcccgaga acatcgtgat cgaaatggcc 2340agagagaacc agaccaccca gaagggacag aagaacagcc gcgagagaat gaagcggatc 2400gaagagggca tcaaagagct gggcagccag atcctgaaag aacaccccgt ggaaaacacc 2460cagctgcaga acgagaagct gtacctgtac tacctgcaga atgggcggga tatgtacgtg 2520gaccaggaac tggacatcaa ccggctgtcc gactacgatg tggaccatat cgtgcctcag 2580agctttctga aggacgactc catcgacaac aaggtgctga ccagaagcga caagaaccgg 2640ggcaagagcg acaacgtgcc ctccgaagag gtcgtgaaga agatgaagaa ctactggcgg 2700cagctgctga acgccaagct gattacccag agaaagttcg acaatctgac caaggccgag 2760agaggcggcc tgagcgaact ggataaggcc ggcttcatca agagacagct ggtggaaacc 2820cggcagatca caaagcacgt ggcacagatc ctggactccc ggatgaacac taagtacgac 2880gagaatgaca agctgatccg ggaagtgaaa gtgatcaccc tgaagtccaa gctggtgtcc 2940gatttccgga aggatttcca gttttacaaa gtgcgcgaga tcaacaacta ccaccacgcc 3000cacgacgcct acctgaacgc cgtcgtggga accgccctga tcaaaaagta ccctaagctg 3060gaaagcgagt tcgtgtacgg cgactacaag gtgtacgacg tgcggaagat gatcgccaag 3120agcgagcagg aaatcggcaa ggctaccgcc aagtacttct tctacagcaa catcatgaac 3180tttttcaaga ccgagattac cctggccaac ggcgagatcc ggaagcggcc tctgatcgag 3240acaaacggcg aaaccgggga gatcgtgtgg gataagggcc gggattttgc caccgtgcgg 3300aaagtgctga gcatgcccca agtgaatatc gtgaaaaaga ccaaaaggcc ggcggccacg 3360aaaaaggccg gccaggcaaa aaagaaaaag taa 3393633849DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 63atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa

attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg ggtggaggtg gctcgggtgg aggtggctcg 600ggtggaggtg gctcggtgaa caccgagatc accaaggccc ccctgagcgc ctctatgatc 660aagagatacg acgagcacca ccaggacctg accctgctga aagctctcgt gcggcagcag 720ctgcctgaga agtacaaaga gattttcttc gaccagagca agaacggcta cgccggctac 780attgacggcg gagccagcca ggaagagttc tacaagttca tcaagcccat cctggaaaag 840atggacggca ccgaggaact gctcgtgaag ctgaacagag aggacctgct gcggaagcag 900cggaccttcg acaacggcag catcccccac cagatccacc tgggagagct gcacgccatt 960ctgcggcggc aggaagattt ttacccattc ctgaaggaca accgggaaaa gatcgagaag 1020atcctgacct tccgcatccc ctactacgtg ggccctctgg ccaggggaaa cagcagattc 1080gcctggatga ccagaaagag cgaggaaacc atcaccccct ggaacttcga ggaagtggtg 1140gacaagggcg cttccgccca gagcttcatc gagcggatga ccaacttcga taagaacctg 1200cccaacgaga aggtgctgcc caagcacagc ctgctgtacg agtacttcac cgtgtataac 1260gagctgacca aagtgaaata cgtgaccgag ggaatgagaa agcccgcctt cctgagcggc 1320gagcagaaaa aggccatcgt ggacctgctg ttcaagacca accggaaagt gaccgtgaag 1380cagctgaaag aggactactt caagaaaatc gagtgcttcg actccgtgga aatctccggc 1440gtggaagatc ggttcaacgc ctccctgggc acataccacg atctgctgaa aattatcaag 1500gacaaggact tcctggacaa tgaggaaaac gaggacattc tggaagatat cgtgctgacc 1560ctgacactgt ttgaggacag agagatgatc gaggaacggc tgaaaaccta tgcccacctg 1620ttcgacgaca aagtgatgaa gcagctgaag cggcggagat acaccggctg gggcaggctg 1680agccggaagc tgatcaacgg catccgggac aagcagtccg gcaagacaat cctggatttc 1740ctgaagtccg acggcttcgc caacagaaac ttcatgcagc tgatccacga cgacagcctg 1800acctttaaag aggacatcca gaaagcccag gtgtccggcc agggcgatag cctgcacgag 1860cacattgcca atctggccgg cagccccgcc attaagaagg gcatcctgca gacagtgaag 1920gtggtggacg agctcgtgaa agtgatgggc cggcacaagc ccgagaacat cgtgatcgaa 1980atggccagag agaaccagac cacccagaag ggacagaaga acagccgcga gagaatgaag 2040cggatcgaag agggcatcaa agagctgggc agccagatcc tgaaagaaca ccccgtggaa 2100aacacccagc tgcagaacga gaagctgtac ctgtactacc tgcagaatgg gcgggatatg 2160tacgtggacc aggaactgga catcaaccgg ctgtccgact acgatgtgga ccatatcgtg 2220cctcagagct ttctgaagga cgactccatc gacaacaagg tgctgaccag aagcgacaag 2280aaccggggca agagcgacaa cgtgccctcc gaagaggtcg tgaagaagat gaagaactac 2340tggcggcagc tgctgaacgc caagctgatt acccagagaa agttcgacaa tctgaccaag 2400gccgagagag gcggcctgag cgaactggat aaggccggct tcatcaagag acagctggtg 2460gaaacccggc agatcacaaa gcacgtggca cagatcctgg actcccggat gaacactaag 2520tacgacgaga atgacaagct gatccgggaa gtgaaagtga tcaccctgaa gtccaagctg 2580gtgtccgatt tccggaagga tttccagttt tacaaagtgc gcgagatcaa caactaccac 2640cacgcccacg acgcctacct gaacgccgtc gtgggaaccg ccctgatcaa aaagtaccct 2700aagctggaaa gcgagttcgt gtacggcgac tacaaggtgt acgacgtgcg gaagatgatc 2760gccaagagcg agcaggaaat cggcaaggct accgccaagt acttcttcta cagcaacatc 2820atgaactttt tcaagaccga gattaccctg gccaacggcg agatccggaa gcggcctctg 2880atcgagacaa acggcgaaac cggggagatc gtgtgggata agggccggga ttttgccacc 2940gtgcggaaag tgctgagcat gccccaagtg aatatcgtga aaaagaccga ggtgcagaca 3000ggcggcttca gcaaagagtc tatcctgccc aagaggaaca gcgataagct gatcgccaga 3060aagaaggact gggaccctaa gaagtacggc ggcttcgaca gccccaccgt ggcctattct 3120gtgctggtgg tggccaaagt ggaaaagggc aagtccaaga aactgaagag tgtgaaagag 3180ctgctgggga tcaccatcat ggaaagaagc agcttcgaga agaatcccat cgactttctg 3240gaagccaagg gctacaaaga agtgaaaaag gacctgatca tcaagctgcc taagtactcc 3300ctgttcgagc tggaaaacgg ccggaagaga atgctggcct ctgccggcga actgcagaag 3360ggaaacgaac tggccctgcc ctccaaatat gtgaacttcc tgtacctggc cagccactat 3420gagaagctga agggctcccc cgaggataat gagcagaaac agctgtttgt ggaacagcac 3480aagcactacc tggacgagat catcgagcag atcagcgagt tctccaagag agtgatcctg 3540gccgacgcta atctggacaa agtgctgtcc gcctacaaca agcaccggga taagcccatc 3600agagagcagg ccgagaatat catccacctg tttaccctga ccaatctggg agcccctgcc 3660gccttcaagt actttgacac caccatcgac cggaagaggt acaccagcac caaagaggtg 3720ctggacgcca ccctgatcca ccagagcatc accggcctgt acgagacacg gatcgacctg 3780tctcagctgg gaggcgacaa aaggccggcg gccacgaaaa aggccggcca ggcaaaaaag 3840aaaaagtaa 3849643894DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 64atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg ggtggaggtg gctcgggtgg aggtggctcg 600ggtggaggtg gctcgggtgg aggtggctcg ggtggaggtg gctcgggtgg aggtggctcg 660gtgaacaccg agatcaccaa ggcccccctg agcgcctcta tgatcaagag atacgacgag 720caccaccagg acctgaccct gctgaaagct ctcgtgcggc agcagctgcc tgagaagtac 780aaagagattt tcttcgacca gagcaagaac ggctacgccg gctacattga cggcggagcc 840agccaggaag agttctacaa gttcatcaag cccatcctgg aaaagatgga cggcaccgag 900gaactgctcg tgaagctgaa cagagaggac ctgctgcgga agcagcggac cttcgacaac 960ggcagcatcc cccaccagat ccacctggga gagctgcacg ccattctgcg gcggcaggaa 1020gatttttacc cattcctgaa ggacaaccgg gaaaagatcg agaagatcct gaccttccgc 1080atcccctact acgtgggccc tctggccagg ggaaacagca gattcgcctg gatgaccaga 1140aagagcgagg aaaccatcac cccctggaac ttcgaggaag tggtggacaa gggcgcttcc 1200gcccagagct tcatcgagcg gatgaccaac ttcgataaga acctgcccaa cgagaaggtg 1260ctgcccaagc acagcctgct gtacgagtac ttcaccgtgt ataacgagct gaccaaagtg 1320aaatacgtga ccgagggaat gagaaagccc gccttcctga gcggcgagca gaaaaaggcc 1380atcgtggacc tgctgttcaa gaccaaccgg aaagtgaccg tgaagcagct gaaagaggac 1440tacttcaaga aaatcgagtg cttcgactcc gtggaaatct ccggcgtgga agatcggttc 1500aacgcctccc tgggcacata ccacgatctg ctgaaaatta tcaaggacaa ggacttcctg 1560gacaatgagg aaaacgagga cattctggaa gatatcgtgc tgaccctgac actgtttgag 1620gacagagaga tgatcgagga acggctgaaa acctatgccc acctgttcga cgacaaagtg 1680atgaagcagc tgaagcggcg gagatacacc ggctggggca ggctgagccg gaagctgatc 1740aacggcatcc gggacaagca gtccggcaag acaatcctgg atttcctgaa gtccgacggc 1800ttcgccaaca gaaacttcat gcagctgatc cacgacgaca gcctgacctt taaagaggac 1860atccagaaag cccaggtgtc cggccagggc gatagcctgc acgagcacat tgccaatctg 1920gccggcagcc ccgccattaa gaagggcatc ctgcagacag tgaaggtggt ggacgagctc 1980gtgaaagtga tgggccggca caagcccgag aacatcgtga tcgaaatggc cagagagaac 2040cagaccaccc agaagggaca gaagaacagc cgcgagagaa tgaagcggat cgaagagggc 2100atcaaagagc tgggcagcca gatcctgaaa gaacaccccg tggaaaacac ccagctgcag 2160aacgagaagc tgtacctgta ctacctgcag aatgggcggg atatgtacgt ggaccaggaa 2220ctggacatca accggctgtc cgactacgat gtggaccata tcgtgcctca gagctttctg 2280aaggacgact ccatcgacaa caaggtgctg accagaagcg acaagaaccg gggcaagagc 2340gacaacgtgc cctccgaaga ggtcgtgaag aagatgaaga actactggcg gcagctgctg 2400aacgccaagc tgattaccca gagaaagttc gacaatctga ccaaggccga gagaggcggc 2460ctgagcgaac tggataaggc cggcttcatc aagagacagc tggtggaaac ccggcagatc 2520acaaagcacg tggcacagat cctggactcc cggatgaaca ctaagtacga cgagaatgac 2580aagctgatcc gggaagtgaa agtgatcacc ctgaagtcca agctggtgtc cgatttccgg 2640aaggatttcc agttttacaa agtgcgcgag atcaacaact accaccacgc ccacgacgcc 2700tacctgaacg ccgtcgtggg aaccgccctg atcaaaaagt accctaagct ggaaagcgag 2760ttcgtgtacg gcgactacaa ggtgtacgac gtgcggaaga tgatcgccaa gagcgagcag 2820gaaatcggca aggctaccgc caagtacttc ttctacagca acatcatgaa ctttttcaag 2880accgagatta ccctggccaa cggcgagatc cggaagcggc ctctgatcga gacaaacggc 2940gaaaccgggg agatcgtgtg ggataagggc cgggattttg ccaccgtgcg gaaagtgctg 3000agcatgcccc aagtgaatat cgtgaaaaag accgaggtgc agacaggcgg cttcagcaaa 3060gagtctatcc tgcccaagag gaacagcgat aagctgatcg ccagaaagaa ggactgggac 3120cctaagaagt acggcggctt cgacagcccc accgtggcct attctgtgct ggtggtggcc 3180aaagtggaaa agggcaagtc caagaaactg aagagtgtga aagagctgct ggggatcacc 3240atcatggaaa gaagcagctt cgagaagaat cccatcgact ttctggaagc caagggctac 3300aaagaagtga aaaaggacct gatcatcaag ctgcctaagt actccctgtt cgagctggaa 3360aacggccgga agagaatgct ggcctctgcc ggcgaactgc agaagggaaa cgaactggcc 3420ctgccctcca aatatgtgaa cttcctgtac ctggccagcc actatgagaa gctgaagggc 3480tcccccgagg ataatgagca gaaacagctg tttgtggaac agcacaagca ctacctggac 3540gagatcatcg agcagatcag cgagttctcc aagagagtga tcctggccga cgctaatctg 3600gacaaagtgc tgtccgccta caacaagcac cgggataagc ccatcagaga gcaggccgag 3660aatatcatcc acctgtttac cctgaccaat ctgggagccc ctgccgcctt caagtacttt 3720gacaccacca tcgaccggaa gaggtacacc agcaccaaag aggtgctgga cgccaccctg 3780atccaccaga gcatcaccgg cctgtacgag acacggatcg acctgtctca gctgggaggc 3840gacaaaaggc cggcggccac gaaaaaggcc ggccaggcaa aaaagaaaaa gtaa 3894653939DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 65atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg ggtggaggtg gctcgggtgg aggtggctcg 600ggtggaggtg gctcgggtgg aggtggctcg ggtggaggtg gctcgggtgg aggtggctcg 660ggtggaggtg gctcgggtgg aggtggctcg ggtggaggtg gctcggtgaa caccgagatc 720accaaggccc ccctgagcgc ctctatgatc aagagatacg acgagcacca ccaggacctg 780accctgctga aagctctcgt gcggcagcag ctgcctgaga agtacaaaga gattttcttc 840gaccagagca agaacggcta cgccggctac attgacggcg gagccagcca ggaagagttc 900tacaagttca tcaagcccat cctggaaaag atggacggca ccgaggaact gctcgtgaag 960ctgaacagag aggacctgct gcggaagcag cggaccttcg acaacggcag catcccccac 1020cagatccacc tgggagagct gcacgccatt ctgcggcggc aggaagattt ttacccattc 1080ctgaaggaca accgggaaaa gatcgagaag atcctgacct tccgcatccc ctactacgtg 1140ggccctctgg ccaggggaaa cagcagattc gcctggatga ccagaaagag cgaggaaacc 1200atcaccccct ggaacttcga ggaagtggtg gacaagggcg cttccgccca gagcttcatc 1260gagcggatga ccaacttcga taagaacctg cccaacgaga aggtgctgcc caagcacagc 1320ctgctgtacg agtacttcac cgtgtataac gagctgacca aagtgaaata cgtgaccgag 1380ggaatgagaa agcccgcctt cctgagcggc gagcagaaaa aggccatcgt ggacctgctg 1440ttcaagacca accggaaagt gaccgtgaag cagctgaaag aggactactt caagaaaatc 1500gagtgcttcg actccgtgga aatctccggc gtggaagatc ggttcaacgc ctccctgggc 1560acataccacg atctgctgaa aattatcaag gacaaggact tcctggacaa tgaggaaaac 1620gaggacattc tggaagatat cgtgctgacc ctgacactgt ttgaggacag agagatgatc 1680gaggaacggc tgaaaaccta tgcccacctg ttcgacgaca aagtgatgaa gcagctgaag 1740cggcggagat acaccggctg gggcaggctg agccggaagc tgatcaacgg catccgggac 1800aagcagtccg gcaagacaat cctggatttc ctgaagtccg acggcttcgc caacagaaac 1860ttcatgcagc tgatccacga cgacagcctg acctttaaag aggacatcca gaaagcccag 1920gtgtccggcc agggcgatag cctgcacgag cacattgcca atctggccgg cagccccgcc 1980attaagaagg gcatcctgca gacagtgaag gtggtggacg agctcgtgaa agtgatgggc 2040cggcacaagc ccgagaacat cgtgatcgaa atggccagag agaaccagac cacccagaag 2100ggacagaaga acagccgcga gagaatgaag cggatcgaag agggcatcaa agagctgggc 2160agccagatcc tgaaagaaca ccccgtggaa aacacccagc tgcagaacga gaagctgtac 2220ctgtactacc tgcagaatgg gcgggatatg tacgtggacc aggaactgga catcaaccgg 2280ctgtccgact acgatgtgga ccatatcgtg cctcagagct ttctgaagga cgactccatc 2340gacaacaagg tgctgaccag aagcgacaag aaccggggca agagcgacaa cgtgccctcc 2400gaagaggtcg tgaagaagat gaagaactac tggcggcagc tgctgaacgc caagctgatt 2460acccagagaa agttcgacaa tctgaccaag gccgagagag gcggcctgag cgaactggat 2520aaggccggct tcatcaagag acagctggtg gaaacccggc agatcacaaa gcacgtggca 2580cagatcctgg actcccggat gaacactaag tacgacgaga atgacaagct gatccgggaa 2640gtgaaagtga tcaccctgaa gtccaagctg gtgtccgatt tccggaagga tttccagttt 2700tacaaagtgc gcgagatcaa caactaccac cacgcccacg acgcctacct gaacgccgtc 2760gtgggaaccg ccctgatcaa aaagtaccct aagctggaaa gcgagttcgt gtacggcgac 2820tacaaggtgt acgacgtgcg gaagatgatc gccaagagcg agcaggaaat cggcaaggct 2880accgccaagt acttcttcta cagcaacatc atgaactttt tcaagaccga gattaccctg 2940gccaacggcg agatccggaa gcggcctctg atcgagacaa acggcgaaac cggggagatc 3000gtgtgggata agggccggga ttttgccacc gtgcggaaag tgctgagcat gccccaagtg 3060aatatcgtga aaaagaccga ggtgcagaca ggcggcttca gcaaagagtc tatcctgccc 3120aagaggaaca gcgataagct gatcgccaga aagaaggact gggaccctaa gaagtacggc 3180ggcttcgaca gccccaccgt ggcctattct gtgctggtgg tggccaaagt ggaaaagggc 3240aagtccaaga aactgaagag tgtgaaagag ctgctgggga tcaccatcat ggaaagaagc 3300agcttcgaga agaatcccat cgactttctg gaagccaagg gctacaaaga agtgaaaaag 3360gacctgatca tcaagctgcc taagtactcc ctgttcgagc tggaaaacgg ccggaagaga 3420atgctggcct ctgccggcga actgcagaag ggaaacgaac tggccctgcc ctccaaatat 3480gtgaacttcc tgtacctggc cagccactat gagaagctga agggctcccc cgaggataat 3540gagcagaaac agctgtttgt ggaacagcac aagcactacc tggacgagat catcgagcag 3600atcagcgagt tctccaagag agtgatcctg gccgacgcta atctggacaa agtgctgtcc 3660gcctacaaca agcaccggga taagcccatc agagagcagg ccgagaatat catccacctg 3720tttaccctga ccaatctggg agcccctgcc gccttcaagt actttgacac caccatcgac 3780cggaagaggt acaccagcac caaagaggtg ctggacgcca ccctgatcca ccagagcatc 3840accggcctgt acgagacacg gatcgacctg tctcagctgg gaggcgacaa aaggccggcg 3900gccacgaaaa aggccggcca ggcaaaaaag aaaaagtaa 3939663984DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 66atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg ggtggaggtg gttcgggtgg cggtggctcg 600ggtggaggtg gatcgggtgg cggtggttcg ggtggaggtg gctcgggcgg aggtggatcg 660ggtggcggtg gctcgggtgg aggtggctcg ggtggaggtg gctcgggtgg cggtggatcg 720ggtggaggtg gatcgggtgg aggtggttcg gtgaacaccg agatcaccaa ggcccccctg 780agcgcctcta tgatcaagag atacgacgag caccaccagg acctgaccct gctgaaagct 840ctcgtgcggc agcagctgcc tgagaagtac aaagagattt tcttcgacca gagcaagaac 900ggctacgccg gctacattga cggcggagcc agccaggaag agttctacaa gttcatcaag 960cccatcctgg aaaagatgga cggcaccgag gaactgctcg tgaagctgaa cagagaggac 1020ctgctgcgga agcagcggac cttcgacaac ggcagcatcc cccaccagat ccacctggga 1080gagctgcacg ccattctgcg gcggcaggaa gatttttacc cattcctgaa ggacaaccgg 1140gaaaagatcg agaagatcct gaccttccgc atcccctact acgtgggccc tctggccagg 1200ggaaacagca gattcgcctg gatgaccaga aagagcgagg aaaccatcac cccctggaac 1260ttcgaggaag tggtggacaa gggcgcttcc gcccagagct tcatcgagcg gatgaccaac 1320ttcgataaga acctgcccaa cgagaaggtg ctgcccaagc acagcctgct gtacgagtac 1380ttcaccgtgt ataacgagct gaccaaagtg aaatacgtga ccgagggaat gagaaagccc 1440gccttcctga gcggcgagca gaaaaaggcc atcgtggacc tgctgttcaa gaccaaccgg 1500aaagtgaccg tgaagcagct gaaagaggac tacttcaaga aaatcgagtg cttcgactcc 1560gtggaaatct ccggcgtgga agatcggttc aacgcctccc tgggcacata ccacgatctg 1620ctgaaaatta tcaaggacaa ggacttcctg gacaatgagg aaaacgagga cattctggaa 1680gatatcgtgc tgaccctgac actgtttgag gacagagaga tgatcgagga acggctgaaa 1740acctatgccc acctgttcga cgacaaagtg atgaagcagc tgaagcggcg gagatacacc 1800ggctggggca ggctgagccg gaagctgatc aacggcatcc gggacaagca gtccggcaag 1860acaatcctgg atttcctgaa gtccgacggc ttcgccaaca gaaacttcat gcagctgatc 1920cacgacgaca gcctgacctt taaagaggac atccagaaag cccaggtgtc cggccagggc 1980gatagcctgc acgagcacat tgccaatctg gccggcagcc ccgccattaa gaagggcatc 2040ctgcagacag tgaaggtggt ggacgagctc gtgaaagtga tgggccggca caagcccgag 2100aacatcgtga tcgaaatggc cagagagaac cagaccaccc agaagggaca gaagaacagc 2160cgcgagagaa tgaagcggat cgaagagggc atcaaagagc tgggcagcca gatcctgaaa 2220gaacaccccg tggaaaacac ccagctgcag aacgagaagc tgtacctgta ctacctgcag 2280aatgggcggg atatgtacgt ggaccaggaa ctggacatca accggctgtc cgactacgat 2340gtggaccata tcgtgcctca gagctttctg aaggacgact ccatcgacaa caaggtgctg 2400accagaagcg acaagaaccg gggcaagagc gacaacgtgc cctccgaaga ggtcgtgaag 2460aagatgaaga actactggcg gcagctgctg aacgccaagc tgattaccca gagaaagttc 2520gacaatctga ccaaggccga gagaggcggc ctgagcgaac tggataaggc cggcttcatc 2580aagagacagc tggtggaaac ccggcagatc acaaagcacg tggcacagat cctggactcc 2640cggatgaaca ctaagtacga cgagaatgac aagctgatcc gggaagtgaa agtgatcacc 2700ctgaagtcca agctggtgtc cgatttccgg aaggatttcc agttttacaa agtgcgcgag 2760atcaacaact accaccacgc ccacgacgcc tacctgaacg ccgtcgtggg aaccgccctg 2820atcaaaaagt accctaagct ggaaagcgag ttcgtgtacg gcgactacaa ggtgtacgac 2880gtgcggaaga tgatcgccaa gagcgagcag gaaatcggca aggctaccgc caagtacttc 2940ttctacagca acatcatgaa ctttttcaag accgagatta ccctggccaa cggcgagatc 3000cggaagcggc ctctgatcga gacaaacggc gaaaccgggg agatcgtgtg ggataagggc 3060cgggattttg ccaccgtgcg gaaagtgctg agcatgcccc aagtgaatat cgtgaaaaag 3120accgaggtgc agacaggcgg

cttcagcaaa gagtctatcc tgcccaagag gaacagcgat 3180aagctgatcg ccagaaagaa ggactgggac cctaagaagt acggcggctt cgacagcccc 3240accgtggcct attctgtgct ggtggtggcc aaagtggaaa agggcaagtc caagaaactg 3300aagagtgtga aagagctgct ggggatcacc atcatggaaa gaagcagctt cgagaagaat 3360cccatcgact ttctggaagc caagggctac aaagaagtga aaaaggacct gatcatcaag 3420ctgcctaagt actccctgtt cgagctggaa aacggccgga agagaatgct ggcctctgcc 3480ggcgaactgc agaagggaaa cgaactggcc ctgccctcca aatatgtgaa cttcctgtac 3540ctggccagcc actatgagaa gctgaagggc tcccccgagg ataatgagca gaaacagctg 3600tttgtggaac agcacaagca ctacctggac gagatcatcg agcagatcag cgagttctcc 3660aagagagtga tcctggccga cgctaatctg gacaaagtgc tgtccgccta caacaagcac 3720cgggataagc ccatcagaga gcaggccgag aatatcatcc acctgtttac cctgaccaat 3780ctgggagccc ctgccgcctt caagtacttt gacaccacca tcgaccggaa gaggtacacc 3840agcaccaaag aggtgctgga cgccaccctg atccaccaga gcatcaccgg cctgtacgag 3900acacggatcg acctgtctca gctgggaggc gacaaaaggc cggcggccac gaaaaaggcc 3960ggccaggcaa aaaagaaaaa gtaa 3984673855DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 67atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg gctgaagctg ctgctaaaga agctgctgct 600aaagaagctg ctgctaaagc tgtgaacacc gagatcacca aggcccccct gagcgcctct 660atgatcaaga gatacgacga gcaccaccag gacctgaccc tgctgaaagc tctcgtgcgg 720cagcagctgc ctgagaagta caaagagatt ttcttcgacc agagcaagaa cggctacgcc 780ggctacattg acggcggagc cagccaggaa gagttctaca agttcatcaa gcccatcctg 840gaaaagatgg acggcaccga ggaactgctc gtgaagctga acagagagga cctgctgcgg 900aagcagcgga ccttcgacaa cggcagcatc ccccaccaga tccacctggg agagctgcac 960gccattctgc ggcggcagga agatttttac ccattcctga aggacaaccg ggaaaagatc 1020gagaagatcc tgaccttccg catcccctac tacgtgggcc ctctggccag gggaaacagc 1080agattcgcct ggatgaccag aaagagcgag gaaaccatca ccccctggaa cttcgaggaa 1140gtggtggaca agggcgcttc cgcccagagc ttcatcgagc ggatgaccaa cttcgataag 1200aacctgccca acgagaaggt gctgcccaag cacagcctgc tgtacgagta cttcaccgtg 1260tataacgagc tgaccaaagt gaaatacgtg accgagggaa tgagaaagcc cgccttcctg 1320agcggcgagc agaaaaaggc catcgtggac ctgctgttca agaccaaccg gaaagtgacc 1380gtgaagcagc tgaaagagga ctacttcaag aaaatcgagt gcttcgactc cgtggaaatc 1440tccggcgtgg aagatcggtt caacgcctcc ctgggcacat accacgatct gctgaaaatt 1500atcaaggaca aggacttcct ggacaatgag gaaaacgagg acattctgga agatatcgtg 1560ctgaccctga cactgtttga ggacagagag atgatcgagg aacggctgaa aacctatgcc 1620cacctgttcg acgacaaagt gatgaagcag ctgaagcggc ggagatacac cggctggggc 1680aggctgagcc ggaagctgat caacggcatc cgggacaagc agtccggcaa gacaatcctg 1740gatttcctga agtccgacgg cttcgccaac agaaacttca tgcagctgat ccacgacgac 1800agcctgacct ttaaagagga catccagaaa gcccaggtgt ccggccaggg cgatagcctg 1860cacgagcaca ttgccaatct ggccggcagc cccgccatta agaagggcat cctgcagaca 1920gtgaaggtgg tggacgagct cgtgaaagtg atgggccggc acaagcccga gaacatcgtg 1980atcgaaatgg ccagagagaa ccagaccacc cagaagggac agaagaacag ccgcgagaga 2040atgaagcgga tcgaagaggg catcaaagag ctgggcagcc agatcctgaa agaacacccc 2100gtggaaaaca cccagctgca gaacgagaag ctgtacctgt actacctgca gaatgggcgg 2160gatatgtacg tggaccagga actggacatc aaccggctgt ccgactacga tgtggaccat 2220atcgtgcctc agagctttct gaaggacgac tccatcgaca acaaggtgct gaccagaagc 2280gacaagaacc ggggcaagag cgacaacgtg ccctccgaag aggtcgtgaa gaagatgaag 2340aactactggc ggcagctgct gaacgccaag ctgattaccc agagaaagtt cgacaatctg 2400accaaggccg agagaggcgg cctgagcgaa ctggataagg ccggcttcat caagagacag 2460ctggtggaaa cccggcagat cacaaagcac gtggcacaga tcctggactc ccggatgaac 2520actaagtacg acgagaatga caagctgatc cgggaagtga aagtgatcac cctgaagtcc 2580aagctggtgt ccgatttccg gaaggatttc cagttttaca aagtgcgcga gatcaacaac 2640taccaccacg cccacgacgc ctacctgaac gccgtcgtgg gaaccgccct gatcaaaaag 2700taccctaagc tggaaagcga gttcgtgtac ggcgactaca aggtgtacga cgtgcggaag 2760atgatcgcca agagcgagca ggaaatcggc aaggctaccg ccaagtactt cttctacagc 2820aacatcatga actttttcaa gaccgagatt accctggcca acggcgagat ccggaagcgg 2880cctctgatcg agacaaacgg cgaaaccggg gagatcgtgt gggataaggg ccgggatttt 2940gccaccgtgc ggaaagtgct gagcatgccc caagtgaata tcgtgaaaaa gaccgaggtg 3000cagacaggcg gcttcagcaa agagtctatc ctgcccaaga ggaacagcga taagctgatc 3060gccagaaaga aggactggga ccctaagaag tacggcggct tcgacagccc caccgtggcc 3120tattctgtgc tggtggtggc caaagtggaa aagggcaagt ccaagaaact gaagagtgtg 3180aaagagctgc tggggatcac catcatggaa agaagcagct tcgagaagaa tcccatcgac 3240tttctggaag ccaagggcta caaagaagtg aaaaaggacc tgatcatcaa gctgcctaag 3300tactccctgt tcgagctgga aaacggccgg aagagaatgc tggcctctgc cggcgaactg 3360cagaagggaa acgaactggc cctgccctcc aaatatgtga acttcctgta cctggccagc 3420cactatgaga agctgaaggg ctcccccgag gataatgagc agaaacagct gtttgtggaa 3480cagcacaagc actacctgga cgagatcatc gagcagatca gcgagttctc caagagagtg 3540atcctggccg acgctaatct ggacaaagtg ctgtccgcct acaacaagca ccgggataag 3600cccatcagag agcaggccga gaatatcatc cacctgttta ccctgaccaa tctgggagcc 3660cctgccgcct tcaagtactt tgacaccacc atcgaccgga agaggtacac cagcaccaaa 3720gaggtgctgg acgccaccct gatccaccag agcatcaccg gcctgtacga gacacggatc 3780gacctgtctc agctgggagg cgacaaaagg ccggcggcca cgaaaaaggc cggccaggca 3840aaaaagaaaa agtaa 3855683912DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 68atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg gctgaagccg ctgctaaaga agccgctgct 600aaagaagccg ctgctaaagc cctggaggct gaagccgctg ctaaagaagc cgctgctaaa 660gaagccgctg ctaaagctgt gaacaccgag atcaccaagg cccccctgag cgcctctatg 720atcaagagat acgacgagca ccaccaggac ctgaccctgc tgaaagctct cgtgcggcag 780cagctgcctg agaagtacaa agagattttc ttcgaccaga gcaagaacgg ctacgccggc 840tacattgacg gcggagccag ccaggaagag ttctacaagt tcatcaagcc catcctggaa 900aagatggacg gcaccgagga actgctcgtg aagctgaaca gagaggacct gctgcggaag 960cagcggacct tcgacaacgg cagcatcccc caccagatcc acctgggaga gctgcacgcc 1020attctgcggc ggcaggaaga tttttaccca ttcctgaagg acaaccggga aaagatcgag 1080aagatcctga ccttccgcat cccctactac gtgggccctc tggccagggg aaacagcaga 1140ttcgcctgga tgaccagaaa gagcgaggaa accatcaccc cctggaactt cgaggaagtg 1200gtggacaagg gcgcttccgc ccagagcttc atcgagcgga tgaccaactt cgataagaac 1260ctgcccaacg agaaggtgct gcccaagcac agcctgctgt acgagtactt caccgtgtat 1320aacgagctga ccaaagtgaa atacgtgacc gagggaatga gaaagcccgc cttcctgagc 1380ggcgagcaga aaaaggccat cgtggacctg ctgttcaaga ccaaccggaa agtgaccgtg 1440aagcagctga aagaggacta cttcaagaaa atcgagtgct tcgactccgt ggaaatctcc 1500ggcgtggaag atcggttcaa cgcctccctg ggcacatacc acgatctgct gaaaattatc 1560aaggacaagg acttcctgga caatgaggaa aacgaggaca ttctggaaga tatcgtgctg 1620accctgacac tgtttgagga cagagagatg atcgaggaac ggctgaaaac ctatgcccac 1680ctgttcgacg acaaagtgat gaagcagctg aagcggcgga gatacaccgg ctggggcagg 1740ctgagccgga agctgatcaa cggcatccgg gacaagcagt ccggcaagac aatcctggat 1800ttcctgaagt ccgacggctt cgccaacaga aacttcatgc agctgatcca cgacgacagc 1860ctgaccttta aagaggacat ccagaaagcc caggtgtccg gccagggcga tagcctgcac 1920gagcacattg ccaatctggc cggcagcccc gccattaaga agggcatcct gcagacagtg 1980aaggtggtgg acgagctcgt gaaagtgatg ggccggcaca agcccgagaa catcgtgatc 2040gaaatggcca gagagaacca gaccacccag aagggacaga agaacagccg cgagagaatg 2100aagcggatcg aagagggcat caaagagctg ggcagccaga tcctgaaaga acaccccgtg 2160gaaaacaccc agctgcagaa cgagaagctg tacctgtact acctgcagaa tgggcgggat 2220atgtacgtgg accaggaact ggacatcaac cggctgtccg actacgatgt ggaccatatc 2280gtgcctcaga gctttctgaa ggacgactcc atcgacaaca aggtgctgac cagaagcgac 2340aagaaccggg gcaagagcga caacgtgccc tccgaagagg tcgtgaagaa gatgaagaac 2400tactggcggc agctgctgaa cgccaagctg attacccaga gaaagttcga caatctgacc 2460aaggccgaga gaggcggcct gagcgaactg gataaggccg gcttcatcaa gagacagctg 2520gtggaaaccc ggcagatcac aaagcacgtg gcacagatcc tggactcccg gatgaacact 2580aagtacgacg agaatgacaa gctgatccgg gaagtgaaag tgatcaccct gaagtccaag 2640ctggtgtccg atttccggaa ggatttccag ttttacaaag tgcgcgagat caacaactac 2700caccacgccc acgacgccta cctgaacgcc gtcgtgggaa ccgccctgat caaaaagtac 2760cctaagctgg aaagcgagtt cgtgtacggc gactacaagg tgtacgacgt gcggaagatg 2820atcgccaaga gcgagcagga aatcggcaag gctaccgcca agtacttctt ctacagcaac 2880atcatgaact ttttcaagac cgagattacc ctggccaacg gcgagatccg gaagcggcct 2940ctgatcgaga caaacggcga aaccggggag atcgtgtggg ataagggccg ggattttgcc 3000accgtgcgga aagtgctgag catgccccaa gtgaatatcg tgaaaaagac cgaggtgcag 3060acaggcggct tcagcaaaga gtctatcctg cccaagagga acagcgataa gctgatcgcc 3120agaaagaagg actgggaccc taagaagtac ggcggcttcg acagccccac cgtggcctat 3180tctgtgctgg tggtggccaa agtggaaaag ggcaagtcca agaaactgaa gagtgtgaaa 3240gagctgctgg ggatcaccat catggaaaga agcagcttcg agaagaatcc catcgacttt 3300ctggaagcca agggctacaa agaagtgaaa aaggacctga tcatcaagct gcctaagtac 3360tccctgttcg agctggaaaa cggccggaag agaatgctgg cctctgccgg cgaactgcag 3420aagggaaacg aactggccct gccctccaaa tatgtgaact tcctgtacct ggccagccac 3480tatgagaagc tgaagggctc ccccgaggat aatgagcaga aacagctgtt tgtggaacag 3540cacaagcact acctggacga gatcatcgag cagatcagcg agttctccaa gagagtgatc 3600ctggccgacg ctaatctgga caaagtgctg tccgcctaca acaagcaccg ggataagccc 3660atcagagagc aggccgagaa tatcatccac ctgtttaccc tgaccaatct gggagcccct 3720gccgccttca agtactttga caccaccatc gaccggaaga ggtacaccag caccaaagag 3780gtgctggacg ccaccctgat ccaccagagc atcaccggcc tgtacgagac acggatcgac 3840ctgtctcagc tgggaggcga caaaaggccg gcggccacga aaaaggccgg ccaggcaaaa 3900aagaaaaagt aa 3912693969DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 69atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg gctgaagctg ctgctaaaga agctgctgct 600aaagaagctg ctgctaaagc cctggaggct gaagctgctg ctaaagaagc tgctgctaaa 660gaagctgctg ctaaagccct ggaggctgaa gctgctgcta aagaagctgc tgctaaagaa 720gctgctgcta aagctgtgaa caccgagatc accaaggccc ccctgagcgc ctctatgatc 780aagagatacg acgagcacca ccaggacctg accctgctga aagctctcgt gcggcagcag 840ctgcctgaga agtacaaaga gattttcttc gaccagagca agaacggcta cgccggctac 900attgacggcg gagccagcca ggaagagttc tacaagttca tcaagcccat cctggaaaag 960atggacggca ccgaggaact gctcgtgaag ctgaacagag aggacctgct gcggaagcag 1020cggaccttcg acaacggcag catcccccac cagatccacc tgggagagct gcacgccatt 1080ctgcggcggc aggaagattt ttacccattc ctgaaggaca accgggaaaa gatcgagaag 1140atcctgacct tccgcatccc ctactacgtg ggccctctgg ccaggggaaa cagcagattc 1200gcctggatga ccagaaagag cgaggaaacc atcaccccct ggaacttcga ggaagtggtg 1260gacaagggcg cttccgccca gagcttcatc gagcggatga ccaacttcga taagaacctg 1320cccaacgaga aggtgctgcc caagcacagc ctgctgtacg agtacttcac cgtgtataac 1380gagctgacca aagtgaaata cgtgaccgag ggaatgagaa agcccgcctt cctgagcggc 1440gagcagaaaa aggccatcgt ggacctgctg ttcaagacca accggaaagt gaccgtgaag 1500cagctgaaag aggactactt caagaaaatc gagtgcttcg actccgtgga aatctccggc 1560gtggaagatc ggttcaacgc ctccctgggc acataccacg atctgctgaa aattatcaag 1620gacaaggact tcctggacaa tgaggaaaac gaggacattc tggaagatat cgtgctgacc 1680ctgacactgt ttgaggacag agagatgatc gaggaacggc tgaaaaccta tgcccacctg 1740ttcgacgaca aagtgatgaa gcagctgaag cggcggagat acaccggctg gggcaggctg 1800agccggaagc tgatcaacgg catccgggac aagcagtccg gcaagacaat cctggatttc 1860ctgaagtccg acggcttcgc caacagaaac ttcatgcagc tgatccacga cgacagcctg 1920acctttaaag aggacatcca gaaagcccag gtgtccggcc agggcgatag cctgcacgag 1980cacattgcca atctggccgg cagccccgcc attaagaagg gcatcctgca gacagtgaag 2040gtggtggacg agctcgtgaa agtgatgggc cggcacaagc ccgagaacat cgtgatcgaa 2100atggccagag agaaccagac cacccagaag ggacagaaga acagccgcga gagaatgaag 2160cggatcgaag agggcatcaa agagctgggc agccagatcc tgaaagaaca ccccgtggaa 2220aacacccagc tgcagaacga gaagctgtac ctgtactacc tgcagaatgg gcgggatatg 2280tacgtggacc aggaactgga catcaaccgg ctgtccgact acgatgtgga ccatatcgtg 2340cctcagagct ttctgaagga cgactccatc gacaacaagg tgctgaccag aagcgacaag 2400aaccggggca agagcgacaa cgtgccctcc gaagaggtcg tgaagaagat gaagaactac 2460tggcggcagc tgctgaacgc caagctgatt acccagagaa agttcgacaa tctgaccaag 2520gccgagagag gcggcctgag cgaactggat aaggccggct tcatcaagag acagctggtg 2580gaaacccggc agatcacaaa gcacgtggca cagatcctgg actcccggat gaacactaag 2640tacgacgaga atgacaagct gatccgggaa gtgaaagtga tcaccctgaa gtccaagctg 2700gtgtccgatt tccggaagga tttccagttt tacaaagtgc gcgagatcaa caactaccac 2760cacgcccacg acgcctacct gaacgccgtc gtgggaaccg ccctgatcaa aaagtaccct 2820aagctggaaa gcgagttcgt gtacggcgac tacaaggtgt acgacgtgcg gaagatgatc 2880gccaagagcg agcaggaaat cggcaaggct accgccaagt acttcttcta cagcaacatc 2940atgaactttt tcaagaccga gattaccctg gccaacggcg agatccggaa gcggcctctg 3000atcgagacaa acggcgaaac cggggagatc gtgtgggata agggccggga ttttgccacc 3060gtgcggaaag tgctgagcat gccccaagtg aatatcgtga aaaagaccga ggtgcagaca 3120ggcggcttca gcaaagagtc tatcctgccc aagaggaaca gcgataagct gatcgccaga 3180aagaaggact gggaccctaa gaagtacggc ggcttcgaca gccccaccgt ggcctattct 3240gtgctggtgg tggccaaagt ggaaaagggc aagtccaaga aactgaagag tgtgaaagag 3300ctgctgggga tcaccatcat ggaaagaagc agcttcgaga agaatcccat cgactttctg 3360gaagccaagg gctacaaaga agtgaaaaag gacctgatca tcaagctgcc taagtactcc 3420ctgttcgagc tggaaaacgg ccggaagaga atgctggcct ctgccggcga actgcagaag 3480ggaaacgaac tggccctgcc ctccaaatat gtgaacttcc tgtacctggc cagccactat 3540gagaagctga agggctcccc cgaggataat gagcagaaac agctgtttgt ggaacagcac 3600aagcactacc tggacgagat catcgagcag atcagcgagt tctccaagag agtgatcctg 3660gccgacgcta atctggacaa agtgctgtcc gcctacaaca agcaccggga taagcccatc 3720agagagcagg ccgagaatat catccacctg tttaccctga ccaatctggg agcccctgcc 3780gccttcaagt actttgacac caccatcgac cggaagaggt acaccagcac caaagaggtg 3840ctggacgcca ccctgatcca ccagagcatc accggcctgt acgagacacg gatcgacctg 3900tctcagctgg gaggcgacaa aaggccggcg gccacgaaaa aggccggcca ggcaaaaaag 3960aaaaagtaa 3969704026DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 70atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg gctgaagctg ctgctaaaga agctgctgct 600aaagaagctg ctgctaaagc cctggaggct gaagctgctg ctaaagaagc tgctgctaaa 660gaagctgctg ctaaagccct ggaggctgaa gctgctgcta aagaagctgc tgctaaagaa 720gctgctgcta aagccctgga ggctgaagct gctgctaaag aagctgctgc taaagaagct 780gctgctaaag ctgtgaacac cgagatcacc aaggcccccc tgagcgcctc tatgatcaag 840agatacgacg agcaccacca ggacctgacc ctgctgaaag ctctcgtgcg gcagcagctg 900cctgagaagt acaaagagat tttcttcgac cagagcaaga acggctacgc cggctacatt 960gacggcggag ccagccagga agagttctac aagttcatca agcccatcct ggaaaagatg 1020gacggcaccg aggaactgct cgtgaagctg aacagagagg acctgctgcg gaagcagcgg 1080accttcgaca acggcagcat cccccaccag atccacctgg gagagctgca cgccattctg 1140cggcggcagg aagattttta cccattcctg aaggacaacc gggaaaagat cgagaagatc 1200ctgaccttcc gcatccccta ctacgtgggc cctctggcca ggggaaacag cagattcgcc 1260tggatgacca gaaagagcga ggaaaccatc accccctgga acttcgagga agtggtggac 1320aagggcgctt ccgcccagag cttcatcgag cggatgacca acttcgataa gaacctgccc 1380aacgagaagg tgctgcccaa gcacagcctg ctgtacgagt acttcaccgt gtataacgag 1440ctgaccaaag tgaaatacgt gaccgaggga atgagaaagc ccgccttcct gagcggcgag 1500cagaaaaagg ccatcgtgga cctgctgttc aagaccaacc ggaaagtgac cgtgaagcag 1560ctgaaagagg actacttcaa gaaaatcgag tgcttcgact ccgtggaaat ctccggcgtg 1620gaagatcggt tcaacgcctc cctgggcaca taccacgatc tgctgaaaat tatcaaggac 1680aaggacttcc tggacaatga ggaaaacgag gacattctgg aagatatcgt gctgaccctg 1740acactgtttg aggacagaga gatgatcgag gaacggctga aaacctatgc ccacctgttc 1800gacgacaaag tgatgaagca gctgaagcgg cggagataca ccggctgggg caggctgagc 1860cggaagctga tcaacggcat ccgggacaag cagtccggca agacaatcct

ggatttcctg 1920aagtccgacg gcttcgccaa cagaaacttc atgcagctga tccacgacga cagcctgacc 1980tttaaagagg acatccagaa agcccaggtg tccggccagg gcgatagcct gcacgagcac 2040attgccaatc tggccggcag ccccgccatt aagaagggca tcctgcagac agtgaaggtg 2100gtggacgagc tcgtgaaagt gatgggccgg cacaagcccg agaacatcgt gatcgaaatg 2160gccagagaga accagaccac ccagaaggga cagaagaaca gccgcgagag aatgaagcgg 2220atcgaagagg gcatcaaaga gctgggcagc cagatcctga aagaacaccc cgtggaaaac 2280acccagctgc agaacgagaa gctgtacctg tactacctgc agaatgggcg ggatatgtac 2340gtggaccagg aactggacat caaccggctg tccgactacg atgtggacca tatcgtgcct 2400cagagctttc tgaaggacga ctccatcgac aacaaggtgc tgaccagaag cgacaagaac 2460cggggcaaga gcgacaacgt gccctccgaa gaggtcgtga agaagatgaa gaactactgg 2520cggcagctgc tgaacgccaa gctgattacc cagagaaagt tcgacaatct gaccaaggcc 2580gagagaggcg gcctgagcga actggataag gccggcttca tcaagagaca gctggtggaa 2640acccggcaga tcacaaagca cgtggcacag atcctggact cccggatgaa cactaagtac 2700gacgagaatg acaagctgat ccgggaagtg aaagtgatca ccctgaagtc caagctggtg 2760tccgatttcc ggaaggattt ccagttttac aaagtgcgcg agatcaacaa ctaccaccac 2820gcccacgacg cctacctgaa cgccgtcgtg ggaaccgccc tgatcaaaaa gtaccctaag 2880ctggaaagcg agttcgtgta cggcgactac aaggtgtacg acgtgcggaa gatgatcgcc 2940aagagcgagc aggaaatcgg caaggctacc gccaagtact tcttctacag caacatcatg 3000aactttttca agaccgagat taccctggcc aacggcgaga tccggaagcg gcctctgatc 3060gagacaaacg gcgaaaccgg ggagatcgtg tgggataagg gccgggattt tgccaccgtg 3120cggaaagtgc tgagcatgcc ccaagtgaat atcgtgaaaa agaccgaggt gcagacaggc 3180ggcttcagca aagagtctat cctgcccaag aggaacagcg ataagctgat cgccagaaag 3240aaggactggg accctaagaa gtacggcggc ttcgacagcc ccaccgtggc ctattctgtg 3300ctggtggtgg ccaaagtgga aaagggcaag tccaagaaac tgaagagtgt gaaagagctg 3360ctggggatca ccatcatgga aagaagcagc ttcgagaaga atcccatcga ctttctggaa 3420gccaagggct acaaagaagt gaaaaaggac ctgatcatca agctgcctaa gtactccctg 3480ttcgagctgg aaaacggccg gaagagaatg ctggcctctg ccggcgaact gcagaaggga 3540aacgaactgg ccctgccctc caaatatgtg aacttcctgt acctggccag ccactatgag 3600aagctgaagg gctcccccga ggataatgag cagaaacagc tgtttgtgga acagcacaag 3660cactacctgg acgagatcat cgagcagatc agcgagttct ccaagagagt gatcctggcc 3720gacgctaatc tggacaaagt gctgtccgcc tacaacaagc accgggataa gcccatcaga 3780gagcaggccg agaatatcat ccacctgttt accctgacca atctgggagc ccctgccgcc 3840ttcaagtact ttgacaccac catcgaccgg aagaggtaca ccagcaccaa agaggtgctg 3900gacgccaccc tgatccacca gagcatcacc ggcctgtacg agacacggat cgacctgtct 3960cagctgggag gcgacaaaag gccggcggcc acgaaaaagg ccggccaggc aaaaaagaaa 4020aagtaa 4026714203DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 71atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac gccgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg aaccccgaca acagcgacgt ggacaagctg 600ttcatccagc tggtgcagac ctacaaccag ctgttcgagg aaaaccccat caacgccagc 660ggcgtggacg ccaaggccat cctgtctgcc agactgagca agagcagacg gctggaaaat 720ctgatcgccc agctgcccgg cgagaagaag aatggcctgt tcggaaacct gattgccctg 780agcctgggcc tgacccccaa cttcaagagc aacttcgacc tggccgagga tgccaaactg 840cagctgagca aggacaccta cgacgacgac ctggacaacc tgctggccca gatcggcgac 900cagtacgccg acctgtttct ggccgccaag aacctgtccg acgccatcct gctgagcgac 960atcctgagag tgaacaccga gatcaccaag gcccccctga gcgcctctat gatcaagaga 1020tacgacgagc accaccagga cctgaccctg ctgaaagctc tcgtgcggca gcagctgcct 1080gagaagtaca aagagatttt cttcgaccag agcaagaacg gctacgccgg ctacattgac 1140ggcggagcca gccaggaaga gttctacaag ttcatcaagc ccatcctgga aaagatggac 1200ggcaccgagg aactgctcgt gaagctgaac agagaggacc tgctgcggaa gcagcggacc 1260ttcgacaacg gcagcatccc ccaccagatc cacctgggag agctgcacgc cattctgcgg 1320cggcaggaag atttttaccc attcctgaag gacaaccggg aaaagatcga gaagatcctg 1380accttccgca tcccctacta cgtgggccct ctggccaggg gaaacagcag attcgcctgg 1440atgaccagaa agagcgagga aaccatcacc ccctggaact tcgaggaagt ggtggacaag 1500ggcgcttccg cccagagctt catcgagcgg atgaccaact tcgataagaa cctgcccaac 1560gagaaggtgc tgcccaagca cagcctgctg tacgagtact tcaccgtgta taacgagctg 1620accaaagtga aatacgtgac cgagggaatg agaaagcccg ccttcctgag cggcgagcag 1680aaaaaggcca tcgtggacct gctgttcaag accaaccgga aagtgaccgt gaagcagctg 1740aaagaggact acttcaagaa aatcgagtgc ttcgactccg tggaaatctc cggcgtggaa 1800gatcggttca acgcctccct gggcacatac cacgatctgc tgaaaattat caaggacaag 1860gacttcctgg acaatgagga aaacgaggac attctggaag atatcgtgct gaccctgaca 1920ctgtttgagg acagagagat gatcgaggaa cggctgaaaa cctatgccca cctgttcgac 1980gacaaagtga tgaagcagct gaagcggcgg agatacaccg gctggggcag gctgagccgg 2040aagctgatca acggcatccg ggacaagcag tccggcaaga caatcctgga tttcctgaag 2100tccgacggct tcgccaacag aaacttcatg cagctgatcc acgacgacag cctgaccttt 2160aaagaggaca tccagaaagc ccaggtgtcc ggccagggcg atagcctgca cgagcacatt 2220gccaatctgg ccggcagccc cgccattaag aagggcatcc tgcagacagt gaaggtggtg 2280gacgagctcg tgaaagtgat gggccggcac aagcccgaga acatcgtgat cgaaatggcc 2340agagagaacc agaccaccca gaagggacag aagaacagcc gcgagagaat gaagcggatc 2400gaagagggca tcaaagagct gggcagccag atcctgaaag aacaccccgt ggaaaacacc 2460cagctgcaga acgagaagct gtacctgtac tacctgcaga atgggcggga tatgtacgtg 2520gaccaggaac tggacatcaa ccggctgtcc gactacgatg tggaccatat cgtgcctcag 2580agctttctga aggacgactc catcgacaac aaggtgctga ccagaagcga caagaaccgg 2640ggcaagagcg acaacgtgcc ctccgaagag gtcgtgaaga agatgaagaa ctactggcgg 2700cagctgctga acgccaagct gattacccag agaaagttcg acaatctgac caaggccgag 2760agaggcggcc tgagcgaact ggataaggcc ggcttcatca agagacagct ggtggaaacc 2820cggcagatca caaagcacgt ggcacagatc ctggactccc ggatgaacac taagtacgac 2880gagaatgaca agctgatccg ggaagtgaaa gtgatcaccc tgaagtccaa gctggtgtcc 2940gatttccgga aggatttcca gttttacaaa gtgcgcgaga tcaacaacta ccaccacgcc 3000cacgacgcct acctgaacgc cgtcgtggga accgccctga tcaaaaagta ccctaagctg 3060gaaagcgagt tcgtgtacgg cgactacaag gtgtacgacg tgcggaagat gatcgccaag 3120agcgagcagg aaatcggcaa ggctaccgcc aagtacttct tctacagcaa catcatgaac 3180tttttcaaga ccgagattac cctggccaac ggcgagatcc ggaagcggcc tctgatcgag 3240acaaacggcg aaaccgggga gatcgtgtgg gataagggcc gggattttgc caccgtgcgg 3300aaagtgctga gcatgcccca agtgaatatc gtgaaaaaga ccgaggtgca gacaggcggc 3360ttcagcaaag agtctatcct gcccaagagg aacagcgata agctgatcgc cagaaagaag 3420gactgggacc ctaagaagta cggcggcttc gacagcccca ccgtggccta ttctgtgctg 3480gtggtggcca aagtggaaaa gggcaagtcc aagaaactga agagtgtgaa agagctgctg 3540gggatcacca tcatggaaag aagcagcttc gagaagaatc ccatcgactt tctggaagcc 3600aagggctaca aagaagtgaa aaaggacctg atcatcaagc tgcctaagta ctccctgttc 3660gagctggaaa acggccggaa gagaatgctg gcctctgccg gcgaactgca gaagggaaac 3720gaactggccc tgccctccaa atatgtgaac ttcctgtacc tggccagcca ctatgagaag 3780ctgaagggct cccccgagga taatgagcag aaacagctgt ttgtggaaca gcacaagcac 3840tacctggacg agatcatcga gcagatcagc gagttctcca agagagtgat cctggccgac 3900gctaatctgg acaaagtgct gtccgcctac aacaagcacc gggataagcc catcagagag 3960caggccgaga atatcatcca cctgtttacc ctgaccaatc tgggagcccc tgccgccttc 4020aagtactttg acaccaccat cgaccggaag aggtacacca gcaccaaaga ggtgctggac 4080gccaccctga tccaccagag catcaccggc ctgtacgaga cacggatcga cctgtctcag 4140ctgggaggcg acaaaaggcc ggcggccacg aaaaaggccg gccaggcaaa aaagaaaaag 4200taa 4203724203DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 72atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg aaccccgaca acagcgacgt ggacaagctg 600ttcatccagc tggtgcagac ctacaaccag ctgttcgagg aaaaccccat caacgccagc 660ggcgtggacg ccaaggccat cctgtctgcc agactgagca agagcagacg gctggaaaat 720ctgatcgccc agctgcccgg cgagaagaag aatggcctgt tcggaaacct gattgccctg 780agcctgggcc tgacccccaa cttcaagagc aacttcgacc tggccgagga tgccaaactg 840cagctgagca aggacaccta cgacgacgac ctggacaacc tgctggccca gatcggcgac 900cagtacgccg acctgtttct ggccgccaag aacctgtccg acgccatcct gctgagcgac 960atcctgagag tgaacaccga gatcaccaag gcccccctga gcgcctctat gatcaagaga 1020tacgacgagc accaccagga cctgaccctg ctgaaagctc tcgtgcggca gcagctgcct 1080gagaagtaca aagagatttt cttcgaccag agcaagaacg gctacgccgg ctacattgac 1140ggcggagcca gccaggaaga gttctacaag ttcatcaagc ccatcctgga aaagatggac 1200ggcaccgagg aactgctcgt gaagctgaac agagaggacc tgctgcggaa gcagcggacc 1260ttcgacaacg gcagcatccc ccaccagatc cacctgggag agctgcacgc cattctgcgg 1320cggcaggaag atttttaccc attcctgaag gacaaccggg aaaagatcga gaagatcctg 1380accttccgca tcccctacta cgtgggccct ctggccaggg gaaacagcag attcgcctgg 1440atgaccagaa agagcgagga aaccatcacc ccctggaact tcgaggaagt ggtggacaag 1500ggcgcttccg cccagagctt catcgagcgg atgaccaact tcgataagaa cctgcccaac 1560gagaaggtgc tgcccaagca cagcctgctg tacgagtact tcaccgtgta taacgagctg 1620accaaagtga aatacgtgac cgagggaatg agaaagcccg ccttcctgag cggcgagcag 1680aaaaaggcca tcgtggacct gctgttcaag accaaccgga aagtgaccgt gaagcagctg 1740aaagaggact acttcaagaa aatcgagtgc ttcgactccg tggaaatctc cggcgtggaa 1800gatcggttca acgcctccct gggcacatac cacgatctgc tgaaaattat caaggacaag 1860gacttcctgg acaatgagga aaacgaggac attctggaag atatcgtgct gaccctgaca 1920ctgtttgagg acagagagat gatcgaggaa cggctgaaaa cctatgccca cctgttcgac 1980gacaaagtga tgaagcagct gaagcggcgg agatacaccg gctggggcag gctgagccgg 2040aagctgatca acggcatccg ggacaagcag tccggcaaga caatcctgga tttcctgaag 2100tccgacggct tcgccaacag aaacttcatg cagctgatcc acgacgacag cctgaccttt 2160aaagaggaca tccagaaagc ccaggtgtcc ggccagggcg atagcctgca cgagcacatt 2220gccaatctgg ccggcagccc cgccattaag aagggcatcc tgcagacagt gaaggtggtg 2280gacgagctcg tgaaagtgat gggccggcac aagcccgaga acatcgtgat cgccatggcc 2340agagagaacc agaccaccca gaagggacag aagaacagcc gcgagagaat gaagcggatc 2400gaagagggca tcaaagagct gggcagccag atcctgaaag aacaccccgt ggaaaacacc 2460cagctgcaga acgagaagct gtacctgtac tacctgcaga atgggcggga tatgtacgtg 2520gaccaggaac tggacatcaa ccggctgtcc gactacgatg tggaccatat cgtgcctcag 2580agctttctga aggacgactc catcgacaac aaggtgctga ccagaagcga caagaaccgg 2640ggcaagagcg acaacgtgcc ctccgaagag gtcgtgaaga agatgaagaa ctactggcgg 2700cagctgctga acgccaagct gattacccag agaaagttcg acaatctgac caaggccgag 2760agaggcggcc tgagcgaact ggataaggcc ggcttcatca agagacagct ggtggaaacc 2820cggcagatca caaagcacgt ggcacagatc ctggactccc ggatgaacac taagtacgac 2880gagaatgaca agctgatccg ggaagtgaaa gtgatcaccc tgaagtccaa gctggtgtcc 2940gatttccgga aggatttcca gttttacaaa gtgcgcgaga tcaacaacta ccaccacgcc 3000cacgacgcct acctgaacgc cgtcgtggga accgccctga tcaaaaagta ccctaagctg 3060gaaagcgagt tcgtgtacgg cgactacaag gtgtacgacg tgcggaagat gatcgccaag 3120agcgagcagg aaatcggcaa ggctaccgcc aagtacttct tctacagcaa catcatgaac 3180tttttcaaga ccgagattac cctggccaac ggcgagatcc ggaagcggcc tctgatcgag 3240acaaacggcg aaaccgggga gatcgtgtgg gataagggcc gggattttgc caccgtgcgg 3300aaagtgctga gcatgcccca agtgaatatc gtgaaaaaga ccgaggtgca gacaggcggc 3360ttcagcaaag agtctatcct gcccaagagg aacagcgata agctgatcgc cagaaagaag 3420gactgggacc ctaagaagta cggcggcttc gacagcccca ccgtggccta ttctgtgctg 3480gtggtggcca aagtggaaaa gggcaagtcc aagaaactga agagtgtgaa agagctgctg 3540gggatcacca tcatggaaag aagcagcttc gagaagaatc ccatcgactt tctggaagcc 3600aagggctaca aagaagtgaa aaaggacctg atcatcaagc tgcctaagta ctccctgttc 3660gagctggaaa acggccggaa gagaatgctg gcctctgccg gcgaactgca gaagggaaac 3720gaactggccc tgccctccaa atatgtgaac ttcctgtacc tggccagcca ctatgagaag 3780ctgaagggct cccccgagga taatgagcag aaacagctgt ttgtggaaca gcacaagcac 3840tacctggacg agatcatcga gcagatcagc gagttctcca agagagtgat cctggccgac 3900gctaatctgg acaaagtgct gtccgcctac aacaagcacc gggataagcc catcagagag 3960caggccgaga atatcatcca cctgtttacc ctgaccaatc tgggagcccc tgccgccttc 4020aagtactttg acaccaccat cgaccggaag aggtacacca gcaccaaaga ggtgctggac 4080gccaccctga tccaccagag catcaccggc ctgtacgaga cacggatcga cctgtctcag 4140ctgggaggcg acaaaaggcc ggcggccacg aaaaaggccg gccaggcaaa aaagaaaaag 4200taa 4203734203DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 73atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg aaccccgaca acagcgacgt ggacaagctg 600ttcatccagc tggtgcagac ctacaaccag ctgttcgagg aaaaccccat caacgccagc 660ggcgtggacg ccaaggccat cctgtctgcc agactgagca agagcagacg gctggaaaat 720ctgatcgccc agctgcccgg cgagaagaag aatggcctgt tcggaaacct gattgccctg 780agcctgggcc tgacccccaa cttcaagagc aacttcgacc tggccgagga tgccaaactg 840cagctgagca aggacaccta cgacgacgac ctggacaacc tgctggccca gatcggcgac 900cagtacgccg acctgtttct ggccgccaag aacctgtccg acgccatcct gctgagcgac 960atcctgagag tgaacaccga gatcaccaag gcccccctga gcgcctctat gatcaagaga 1020tacgacgagc accaccagga cctgaccctg ctgaaagctc tcgtgcggca gcagctgcct 1080gagaagtaca aagagatttt cttcgaccag agcaagaacg gctacgccgg ctacattgac 1140ggcggagcca gccaggaaga gttctacaag ttcatcaagc ccatcctgga aaagatggac 1200ggcaccgagg aactgctcgt gaagctgaac agagaggacc tgctgcggaa gcagcggacc 1260ttcgacaacg gcagcatccc ccaccagatc cacctgggag agctgcacgc cattctgcgg 1320cggcaggaag atttttaccc attcctgaag gacaaccggg aaaagatcga gaagatcctg 1380accttccgca tcccctacta cgtgggccct ctggccaggg gaaacagcag attcgcctgg 1440atgaccagaa agagcgagga aaccatcacc ccctggaact tcgaggaagt ggtggacaag 1500ggcgcttccg cccagagctt catcgagcgg atgaccaact tcgataagaa cctgcccaac 1560gagaaggtgc tgcccaagca cagcctgctg tacgagtact tcaccgtgta taacgagctg 1620accaaagtga aatacgtgac cgagggaatg agaaagcccg ccttcctgag cggcgagcag 1680aaaaaggcca tcgtggacct gctgttcaag accaaccgga aagtgaccgt gaagcagctg 1740aaagaggact acttcaagaa aatcgagtgc ttcgactccg tggaaatctc cggcgtggaa 1800gatcggttca acgcctccct gggcacatac cacgatctgc tgaaaattat caaggacaag 1860gacttcctgg acaatgagga aaacgaggac attctggaag atatcgtgct gaccctgaca 1920ctgtttgagg acagagagat gatcgaggaa cggctgaaaa cctatgccca cctgttcgac 1980gacaaagtga tgaagcagct gaagcggcgg agatacaccg gctggggcag gctgagccgg 2040aagctgatca acggcatccg ggacaagcag tccggcaaga caatcctgga tttcctgaag 2100tccgacggct tcgccaacag aaacttcatg cagctgatcc acgacgacag cctgaccttt 2160aaagaggaca tccagaaagc ccaggtgtcc ggccagggcg atagcctgca cgagcacatt 2220gccaatctgg ccggcagccc cgccattaag aagggcatcc tgcagacagt gaaggtggtg 2280gacgagctcg tgaaagtgat gggccggcac aagcccgaga acatcgtgat cgaaatggcc 2340agagagaacc agaccaccca gaagggacag aagaacagcc gcgagagaat gaagcggatc 2400gaagagggca tcaaagagct gggcagccag atcctgaaag aacaccccgt ggaaaacacc 2460cagctgcaga acgagaagct gtacctgtac tacctgcaga atgggcggga tatgtacgtg 2520gaccaggaac tggacatcaa ccggctgtcc gactacgatg tggaccatat cgtgcctcag 2580agctttctga aggacgactc catcgacaac aaggtgctga ccagaagcga caagaaccgg 2640ggcaagagcg acaacgtgcc ctccgaagag gtcgtgaaga agatgaagaa ctactggcgg 2700cagctgctga acgccaagct gattacccag agaaagttcg acaatctgac caaggccgag 2760agaggcggcc tgagcgaact ggataaggcc ggcttcatca agagacagct ggtggaaacc 2820cggcagatca caaagcacgt ggcacagatc ctggactccc ggatgaacac taagtacgac 2880gagaatgaca agctgatccg ggaagtgaaa gtgatcaccc tgaagtccaa gctggtgtcc 2940gatttccgga aggatttcca gttttacaaa gtgcgcgaga tcaacaacta cgcccacgcc 3000cacgacgcct acctgaacgc cgtcgtggga accgccctga tcaaaaagta ccctaagctg 3060gaaagcgagt tcgtgtacgg cgactacaag gtgtacgacg tgcggaagat gatcgccaag 3120agcgagcagg aaatcggcaa ggctaccgcc aagtacttct tctacagcaa catcatgaac 3180tttttcaaga ccgagattac cctggccaac ggcgagatcc ggaagcggcc tctgatcgag 3240acaaacggcg aaaccgggga gatcgtgtgg gataagggcc gggattttgc caccgtgcgg 3300aaagtgctga gcatgcccca agtgaatatc gtgaaaaaga ccgaggtgca gacaggcggc 3360ttcagcaaag agtctatcct gcccaagagg aacagcgata agctgatcgc cagaaagaag 3420gactgggacc ctaagaagta cggcggcttc gacagcccca ccgtggccta ttctgtgctg 3480gtggtggcca aagtggaaaa gggcaagtcc aagaaactga agagtgtgaa agagctgctg 3540gggatcacca tcatggaaag aagcagcttc gagaagaatc ccatcgactt tctggaagcc 3600aagggctaca aagaagtgaa aaaggacctg atcatcaagc tgcctaagta ctccctgttc 3660gagctggaaa acggccggaa gagaatgctg gcctctgccg gcgaactgca gaagggaaac 3720gaactggccc tgccctccaa atatgtgaac ttcctgtacc tggccagcca ctatgagaag 3780ctgaagggct cccccgagga taatgagcag aaacagctgt ttgtggaaca gcacaagcac 3840tacctggacg agatcatcga gcagatcagc gagttctcca agagagtgat cctggccgac 3900gctaatctgg acaaagtgct gtccgcctac aacaagcacc gggataagcc catcagagag 3960caggccgaga atatcatcca cctgtttacc ctgaccaatc tgggagcccc tgccgccttc 4020aagtactttg acaccaccat cgaccggaag aggtacacca gcaccaaaga

ggtgctggac 4080gccaccctga tccaccagag catcaccggc ctgtacgaga cacggatcga cctgtctcag 4140ctgggaggcg acaaaaggcc ggcggccacg aaaaaggccg gccaggcaaa aaagaaaaag 4200taa 4203744203DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 74atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg aaccccgaca acagcgacgt ggacaagctg 600ttcatccagc tggtgcagac ctacaaccag ctgttcgagg aaaaccccat caacgccagc 660ggcgtggacg ccaaggccat cctgtctgcc agactgagca agagcagacg gctggaaaat 720ctgatcgccc agctgcccgg cgagaagaag aatggcctgt tcggaaacct gattgccctg 780agcctgggcc tgacccccaa cttcaagagc aacttcgacc tggccgagga tgccaaactg 840cagctgagca aggacaccta cgacgacgac ctggacaacc tgctggccca gatcggcgac 900cagtacgccg acctgtttct ggccgccaag aacctgtccg acgccatcct gctgagcgac 960atcctgagag tgaacaccga gatcaccaag gcccccctga gcgcctctat gatcaagaga 1020tacgacgagc accaccagga cctgaccctg ctgaaagctc tcgtgcggca gcagctgcct 1080gagaagtaca aagagatttt cttcgaccag agcaagaacg gctacgccgg ctacattgac 1140ggcggagcca gccaggaaga gttctacaag ttcatcaagc ccatcctgga aaagatggac 1200ggcaccgagg aactgctcgt gaagctgaac agagaggacc tgctgcggaa gcagcggacc 1260ttcgacaacg gcagcatccc ccaccagatc cacctgggag agctgcacgc cattctgcgg 1320cggcaggaag atttttaccc attcctgaag gacaaccggg aaaagatcga gaagatcctg 1380accttccgca tcccctacta cgtgggccct ctggccaggg gaaacagcag attcgcctgg 1440atgaccagaa agagcgagga aaccatcacc ccctggaact tcgaggaagt ggtggacaag 1500ggcgcttccg cccagagctt catcgagcgg atgaccaact tcgataagaa cctgcccaac 1560gagaaggtgc tgcccaagca cagcctgctg tacgagtact tcaccgtgta taacgagctg 1620accaaagtga aatacgtgac cgagggaatg agaaagcccg ccttcctgag cggcgagcag 1680aaaaaggcca tcgtggacct gctgttcaag accaaccgga aagtgaccgt gaagcagctg 1740aaagaggact acttcaagaa aatcgagtgc ttcgactccg tggaaatctc cggcgtggaa 1800gatcggttca acgcctccct gggcacatac cacgatctgc tgaaaattat caaggacaag 1860gacttcctgg acaatgagga aaacgaggac attctggaag atatcgtgct gaccctgaca 1920ctgtttgagg acagagagat gatcgaggaa cggctgaaaa cctatgccca cctgttcgac 1980gacaaagtga tgaagcagct gaagcggcgg agatacaccg gctggggcag gctgagccgg 2040aagctgatca acggcatccg ggacaagcag tccggcaaga caatcctgga tttcctgaag 2100tccgacggct tcgccaacag aaacttcatg cagctgatcc acgacgacag cctgaccttt 2160aaagaggaca tccagaaagc ccaggtgtcc ggccagggcg atagcctgca cgagcacatt 2220gccaatctgg ccggcagccc cgccattaag aagggcatcc tgcagacagt gaaggtggtg 2280gacgagctcg tgaaagtgat gggccggcac aagcccgaga acatcgtgat cgaaatggcc 2340agagagaacc agaccaccca gaagggacag aagaacagcc gcgagagaat gaagcggatc 2400gaagagggca tcaaagagct gggcagccag atcctgaaag aacaccccgt ggaaaacacc 2460cagctgcaga acgagaagct gtacctgtac tacctgcaga atgggcggga tatgtacgtg 2520gaccaggaac tggacatcaa ccggctgtcc gactacgatg tggaccatat cgtgcctcag 2580agctttctga aggacgactc catcgacaac aaggtgctga ccagaagcga caagaaccgg 2640ggcaagagcg acaacgtgcc ctccgaagag gtcgtgaaga agatgaagaa ctactggcgg 2700cagctgctga acgccaagct gattacccag agaaagttcg acaatctgac caaggccgag 2760agaggcggcc tgagcgaact ggataaggcc ggcttcatca agagacagct ggtggaaacc 2820cggcagatca caaagcacgt ggcacagatc ctggactccc ggatgaacac taagtacgac 2880gagaatgaca agctgatccg ggaagtgaaa gtgatcaccc tgaagtccaa gctggtgtcc 2940gatttccgga aggatttcca gttttacaaa gtgcgcgaga tcaacaacta ccacgccgcc 3000cacgacgcct acctgaacgc cgtcgtggga accgccctga tcaaaaagta ccctaagctg 3060gaaagcgagt tcgtgtacgg cgactacaag gtgtacgacg tgcggaagat gatcgccaag 3120agcgagcagg aaatcggcaa ggctaccgcc aagtacttct tctacagcaa catcatgaac 3180tttttcaaga ccgagattac cctggccaac ggcgagatcc ggaagcggcc tctgatcgag 3240acaaacggcg aaaccgggga gatcgtgtgg gataagggcc gggattttgc caccgtgcgg 3300aaagtgctga gcatgcccca agtgaatatc gtgaaaaaga ccgaggtgca gacaggcggc 3360ttcagcaaag agtctatcct gcccaagagg aacagcgata agctgatcgc cagaaagaag 3420gactgggacc ctaagaagta cggcggcttc gacagcccca ccgtggccta ttctgtgctg 3480gtggtggcca aagtggaaaa gggcaagtcc aagaaactga agagtgtgaa agagctgctg 3540gggatcacca tcatggaaag aagcagcttc gagaagaatc ccatcgactt tctggaagcc 3600aagggctaca aagaagtgaa aaaggacctg atcatcaagc tgcctaagta ctccctgttc 3660gagctggaaa acggccggaa gagaatgctg gcctctgccg gcgaactgca gaagggaaac 3720gaactggccc tgccctccaa atatgtgaac ttcctgtacc tggccagcca ctatgagaag 3780ctgaagggct cccccgagga taatgagcag aaacagctgt ttgtggaaca gcacaagcac 3840tacctggacg agatcatcga gcagatcagc gagttctcca agagagtgat cctggccgac 3900gctaatctgg acaaagtgct gtccgcctac aacaagcacc gggataagcc catcagagag 3960caggccgaga atatcatcca cctgtttacc ctgaccaatc tgggagcccc tgccgccttc 4020aagtactttg acaccaccat cgaccggaag aggtacacca gcaccaaaga ggtgctggac 4080gccaccctga tccaccagag catcaccggc ctgtacgaga cacggatcga cctgtctcag 4140ctgggaggcg acaaaaggcc ggcggccacg aaaaaggccg gccaggcaaa aaagaaaaag 4200taa 4203754200DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 75atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cgacaagaag 60tacagcatcg gcctggacat cggcaccaac tctgtgggct gggccgtgat caccgacgag 120tacaaggtgc ccagcaagaa attcaaggtg ctgggcaaca ccgaccggca cagcatcaag 180aagaacctga tcggagccct gctgttcgac agcggcgaaa cagccgaggc cacccggctg 240aagagaaccg ccagaagaag atacaccaga cggaagaacc ggatctgcta tctgcaagag 300atcttcagca acgagatggc caaggtggac gacagcttct tccacagact ggaagagtcc 360ttcctggtgg aagaggataa gaagcacgag cggcacccca tcttcggcaa catcgtggac 420gaggtggcct accacgagaa gtaccccacc atctaccacc tgagaaagaa actggtggac 480agcaccgaca aggccgacct gcggctgatc tatctggccc tggcccacat gatcaagttc 540cggggccact tcctgatcga gggcgacctg aaccccgaca acagcgacgt ggacaagctg 600ttcatccagc tggtgcagac ctacaaccag ctgttcgagg aaaaccccat caacgccagc 660ggcgtggacg ccaaggccat cctgtctgcc agactgagca agagcagacg gctggaaaat 720ctgatcgccc agctgcccgg cgagaagaag aatggcctgt tcggaaacct gattgccctg 780agcctgggcc tgacccccaa cttcaagagc aacttcgacc tggccgagga tgccaaactg 840cagctgagca aggacaccta cgacgacgac ctggacaacc tgctggccca gatcggcgac 900cagtacgccg acctgtttct ggccgccaag aacctgtccg acgccatcct gctgagcgac 960atcctgagag tgaacaccga gatcaccaag gcccccctga gcgcctctat gatcaagaga 1020tacgacgagc accaccagga cctgaccctg ctgaaagctc tcgtgcggca gcagctgcct 1080gagaagtaca aagagatttt cttcgaccag agcaagaacg gctacgccgg ctacattgac 1140ggcggagcca gccaggaaga gttctacaag ttcatcaagc ccatcctgga aaagatggac 1200ggcaccgagg aactgctcgt gaagctgaac agagaggacc tgctgcggaa gcagcggacc 1260ttcgacaacg gcagcatccc ccaccagatc cacctgggag agctgcacgc cattctgcgg 1320cggcaggaag atttttaccc attcctgaag gacaaccggg aaaagatcga gaagatcctg 1380accttccgca tcccctacta cgtgggccct ctggccaggg gaaacagcag attcgcctgg 1440atgaccagaa agagcgagga aaccatcacc ccctggaact tcgaggaagt ggtggacaag 1500ggcgcttccg cccagagctt catcgagcgg atgaccaact tcgataagaa cctgcccaac 1560gagaaggtgc tgcccaagca cagcctgctg tacgagtact tcaccgtgta taacgagctg 1620accaaagtga aatacgtgac cgagggaatg agaaagcccg ccttcctgag cggcgagcag 1680aaaaaggcca tcgtggacct gctgttcaag accaaccgga aagtgaccgt gaagcagctg 1740aaagaggact acttcaagaa aatcgagtgc ttcgactccg tggaaatctc cggcgtggaa 1800gatcggttca acgcctccct gggcacatac cacgatctgc tgaaaattat caaggacaag 1860gacttcctgg acaatgagga aaacgaggac attctggaag atatcgtgct gaccctgaca 1920ctgtttgagg acagagagat gatcgaggaa cggctgaaaa cctatgccca cctgttcgac 1980gacaaagtga tgaagcagct gaagcggcgg agatacaccg gctggggcag gctgagccgg 2040aagctgatca acggcatccg ggacaagcag tccggcaaga caatcctgga tttcctgaag 2100tccgacggct tcgccaacag aaacttcatg cagctgatcc acgacgacag cctgaccttt 2160aaagaggaca tccagaaagc ccaggtgtcc ggccagggcg atagcctgca cgagcacatt 2220gccaatctgg ccggcagccc cgccattaag aagggcatcc tgcagacagt gaaggtggtg 2280gacgagctcg tgaaagtgat gggccggcac aagcccgaga acatcgtgat cgaaatggcc 2340agagagaacc agaccaccca gaagggacag aagaacagcc gcgagagaat gaagcggatc 2400gaagagggca tcaaagagct gggcagccag atcctgaaag aacaccccgt ggaaaacacc 2460cagctgcaga acgagaagct gtacctgtac tacctgcaga atgggcggga tatgtacgtg 2520gaccaggaac tggacatcaa ccggctgtcc gactacgatg tggaccatat cgtgcctcag 2580agctttctga aggacgactc catcgacaac aaggtgctga ccagaagcga caagaaccgg 2640ggcaagagcg acaacgtgcc ctccgaagag gtcgtgaaga agatgaagaa ctactggcgg 2700cagctgctga acgccaagct gattacccag agaaagttcg acaatctgac caaggccgag 2760agaggcggcc tgagcgaact ggataaggcc ggcttcatca agagacagct ggtggaaacc 2820cggcagatca caaagcacgt ggcacagatc ctggactccc ggatgaacac taagtacgac 2880gagaatgaca agctgatccg ggaagtgaaa gtgatcaccc tgaagtccaa gctggtgtcc 2940gatttccgga aggatttcca gttttacaaa gtgcgcgaga tcaacaacta ccaccacgcc 3000cacgccgcct acctgaacgc cgtcgtggga accgccctga tcaaaaagta ccctaagctg 3060gaaagcgagt tcgtgtacgg cgactacaag gtgtacgacg tgcggaagat gatcgccaag 3120agcgagcagg aaatcggcaa ggctaccgcc aagtacttct tctacagcaa catcatgaac 3180tttttcaaga ccgagattac cctggccaac ggcgagatcc ggaagcggcc tctgatcgag 3240acaaacggcg aaaccgggga gatcgtgtgg gataagggcc gggattttgc caccgtgcgg 3300aaagtgctga gcatgcccca agtgaatatc gtgaaaaaga ccgaggtgca gacaggcggc 3360ttcagcaaag agtctatcct gcccaagagg aacagcgata agctgatcgc cagaaagaag 3420gactgggacc ctaagaagta cggcggcttc gacagcccca ccgtggccta ttctgtgctg 3480gtggtggcca aagtggaaaa gggcaagtcc aagaaactga agagtgtgaa agagctgctg 3540gggatcacca tcatggaaag aagcagcttc gagaagaatc ccatcgactt tctggaagcc 3600aagggctaca aagaagtgaa aaaggacctg atcatcaagc tgcctaagta ctccctgttc 3660gagctggaaa acggccggaa gagaatgctg gcctctgccg gcgaactgca gaagggaaac 3720gaactggccc tgccctccaa atatgtgaac ttcctgtacc tggccagcca ctatgagaag 3780ctgaagggct cccccgagga taatgagcag aaacagctgt ttgtggaaca gcacaagcac 3840tacctggacg agatcatcga gcagatcagc gagttctcca agagagtgat cctggccgac 3900gctaatctgg acaaagtgct gtccgcctac aacaagcacc gggataagcc catcagagag 3960caggccgaga atatcatcca cctgtttacc ctgaccaatc tgggagcccc tgccgccttc 4020aagtactttg acaccaccat cgaccggaag aggtacacca gcaccaaaga ggtgctggac 4080gccaccctga tccaccagag catcaccggc ctgtacgaga cacggatcga cctgtctcag 4140ctgggaggcg acaaaaggcc ggcggccacg aaaaaggccg gccaggcaaa aaagaaaaag 4200764269DNAStreptococcus pyogenes 76atggactata aggaccacga cggagactac aaggatcatg atattgatta caaagacgat 60gacgataaga tggccccaaa gaagaagcgg aaggtcggta tccacggagt cccagcagcc 120gacaagaagt acagcatcgg cctggacatc ggcaccaact ctgtgggctg ggccgtgatc 180accgacgagt acaaggtgcc cagcaagaaa ttcaaggtgc tgggcaacac cgaccggcac 240agcatcaaga agaacctgat cggagccctg ctgttcgaca gcggcgaaac agccgaggcc 300acccggctga agagaaccgc cagaagaaga tacaccagac ggaagaaccg gatctgctat 360ctgcaagaga tcttcagcaa cgagatggcc aaggtggacg acagcttctt ccacagactg 420gaagagtcct tcctggtgga agaggataag aagcacgagc ggcaccccat cttcggcaac 480atcgtggacg aggtggccta ccacgagaag taccccacca tctaccacct gagaaagaaa 540ctggtggaca gcaccgacaa ggccgacctg cggctgatct atctggccct ggcccacatg 600atcaagttcc ggggccactt cctgatcgag ggcgacctga accccgacaa cagcgacgtg 660gacaagctgt tcatccagct ggtgcagacc tacaaccagc tgttcgagga aaaccccatc 720aacgccagcg gcgtggacgc caaggccatc ctgtctgcca gactgagcaa gagcagacgg 780ctggaaaatc tgatcgccca gctgcccggc gagaagaaga atggcctgtt cggcaacctg 840attgccctga gcctgggcct gacccccaac ttcaagagca acttcgacct ggccgaggat 900gccaaactgc agctgagcaa ggacacctac gacgacgacc tggacaacct gctggcccag 960atcggcgacc agtacgccga cctgtttctg gccgccaaga acctgtccga cgccatcctg 1020ctgagcgaca tcctgagagt gaacaccgag atcaccaagg cccccctgag cgcctctatg 1080atcaagagat acgacgagca ccaccaggac ctgaccctgc tgaaagctct cgtgcggcag 1140cagctgcctg agaagtacaa agagattttc ttcgaccaga gcaagaacgg ctacgccggc 1200tacattgacg gcggagccag ccaggaagag ttctacaagt tcatcaagcc catcctggaa 1260aagatggacg gcaccgagga actgctcgtg aagctgaaca gagaggacct gctgcggaag 1320cagcggacct tcgacaacgg cagcatcccc caccagatcc acctgggaga gctgcacgcc 1380attctgcggc ggcaggaaga tttttaccca ttcctgaagg acaaccggga aaagatcgag 1440aagatcctga ccttccgcat cccctactac gtgggccctc tggccagggg aaacagcaga 1500ttcgcctgga tgaccagaaa gagcgaggaa accatcaccc cctggaactt cgaggaagtg 1560gtggacaagg gcgcttccgc ccagagcttc atcgagcgga tgaccaactt cgataagaac 1620ctgcccaacg agaaggtgct gcccaagcac agcctgctgt acgagtactt caccgtgtat 1680aacgagctga ccaaagtgaa atacgtgacc gagggaatga gaaagcccgc cttcctgagc 1740ggcgagcaga aaaaggccat cgtggacctg ctgttcaaga ccaaccggaa agtgaccgtg 1800aagcagctga aagaggacta cttcaagaaa atcgagtgct tcgactccgt ggaaatctcc 1860ggcgtggaag atcggttcaa cgcctccctg ggcacatacc acgatctgct gaaaattatc 1920aaggacaagg acttcctgga caatgaggaa aacgaggaca ttctggaaga tatcgtgctg 1980accctgacac tgtttgagga cagagagatg atcgaggaac ggctgaaaac ctatgcccac 2040ctgttcgacg acaaagtgat gaagcagctg aagcggcgga gatacaccgg ctggggcagg 2100ctgagccgga agctgatcaa cggcatccgg gacaagcagt ccggcaagac aatcctggat 2160ttcctgaagt ccgacggctt cgccaacaga aacttcatgc agctgatcca cgacgacagc 2220ctgaccttta aagaggacat ccagaaagcc caggtgtccg gccagggcga tagcctgcac 2280gagcacattg ccaatctggc cggcagcccc gccattaaga agggcatcct gcagacagtg 2340aaggtggtgg acgagctcgt gaaagtgatg ggccggcaca agcccgagaa catcgtgatc 2400gaaatggcca gagagaacca gaccacccag aagggacaga agaacagccg cgagagaatg 2460aagcggatcg aagagggcat caaagagctg ggcagccaga tcctgaaaga acaccccgtg 2520gaaaacaccc agctgcagaa cgagaagctg tacctgtact acctgcagaa tgggcgggat 2580atgtacgtgg accaggaact ggacatcaac cggctgtccg actacgatgt ggaccatatc 2640gtgcctcaga gctttctgaa ggacgactcc atcgacaaca aggtgctgac cagaagcgac 2700aagaaccggg gcaagagcga caacgtgccc tccgaagagg tcgtgaagaa gatgaagaac 2760tactggcggc agctgctgaa cgccaagctg attacccaga gaaagttcga caatctgacc 2820aaggccgaga gaggcggcct gagcgaactg gataaggccg gcttcatcaa gagacagctg 2880gtggaaaccc ggcagatcac aaagcacgtg gcacagatcc tggactcccg gatgaacact 2940aagtacgacg agaatgacaa gctgatccgg gaagtgaaag tgatcaccct gaagtccaag 3000ctggtgtccg atttccggaa ggatttccag ttttacaaag tgcgcgagat caacaactac 3060caccacgccc acgacgccta cctgaacgcc gtcgtgggaa ccgccctgat caaaaagtac 3120cctaagctgg aaagcgagtt cgtgtacggc gactacaagg tgtacgacgt gcggaagatg 3180atcgccaaga gcgagcagga aatcggcaag gctaccgcca agtacttctt ctacagcaac 3240atcatgaact ttttcaagac cgagattacc ctggccaacg gcgagatccg gaagcggcct 3300ctgatcgaga caaacggcga aaccggggag atcgtgtggg ataagggccg ggattttgcc 3360accgtgcgga aagtgctgag catgccccaa gtgaatatcg tgaaaaagac cgaggtgcag 3420acaggcggct tcagcaaaga gtctatcctg cccaagagga acagcgataa gctgatcgcc 3480agaaagaagg actgggaccc taagaagtac ggcggcttcg acagccccac cgtggcctat 3540tctgtgctgg tggtggccaa agtggaaaag ggcaagtcca agaaactgaa gagtgtgaaa 3600gagctgctgg ggatcaccat catggaaaga agcagcttcg agaagaatcc catcgacttt 3660ctggaagcca agggctacaa agaagtgaaa aaggacctga tcatcaagct gcctaagtac 3720tccctgttcg agctggaaaa cggccggaag agaatgctgg cctctgccgg cgaactgcag 3780aagggaaacg aactggccct gccctccaaa tatgtgaact tcctgtacct ggccagccac 3840tatgagaagc tgaagggctc ccccgaggat aatgagcaga aacagctgtt tgtggaacag 3900cacaagcact acctggacga gatcatcgag cagatcagcg agttctccaa gagagtgatc 3960ctggccgacg ctaatctgga caaagtgctg tccgcctaca acaagcaccg ggataagccc 4020atcagagagc aggccgagaa tatcatccac ctgtttaccc tgaccaatct gggagcccct 4080gccgccttca agtactttga caccaccatc gaccggaaga ggtacaccag caccaaagag 4140gtgctggacg ccaccctgat ccaccagagc atcaccggcc tgtacgagac acggatcgac 4200ctgtctcagc tgggaggcga caaaaggccg gcggccacga aaaaggccgg ccaggcaaaa 4260aagaaaaag 4269774107DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 77atggactata aggaccacga cggagactac aaggatcatg atattgatta caaagacgat 60gacgataaga tggccccaaa gaagaagcgg aaggtcggta tccacggagt cccagcagcc 120gacaagaagt acagcatcgg cctggacatc ggcaccaact ctgtgggctg ggccgtgatc 180accgacgagt acaaggtgcc cagcaagaaa ttcaaggtgc tgggcaacac cgaccggcac 240agcatcaaga agaacctgat cggagccctg ctgttcgaca gcggcgaaac agccgaggcc 300acccggctga agagaaccgc cagaagaaga tacaccagac ggaagaaccg gatctgctat 360ctgcaagaga tcttcagcaa cgagatggcc aaggtggacg acagcctgcg gctgatctat 420ctggccctgg cccacatgat caagttccgg ggccacttcc tgatcgaggg cgacctgaac 480cccgacaaca gcgacgtgga caagctgttc atccagctgg tgcagaccta caaccagctg 540ttcgaggaaa accccatcaa cgccagcggc gtggacgcca aggccatcct gtctgccaga 600ctgagcaaga gcagacggct ggaaaatctg atcgcccagc tgcccggcga gaagaagaat 660ggcctgttcg gaaacctgat tgccctgagc ctgggcctga cccccaactt caagagcaac 720ttcgacctgg ccgaggatgc caaactgcag ctgagcaagg acacctacga cgacgacctg 780gacaacctgc tggcccagat cggcgaccag tacgccgacc tgtttctggc cgccaagaac 840ctgtccgacg ccatcctgct gagcgacatc ctgagagtga acaccgagat caccaaggcc 900cccctgagcg cctctatgat caagagatac gacgagcacc accaggacct gaccctgctg 960aaagctctcg tgcggcagca gctgcctgag aagtacaaag agattttctt cgaccagagc 1020aagaacggct acgccggcta cattgacggc ggagccagcc aggaagagtt ctacaagttc 1080atcaagccca tcctggaaaa gatggacggc accgaggaac tgctcgtgaa gctgaacaga 1140gaggacctgc tgcggaagca gcggaccttc gacaacggca gcatccccca ccagatccac 1200ctgggagagc tgcacgccat tctgcggcgg caggaagatt tttacccatt cctgaaggac 1260aaccgggaaa agatcgagaa gatcctgacc ttccgcatcc cctactacgt gggccctctg 1320gccaggggaa acagcagatt cgcctggatg accagaaaga gcgaggaaac catcaccccc 1380tggaacttcg aggaagtggt ggacaagggc gcttccgccc agagcttcat cgagcggatg 1440accaacttcg ataagaacct gcccaacgag aaggtgctgc ccaagcacag cctgctgtac 1500gagtacttca ccgtgtataa cgagctgacc aaagtgaaat acgtgaccga gggaatgaga 1560aagcccgcct tcctgagcgg cgagcagaaa aaggccatcg tggacctgct gttcaagacc 1620aaccggaaag tgaccgtgaa gcagctgaaa gaggactact tcaagaaaat cgagtgcttc 1680gactccgtgg aaatctccgg cgtggaagat cggttcaacg cctccctggg cacataccac 1740gatctgctga

aaattatcaa ggacaaggac ttcctggaca atgaggaaaa cgaggacatt 1800ctggaagata tcgtgctgac cctgacactg tttgaggaca gagagatgat cgaggaacgg 1860ctgaaaacct atgcccacct gttcgacgac aaagtgatga agcagctgaa gcggcggaga 1920tacaccggct ggggcaggct gagccggaag ctgatcaacg gcatccggga caagcagtcc 1980ggcaagacaa tcctggattt cctgaagtcc gacggcttcg ccaacagaaa cttcatgcag 2040ctgatccacg acgacagcct gacctttaaa gaggacatcc agaaagccca ggtgtccggc 2100cagggcgata gcctgcacga gcacattgcc aatctggccg gcagccccgc cattaagaag 2160ggcatcctgc agacagtgaa ggtggtggac gagctcgtga aagtgatggg ccggcacaag 2220cccgagaaca tcgtgatcga aatggccaga gagaaccaga ccacccagaa gggacagaag 2280aacagccgcg agagaatgaa gcggatcgaa gagggcatca aagagctggg cagccagatc 2340ctgaaagaac accccgtgga aaacacccag ctgcagaacg agaagctgta cctgtactac 2400ctgcagaatg ggcgggatat gtacgtggac caggaactgg acatcaaccg gctgtccgac 2460tacgatgtgg accatatcgt gcctcagagc tttctgaagg acgactccat cgacaacaag 2520gtgctgacca gaagcgacaa gaaccggggc aagagcgaca acgtgccctc cgaagaggtc 2580gtgaagaaga tgaagaacta ctggcggcag ctgctgaacg ccaagctgat tacccagaga 2640aagttcgaca atctgaccaa ggccgagaga ggcggcctga gcgaactgga taaggccggc 2700ttcatcaaga gacagctggt ggaaacccgg cagatcacaa agcacgtggc acagatcctg 2760gactcccgga tgaacactaa gtacgacgag aatgacaagc tgatccggga agtgaaagtg 2820atcaccctga agtccaagct ggtgtccgat ttccggaagg atttccagtt ttacaaagtg 2880cgcgagatca acaactacca ccacgcccac gacgcctacc tgaacgccgt cgtgggaacc 2940gccctgatca aaaagtaccc taagctggaa agcgagttcg tgtacggcga ctacaaggtg 3000tacgacgtgc ggaagatgat cgccaagagc gagcaggaaa tcggcaaggc taccgccaag 3060tacttcttct acagcaacat catgaacttt ttcaagaccg agattaccct ggccaacggc 3120gagatccgga agcggcctct gatcgagaca aacggcgaaa ccggggagat cgtgtgggat 3180aagggccggg attttgccac cgtgcggaaa gtgctgagca tgccccaagt gaatatcgtg 3240aaaaagaccg aggtgcagac aggcggcttc agcaaagagt ctatcctgcc caagaggaac 3300agcgataagc tgatcgccag aaagaaggac tgggacccta agaagtacgg cggcttcgac 3360agccccaccg tggcctattc tgtgctggtg gtggccaaag tggaaaaggg caagtccaag 3420aaactgaaga gtgtgaaaga gctgctgggg atcaccatca tggaaagaag cagcttcgag 3480aagaatccca tcgactttct ggaagccaag ggctacaaag aagtgaaaaa ggacctgatc 3540atcaagctgc ctaagtactc cctgttcgag ctggaaaacg gccggaagag aatgctggcc 3600tctgccggcg aactgcagaa gggaaacgaa ctggccctgc cctccaaata tgtgaacttc 3660ctgtacctgg ccagccacta tgagaagctg aagggctccc ccgaggataa tgagcagaaa 3720cagctgtttg tggaacagca caagcactac ctggacgaga tcatcgagca gatcagcgag 3780ttctccaaga gagtgatcct ggccgacgct aatctggaca aagtgctgtc cgcctacaac 3840aagcaccggg ataagcccat cagagagcag gccgagaata tcatccacct gtttaccctg 3900accaatctgg gagcccctgc cgccttcaag tactttgaca ccaccatcga ccggaagagg 3960tacaccagca ccaaagaggt gctggacgcc accctgatcc accagagcat caccggcctg 4020tacgagacac ggatcgacct gtctcagctg ggaggcgaca aaaggccggc ggccacgaaa 4080aaggccggcc aggcaaaaaa gaaaaag 4107783870DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 78atggactata aggaccacga cggagactac aaggatcatg atattgatta caaagacgat 60gacgataaga tggccccaaa gaagaagcgg aaggtcggta tccacggagt cccagcagcc 120gacaagaagt acagcatcgg cctggacatc ggcaccaact ctgtgggctg ggccgtgatc 180accgacgagt acaaggtgcc cagcaagaaa ttcaaggtgc tgggcaacac cgaccggcac 240agcatcaaga agaacctgat cggagccctg ctgttcgaca gcggcgaaac agccgaggcc 300acccggctga agagaaccgc cagaagaaga tacaccagac ggaagaaccg gatctgctat 360ctgcaagaga tcttcagcaa cgagatggcc aaggtggacg acagcttctt ccacagactg 420gaagagtcct tcctggtgga agaggataag aagcacgagc ggcaccccat cttcggcaac 480atcgtggacg aggtggccta ccacgagaag taccccacca tctaccacct gagaaagaaa 540ctggtggaca gcaccgacaa ggccgacctg cggctgatct atctggccct ggcccacatg 600atcaagttcc ggggccactt cctgatcgag ggcgacctgg tgaacaccga gatcaccaag 660gcccccctga gcgcctctat gatcaagaga tacgacgagc accaccagga cctgaccctg 720ctgaaagctc tcgtgcggca gcagctgcct gagaagtaca aagagatttt cttcgaccag 780agcaagaacg gctacgccgg ctacattgac ggcggagcca gccaggaaga gttctacaag 840ttcatcaagc ccatcctgga aaagatggac ggcaccgagg aactgctcgt gaagctgaac 900agagaggacc tgctgcggaa gcagcggacc ttcgacaacg gcagcatccc ccaccagatc 960cacctgggag agctgcacgc cattctgcgg cggcaggaag atttttaccc attcctgaag 1020gacaaccggg aaaagatcga gaagatcctg accttccgca tcccctacta cgtgggccct 1080ctggccaggg gaaacagcag attcgcctgg atgaccagaa agagcgagga aaccatcacc 1140ccctggaact tcgaggaagt ggtggacaag ggcgcttccg cccagagctt catcgagcgg 1200atgaccaact tcgataagaa cctgcccaac gagaaggtgc tgcccaagca cagcctgctg 1260tacgagtact tcaccgtgta taacgagctg accaaagtga aatacgtgac cgagggaatg 1320agaaagcccg ccttcctgag cggcgagcag aaaaaggcca tcgtggacct gctgttcaag 1380accaaccgga aagtgaccgt gaagcagctg aaagaggact acttcaagaa aatcgagtgc 1440ttcgactccg tggaaatctc cggcgtggaa gatcggttca acgcctccct gggcacatac 1500cacgatctgc tgaaaattat caaggacaag gacttcctgg acaatgagga aaacgaggac 1560attctggaag atatcgtgct gaccctgaca ctgtttgagg acagagagat gatcgaggaa 1620cggctgaaaa cctatgccca cctgttcgac gacaaagtga tgaagcagct gaagcggcgg 1680agatacaccg gctggggcag gctgagccgg aagctgatca acggcatccg ggacaagcag 1740tccggcaaga caatcctgga tttcctgaag tccgacggct tcgccaacag aaacttcatg 1800cagctgatcc acgacgacag cctgaccttt aaagaggaca tccagaaagc ccaggtgtcc 1860ggccagggcg atagcctgca cgagcacatt gccaatctgg ccggcagccc cgccattaag 1920aagggcatcc tgcagacagt gaaggtggtg gacgagctcg tgaaagtgat gggccggcac 1980aagcccgaga acatcgtgat cgaaatggcc agagagaacc agaccaccca gaagggacag 2040aagaacagcc gcgagagaat gaagcggatc gaagagggca tcaaagagct gggcagccag 2100atcctgaaag aacaccccgt ggaaaacacc cagctgcaga acgagaagct gtacctgtac 2160tacctgcaga atgggcggga tatgtacgtg gaccaggaac tggacatcaa ccggctgtcc 2220gactacgatg tggaccatat cgtgcctcag agctttctga aggacgactc catcgacaac 2280aaggtgctga ccagaagcga caagaaccgg ggcaagagcg acaacgtgcc ctccgaagag 2340gtcgtgaaga agatgaagaa ctactggcgg cagctgctga acgccaagct gattacccag 2400agaaagttcg acaatctgac caaggccgag agaggcggcc tgagcgaact ggataaggcc 2460ggcttcatca agagacagct ggtggaaacc cggcagatca caaagcacgt ggcacagatc 2520ctggactccc ggatgaacac taagtacgac gagaatgaca agctgatccg ggaagtgaaa 2580gtgatcaccc tgaagtccaa gctggtgtcc gatttccgga aggatttcca gttttacaaa 2640gtgcgcgaga tcaacaacta ccaccacgcc cacgacgcct acctgaacgc cgtcgtggga 2700accgccctga tcaaaaagta ccctaagctg gaaagcgagt tcgtgtacgg cgactacaag 2760gtgtacgacg tgcggaagat gatcgccaag agcgagcagg aaatcggcaa ggctaccgcc 2820aagtacttct tctacagcaa catcatgaac tttttcaaga ccgagattac cctggccaac 2880ggcgagatcc ggaagcggcc tctgatcgag acaaacggcg aaaccgggga gatcgtgtgg 2940gataagggcc gggattttgc caccgtgcgg aaagtgctga gcatgcccca agtgaatatc 3000gtgaaaaaga ccgaggtgca gacaggcggc ttcagcaaag agtctatcct gcccaagagg 3060aacagcgata agctgatcgc cagaaagaag gactgggacc ctaagaagta cggcggcttc 3120gacagcccca ccgtggccta ttctgtgctg gtggtggcca aagtggaaaa gggcaagtcc 3180aagaaactga agagtgtgaa agagctgctg gggatcacca tcatggaaag aagcagcttc 3240gagaagaatc ccatcgactt tctggaagcc aagggctaca aagaagtgaa aaaggacctg 3300atcatcaagc tgcctaagta ctccctgttc gagctggaaa acggccggaa gagaatgctg 3360gcctctgccg gcgaactgca gaagggaaac gaactggccc tgccctccaa atatgtgaac 3420ttcctgtacc tggccagcca ctatgagaag ctgaagggct cccccgagga taatgagcag 3480aaacagctgt ttgtggaaca gcacaagcac tacctggacg agatcatcga gcagatcagc 3540gagttctcca agagagtgat cctggccgac gctaatctgg acaaagtgct gtccgcctac 3600aacaagcacc gggataagcc catcagagag caggccgaga atatcatcca cctgtttacc 3660ctgaccaatc tgggagcccc tgccgccttc aagtactttg acaccaccat cgaccggaag 3720aggtacacca gcaccaaaga ggtgctggac gccaccctga tccaccagag catcaccggc 3780ctgtacgaga cacggatcga cctgtctcag ctgggaggcg acaaaaggcc ggcggccacg 3840aaaaaggccg gccaggcaaa aaagaaaaag 3870793975DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 79atggactata aggaccacga cggagactac aaggatcatg atattgatta caaagacgat 60gacgataaga tggccccaaa gaagaagcgg aaggtcggta tccacggagt cccagcagcc 120gacaagaagt acagcatcgg cctggacatc ggcaccaact ctgtgggctg ggccgtgatc 180accgacgagt acaaggtgcc cagcaagaaa ttcaaggtgc tgggcaacac cgaccggcac 240agcatcaaga agaacctgat cggagccctg ctgttcgaca gcggcgaaac agccgaggcc 300acccggctga agagaaccgc cagaagaaga tacaccagac ggaagaaccg gatctgctat 360ctgcaagaga tcttcagcaa cgagatggcc aaggtggacg acagcttctt ccacagactg 420gaagagtcct tcctggtgga agaggataag aagcacgagc ggcaccccat cttcggcaac 480atcgtggacg aggtggccta ccacgagaag taccccacca tctaccacct gagaaagaaa 540ctggtggaca gcaccgacaa ggccgacctg cggctgatct atctggccct ggcccacatg 600atcaagttcc ggggccactt cctgatcgag ggcgacctga accccgacaa cagcgacgtg 660gacaagctgt tcatccagct ggtgcagacc tacaaccagc tgttcgagga aaaccccatc 720aacgccagcg gcgtggacgc caaggccatc ctgtctgcca gactgagcaa gagcagacgg 780ctggaaaatc tgatcgccca gctgcccggc gagaagaaga atggcctgtt cggaaacctg 840attgccctga gcctgggcct gacccccaac ttcaagagca acttcgacct ggccgaggat 900gccaaactgc agctgagcaa ggacacctac gacgacgacc tggacaacct gctggcccag 960atcggcgacc agtacgccga cctgtttctg gccgccaaga acctgtccga cgccatcctg 1020ctgagcgaca tcctgagagt gaacaccgag atcccccacc agatccacct gggagagctg 1080cacgccattc tgcggcggca ggaagatttt tacccattcc tgaaggacaa ccgggaaaag 1140atcgagaaga tcctgacctt ccgcatcccc tactacgtgg gccctctggc caggggaaac 1200agcagattcg cctggatgac cagaaagagc gaggaaacca tcaccccctg gaacttcgag 1260gaagtggtgg acaagggcgc ttccgcccag agcttcatcg agcggatgac caacttcgat 1320aagaacctgc ccaacgagaa ggtgctgccc aagcacagcc tgctgtacga gtacttcacc 1380gtgtataacg agctgaccaa agtgaaatac gtgaccgagg gaatgagaaa gcccgccttc 1440ctgagcggcg agcagaaaaa ggccatcgtg gacctgctgt tcaagaccaa ccggaaagtg 1500accgtgaagc agctgaaaga ggactacttc aagaaaatcg agtgcttcga ctccgtggaa 1560atctccggcg tggaagatcg gttcaacgcc tccctgggca cataccacga tctgctgaaa 1620attatcaagg acaaggactt cctggacaat gaggaaaacg aggacattct ggaagatatc 1680gtgctgaccc tgacactgtt tgaggacaga gagatgatcg aggaacggct gaaaacctat 1740gcccacctgt tcgacgacaa agtgatgaag cagctgaagc ggcggagata caccggctgg 1800ggcaggctga gccggaagct gatcaacggc atccgggaca agcagtccgg caagacaatc 1860ctggatttcc tgaagtccga cggcttcgcc aacagaaact tcatgcagct gatccacgac 1920gacagcctga cctttaaaga ggacatccag aaagcccagg tgtccggcca gggcgatagc 1980ctgcacgagc acattgccaa tctggccggc agccccgcca ttaagaaggg catcctgcag 2040acagtgaagg tggtggacga gctcgtgaaa gtgatgggcc ggcacaagcc cgagaacatc 2100gtgatcgaaa tggccagaga gaaccagacc acccagaagg gacagaagaa cagccgcgag 2160agaatgaagc ggatcgaaga gggcatcaaa gagctgggca gccagatcct gaaagaacac 2220cccgtggaaa acacccagct gcagaacgag aagctgtacc tgtactacct gcagaatggg 2280cgggatatgt acgtggacca ggaactggac atcaaccggc tgtccgacta cgatgtggac 2340catatcgtgc ctcagagctt tctgaaggac gactccatcg acaacaaggt gctgaccaga 2400agcgacaaga accggggcaa gagcgacaac gtgccctccg aagaggtcgt gaagaagatg 2460aagaactact ggcggcagct gctgaacgcc aagctgatta cccagagaaa gttcgacaat 2520ctgaccaagg ccgagagagg cggcctgagc gaactggata aggccggctt catcaagaga 2580cagctggtgg aaacccggca gatcacaaag cacgtggcac agatcctgga ctcccggatg 2640aacactaagt acgacgagaa tgacaagctg atccgggaag tgaaagtgat caccctgaag 2700tccaagctgg tgtccgattt ccggaaggat ttccagtttt acaaagtgcg cgagatcaac 2760aactaccacc acgcccacga cgcctacctg aacgccgtcg tgggaaccgc cctgatcaaa 2820aagtacccta agctggaaag cgagttcgtg tacggcgact acaaggtgta cgacgtgcgg 2880aagatgatcg ccaagagcga gcaggaaatc ggcaaggcta ccgccaagta cttcttctac 2940agcaacatca tgaacttttt caagaccgag attaccctgg ccaacggcga gatccggaag 3000cggcctctga tcgagacaaa cggcgaaacc ggggagatcg tgtgggataa gggccgggat 3060tttgccaccg tgcggaaagt gctgagcatg ccccaagtga atatcgtgaa aaagaccgag 3120gtgcagacag gcggcttcag caaagagtct atcctgccca agaggaacag cgataagctg 3180atcgccagaa agaaggactg ggaccctaag aagtacggcg gcttcgacag ccccaccgtg 3240gcctattctg tgctggtggt ggccaaagtg gaaaagggca agtccaagaa actgaagagt 3300gtgaaagagc tgctggggat caccatcatg gaaagaagca gcttcgagaa gaatcccatc 3360gactttctgg aagccaaggg ctacaaagaa gtgaaaaagg acctgatcat caagctgcct 3420aagtactccc tgttcgagct ggaaaacggc cggaagagaa tgctggcctc tgccggcgaa 3480ctgcagaagg gaaacgaact ggccctgccc tccaaatatg tgaacttcct gtacctggcc 3540agccactatg agaagctgaa gggctccccc gaggataatg agcagaaaca gctgtttgtg 3600gaacagcaca agcactacct ggacgagatc atcgagcaga tcagcgagtt ctccaagaga 3660gtgatcctgg ccgacgctaa tctggacaaa gtgctgtccg cctacaacaa gcaccgggat 3720aagcccatca gagagcaggc cgagaatatc atccacctgt ttaccctgac caatctggga 3780gcccctgccg ccttcaagta ctttgacacc accatcgacc ggaagaggta caccagcacc 3840aaagaggtgc tggacgccac cctgatccac cagagcatca ccggcctgta cgagacacgg 3900atcgacctgt ctcagctggg aggcgacaaa aggccggcgg ccacgaaaaa ggccggccag 3960gcaaaaaaga aaaag 3975803459DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 80atggactata aggaccacga cggagactac aaggatcatg atattgatta caaagacgat 60gacgataaga tggccccaaa gaagaagcgg aaggtcggta tccacggagt cccagcagcc 120gacaagaagt acagcatcgg cctggacatc ggcaccaact ctgtgggctg ggccgtgatc 180accgacgagt acaaggtgcc cagcaagaaa ttcaaggtgc tgggcaacac cgaccggcac 240agcatcaaga agaacctgat cggagccctg ctgttcgaca gcggcgaaac agccgaggcc 300acccggctga agagaaccgc cagaagaaga tacaccagac ggaagaaccg gatctgctat 360ctgcaagaga tcttcagcaa cgagatggcc aaggtggacg acagcttctt ccacagactg 420gaagagtcct tcctggtgga agaggataag aagcacgagc ggcaccccat cttcggcaac 480atcgtggacg aggtggccta ccacgagaag taccccacca tctaccacct gagaaagaaa 540ctggtggaca gcaccgacaa ggccgacctg cggctgatct atctggccct ggcccacatg 600atcaagttcc ggggccactt cctgatcgag ggcgacctga accccgacaa cagcgacgtg 660gacaagctgt tcatccagct ggtgcagacc tacaaccagc tgttcgagga aaaccccatc 720aacgccagcg gcgtggacgc caaggccatc ctgtctgcca gactgagcaa gagcagacgg 780ctggaaaatc tgatcgccca gctgcccggc gagaagaaga atggcctgtt cggaaacctg 840attgccctga gcctgggcct gacccccaac ttcaagagca acttcgacct ggccgaggat 900gccaaactgc agctgagcaa ggacacctac gacgacgacc tggacaacct gctggcccag 960atcggcgacc agtacgccga cctgtttctg gccgccaaga acctgtccga cgccatcctg 1020ctgagcgaca tcctgagagt gaacaccgag atcaccaagg cccccctgag cgcctctatg 1080atcaagagat acgacgagca ccaccaggac ctgaccctgc tgaaagctct cgtgcggcag 1140cagctgcctg agaagtacaa agagattttc ttcgaccaga gcaagaacgg ctacgccggc 1200tacattgacg gcggagccag ccaggaagag ttctacaagt tcatcaagcc catcctggaa 1260aagatggacg gcaccgagga actgctcgtg aagctgaaca gagaggacct gctgcggaag 1320cagcggacct tcgacaacgg cagcatcccc caccagatcc acctgggaga gctgcacgcc 1380attctgcggc ggcaggaaga tttttaccca ttcctgaagg acaaccggga aaagatcgag 1440aagatcctga ccttccgcat cccctactac gtgggccctc tggccagggg aaacagcaga 1500ttcgcctgga tgaccagaaa gagcgaggaa accatcaccc cctggaactt cgaggaagtg 1560gtggacaagg gcgcttccgc ccagagcttc atcgagcgga tgaccaactt cgataagaac 1620ctgcccaacg agaaggtgct gcccaagcac agcctgctgt acgagtactt caccgtgtat 1680aacgagctga ccaaagtgaa atacgtgacc gagggaatga gaaagcccgc cttcctgagc 1740ggcgagcaga aaaaggccat cgtggacctg ctgttcaaga ccaaccggaa agtgaccgtg 1800aagcagctga aagaggacta cttcaagaaa atcgagtgct tcgactccgt ggaaatctcc 1860ggcgtggaag atcggttcaa cgcctccctg ggcacatacc acgatctgct gaaaattatc 1920aaggacaagg acttcctgga caatgaggaa aacgaggaca ttctggaaga tatcgtgctg 1980accctgacac tgtttgagga cagagagatg atcgaggaac ggctgaaaac ctatgcccac 2040ctgttcgacg acaaagtgat gaagcagctg aagcggcgga gatacaccgg ctggggcagg 2100ctgagccgga agctgatcaa cggcatccgg gacaagcagt ccggcaagac aatcctggat 2160ttcctgaagt ccgacggctt cgccaacaga aacttcatgc agctgatcca cgacgacagc 2220ctgaccttta aagaggacat ccagaaagcc caggtgtccg gccagggcga tagcctgcac 2280gagcacattg ccaatctggc cggcagcccc gccattaaga agggcatcct gcagacagtg 2340aaggtggtgg acgagctcgt gaaagtgatg ggccggcaca agcccgagaa catcgtgatc 2400gaaatggcca gagagaacca gaccacccag aagggacaga agaacagccg cgagagaatg 2460aagcggatcg aagagggcat caaagagctg ggcagccaga tcctgaaaga acaccccgtg 2520gaaaacaccc agctgcagaa cgagaagctg tacctgtact acctgcagaa tgggcgggat 2580atgtacgtgg accaggaact ggacatcaac cggctgtccg actacgatgt ggaccatatc 2640gtgcctcaga gctttctgaa ggacgactcc atcgacaaca aggtgctgac cagaagcgac 2700aagaaccggg gcaagagcga caacgtgccc tccgaagagg tcgtgaagaa gatgaagaac 2760tactggcggc agctgctgaa cgccaagctg attacccaga gaaagttcga caatctgacc 2820aaggccgaga gaggcggcct gagcgaactg gataaggccg gcttcatcaa gagacagctg 2880gtggaaaccc ggcagatcac aaagcacgtg gcacagatcc tggactcccg gatgaacact 2940aagtacgacg agaatgacaa gctgatccgg gaagtgaaag tgatcaccct gaagtccaag 3000ctggtgtccg atttccggaa ggatttccag ttttacaaag tgcgcgagat caacaactac 3060caccacgccc acgacgccta cctgaacgcc gtcgtgggaa ccgccctgat caaaaagtac 3120cctaagctgg aaagcgagtt cgtgtacggc gactacaagg tgtacgacgt gcggaagatg 3180atcgccaaga gcgagcagga aatcggcaag gctaccgcca agtacttctt ctacagcaac 3240atcatgaact ttttcaagac cgagattacc ctggccaacg gcgagatccg gaagcggcct 3300ctgatcgaga caaacggcga aaccggggag atcgtgtggg ataagggccg ggattttgcc 3360accgtgcgga aagtgctgag catgccccaa gtgaatatcg tgaaaaagac caaaaggccg 3420gcggccacga aaaaggccgg ccaggcaaaa aagaaaaag 3459814347DNAStreptococcus thermophilus 81atggactata aggaccacga cggagactac aaggatcatg atattgatta caaagacgat 60gacgataaga tggccccaaa gaagaagcgg aaggtcggta tccacggagt cccagcagcc 120accaagccct acagcatcgg cctggacatc ggcaccaata gcgtgggctg ggccgtgacc 180accgacaact acaaggtgcc cagcaagaaa atgaaggtgc tgggcaacac ctccaagaag 240tacatcaaga aaaacctgct gggcgtgctg ctgttcgaca gcggcattac agccgagggc 300agacggctga agagaaccgc cagacggcgg tacacccggc ggagaaacag aatcctgtat 360ctgcaagaga tcttcagcac cgagatggct accctggacg acgccttctt ccagcggctg 420gacgacagct tcctggtgcc cgacgacaag cgggacagca agtaccccat cttcggcaac 480ctggtggaag agaaggccta ccacgacgag ttccccacca tctaccacct gagaaagtac 540ctggccgaca gcaccaagaa ggccgacctg agactggtgt atctggccct ggcccacatg 600atcaagtacc ggggccactt cctgatcgag ggcgagttca acagcaagaa caacgacatc 660cagaagaact tccaggactt cctggacacc tacaacgcca tcttcgagag cgacctgtcc 720ctggaaaaca gcaagcagct ggaagagatc gtgaaggaca agatcagcaa gctggaaaag 780aaggaccgca tcctgaagct gttccccggc gagaagaaca gcggaatctt cagcgagttt 840ctgaagctga tcgtgggcaa ccaggccgac ttcagaaagt gcttcaacct ggacgagaaa 900gccagcctgc acttcagcaa

agagagctac gacgaggacc tggaaaccct gctgggatat 960atcggcgacg actacagcga cgtgttcctg aaggccaaga agctgtacga cgctatcctg 1020ctgagcggct tcctgaccgt gaccgacaac gagacagagg ccccactgag cagcgccatg 1080attaagcggt acaacgagca caaagaggat ctggctctgc tgaaagagta catccggaac 1140atcagcctga aaacctacaa tgaggtgttc aaggacgaca ccaagaacgg ctacgccggc 1200tacatcgacg gcaagaccaa ccaggaagag gaagatttct atgtgtacct gaagaagctg 1260ctggccgagt tcgagggggc cgactacttt ctggaaaaaa tcgaccgcga ggatttcctg 1320cggaagcagc ggaccttcga caacggcagc atcccctacc agatccatct gcaggaaatg 1380cgggccatcc tggacaagca ggccaagttc tacccattcc tggccaagaa caaagagcgg 1440atcgagaaga tcctgacctt ccgcatccct tactacgtgg gccccctggc cagaggcaac 1500agcgattttg cctggtccat ccggaagcgc aatgagaaga tcaccccctg gaacttcgag 1560gacgtgatcg acaaagagtc cagcgccgag gccttcatca accggatgac cagcttcgac 1620ctgtacctgc ccgaggaaaa ggtgctgccc aagcacagcc tgctgtacga gacattcaat 1680gtgtataacg agctgaccaa agtgcggttt atcgccgagt ctatgcggga ctaccagttc 1740ctggactcca agcagaaaaa ggacatcgtg cggctgtact tcaaggacaa gcggaaagtg 1800accgataagg acatcatcga gtacctgcac gccatctacg gctacgatgg catcgagctg 1860aagggcatcg agaagcagtt caactccagc ctgagcacat accacgacct gctgaacatt 1920atcaacgaca aagaatttct ggacgactcc agcaacgagg ccatcatcga agagatcatc 1980cacaccctga ccatctttga ggaccgcgag atgatcaagc agcggctgag caagttcgag 2040aacatcttcg acaagagcgt gctgaaaaag ctgagcagac ggcactacac cggctggggc 2100aagctgagcg ccaagctgat caacggcatc cgggacgaga agtccggcaa cacaatcctg 2160gactacctga tcgacgacgg catcagcaac cggaacttca tgcagctgat ccacgacgac 2220gccctgagct tcaagaagaa gatccagaag gcccagatca tcggggacga ggacaagggc 2280aacatcaaag aagtcgtgaa gtccctgccc ggcagccccg ccatcaagaa gggaatcctg 2340cagagcatca agatcgtgga cgagctcgtg aaagtgatgg gcggcagaaa gcccgagagc 2400atcgtggtgg tggtggaaat ggctagagag aaccagtaca ccaatcaggg caagagcaac 2460agccagcaga gactgaagag actggaaaag tccctgaaag agctgggcag caagattctg 2520aaagagaata tccctgccaa gctgtccaag atcgacaaca acgccctgca gaacgaccgg 2580ctgtacctgt actacctgca gaatggcaag gacatgtata caggcgacga cctggatatc 2640gaccgcctga gcaactacga catcgaccat attatccccc aggccttcct gaaagacaac 2700agcattgaca acaaagtgct ggtgtcctcc gccagcaacc gcggcaagtc cgatgatgtg 2760cccagcctgg aagtcgtgaa aaagagaaag accttctggt atcagctgct gaaaagcaag 2820ctgattagcc agaggaagtt cgacaacctg accaaggccg agagaggcgg cctgagccct 2880gaagataagg ccggcttcat ccagagacag ctggtggaaa cccggcagat caccaagcac 2940gtggccagac tgctggatga gaagtttaac aacaagaagg acgagaacaa ccgggccgtg 3000cggaccgtga agatcatcac cctgaagtcc accctggtgt cccagttccg gaaggacttc 3060gagctgtata aagtgcgcga gatcaatgac tttcaccacg cccacgacgc ctacctgaat 3120gccgtggtgg cttccgccct gctgaagaag taccctaagc tggaacccga gttcgtgtac 3180ggcgactacc ccaagtacaa ctccttcaga gagcggaagt ccgccaccga gaaggtgtac 3240ttctactcca acatcatgaa tatctttaag aagtccatct ccctggccga tggcagagtg 3300atcgagcggc ccctgatcga agtgaacgaa gagacaggcg agagcgtgtg gaacaaagaa 3360agcgacctgg ccaccgtgcg gcgggtgctg agttatcctc aagtgaatgt cgtgaagaag 3420gtggaagaac agaaccacgg cctggatcgg ggcaagccca agggcctgtt caacgccaac 3480ctgtccagca agcctaagcc caactccaac gagaatctcg tgggggccaa agagtacctg 3540gaccctaaga agtacgggta cggcggatac gccggcatct ccaatagctt caccgtgctc 3600gtgaagggca caatcgagaa gggcgctaag aaaaagatca caaacgtgct ggaatttcag 3660gggatctcta tcctggaccg gatcaactac cggaaggata agctgaactt tctgctggaa 3720aaaggctaca aggacattga gctgattatc gagctgccta agtactccct gttcgaactg 3780agcgacggct ccagacggat gctggcctcc atcctgtcca ccaacaacaa gcggggcgag 3840atccacaagg gaaaccagat cttcctgagc cagaaatttg tgaaactgct gtaccacgcc 3900aagcggatct ccaacaccat caatgagaac caccggaaat acgtggaaaa ccacaagaaa 3960gagtttgagg aactgttcta ctacatcctg gagttcaacg agaactatgt gggagccaag 4020aagaacggca aactgctgaa ctccgccttc cagagctggc agaaccacag catcgacgag 4080ctgtgcagct ccttcatcgg ccctaccggc agcgagcgga agggactgtt tgagctgacc 4140tccagaggct ctgccgccga ctttgagttc ctgggagtga agatcccccg gtacagagac 4200tacaccccct ctagtctgct gaaggacgcc accctgatcc accagagcgt gaccggcctg 4260tacgaaaccc ggatcgacct ggctaagctg ggcgagggaa aaaggccggc ggccacgaaa 4320aaggccggcc aggcaaaaaa gaaaaag 4347824104DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 82atggacaaga agtacagcat cggcctggac atcggcacca actctgtggg ctgggccgtg 60atcaccgacg agtacaaggt gcccagcaag aaattcaagg tgctgggcaa caccgaccgg 120cacagcatca agaagaacct gatcggagcc ctgctgttcg acagcggcga aacagccgag 180gccacccggc tgaagagaac cgccagaaga agatacacca gacggaagaa ccggatcctg 240tatctgcaag agatcttcag caacgagatg gccaaggtgg acgacagctt cttccacaga 300ctggaagagt ccttcctggt ggaagaggat aagaagcacg agcggcaccc catcttcggc 360aacatcgtgg acgaggtggc ctaccacgag aagtacccca ccatctacca cctgagaaag 420aaactggtgg acagcaccga caaggccgac ctgcggctga tctatctggc cctggcccac 480atgatcaagt tccggggcca cttcctgatc gagggcgacc tgaaccccga caacagcgac 540gtggacaagc tgttcatcca gctggtgcag acctacaacc agctgttcga ggaaaacccc 600atcaacgcca gcggcgtgga cgccaaggcc atcctgtctg ccagactgag caagagcaga 660cggctggaaa atctgatcgc ccagctgccc ggcgagaaga agaatggcct gttcggaaac 720ctgattgccc tgagcctggg cctgaccccc aacttcaaga gcaacttcga cctggccgag 780gatgccaaac tgcagctgag caaggacacc tacgacgacg acctggacaa cctgctggcc 840cagatcggcg accagtacgc cgacctgttt ctggccgcca agaacctgtc cgacgccatc 900ctgctgagcg acatcctgag agtgaacacc gagatcacca aggcccccct gagcgcctct 960atgatcaaga gatacgacga gcaccaccag gacctgaccc tgctgaaagc tctcgtgcgg 1020cagcagctgc ctgagaagta caaagagatt ttcttcgacc agagcaagaa cggctacgcc 1080ggctacattg acggcggagc cagccaggaa gagttctaca agttcatcaa gcccatcctg 1140gaaaagatgg acggcaccga ggaactgctc gtgaagctga acagagagga cctgctgcgg 1200aagcagcgga ccttcgacaa cggcagcatc ccccaccaga tccacctggg agagctgcac 1260gccattctgc ggcggcagga agatttttac ccattcctga aggacaaccg ggaaaagatc 1320gagaagatcc tgaccttccg catcccctac tacgtgggcc ctctggccag gggaaacagc 1380agattcgcct ggatgaccag aaagagcgag gaaaccatca ccccctggaa cttcgaggaa 1440gtggtggaca agggcgcttc cgcccagagc ttcatcgagc ggatgaccaa cttcgataag 1500aacctgccca acgagaaggt gctgcccaag cacagcctgc tgtacgagta cttcaccgtg 1560tataacgagc tgaccaaagt gaaatacgtg accgagggaa tgagaaagcc cgccttcctg 1620agcggcgagc agaaaaaggc catcgtggac ctgctgttca agaccaaccg gaaagtgacc 1680gtgaagcagc tgaaagagga ctacttcaag aaaatcgagg agttcgactc cgtggaaatc 1740tccggcgtgg aagatcggtt caacgcctcc ctgggcacat accacgatct gctgaaaatt 1800atcaaggaca aggacttcct ggacaatgag gaaaacgagg acattctgga agatatcgtg 1860ctgaccctga cactgtttga ggacagagag atgatcgagg aacggctgaa aacctatgcc 1920cacctgttcg acgacaaagt gatgaagcag ctgaagcggc ggagatacac cggctggggc 1980aggctgagcc ggaagctgat caacggcatc cgggacaagc agtccggcaa gacaatcctg 2040gatttcctga agtccgacgg cttcgccaac agaaacttca tgcagctgat ccacgacgac 2100agcctgacct ttaaagagga catccagaaa gcccaggtgt ccggccaggg cgatagcctg 2160cacgagcaca ttgccaatct ggccggcagc cccgccatta agaagggcat cctgcagaca 2220gtgaaggtgg tggacgagct cgtgaaagtg atgggccggc acaagcccga gaacatcgtg 2280atcgaaatgg ccagagagaa ccagaccacc cagaagggac agaagaacag ccgcgagaga 2340atgaagcgga tcgaagaggg catcaaagag ctgggcagcc agatcctgaa agaacacccc 2400gtggaaaaca cccagctgca gaacgagaag ctgtacctgt actacctgca gaatgggcgg 2460gatatgtacg tggaccagga actggacatc aaccggctgt ccgactacga tgtggaccat 2520atcgtgcctc agagctttct gaaggacgac tccatcgaca acaaggtgct gaccagaagc 2580gacaagaacc ggggcaagag cgacaacgtg ccctccgaag aggtcgtgaa gaagatgaag 2640aactactggc ggcagctgct gaacgccaag ctgattaccc agagaaagtt cgacaatctg 2700accaaggccg agagaggcgg cctgagcgaa ctggataagg ccggcttcat caagagacag 2760ctggtggaaa cccggcagat cacaaagcac gtggcacaga tcctggactc ccggatgaac 2820actaagtacg acgagaatga caagctgatc cgggaagtga aagtgatcac cctgaagtcc 2880aagctggtgt ccgatttccg gaaggatttc cagttttaca aagtgcgcga gatcaacaac 2940taccaccacg cccacgacgc ctacctgaac gccgtcgtgg gaaccgccct gatcaaaaag 3000taccctaagc tggaaagcga gttcgtgtac ggcgactaca aggtgtacga cgtgcggaag 3060atgatcgcca agagcgagca ggaaatcggc aaggctaccg ccaagtactt cttctacagc 3120aacatcatga actttttcaa gaccgagatt accctggcca acggcgagat ccggaagcgg 3180cctctgatcg agacaaacgg cgaaaccggg gagatcgtgt gggataaggg ccgggatttt 3240gccaccgtgc ggaaagtgct gagcatgccc caagtgaata tcgtgaaaaa gaccgaggtg 3300cagacaggcg gcttcagcaa agagtctatc ctgcccaaga ggaacagcga taagctgatc 3360gccagaaaga aggactggga ccctaagaag tacggcggct tcgacagccc caccgtggcc 3420tattctgtgc tggtggtggc caaagtggaa aagggcaagt ccaagaaact gaagagtgtg 3480aaagagctgc tggggatcac catcatggaa agaagcagct tcgagaagaa tcccatcgac 3540tttctggaag ccaagggcta caaagaagtg aaaaaggacc tgatcatcaa gctgcctaag 3600tactccctgt tcgagctgga aaacggccgg aagagaatgc tggcctctgc cggcgaactg 3660cagaagggaa acgaactggc cctgccctcc aaatatgtga acttcctgta cctggccagc 3720cactatgaga agctgaaggg ctcccccgag gataatgagc agaaacagct gtttgtggaa 3780cagcacaagc actacctgga cgagatcatc gagcagatca gcgagttctc caagagagtg 3840atcctggccg acgctaatct ggacaaagtg ctgtccgcct acaacaagca ccgggataag 3900cccatcagag agcaggccga gaatatcatc cacctgttta ccctgaccaa tctgggagcc 3960cctgccgcct tcaagtactt tgacaccacc atcgaccgga agaggtacac cagcaccaaa 4020gaggtgctgg acgccaccct gatccaccag agcatcaccg gcctgtacga gacacggatc 4080gacctgtctc agctgggagg cgac 4104834338DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 83atggactata aggaccacga cggagactac aaggatcatg atattgatta caaagacgat 60gacgataaga tggccccaaa gaagaagcgg aaggtcggta tccacggagt cccagcagcc 120gacaagaagt acagcatcgg cctggacatc ggcaccaact ctgtgggctg ggccgtgatc 180accgacgagt acaaggtgcc cagcaagaaa ttcaaggtgc tgggcaacac cgaccggcac 240agcatcaaga agaacctgat cggagccctg ctgttcgaca gcggcgaaac agccgaggcc 300acccggctga agagaaccgc cagaagaaga tacaccagac ggaagaaccg gatctgctat 360ctgcaagaga tcttcagcaa cgagatggcc aaggtggacg acagcttctt ccacagactg 420gaagagtcct tcctggtgga agaggataag aagcacgagc ggcaccccat cttcggcaac 480atcgtggacg aggtggccta ccacgagaag taccccacca tctaccacct gagaaagaaa 540ctggtggaca gcaccgacaa ggccgacctg cggctgatct atctggccct ggcccacatg 600atcaagttcc ggggccactt cctgatcgag ggcgacctga accccgacaa cagcgacgtg 660gacaagctgt tcatccagct ggtgcagacc tacaaccagc tgttcgagga aaaccccatc 720aacgccagcg gcgtggacgc caaggccatc ctgtctgcca gactgagcaa gagcagacgg 780ctggaaaatc tgatcgccca gctgcccggc gagaagaaga atggcctgtt cggaaacctg 840attgccctga gcctgggcct gacccccaac ttcaagagca acttcgacct ggccgaggat 900gccaaactgc agctgagcaa ggacacctac gacgacgacc tggacaacct gctggcccag 960atcggcgacc agtacgccga cctgtttctg gccgccaaga acctgtccga cgccatcctg 1020ctgagcgaca tcctgagagt gaacaccgag atcaccaagg cccccctgag cgcctctatg 1080atcaagagat acgacgagca ccaccaggac ctgaccctgc tgaaagctct cgtgcggcag 1140cagctgcctg agaagtacaa agagattttc ttcgaccaga gcaagaacgg ctacgccggc 1200tacattgacg gcggagccag ccaggaagag ttctacaagt tcatcaagcc catcctggaa 1260aagatggacg gcaccgagga actgctcgtg aagctgaaca gagaggacct gctgcggaag 1320cagcggacct tcgacaacgg cagcatcccc caccagatcc acctgggaga gctgcacgcc 1380attctgcggc ggcaggaaga tttttaccca ttcctgaagg acaaccggga aaagatcgag 1440aagatcctga ccttccgcat cccctactac gtgggccctc tggccagggg aaacagcaga 1500ttcgcctgga tgaccagaaa gagcgaggaa accatcaccc cctggaactt cgaggaagtg 1560gtggacaagg gcgcttccgc ccagagcttc atcgagcgga tgaccaactt cgataagaac 1620ctgcccaacg agaaggtgct gcccaagcac agcctgctgt acgagtactt caccgtgtat 1680aacgagctga ccaaagtgaa atacgtgacc gagggaatga gaaagcccgc cttcctgagc 1740ggcgagcaga aaaaggccat cgtggacctg ctgttcaaga ccaaccggaa agtgaccgtg 1800aagcagctga aagaggacta cttcaagaaa atcgagtgct tcgactccgt ggaaatctcc 1860ggcgtggaag atcggttcaa cgcctccctg ggcacatacc acgatctgct gaaaattatc 1920aaggacaagg acttcctgga caatgaggaa aacgaggaca ttctggaaga tatcgtgctg 1980accctgacac tgtttgagga cagagagatg atcgaggaac ggctgaaaac ctatgcccac 2040ctgttcgacg acaaagtgat gaagcagctg aagcggcgga gatacaccgg ctggggcagg 2100ctgagccgga agctgatcaa cggcatccgg gacaagcagt ccggcaagac aatcctggat 2160ttcctgaagt ccgacggctt cgccaacaga aacttcatgc agctgatcca cgacgacagc 2220ctgaccttta aagaggacat ccagaaagcc caggtgtccg gccagggcga tagcctgcac 2280gagcacattg ccaatctggc cggcagcccc gccattaaga agggcatcct gcagacagtg 2340aaggtggtgg acgagctcgt gaaagtgatg ggccggcaca agcccgagaa catcgtgatc 2400gaaatggcca gagagaacca gaccacccag aagggacaga agaacagccg cgagagaatg 2460aagcggatcg aagagggcat caaagagctg ggcagccaga tcctgaaaga acaccccgtg 2520gaaaacaccc agctgcagaa cgagaagctg tacctgtact acctgcagaa tgggcgggat 2580atgtacgtgg accaggaact ggacatcaac cggctgtccg actacgatgt ggaccatatc 2640gtgcctcaga gctttctgaa ggacgactcc atcgacaaca aggtgctgac cagaagcgac 2700aagaaccggg gcaagagcga caacgtgccc tccgaagagg tcgtgaagaa gatgaagaac 2760tactggcggc agctgctgaa cgccaagctg attacccaga gaaagttcga caatctgacc 2820aaggccgaga gaggcggcct gagcgaactg gataaggccg gcttcatcaa gagacagctg 2880gtggaaaccc ggcagatcac aaagcacgtg gcacagatcc tggactcccg gatgaacact 2940aagtacgacg agaatgacaa gctgatccgg gaagtgaaag tgatcaccct gaagtccaag 3000ctggtgtccg atttccggaa ggatttccag ttttacaaag tgcgcgagat caacaactac 3060caccacgccc acgacgccta cctgaacgcc gtcgtgggaa ccgccctgat caaaaagtac 3120cctaagctgg aaagcgagtt cgtgtacggc gactacaagg tgtacgacgt gcggaagatg 3180atcgccaaga gcgagcagga aatcggcaag gctaccgcca agtacttctt ctacagcaac 3240atcatgaact ttttcaagac cgagattacc ctggccaacg gcgagatccg gaagcggcct 3300ctgatcgaga caaacggcga aaccggggag atcgtgtggg ataagggccg ggattttgcc 3360accgtgcgga aagtgctgag catgccccaa gtgaatatcg tgaaaaagac cgtggaagaa 3420cagaaccacg gcctggatcg gggcaagccc aagggcctgt tcaacgccaa cctgtccagc 3480aagcctaagc ccaactccaa cgagaatctc gtgggggcca aagagtacct ggaccctaag 3540aagtacgggt acggcggata cgccggcatc tccaatagct tcaccgtgct cgtgaagggc 3600acaatcgaga agggcgctaa gaaaaagatc acaaacgtgc tggaatttca ggggatctct 3660atcctggacc ggatcaacta ccggaaggat aagctgaact ttctgctgga aaaaggctac 3720aaggacattg agctgattat cgagctgcct aagtactccc tgttcgaact gagcgacggc 3780tccagacgga tgctggcctc catcctgtcc accaacaaca agcggggcga gatccacaag 3840ggaaaccaga tcttcctgag ccagaaattt gtgaaactgc tgtaccacgc caagcggatc 3900tccaacacca tcaatgagaa ccaccggaaa tacgtggaaa accacaagaa agagtttgag 3960gaactgttct actacatcct ggagttcaac gagaactatg tgggagccaa gaagaacggc 4020aaactgctga actccgcctt ccagagctgg cagaaccaca gcatcgacga gctgtgcagc 4080tccttcatcg gccctaccgg cagcgagcgg aagggactgt ttgagctgac ctccagaggc 4140tctgccgccg actttgagtt cctgggagtg aagatccccc ggtacagaga ctacaccccc 4200tctagtctgc tgaaggacgc caccctgatc caccagagcg tgaccggcct gtacgaaacc 4260cggatcgacc tggctaagct gggcgaggga aaaaggccgg cggccacgaa aaaggccggc 4320caggcaaaaa agaaaaag 4338844215DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 84atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc catgaccaag 60ccctacagca tcggcctgga catcggcacc aatagcgtgg gctgggccgt gaccaccgac 120aactacaagg tgcccagcaa gaaaatgaag gtgctgggca acacctccaa gaagtacatc 180aagaaaaacc tgctgggcgt gctgctgttc gacagcggca ttacagccga gggcagacgg 240ctgaagagaa ccgccagacg gcggtacacc cggcggagaa acagaatcct gtatctgcaa 300gagatcttca gcaccgagat ggctaccctg gacgacgcct tcttccagcg gctggacgac 360agcttcctgg tgcccgacga caagcgggac agcaagtacc ccatcttcgg caacctggtg 420gaagagaagg cctaccacga cgagttcccc accatctacc acctgagaaa gtacctggcc 480gacagcacca agaaggccga cctgagactg gtgtatctgg ccctggccca catgatcaag 540taccggggcc acttcctgat cgagggcgag ttcaacagca agaacaacga catccagaag 600aacttccagg acttcctgga cacctacaac gccatcttcg agagcgacct gtccctggaa 660aacagcaagc agctggaaga gatcgtgaag gacaagatca gcaagctgga aaagaaggac 720cgcatcctga agctgttccc cggcgagaag aacagcggaa tcttcagcga gtttctgaag 780ctgatcgtgg gcaaccaggc cgacttcaga aagtgcttca acctggacga gaaagccagc 840ctgcacttca gcaaagagag ctacgacgag gacctggaaa ccctgctggg atatatcggc 900gacgactaca gcgacgtgtt cctgaaggcc aagaagctgt acgacgctat cctgctgagc 960ggcttcctga ccgtgaccga caacgagaca gaggccccac tgagcagcgc catgattaag 1020cggtacaacg agcacaaaga ggatctggct ctgctgaaag agtacatccg gaacatcagc 1080ctgaaaacct acaatgaggt gttcaaggac gacaccaaga acggctacgc cggctacatc 1140gacggcaaga ccaaccagga agaggaagat ttctatgtgt acctgaagaa gctgctggcc 1200gagttcgagg gggccgacta ctttctggaa aaaatcgacc gcgaggattt cctgcggaag 1260cagcggacct tcgacaacgg cagcatcccc taccagatcc atctgcagga aatgcgggcc 1320atcctggaca agcaggccaa gttctaccca ttcctggcca agaacaaaga gcggatcgag 1380aagatcctga ccttccgcat cccttactac gtgggccccc tggccagagg caacagcgat 1440tttgcctggt ccatccggaa gcgcaatgag aagatcaccc cctggaactt cgaggacgtg 1500atcgacaaag agtccagcgc cgaggccttc atcaaccgga tgaccagctt cgacctgtac 1560ctgcccgagg aaaaggtgct gcccaagcac agcctgctgt acgagacatt caatgtgtat 1620aacgagctga ccaaagtgcg gtttatcgcc gagtctatgc gggactacca gttcctggac 1680tccaagcaga aaaaggacat cgtgcggctg tacttcaagg acaagcggaa agtgaccgat 1740aaggacatca tcgagtacct gcacgccatc tacggctacg atggcatcga gctgaagggc 1800atcgagaagc agttcaactc cagcctgagc acataccacg acctgctgaa cattatcaac 1860gacaaagaat ttctggacga ctccagcaac gaggccatca tcgaagagat catccacacc 1920ctgaccatct ttgaggaccg cgagatgatc aagcagcggc tgagcaagtt cgagaacatc 1980ttcgacaaga gcgtgctgaa aaagctgagc agacggcact acaccggctg gggcaagctg 2040agcgccaagc tgatcaacgg catccgggac gagaagtccg gcaacacaat cctggactac 2100ctgatcgacg acggcatcag caaccggaac ttcatgcagc tgatccacga cgacgccctg 2160agcttcaaga agaagatcca gaaggcccag atcatcgggg acgaggacaa gggcaacatc 2220aaagaagtcg tgaagtccct gcccggcagc cccgccatca agaagggaat cctgcagagc 2280atcaagatcg tggacgagct cgtgaaagtg atgggcggca gaaagcccga gagcatcgtg 2340gtggtggtgg aaatggctag agagaaccag tacaccaatc agggcaagag caacagccag 2400cagagactga agagactgga aaagtccctg aaagagctgg gcagcaagat tctgaaagag 2460aatatccctg ccaagctgtc caagatcgac aacaacgccc tgcagaacga ccggctgtac 2520ctgtactacc tgcagaatgg caaggacatg tatacaggcg acgacctgga tatcgaccgc 2580ctgagcaact acgacatcga ccatattatc ccccaggcct tcctgaaaga caacagcatt 2640gacaacaaag tgctggtgtc ctccgccagc aaccgcggca agtccgatga tgtgcccagc 2700ctggaagtcg tgaaaaagag aaagaccttc tggtatcagc tgctgaaaag caagctgatt 2760agccagagga agttcgacaa

cctgaccaag gccgagagag gcggcctgag ccctgaagat 2820aaggccggct tcatccagag acagctggtg gaaacccggc agatcaccaa gcacgtggcc 2880agactgctgg atgagaagtt taacaacaag aaggacgaga acaaccgggc cgtgcggacc 2940gtgaagatca tcaccctgaa gtccaccctg gtgtcccagt tccggaagga cttcgagctg 3000tataaagtgc gcgagatcaa tgactttcac cacgcccacg acgcctacct gaatgccgtg 3060gtggcttccg ccctgctgaa gaagtaccct aagctggaac ccgagttcgt gtacggcgac 3120taccccaagt acaactcctt cagagagcgg aagtccgcca ccgagaaggt gtacttctac 3180tccaacatca tgaatatctt taagaagtcc atctccctgg ccgatggcag agtgatcgag 3240cggcccctga tcgaagtgaa cgaagagaca ggcgagagcg tgtggaacaa agaaagcgac 3300ctggccaccg tgcggcgggt gctgagttat cctcaagtga atgtcgtgaa gaagaccgag 3360gtgcagacag gcggcttcag caaagagtct atcctgccca agaggaacag cgataagctg 3420atcgccagaa agaaggactg ggaccctaag aagtacggcg gcttcgacag ccccaccgtg 3480gcctattctg tgctggtggt ggccaaagtg gaaaagggca agtccaagaa actgaagagt 3540gtgaaagagc tgctggggat caccatcatg gaaagaagca gcttcgagaa gaatcccatc 3600gactttctgg aagccaaggg ctacaaagaa gtgaaaaagg acctgatcat caagctgcct 3660aagtactccc tgttcgagct ggaaaacggc cggaagagaa tgctggcctc tgccggcgaa 3720ctgcagaagg gaaacgaact ggccctgccc tccaaatatg tgaacttcct gtacctggcc 3780agccactatg agaagctgaa gggctccccc gaggataatg agcagaaaca gctgtttgtg 3840gaacagcaca agcactacct ggacgagatc atcgagcaga tcagcgagtt ctccaagaga 3900gtgatcctgg ccgacgctaa tctggacaaa gtgctgtccg cctacaacaa gcaccgggat 3960aagcccatca gagagcaggc cgagaatatc atccacctgt ttaccctgac caatctggga 4020gcccctgccg ccttcaagta ctttgacacc accatcgacc ggaagaggta caccagcacc 4080aaagaggtgc tggacgccac cctgatccac cagagcatca ccggcctgta cgagacacgg 4140atcgacctgt ctcagctggg aggcgacaaa aggccggcgg ccacgaaaaa ggccggccag 4200gcaaaaaaga aaaag 4215854269DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 85atggactata aggaccacga cggagactac aaggatcatg atattgatta caaagacgat 60gacgataaga tggccccaaa gaagaagcgg aaggtcggta tccacggagt cccagcagcc 120gacaagaagt acagcatcgg cctggacatc ggcaccaact ctgtgggctg ggccgtgatc 180accgacgagt acaaggtgcc cagcaagaaa ttcaaggtgc tgggcaacac cgaccggcac 240agcatcaaga agaacctgat cggagccctg ctgttcgaca gcggcgaaac agccgaggcc 300acccggctga agagaaccgc cagaagaaga tacaccagac ggaagaaccg gatctgctat 360ctgcaagaga tcttcagcaa cgagatggcc aaggtggacg acagcttctt ccacagactg 420gaagagtcct tcctggtgga agaggataag aagcacgagc ggcaccccat cttcggcaac 480atcgtggacg aggtggccta ccacgagaag taccccacca tctaccacct gagaaagaaa 540ctggtggaca gcaccgacaa ggccgacctg cggctgatct atctggccct ggcccacatg 600atcaagttcc ggggccactt cctgatcgag ggcgacctga accccgacaa cagcgacgtg 660gacaagctgt tcatccagct ggtgcagacc tacaaccagc tgttcgagga aaaccccatc 720aacgccagcg gcgtggacgc caaggccatc ctgtctgcca gactgagcaa gagcagacgg 780ctggaaaatc tgatcgccca gctgcccggc gagaagaaga atggcctgtt cggcaacctg 840attgccctga gcctgggcct gacccccaac ttcaagagca acttcgacct ggccgaggat 900gccaaactgc agctgagcaa ggacacctac gacgacgacc tggacaacct gctggcccag 960atcggcgacc agtacgccga cctgtttctg gccgccaaga acctgtccga cgccatcctg 1020ctgagcgaca tcctgagagt gaacaccgag atcaccaagg cccccctgag cgcctctatg 1080atcaagagat acgacgagca ccaccaggac ctgaccctgc tgaaagctct cgtgcggcag 1140cagctgcctg agaagtacaa agagattttc ttcgaccaga gcaagaacgg ctacgccggc 1200tacattgacg gcggagccag ccaggaagag ttctacaagt tcatcaagcc catcctggaa 1260aagatggacg gcaccgagga actgctcgtg aagctgaaca gagaggacct gctgcggaag 1320cagcggacct tcgacaacgg cagcatcccc caccagatcc acctgggaga gctgcacgcc 1380attctgcggc ggcaggaaga tttttaccca ttcctgaagg acaaccggga aaagatcgag 1440aagatcctga ccttccgcat cccctactac gtgggccctc tggccagggg aaacagcaga 1500ttcgcctgga tgaccagaaa gagcgaggaa accatcaccc cctggaactt cgaggaagtg 1560gtggacaagg gcgcttccgc ccagagcttc atcgagcgga tgaccaactt cgataagaac 1620ctgcccaacg agaaggtgct gcccaagcac agcctgctgt acgagtactt caccgtgtat 1680aacgagctga ccaaagtgaa atacgtgacc gagggaatga gaaagcccgc cttcctgagc 1740ggcgagcaga aaaaggccat cgtggacctg ctgttcaaga ccaaccggaa agtgaccgtg 1800aagcagctga aagaggacta cttcaagaaa atcgagtgct tcgactccgt ggaaatctcc 1860ggcgtggaag atcggttcaa cgcctccctg ggcacatacc acgatctgct gaaaattatc 1920aaggacaagg acttcctgga caatgaggaa aacgaggaca ttctggaaga tatcgtgctg 1980accctgacac tgtttgagga cagagagatg atcgaggaac ggctgaaaac ctatgcccac 2040ctgttcgacg acaaagtgat gaagcagctg aagcggcgga gatacaccgg ctggggcagg 2100ctgagccgga agctgatcaa cggcatccgg gacaagcagt ccggcaagac aatcctggat 2160ttcctgaagt ccgacggctt cgccaacaga aacttcatgc agctgatcca cgacgacagc 2220ctgaccttta aagaggacat ccagaaagcc caggtgtccg gccagggcga tagcctgcac 2280gagcacattg ccaatctggc cggcagcccc gccattaaga agggcatcct gcagacagtg 2340aaggtggtgg acgagctcgt gaaagtgatg ggccggcaca agcccgagaa catcgtgatc 2400gaaatggcca gagagaacca gaccacccag aagggacaga agaacagccg cgagagaatg 2460aagcggatcg aagagggcat caaagagctg ggcagccaga tcctgaaaga acaccccgtg 2520gaaaacaccc agctgcagaa cgagaagctg tacctgtact acctgcagaa tgggcgggat 2580atgtacgtgg accaggaact ggacatcaac cggctgtccg actacgatgt ggaccatatc 2640gtgcctcaga gctttctgaa ggacgactcc atcgacaaca aggtgctgac cagaagcgac 2700aagaaccggg gcaagagcga caacgtgccc tccgaagagg tcgtgaagaa gatgaagaac 2760tactggcggc agctgctgaa cgccaagctg attacccaga gaaagttcga caatctgacc 2820aaggccgaga gaggcggcct gagcgaactg gataaggccg gcttcatcaa gagacagctg 2880gtggaaaccc ggcagatcac aaagcacgtg gcacagatcc tggactcccg gatgaacact 2940aagtacgacg agaatgacaa gctgatccgg gaagtgaaag tgatcaccct gaagtccaag 3000ctggtgtccg atttccggaa ggatttccag ttttacaaag tgcgcgagat caacaactac 3060caccacgccc acgacgccta cctgaacgcc gtcgtgggaa ccgccctgat caaaaagtac 3120cctaagctgg aaagcgagtt cgtgtacggc gactacaagg tgtacgacgt gcggaagatg 3180atcgccaaga gcgagcagga aatcggcaag gctaccgcca agtacttctt ctacagcaac 3240atcatgaact ttttcaagac cgagattacc ctggccaacg gcgagatccg gaagcggcct 3300ctgatcgaga caaacggcga aaccggggag atcgtgtggg ataagggccg ggattttgcc 3360accgtgcgga aagtgctgag catgccccaa gtgaatatcg tgaaaaagac cgaggtgcag 3420acaggcggct tcagcaaaga gtctatcctg cccaagagga acagcgataa gctgatcgcc 3480agaaagaagg actgggaccc taagaagtac ggcggcttcg acagccccac cgtggcctat 3540tctgtgctgg tggtggccaa agtggaaaag ggcaagtcca agaaactgaa gagtgtgaaa 3600gagctgctgg ggatcaccat catggaaaga agcagcttcg agaagaatcc catcgacttt 3660ctggaagcca agggctacaa agaagtgaaa aaggacctga tcatcaagct gcctaagtac 3720tccctgttcg agctggaaaa cggccggaag agaatgctgg cctctgccgg cgaactgcag 3780aagggaaacg aactggccct gccctccaaa tatgtgaact tcctgtacct ggccagccac 3840tatgagaagc tgaagggctc ccccgaggat aatgagcaga aacagctgtt tgtggaacag 3900cacaagcact acctggacga gatcatcgag cagatcagcg agttctccaa gagagtgatc 3960ctggccgacg ctaatctgga caaagtgctg tccgcctaca acaagcaccg ggataagccc 4020atcagagagc aggccgagaa tatcatccac ctgtttaccc tgaccaatct gggagcccct 4080gccgccttca agtactttga caccaccatc gaccggaaga ggtacaccag caccaaagag 4140gtgctggacg ccaccctgat ccaccagagc atcaccggcc tgtacgagac acggatcgac 4200ctgtctcagc tgggaggcga caaaaggccg gcggccacga aaaaggccgg ccaggcaaaa 4260aagaaaaag 4269864269DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 86atggactata aggaccacga cggagactac aaggatcatg atattgatta caaagacgat 60gacgataaga tggccccaaa gaagaagcgg aaggtcggta tccacggagt cccagcagcc 120gacaagaagt acagcatcgg cctggacatc ggcaccaact ctgtgggctg ggccgtgatc 180accgacgagt acaaggtgcc cagcaagaaa ttcaaggtgc tgggcaacac cgaccggcac 240agcatcaaga agaacctgat cggagccctg ctgttcgaca gcggcgaaac agccgaggcc 300acccggctga agagaaccgc cagaagaaga tacaccagac ggaagaaccg gatctgctat 360ctgcaagaga tcttcagcaa cgagatggcc aaggtggacg acagcttctt ccacagactg 420gaagagtcct tcctggtgga agaggataag aagcacgagc ggcaccccat cttcggcaac 480atcgtggacg aggtggccta ccacgagaag taccccacca tctaccacct gagaaagaaa 540ctggtggaca gcaccgacaa ggccgacctg cggctgatct atctggccct ggcccacatg 600atcaagttcc ggggccactt cctgatcgag ggcgacctga accccgacaa cagcgacgtg 660gacaagctgt tcatccagct ggtgcagacc tacaaccagc tgttcgagga aaaccccatc 720aacgccagcg gcgtggacgc caaggccatc ctgtctgcca gactgagcaa gagcagacgg 780ctggaaaatc tgatcgccca gctgcccggc gagaagaaga atggcctgtt cggcaacctg 840attgccctga gcctgggcct gacccccaac ttcaagagca acttcgacct ggccgaggat 900gccaaactgc agctgagcaa ggacacctac gacgacgacc tggacaacct gctggcccag 960atcggcgacc agtacgccga cctgtttctg gccgccaaga acctgtccga cgccatcctg 1020ctgagcgaca tcctgagagt gaacaccgag atcaccaagg cccccctgag cgcctctatg 1080atcaagagat acgacgagca ccaccaggac ctgaccctgc tgaaagctct cgtgcggcag 1140cagctgcctg agaagtacaa agagattttc ttcgaccaga gcaagaacgg ctacgccggc 1200tacattgacg gcggagccag ccaggaagag ttctacaagt tcatcaagcc catcctggaa 1260aagatggacg gcaccgagga actgctcgtg aagctgaaca gagaggacct gctgcggaag 1320cagcggacct tcgacaacgg cagcatcccc caccagatcc acctgggaga gctgcacgcc 1380attctgcggc ggcaggaaga tttttaccca ttcctgaagg acaaccggga aaagatcgag 1440aagatcctga ccttccgcat cccctactac gtgggccctc tggccagggg aaacagcaga 1500ttcgcctgga tgaccagaaa gagcgaggaa accatcaccc cctggaactt cgaggaagtg 1560gtggacaagg gcgcttccgc ccagagcttc atcgagcgga tgaccaactt cgataagaac 1620ctgcccaacg agaaggtgct gcccaagcac agcctgctgt acgagtactt caccgtgtat 1680aacgagctga ccaaagtgaa atacgtgacc gagggaatga gaaagcccgc cttcctgagc 1740ggcgagcaga aaaaggccat cgtggacctg ctgttcaaga ccaaccggaa agtgaccgtg 1800aagcagctga aagaggacta cttcaagaaa atcgagtgct tcgactccgt ggaaatctcc 1860ggcgtggaag atcggttcaa cgcctccctg ggcacatacc acgatctgct gaaaattatc 1920aaggacaagg acttcctgga caatgaggaa aacgaggaca ttctggaaga tatcgtgctg 1980accctgacac tgtttgagga cagagagatg atcgaggaac ggctgaaaac ctatgcccac 2040ctgttcgacg acaaagtgat gaagcagctg aagcggcgga gatacaccgg ctggggcagg 2100ctgagccgga agctgatcaa cggcatccgg gacaagcagt ccggcaagac aatcctggat 2160ttcctgaagt ccgacggctt cgccaacaga aacttcatgc agctgatcca cgacgacagc 2220ctgaccttta aagaggacat ccagaaagcc caggtgtccg gccagggcga tagcctgcac 2280gagcacattg ccaatctggc cggcagcccc gccattaaga agggcatcct gcagacagtg 2340aaggtggtgg acgagctcgt gaaagtgatg ggccggcaca agcccgagaa catcgtgatc 2400gaaatggcca gagagaacca gaccacccag aagggacaga agaacagccg cgagagaatg 2460aagcggatcg aagagggcat caaagagctg ggcagccaga tcctgaaaga acaccccgtg 2520gaaaacaccc agctgcagaa cgagaagctg tacctgtact acctgcagaa tgggcgggat 2580atgtacgtgg accaggaact ggacatcaac cggctgtccg actacgatgt ggaccatatc 2640gtgcctcaga gctttctgaa ggacgactcc atcgacaaca aggtgctgac cagaagcgac 2700aagaaccggg gcaagagcga caacgtgccc tccgaagagg tcgtgaagaa gatgaagaac 2760tactggcggc agctgctgaa cgccaagctg attacccaga gaaagttcga caatctgacc 2820aaggccgaga gaggcggcct gagcgaactg gataaggccg gcttcatcaa gagacagctg 2880gtggaaaccc ggcagatcac aaagcacgtg gcacagatcc tggactcccg gatgaacact 2940aagtacgacg agaatgacaa gctgatccgg gaagtgaaag tgatcaccct gaagtccaag 3000ctggtgtccg atttccggaa ggatttccag ttttacaaag tgcgcgagat caacaactac 3060caccacgccc acgacgccta cctgaacgcc gtcgtgggaa ccgccctgat caaaaagtac 3120cctaagctgg aaagcgagtt cgtgtacggc gactacaagg tgtacgacgt gcggaagatg 3180atcgccaaga gcgagcagga aatcggcaag gctaccgcca agtacttctt ctacagcaac 3240atcatgaact ttttcaagac cgagattacc ctggccaacg gcgagatccg gaagcggcct 3300ctgatcgaga caaacggcga aaccggggag atcgtgtggg ataagggccg ggattttgcc 3360accgtgcgga aagtgctgag catgccccaa gtgaatatcg tgaaaaagac cgaggtgcag 3420acaggcggct tcagcaaaga gtctatcctg cccaagagga acagcgataa gctgatcgcc 3480agaaagaagg actgggaccc taagaagtac ggcggcttcg acagccccac cgtggcctat 3540tctgtgctgg tggtggccaa agtggaaaag ggcaagtcca agaaactgaa gagtgtgaaa 3600gagctgctgg ggatcaccat catggaaaga agcagcttcg agaagaatcc catcgacttt 3660ctggaagcca agggctacaa agaagtgaaa aaggacctga tcatcaagct gcctaagtac 3720tccctgttcg agctggaaaa cggccggaag agaatgctgg cctctgccgg cgaactgcag 3780aagggaaacg aactggccct gccctccaaa tatgtgaact tcctgtacct ggccagccac 3840tatgagaagc tgaagggctc ccccgaggat aatgagcaga aacagctgtt tgtggaacag 3900cacaagcact acctggacga gatcatcgag cagatcagcg agttctccaa gagagtgatc 3960ctggccgacg ctaatctgga caaagtgctg tccgcctaca acaagcaccg ggataagccc 4020atcagagagc aggccgagaa tatcatccac ctgtttaccc tgaccaatct gggagcccct 4080gccgccttca agtactttga caccaccatc gaccggaaga ggtacaccag caccaaagag 4140gtgctggacg ccaccctgat ccaccagagc atcaccggcc tgtacgagac acggatcgac 4200ctgtctcagc tgggaggcga caaaaggccg gcggccacga aaaaggccgg ccaggcaaaa 4260aagaaaaag 426987100RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 87gaguccgagc agaagaagaa gccccagagc uagaaauagc aaguuggggu aaggcuaguc 60cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 1008866RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 88gaguccgagc agaagaagaa guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60cguuuu 668985RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 89gaguccgagc agaagaagaa guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60cguuaucaac uugaaaaagu guuuu 8590100RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 90gaguccgagc agaagaagaa gccccagagc uagaaauagc aaguuggggu aaggcuaguc 60cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 1009191RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 91gaguccgagc agaagaagaa guuuuagaga caaguuaaaa uaaggcuagu ccguuaucaa 60cuugaaaaag uggcaccgag ucggugcuuu u 919298RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 92gaguccgagc agaagaagaa guuuuagagc uagaaauagc uuuaaaauaa ggcuaguccg 60uuaucaacuu gaaaaagugg caccgagucg gugcuuuu 9893100RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 93gaguccgagc agaagaagaa guuuuagagc uagaaauagc aaguuaaaau aauucuagua 60aguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 10094100RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 94gaguccgagc agaagaagaa guuuuagagc uagaaauagc aaguuaaaau aagccaugug 60cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 1009596RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 95gaguccgagc agaagaagaa guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60cguaacuuga aaaaguggca ccgagucggu gcuuuu 9696100RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 96gaguccgagc agaagaagaa guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60cguuaucacg ccgaaaggcg ggcaccgagu cggugcuuuu 10097104RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 97gaguccgagc agaagaagaa guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60cguuaucaac uugagaaauc aaguggcacc gagucggugc uuuu 10498100RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 98gaguccgagc agaagaagaa guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60cguuaucaac uugaaaaagu ggccccgcgg cggggcuuuu 10099104RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 99gaguccgagc agaagaagaa guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60cguuaucaac uugaaaaagu ggcaccgaaa guuucggugc uuuu 10410096RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 100gaguccgagc agaagaagaa gccccagagc auuagcaagu ugggguaagc caugugcguu 60aucagggcac cagcccggca ccgagucggu gcuuuu 96101100RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 101gaguccgagc agaagaagaa guuuuagagc uagaaauagc aacuuaaaau aaggcuaguc 60cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100102100RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 102gaguccgagc agaagaagaa guuuuagagc uagaaauagc aagguaaaau aaggcuaguc 60cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100103100RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 103gaguccgagc agaagaagaa guuuuagagc uagaaauagc aagcuaaaau aaggcuaguc 60cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 10010423DNAStreptococcus pyogenes 104gagtccgagc agaagaagaa ggg 2310520DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic primer" 105ccatcccctt ctgtgaatgt 2010620DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic primer" 106ggagattgga gacacggaga 2010725DNAStreptococcus thermophilus 107gctcccatca catcaaccgg tggcg 2510899RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide"modified_base(1)..(20)a, c, u, g, unknown or other 108nnnnnnnnnn nnnnnnnnnn guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60cguuaucaac uugaaaaagu ggcaccgagu cggugcuuu 9910920DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 109gccaagcgca cctaatttcc 2011097RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic

oligonucleotide" 110ggaaauuagg ugcgcuuggc guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60cguuaucaac uugagaaagu ggcaccgagu cggugcu 9711132PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 111Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1 5 10 15Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Ala 20 25 3011247PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 112Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1 5 10 15Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu 20 25 30Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Ala 35 40 4511362PRTArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polypeptide" 113Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1 5 10 15Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu 20 25 30Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala 35 40 45Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Ala 50 55 6011481DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 114gccccagagc tagaaatagc aagttggggt aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8111581DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 115gttttagagc ccgaaagggc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8111677DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 116gttttagagc gaaagcaagt taaaataagg ctagtccgtt atcaacttga aaaagtggca 60ccgagtcggt gcttttt 7711775DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 117gttttagagg aaacaagtta aaataaggct agtccgttat caacttgaaa aagtggcacc 60gagtcggtgc ttttt 7511872DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 118gttttagaga caagttaaaa taaggctagt ccgttatcaa cttgaaaaag tggcaccgag 60tcggtgcttt tt 7211979DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 119gttttagagc tagaaatagc tttaaaataa ggctagtccg ttatcaactt gaaaaagtgg 60caccgagtcg gtgcttttt 7912079DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 120gttttagcgc tagaaatagc gttaaaataa ggctagtccg ttatcaactt gaaaaagtgg 60caccgagtcg gtgcttttt 7912181DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 121gttttagcgc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8112281DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 122gttttagtgc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8112381DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 123gttttagggc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8112481DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 124gttttagagc tagaaatagc ttgttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8112581DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 125gttttagagc tagaaatagc aacttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8112681DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 126gttttagagc tagaaatagc aaattaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8112781DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 127gttttagagc tagaaatagc aatttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8112877DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 128gttttagagc tagaaatagc aagttaaaat aaggctagtc cgtaacttga aaaagtggca 60ccgagtcggt gcttttt 7712981DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 129gttttagagc tagaaatagc aagttaaaat aaggctagtc cgtatagaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8113081DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 130gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcacg ccgaaaggcg 60ggcaccgagt cggtgctttt t 8113189DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 131gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcacg ccggccgaaa 60ggccggcggg caccgagtcg gtgcttttt 8913281DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 132gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttaaagaagt 60ggcaccgagt cggtgctttt t 8113381DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 133gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggccccgcgg cggggctttt t 8113483DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 134gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgaag ttcggtgctt ttt 8313585DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 135gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgaaa gtttcggtgc ttttt 8513681DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 136gttttagagc tagaaatagc aagctaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8113781DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 137gttttagatc tagaaatagc aaggtaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8113881DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 138gttttagagc tagaaatagc aagataaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8113981DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 139gttttagagc tagaaatagc aagttaaaac aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8114081DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 140tttttagagc tagaaatagc aagttaaaag aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8114181DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 141gttttagagc tagaaatagc aagttaaaaa aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8114281DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 142gttttagagc tagaaatagc aagttaaaat aaggctagac cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8114381DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 143gttttagagc tagaaatagc aagttaaaat aaggctagcc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 8114481DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 144gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgaat cggtgctttt t 8114581DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 145gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgact cggtgctttt t 8114681DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 146gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgatt cggtgctttt t 8114781DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 147gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgaga cggtgctttt t 8114881DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 148gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagc cggtgctttt t 8114981DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 149gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60ggcaccgagt cggtgctttt t 81150111DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 150gttttagagc taggccaaca tgaggatcac ccatgtctgc agggcctagc aagttaaaat 60aaggctagtc cgttatcacg ccgaaaggcg ggcaccgagt cggtgctttt t 111151111DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 151gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttggccaaca 60tgaggatcac ccatgtctgc agggccaagt ggcaccgagt cggtgctttt t 111152141DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic polynucleotide" 152gttttagagc taggccaaca tgaggatcac ccatgtctgc agggcctagc aagttaaaat 60aaggctagtc cgttatcaac ttggccaaca tgaggatcac ccatgtctgc agggccaagt 120ggcaccgagt cggtgctttt t 14115325DNAHomo sapiens 153gagtccgagc agaagaagaa gggct 2515450DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 154ccatcacatc aaccggtggc gcattgccac gaagcaggcc aatggggagg 5015523DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 155ccagccaagc gcacctaatt tcc 2315698RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 156ggaaauuagg ugcgcuuggc guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60cguuaucaac uugaaaaagu ggcaccgagu cggugcuu 9815780RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 157guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc cguuaucaac uugaaaaagu 60ggcaccgagu cggugcuuuu 8015846RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 158guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc cguuuu 4615965RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 159guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc cguuaucaac uugaaaaagu 60guuuu 6516080RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 160gccccagagc uagaaauagc aaguuggggu aaggcuaguc cguuaucaac uugaaaaagu 60ggcaccgagu cggugcuuuu 8016171RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 161guuuuagaga caaguuaaaa uaaggcuagu ccguuaucaa cuugaaaaag uggcaccgag 60ucggugcuuu u 7116278RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 162guuuuagagc uagaaauagc uuuaaaauaa ggcuaguccg uuaucaacuu gaaaaagugg 60caccgagucg gugcuuuu 7816380RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 163guuuuagagc uagaaauagc aaguuaaaau aauucuagua aguuaucaac uugaaaaagu 60ggcaccgagu cggugcuuuu 8016480RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 164guuuuagagc uagaaauagc aaguuaaaau aagccaugug cguuaucaac uugaaaaagu 60ggcaccgagu cggugcuuuu 8016576RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 165guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc cguaacuuga aaaaguggca 60ccgagucggu gcuuuu 7616680RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 166guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc cguuaucacg ccgaaaggcg 60ggcaccgagu cggugcuuuu 8016784RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 167guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc cguuaucaac uugagaaauc 60aaguggcacc gagucggugc uuuu 8416880RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 168guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc cguuaucaac uugaaaaagu 60ggccccgcgg cggggcuuuu 8016984RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 169guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc cguuaucaac uugaaaaagu 60ggcaccgaaa guuucggugc uuuu 8417076RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 170gccccagagc auuagcaagu ugggguaagc caugugcguu aucagggcac cagcccggca 60ccgagucggu gcuuuu 7617120DNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 171gccaagcgca cctaatttcc 2017297RNAArtificial Sequencesource/note="Description of Artificial Sequence Synthetic oligonucleotide" 172ggaaauuagg ugcgcuuggc guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60cguuaucaac uugaaaaagu ggcaccgagu cggugcu 9717356DNAHomo sapiens 173aagctggagg aggagggcct gagtccgagc agaagaagaa gggctcccat cacatc 561741368PRTStreptococcus pyogenes 174Met Asp Lys Lys Tyr Ser Ile Gly Leu Asp Ile Gly Thr Asn Ser Val1 5 10

15Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe 20 25 30Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile 35 40 45Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu 50 55 60Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Cys65 70 75 80Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp Ser 85 90 95Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys 100 105 110His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr 115 120 125His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys Leu Val Asp 130 135 140Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His145 150 155 160Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro 165 170 175Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr 180 185 190Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala 195 200 205Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn 210 215 220Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn225 230 235 240Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe 245 250 255Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp 260 265 270Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp 275 280 285Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp 290 295 300Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser305 310 315 320Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu Lys 325 330 335Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe 340 345 350Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser 355 360 365Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu Lys Met Asp 370 375 380Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp Leu Leu Arg385 390 395 400Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His Leu 405 410 415Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe 420 425 430Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile 435 440 445Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp 450 455 460Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu465 470 475 480Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu Arg Met Thr 485 490 495Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro Lys His Ser 500 505 510Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys 515 520 525Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln 530 535 540Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr545 550 555 560Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp 565 570 575Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu Gly 580 585 590Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp 595 600 605Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu Thr Leu Thr 610 615 620Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr Ala625 630 635 640His Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr 645 650 655Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp 660 665 670Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe 675 680 685Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe 690 695 700Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly Asp Ser Leu705 710 715 720His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile Lys Lys Gly 725 730 735Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys Val Met Gly 740 745 750Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg Glu Asn Gln 755 760 765Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile 770 775 780Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro785 790 795 800Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu 805 810 815Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg 820 825 830Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys 835 840 845Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg 850 855 860Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys865 870 875 880Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys 885 890 895Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp 900 905 910Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr 915 920 925Lys His Val Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp 930 935 940Glu Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Leu Lys Ser945 950 955 960Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg 965 970 975Glu Ile Asn Asn Tyr His His Ala His Asp Ala Tyr Leu Asn Ala Val 980 985 990Val Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys Leu Glu Ser Glu Phe 995 1000 1005Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met Ile Ala 1010 1015 1020Lys Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr Phe Phe 1025 1030 1035Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr Glu Ile Thr Leu Ala 1040 1045 1050Asn Gly Glu Ile Arg Lys Arg Pro Leu Ile Glu Thr Asn Gly Glu 1055 1060 1065Thr Gly Glu Ile Val Trp Asp Lys Gly Arg Asp Phe Ala Thr Val 1070 1075 1080Arg Lys Val Leu Ser Met Pro Gln Val Asn Ile Val Lys Lys Thr 1085 1090 1095Glu Val Gln Thr Gly Gly Phe Ser Lys Glu Ser Ile Leu Pro Lys 1100 1105 1110Arg Asn Ser Asp Lys Leu Ile Ala Arg Lys Lys Asp Trp Asp Pro 1115 1120 1125Lys Lys Tyr Gly Gly Phe Asp Ser Pro Thr Val Ala Tyr Ser Val 1130 1135 1140Leu Val Val Ala Lys Val Glu Lys Gly Lys Ser Lys Lys Leu Lys 1145 1150 1155Ser Val Lys Glu Leu Leu Gly Ile Thr Ile Met Glu Arg Ser Ser 1160 1165 1170Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala Lys Gly Tyr Lys 1175 1180 1185Glu Val Lys Lys Asp Leu Ile Ile Lys Leu Pro Lys Tyr Ser Leu 1190 1195 1200Phe Glu Leu Glu Asn Gly Arg Lys Arg Met Leu Ala Ser Ala Gly 1205 1210 1215Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro Ser Lys Tyr Val 1220 1225 1230Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu Lys Gly Ser 1235 1240 1245Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln His Lys 1250 1255 1260His Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe Ser Lys 1265 1270 1275Arg Val Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu Ser Ala 1280 1285 1290Tyr Asn Lys His Arg Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn 1295 1300 1305Ile Ile His Leu Phe Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala 1310 1315 1320Phe Lys Tyr Phe Asp Thr Thr Ile Asp Arg Lys Arg Tyr Thr Ser 1325 1330 1335Thr Lys Glu Val Leu Asp Ala Thr Leu Ile His Gln Ser Ile Thr 1340 1345 1350Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ser Gln Leu Gly Gly Asp 1355 1360 13651751345PRTStreptococcus mutans 175Met Lys Lys Pro Tyr Ser Ile Gly Leu Asp Ile Gly Thr Asn Ser Val1 5 10 15Gly Trp Ala Val Val Thr Asp Asp Tyr Lys Val Pro Ala Lys Lys Met 20 25 30Lys Val Leu Gly Asn Thr Asp Lys Ser His Ile Glu Lys Asn Leu Leu 35 40 45Gly Ala Leu Leu Phe Asp Ser Gly Asn Thr Ala Glu Asp Arg Arg Leu 50 55 60Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Arg Asn Arg Ile Leu65 70 75 80Tyr Leu Gln Glu Ile Phe Ser Glu Glu Met Gly Lys Val Asp Asp Ser 85 90 95Phe Phe His Arg Leu Glu Asp Ser Phe Leu Val Thr Glu Asp Lys Arg 100 105 110Gly Glu Arg His Pro Ile Phe Gly Asn Leu Glu Glu Glu Val Lys Tyr 115 120 125His Glu Asn Phe Pro Thr Ile Tyr His Leu Arg Gln Tyr Leu Ala Asp 130 135 140Asn Pro Glu Lys Val Asp Leu Arg Leu Val Tyr Leu Ala Leu Ala His145 150 155 160Ile Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Lys Phe Asp Thr 165 170 175Arg Asn Asn Asp Val Gln Arg Leu Phe Gln Glu Phe Leu Ala Val Tyr 180 185 190Asp Asn Thr Phe Glu Asn Ser Ser Leu Gln Glu Gln Asn Val Gln Val 195 200 205Glu Glu Ile Leu Thr Asp Lys Ile Ser Lys Ser Ala Lys Lys Asp Arg 210 215 220Val Leu Lys Leu Phe Pro Asn Glu Lys Ser Asn Gly Arg Phe Ala Glu225 230 235 240Phe Leu Lys Leu Ile Val Gly Asn Gln Ala Asp Phe Lys Lys His Phe 245 250 255Glu Leu Glu Glu Lys Ala Pro Leu Gln Phe Ser Lys Asp Thr Tyr Glu 260 265 270Glu Glu Leu Glu Val Leu Leu Ala Gln Ile Gly Asp Asn Tyr Ala Glu 275 280 285Leu Phe Leu Ser Ala Lys Lys Leu Tyr Asp Ser Ile Leu Leu Ser Gly 290 295 300Ile Leu Thr Val Thr Asp Val Gly Thr Lys Ala Pro Leu Ser Ala Ser305 310 315 320Met Ile Gln Arg Tyr Asn Glu His Gln Met Asp Leu Ala Gln Leu Lys 325 330 335Gln Phe Ile Arg Gln Lys Leu Ser Asp Lys Tyr Asn Glu Val Phe Ser 340 345 350Asp Val Ser Lys Asp Gly Tyr Ala Gly Tyr Ile Asp Gly Lys Thr Asn 355 360 365Gln Glu Ala Phe Tyr Lys Tyr Leu Lys Gly Leu Leu Asn Lys Ile Glu 370 375 380Gly Ser Gly Tyr Phe Leu Asp Lys Ile Glu Arg Glu Asp Phe Leu Arg385 390 395 400Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His Leu 405 410 415Gln Glu Met Arg Ala Ile Ile Arg Arg Gln Ala Glu Phe Tyr Pro Phe 420 425 430Leu Ala Asp Asn Gln Asp Arg Ile Glu Lys Leu Leu Thr Phe Arg Ile 435 440 445Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Lys Ser Asp Phe Ala Trp 450 455 460Leu Ser Arg Lys Ser Ala Asp Lys Ile Thr Pro Trp Asn Phe Asp Glu465 470 475 480Ile Val Asp Lys Glu Ser Ser Ala Glu Ala Phe Ile Asn Arg Met Thr 485 490 495Asn Tyr Asp Leu Tyr Leu Pro Asn Gln Lys Val Leu Pro Lys His Ser 500 505 510Leu Leu Tyr Glu Lys Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys 515 520 525Tyr Lys Thr Glu Gln Gly Lys Thr Ala Phe Phe Asp Ala Asn Met Lys 530 535 540Gln Glu Ile Phe Asp Gly Val Phe Lys Val Tyr Arg Lys Val Thr Lys545 550 555 560Asp Lys Leu Met Asp Phe Leu Glu Lys Glu Phe Asp Glu Phe Arg Ile 565 570 575Val Asp Leu Thr Gly Leu Asp Lys Glu Asn Lys Val Phe Asn Ala Ser 580 585 590Tyr Gly Thr Tyr His Asp Leu Cys Lys Ile Leu Asp Lys Asp Phe Leu 595 600 605Asp Asn Ser Lys Asn Glu Lys Ile Leu Glu Asp Ile Val Leu Thr Leu 610 615 620Thr Leu Phe Glu Asp Arg Glu Met Ile Arg Lys Arg Leu Glu Asn Tyr625 630 635 640Ser Asp Leu Leu Thr Lys Glu Gln Val Lys Lys Leu Glu Arg Arg His 645 650 655Tyr Thr Gly Trp Gly Arg Leu Ser Ala Glu Leu Ile His Gly Ile Arg 660 665 670Asn Lys Glu Ser Arg Lys Thr Ile Leu Asp Tyr Leu Ile Asp Asp Gly 675 680 685Asn Ser Asn Arg Asn Phe Met Gln Leu Ile Asn Asp Asp Ala Leu Ser 690 695 700Phe Lys Glu Glu Ile Ala Lys Ala Gln Val Ile Gly Glu Thr Asp Asn705 710 715 720Leu Asn Gln Val Val Ser Asp Ile Ala Gly Ser Pro Ala Ile Lys Lys 725 730 735Gly Ile Leu Gln Ser Leu Lys Ile Val Asp Glu Leu Val Lys Ile Met 740 745 750Gly His Gln Pro Glu Asn Ile Val Val Glu Met Ala Arg Glu Asn Gln 755 760 765Phe Thr Asn Gln Gly Arg Arg Asn Ser Gln Gln Arg Leu Lys Gly Leu 770 775 780Thr Asp Ser Ile Lys Glu Phe Gly Ser Gln Ile Leu Lys Glu His Pro785 790 795 800Val Glu Asn Ser Gln Leu Gln Asn Asp Arg Leu Phe Leu Tyr Tyr Leu 805 810 815Gln Asn Gly Arg Asp Met Tyr Thr Gly Glu Glu Leu Asp Ile Asp Tyr 820 825 830Leu Ser Gln Tyr Asp Ile Asp His Ile Ile Pro Gln Ala Phe Ile Lys 835 840 845Asp Asn Ser Ile Asp Asn Arg Val Leu Thr Ser Ser Lys Glu Asn Arg 850 855 860Gly Lys Ser Asp Asp Val Pro Ser Lys Asp Val Val Arg Lys Met Lys865 870 875 880Ser Tyr Trp Ser Lys Leu Leu Ser Ala Lys Leu Ile Thr Gln Arg Lys 885 890 895Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Thr Asp Asp Asp 900 905 910Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr 915 920 925Lys His Val Ala Arg Ile Leu Asp Glu Arg Phe Asn Thr Glu Thr Asp 930 935 940Glu Asn Asn Lys Lys Ile Arg Gln Val Lys Ile Val Thr Leu Lys Ser945 950 955 960Asn Leu Val Ser Asn Phe Arg Lys Glu Phe Glu Leu Tyr Lys Val Arg 965 970 975Glu Ile Asn Asp Tyr His His Ala His Asp Ala Tyr Leu Asn Ala Val 980 985 990Ile Gly Lys Ala Leu Leu Gly Val Tyr Pro Gln Leu Glu Pro Glu Phe 995 1000 1005Val Tyr Gly Asp Tyr Pro His Phe His Gly His Lys Glu Asn Lys 1010 1015 1020Ala Thr Ala Lys Lys Phe Phe Tyr Ser Asn Ile Met Asn Phe Phe 1025 1030 1035Lys Lys Asp Asp Val Arg Thr Asp Lys Asn Gly Glu Ile Ile Trp 1040 1045 1050Lys Lys Asp Glu His Ile Ser Asn Ile Lys Lys Val Leu Ser Tyr 1055 1060 1065Pro Gln Val Asn Ile Val Lys Lys Val Glu Glu Gln Thr Gly Gly 1070 1075 1080Phe Ser Lys Glu Ser Ile Leu Pro Lys Gly Asn Ser Asp Lys Leu 1085 1090 1095Ile Pro Arg Lys Thr Lys Lys Phe Tyr Trp Asp Thr Lys Lys Tyr

1100 1105 1110Gly Gly Phe Asp Ser Pro Ile Val Ala Tyr Ser Ile Leu Val Ile 1115 1120 1125Ala Asp Ile Glu Lys Gly Lys Ser Lys Lys Leu Lys Thr Val Lys 1130 1135 1140Ala Leu Val Gly Val Thr Ile Met Glu Lys Met Thr Phe Glu Arg 1145 1150 1155Asp Pro Val Ala Phe Leu Glu Arg Lys Gly Tyr Arg Asn Val Gln 1160 1165 1170Glu Glu Asn Ile Ile Lys Leu Pro Lys Tyr Ser Leu Phe Lys Leu 1175 1180 1185Glu Asn Gly Arg Lys Arg Leu Leu Ala Ser Ala Arg Glu Leu Gln 1190 1195 1200Lys Gly Asn Glu Ile Val Leu Pro Asn His Leu Gly Thr Leu Leu 1205 1210 1215Tyr His Ala Lys Asn Ile His Lys Val Asp Glu Pro Lys His Leu 1220 1225 1230Asp Tyr Val Asp Lys His Lys Asp Glu Phe Lys Glu Leu Leu Asp 1235 1240 1245Val Val Ser Asn Phe Ser Lys Lys Tyr Thr Leu Ala Glu Gly Asn 1250 1255 1260Leu Glu Lys Ile Lys Glu Leu Tyr Ala Gln Asn Asn Gly Glu Asp 1265 1270 1275Leu Lys Glu Leu Ala Ser Ser Phe Ile Asn Leu Leu Thr Phe Thr 1280 1285 1290Ala Ile Gly Ala Pro Ala Thr Phe Lys Phe Phe Asp Lys Asn Ile 1295 1300 1305Asp Arg Lys Arg Tyr Thr Ser Thr Thr Glu Ile Leu Asn Ala Thr 1310 1315 1320Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile Asp 1325 1330 1335Leu Asn Lys Leu Gly Gly Asp 1340 13451761388PRTStreptococcus thermophilus 176Met Thr Lys Pro Tyr Ser Ile Gly Leu Asp Ile Gly Thr Asn Ser Val1 5 10 15Gly Trp Ala Val Thr Thr Asp Asn Tyr Lys Val Pro Ser Lys Lys Met 20 25 30Lys Val Leu Gly Asn Thr Ser Lys Lys Tyr Ile Lys Lys Asn Leu Leu 35 40 45Gly Val Leu Leu Phe Asp Ser Gly Ile Thr Ala Glu Gly Arg Arg Leu 50 55 60Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Arg Asn Arg Ile Leu65 70 75 80Tyr Leu Gln Glu Ile Phe Ser Thr Glu Met Ala Thr Leu Asp Asp Ala 85 90 95Phe Phe Gln Arg Leu Asp Asp Ser Phe Leu Val Pro Asp Asp Lys Arg 100 105 110Asp Ser Lys Tyr Pro Ile Phe Gly Asn Leu Val Glu Glu Lys Ala Tyr 115 120 125His Asp Glu Phe Pro Thr Ile Tyr His Leu Arg Lys Tyr Leu Ala Asp 130 135 140Ser Thr Lys Lys Ala Asp Leu Arg Leu Val Tyr Leu Ala Leu Ala His145 150 155 160Met Ile Lys Tyr Arg Gly His Phe Leu Ile Glu Gly Glu Phe Asn Ser 165 170 175Lys Asn Asn Asp Ile Gln Lys Asn Phe Gln Asp Phe Leu Asp Thr Tyr 180 185 190Asn Ala Ile Phe Glu Ser Asp Leu Ser Leu Glu Asn Ser Lys Gln Leu 195 200 205Glu Glu Ile Val Lys Asp Lys Ile Ser Lys Leu Glu Lys Lys Asp Arg 210 215 220Ile Leu Lys Leu Phe Pro Gly Glu Lys Asn Ser Gly Ile Phe Ser Glu225 230 235 240Phe Leu Lys Leu Ile Val Gly Asn Gln Ala Asp Phe Arg Lys Cys Phe 245 250 255Asn Leu Asp Glu Lys Ala Ser Leu His Phe Ser Lys Glu Ser Tyr Asp 260 265 270Glu Asp Leu Glu Thr Leu Leu Gly Tyr Ile Gly Asp Asp Tyr Ser Asp 275 280 285Val Phe Leu Lys Ala Lys Lys Leu Tyr Asp Ala Ile Leu Leu Ser Gly 290 295 300Phe Leu Thr Val Thr Asp Asn Glu Thr Glu Ala Pro Leu Ser Ser Ala305 310 315 320Met Ile Lys Arg Tyr Asn Glu His Lys Glu Asp Leu Ala Leu Leu Lys 325 330 335Glu Tyr Ile Arg Asn Ile Ser Leu Lys Thr Tyr Asn Glu Val Phe Lys 340 345 350Asp Asp Thr Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Lys Thr Asn 355 360 365Gln Glu Asp Phe Tyr Val Tyr Leu Lys Lys Leu Leu Ala Glu Phe Glu 370 375 380Gly Ala Asp Tyr Phe Leu Glu Lys Ile Asp Arg Glu Asp Phe Leu Arg385 390 395 400Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro Tyr Gln Ile His Leu 405 410 415Gln Glu Met Arg Ala Ile Leu Asp Lys Gln Ala Lys Phe Tyr Pro Phe 420 425 430Leu Ala Lys Asn Lys Glu Arg Ile Glu Lys Ile Leu Thr Phe Arg Ile 435 440 445Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Asp Phe Ala Trp 450 455 460Ser Ile Arg Lys Arg Asn Glu Lys Ile Thr Pro Trp Asn Phe Glu Asp465 470 475 480Val Ile Asp Lys Glu Ser Ser Ala Glu Ala Phe Ile Asn Arg Met Thr 485 490 495Ser Phe Asp Leu Tyr Leu Pro Glu Glu Lys Val Leu Pro Lys His Ser 500 505 510Leu Leu Tyr Glu Thr Phe Asn Val Tyr Asn Glu Leu Thr Lys Val Arg 515 520 525Phe Ile Ala Glu Ser Met Arg Asp Tyr Gln Phe Leu Asp Ser Lys Gln 530 535 540Lys Lys Asp Ile Val Arg Leu Tyr Phe Lys Asp Lys Arg Lys Val Thr545 550 555 560Asp Lys Asp Ile Ile Glu Tyr Leu His Ala Ile Tyr Gly Tyr Asp Gly 565 570 575Ile Glu Leu Lys Gly Ile Glu Lys Gln Phe Asn Ser Ser Leu Ser Thr 580 585 590Tyr His Asp Leu Leu Asn Ile Ile Asn Asp Lys Glu Phe Leu Asp Asp 595 600 605Ser Ser Asn Glu Ala Ile Ile Glu Glu Ile Ile His Thr Leu Thr Ile 610 615 620Phe Glu Asp Arg Glu Met Ile Lys Gln Arg Leu Ser Lys Phe Glu Asn625 630 635 640Ile Phe Asp Lys Ser Val Leu Lys Lys Leu Ser Arg Arg His Tyr Thr 645 650 655Gly Trp Gly Lys Leu Ser Ala Lys Leu Ile Asn Gly Ile Arg Asp Glu 660 665 670Lys Ser Gly Asn Thr Ile Leu Asp Tyr Leu Ile Asp Asp Gly Ile Ser 675 680 685Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ala Leu Ser Phe Lys 690 695 700Lys Lys Ile Gln Lys Ala Gln Ile Ile Gly Asp Glu Asp Lys Gly Asn705 710 715 720Ile Lys Glu Val Val Lys Ser Leu Pro Gly Ser Pro Ala Ile Lys Lys 725 730 735Gly Ile Leu Gln Ser Ile Lys Ile Val Asp Glu Leu Val Lys Val Met 740 745 750Gly Gly Arg Lys Pro Glu Ser Ile Val Val Glu Met Ala Arg Glu Asn 755 760 765Gln Tyr Thr Asn Gln Gly Lys Ser Asn Ser Gln Gln Arg Leu Lys Arg 770 775 780Leu Glu Lys Ser Leu Lys Glu Leu Gly Ser Lys Ile Leu Lys Glu Asn785 790 795 800Ile Pro Ala Lys Leu Ser Lys Ile Asp Asn Asn Ala Leu Gln Asn Asp 805 810 815Arg Leu Tyr Leu Tyr Tyr Leu Gln Asn Gly Lys Asp Met Tyr Thr Gly 820 825 830Asp Asp Leu Asp Ile Asp Arg Leu Ser Asn Tyr Asp Ile Asp His Ile 835 840 845Ile Pro Gln Ala Phe Leu Lys Asp Asn Ser Ile Asp Asn Lys Val Leu 850 855 860Val Ser Ser Ala Ser Asn Arg Gly Lys Ser Asp Asp Val Pro Ser Leu865 870 875 880Glu Val Val Lys Lys Arg Lys Thr Phe Trp Tyr Gln Leu Leu Lys Ser 885 890 895Lys Leu Ile Ser Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg 900 905 910Gly Gly Leu Ser Pro Glu Asp Lys Ala Gly Phe Ile Gln Arg Gln Leu 915 920 925Val Glu Thr Arg Gln Ile Thr Lys His Val Ala Arg Leu Leu Asp Glu 930 935 940Lys Phe Asn Asn Lys Lys Asp Glu Asn Asn Arg Ala Val Arg Thr Val945 950 955 960Lys Ile Ile Thr Leu Lys Ser Thr Leu Val Ser Gln Phe Arg Lys Asp 965 970 975Phe Glu Leu Tyr Lys Val Arg Glu Ile Asn Asp Phe His His Ala His 980 985 990Asp Ala Tyr Leu Asn Ala Val Val Ala Ser Ala Leu Leu Lys Lys Tyr 995 1000 1005Pro Lys Leu Glu Pro Glu Phe Val Tyr Gly Asp Tyr Pro Lys Tyr 1010 1015 1020Asn Ser Phe Arg Glu Arg Lys Ser Ala Thr Glu Lys Val Tyr Phe 1025 1030 1035Tyr Ser Asn Ile Met Asn Ile Phe Lys Lys Ser Ile Ser Leu Ala 1040 1045 1050Asp Gly Arg Val Ile Glu Arg Pro Leu Ile Glu Val Asn Glu Glu 1055 1060 1065Thr Gly Glu Ser Val Trp Asn Lys Glu Ser Asp Leu Ala Thr Val 1070 1075 1080Arg Arg Val Leu Ser Tyr Pro Gln Val Asn Val Val Lys Lys Val 1085 1090 1095Glu Glu Gln Asn His Gly Leu Asp Arg Gly Lys Pro Lys Gly Leu 1100 1105 1110Phe Asn Ala Asn Leu Ser Ser Lys Pro Lys Pro Asn Ser Asn Glu 1115 1120 1125Asn Leu Val Gly Ala Lys Glu Tyr Leu Asp Pro Lys Lys Tyr Gly 1130 1135 1140Gly Tyr Ala Gly Ile Ser Asn Ser Phe Thr Val Leu Val Lys Gly 1145 1150 1155Thr Ile Glu Lys Gly Ala Lys Lys Lys Ile Thr Asn Val Leu Glu 1160 1165 1170Phe Gln Gly Ile Ser Ile Leu Asp Arg Ile Asn Tyr Arg Lys Asp 1175 1180 1185Lys Leu Asn Phe Leu Leu Glu Lys Gly Tyr Lys Asp Ile Glu Leu 1190 1195 1200Ile Ile Glu Leu Pro Lys Tyr Ser Leu Phe Glu Leu Ser Asp Gly 1205 1210 1215Ser Arg Arg Met Leu Ala Ser Ile Leu Ser Thr Asn Asn Lys Arg 1220 1225 1230Gly Glu Ile His Lys Gly Asn Gln Ile Phe Leu Ser Gln Lys Phe 1235 1240 1245Val Lys Leu Leu Tyr His Ala Lys Arg Ile Ser Asn Thr Ile Asn 1250 1255 1260Glu Asn His Arg Lys Tyr Val Glu Asn His Lys Lys Glu Phe Glu 1265 1270 1275Glu Leu Phe Tyr Tyr Ile Leu Glu Phe Asn Glu Asn Tyr Val Gly 1280 1285 1290Ala Lys Lys Asn Gly Lys Leu Leu Asn Ser Ala Phe Gln Ser Trp 1295 1300 1305Gln Asn His Ser Ile Asp Glu Leu Cys Ser Ser Phe Ile Gly Pro 1310 1315 1320Thr Gly Ser Glu Arg Lys Gly Leu Phe Glu Leu Thr Ser Arg Gly 1325 1330 1335Ser Ala Ala Asp Phe Glu Phe Leu Gly Val Lys Ile Pro Arg Tyr 1340 1345 1350Arg Asp Tyr Thr Pro Ser Ser Leu Leu Lys Asp Ala Thr Leu Ile 1355 1360 1365His Gln Ser Val Thr Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ala 1370 1375 1380Lys Leu Gly Glu Gly 13851771121PRTStreptococcus thermophilus 177Met Ser Asp Leu Val Leu Gly Leu Asp Ile Gly Ile Gly Ser Val Gly1 5 10 15Val Gly Ile Leu Asn Lys Val Thr Gly Glu Ile Ile His Lys Asn Ser 20 25 30Arg Ile Phe Pro Ala Ala Gln Ala Glu Asn Asn Leu Val Arg Arg Thr 35 40 45Asn Arg Gln Gly Arg Arg Leu Ala Arg Arg Lys Lys His Arg Arg Val 50 55 60Arg Leu Asn Arg Leu Phe Glu Glu Ser Gly Leu Ile Thr Asp Phe Thr65 70 75 80Lys Ile Ser Ile Asn Leu Asn Pro Tyr Gln Leu Arg Val Lys Gly Leu 85 90 95Thr Asp Glu Leu Ser Asn Glu Glu Leu Phe Ile Ala Leu Lys Asn Met 100 105 110Val Lys His Arg Gly Ile Ser Tyr Leu Asp Asp Ala Ser Asp Asp Gly 115 120 125Asn Ser Ser Val Gly Asp Tyr Ala Gln Ile Val Lys Glu Asn Ser Lys 130 135 140Gln Leu Glu Thr Lys Thr Pro Gly Gln Ile Gln Leu Glu Arg Tyr Gln145 150 155 160Thr Tyr Gly Gln Leu Arg Gly Asp Phe Thr Val Glu Lys Asp Gly Lys 165 170 175Lys His Arg Leu Ile Asn Val Phe Pro Thr Ser Ala Tyr Arg Ser Glu 180 185 190Ala Leu Arg Ile Leu Gln Thr Gln Gln Glu Phe Asn Pro Gln Ile Thr 195 200 205Asp Glu Phe Ile Asn Arg Tyr Leu Glu Ile Leu Thr Gly Lys Arg Lys 210 215 220Tyr Tyr His Gly Pro Gly Asn Glu Lys Ser Arg Thr Asp Tyr Gly Arg225 230 235 240Tyr Arg Thr Ser Gly Glu Thr Leu Asp Asn Ile Phe Gly Ile Leu Ile 245 250 255Gly Lys Cys Thr Phe Tyr Pro Asp Glu Phe Arg Ala Ala Lys Ala Ser 260 265 270Tyr Thr Ala Gln Glu Phe Asn Leu Leu Asn Asp Leu Asn Asn Leu Thr 275 280 285Val Pro Thr Glu Thr Lys Lys Leu Ser Lys Glu Gln Lys Asn Gln Ile 290 295 300Ile Asn Tyr Val Lys Asn Glu Lys Ala Met Gly Pro Ala Lys Leu Phe305 310 315 320Lys Tyr Ile Ala Lys Leu Leu Ser Cys Asp Val Ala Asp Ile Lys Gly 325 330 335Tyr Arg Ile Asp Lys Ser Gly Lys Ala Glu Ile His Thr Phe Glu Ala 340 345 350Tyr Arg Lys Met Lys Thr Leu Glu Thr Leu Asp Ile Glu Gln Met Asp 355 360 365Arg Glu Thr Leu Asp Lys Leu Ala Tyr Val Leu Thr Leu Asn Thr Glu 370 375 380Arg Glu Gly Ile Gln Glu Ala Leu Glu His Glu Phe Ala Asp Gly Ser385 390 395 400Phe Ser Gln Lys Gln Val Asp Glu Leu Val Gln Phe Arg Lys Ala Asn 405 410 415Ser Ser Ile Phe Gly Lys Gly Trp His Asn Phe Ser Val Lys Leu Met 420 425 430Met Glu Leu Ile Pro Glu Leu Tyr Glu Thr Ser Glu Glu Gln Met Thr 435 440 445Ile Leu Thr Arg Leu Gly Lys Gln Lys Thr Thr Ser Ser Ser Asn Lys 450 455 460Thr Lys Tyr Ile Asp Glu Lys Leu Leu Thr Glu Glu Ile Tyr Asn Pro465 470 475 480Val Val Ala Lys Ser Val Arg Gln Ala Ile Lys Ile Val Asn Ala Ala 485 490 495Ile Lys Glu Tyr Gly Asp Phe Asp Asn Ile Val Ile Glu Met Ala Arg 500 505 510Glu Thr Asn Glu Asp Asp Glu Lys Lys Ala Ile Gln Lys Ile Gln Lys 515 520 525Ala Asn Lys Asp Glu Lys Asp Ala Ala Met Leu Lys Ala Ala Asn Gln 530 535 540Tyr Asn Gly Lys Ala Glu Leu Pro His Ser Val Phe His Gly His Lys545 550 555 560Gln Leu Ala Thr Lys Ile Arg Leu Trp His Gln Gln Gly Glu Arg Cys 565 570 575Leu Tyr Thr Gly Lys Thr Ile Ser Ile His Asp Leu Ile Asn Asn Ser 580 585 590Asn Gln Phe Glu Val Asp His Ile Leu Pro Leu Ser Ile Thr Phe Asp 595 600 605Asp Ser Leu Ala Asn Lys Val Leu Val Tyr Ala Thr Ala Asn Gln Glu 610 615 620Lys Gly Gln Arg Thr Pro Tyr Gln Ala Leu Asp Ser Met Asp Asp Ala625 630 635 640Trp Ser Phe Arg Glu Leu Lys Ala Phe Val Arg Glu Ser Lys Thr Leu 645 650 655Ser Asn Lys Lys Lys Glu Tyr Leu Leu Thr Glu Glu Asp Ile Ser Lys 660 665 670Phe Asp Val Arg Lys Lys Phe Ile Glu Arg Asn Leu Val Asp Thr Arg 675 680 685Tyr Ala Ser Arg Val Val Leu Asn Ala Leu Gln Glu His Phe Arg Ala 690 695 700His Lys Ile Asp Thr Lys Val Ser Val Val Arg Gly Gln Phe Thr Ser705 710 715 720Gln Leu Arg Arg His Trp Gly Ile Glu Lys Thr Arg Asp Thr Tyr His 725 730 735His His Ala Val Asp Ala Leu Ile Ile Ala Ala Ser Ser Gln Leu Asn 740 745 750Leu Trp Lys Lys Gln Lys Asn Thr Leu Val Ser Tyr Ser Glu Asp Gln 755 760 765Leu Leu Asp Ile Glu Thr Gly Glu Leu Ile Ser Asp Asp Glu Tyr Lys 770 775 780Glu Ser Val Phe Lys Ala Pro Tyr Gln His Phe Val Asp Thr Leu Lys785 790 795 800Ser Lys Glu Phe Glu Asp Ser Ile Leu Phe Ser Tyr Gln Val Asp Ser 805 810 815Lys Phe Asn Arg Lys Ile Ser Asp Ala Thr Ile Tyr Ala Thr Arg Gln

820 825 830Ala Lys Val Gly Lys Asp Lys Ala Asp Glu Thr Tyr Val Leu Gly Lys 835 840 845Ile Lys Asp Ile Tyr Thr Gln Asp Gly Tyr Asp Ala Phe Met Lys Ile 850 855 860Tyr Lys Lys Asp Lys Ser Lys Phe Leu Met Tyr Arg His Asp Pro Gln865 870 875 880Thr Phe Glu Lys Val Ile Glu Pro Ile Leu Glu Asn Tyr Pro Asn Lys 885 890 895Gln Ile Asn Glu Lys Gly Lys Glu Val Pro Cys Asn Pro Phe Leu Lys 900 905 910Tyr Lys Glu Glu His Gly Tyr Ile Arg Lys Tyr Ser Lys Lys Gly Asn 915 920 925Gly Pro Glu Ile Lys Ser Leu Lys Tyr Tyr Asp Ser Lys Leu Gly Asn 930 935 940His Ile Asp Ile Thr Pro Lys Asp Ser Asn Asn Lys Val Val Leu Gln945 950 955 960Ser Val Ser Pro Trp Arg Ala Asp Val Tyr Phe Asn Lys Thr Thr Gly 965 970 975Lys Tyr Glu Ile Leu Gly Leu Lys Tyr Ala Asp Leu Gln Phe Glu Lys 980 985 990Gly Thr Gly Thr Tyr Lys Ile Ser Gln Glu Lys Tyr Asn Asp Ile Lys 995 1000 1005Lys Lys Glu Gly Val Asp Ser Asp Ser Glu Phe Lys Phe Thr Leu 1010 1015 1020Tyr Lys Asn Asp Leu Leu Leu Val Lys Asp Thr Glu Thr Lys Glu 1025 1030 1035Gln Gln Leu Phe Arg Phe Leu Ser Arg Thr Met Pro Lys Gln Lys 1040 1045 1050His Tyr Val Glu Leu Lys Pro Tyr Asp Lys Gln Lys Phe Glu Gly 1055 1060 1065Gly Glu Ala Leu Ile Lys Val Leu Gly Asn Val Ala Asn Ser Gly 1070 1075 1080Gln Cys Lys Lys Gly Leu Gly Lys Ser Asn Ile Ser Ile Tyr Lys 1085 1090 1095Val Arg Thr Asp Val Leu Gly Asn Gln His Ile Ile Lys Asn Glu 1100 1105 1110Gly Asp Lys Pro Lys Leu Asp Phe 1115 1120178984PRTCampylobacter jejuni 178Met Ala Arg Ile Leu Ala Phe Asp Ile Gly Ile Ser Ser Ile Gly Trp1 5 10 15Ala Phe Ser Glu Asn Asp Glu Leu Lys Asp Cys Gly Val Arg Ile Phe 20 25 30Thr Lys Val Glu Asn Pro Lys Thr Gly Glu Ser Leu Ala Leu Pro Arg 35 40 45Arg Leu Ala Arg Ser Ala Arg Lys Arg Leu Ala Arg Arg Lys Ala Arg 50 55 60Leu Asn His Leu Lys His Leu Ile Ala Asn Glu Phe Lys Leu Asn Tyr65 70 75 80Glu Asp Tyr Gln Ser Phe Asp Glu Ser Leu Ala Lys Ala Tyr Lys Gly 85 90 95Ser Leu Ile Ser Pro Tyr Glu Leu Arg Phe Arg Ala Leu Asn Glu Leu 100 105 110Leu Ser Lys Gln Asp Phe Ala Arg Val Ile Leu His Ile Ala Lys Arg 115 120 125Arg Gly Tyr Asp Asp Ile Lys Asn Ser Asp Asp Lys Glu Lys Gly Ala 130 135 140Ile Leu Lys Ala Ile Lys Gln Asn Glu Glu Lys Leu Ala Asn Tyr Gln145 150 155 160Ser Val Gly Glu Tyr Leu Tyr Lys Glu Tyr Phe Gln Lys Phe Lys Glu 165 170 175Asn Ser Lys Glu Phe Thr Asn Val Arg Asn Lys Lys Glu Ser Tyr Glu 180 185 190Arg Cys Ile Ala Gln Ser Phe Leu Lys Asp Glu Leu Lys Leu Ile Phe 195 200 205Lys Lys Gln Arg Glu Phe Gly Phe Ser Phe Ser Lys Lys Phe Glu Glu 210 215 220Glu Val Leu Ser Val Ala Phe Tyr Lys Arg Ala Leu Lys Asp Phe Ser225 230 235 240His Leu Val Gly Asn Cys Ser Phe Phe Thr Asp Glu Lys Arg Ala Pro 245 250 255Lys Asn Ser Pro Leu Ala Phe Met Phe Val Ala Leu Thr Arg Ile Ile 260 265 270Asn Leu Leu Asn Asn Leu Lys Asn Thr Glu Gly Ile Leu Tyr Thr Lys 275 280 285Asp Asp Leu Asn Ala Leu Leu Asn Glu Val Leu Lys Asn Gly Thr Leu 290 295 300Thr Tyr Lys Gln Thr Lys Lys Leu Leu Gly Leu Ser Asp Asp Tyr Glu305 310 315 320Phe Lys Gly Glu Lys Gly Thr Tyr Phe Ile Glu Phe Lys Lys Tyr Lys 325 330 335Glu Phe Ile Lys Ala Leu Gly Glu His Asn Leu Ser Gln Asp Asp Leu 340 345 350Asn Glu Ile Ala Lys Asp Ile Thr Leu Ile Lys Asp Glu Ile Lys Leu 355 360 365Lys Lys Ala Leu Ala Lys Tyr Asp Leu Asn Gln Asn Gln Ile Asp Ser 370 375 380Leu Ser Lys Leu Glu Phe Lys Asp His Leu Asn Ile Ser Phe Lys Ala385 390 395 400Leu Lys Leu Val Thr Pro Leu Met Leu Glu Gly Lys Lys Tyr Asp Glu 405 410 415Ala Cys Asn Glu Leu Asn Leu Lys Val Ala Ile Asn Glu Asp Lys Lys 420 425 430Asp Phe Leu Pro Ala Phe Asn Glu Thr Tyr Tyr Lys Asp Glu Val Thr 435 440 445Asn Pro Val Val Leu Arg Ala Ile Lys Glu Tyr Arg Lys Val Leu Asn 450 455 460Ala Leu Leu Lys Lys Tyr Gly Lys Val His Lys Ile Asn Ile Glu Leu465 470 475 480Ala Arg Glu Val Gly Lys Asn His Ser Gln Arg Ala Lys Ile Glu Lys 485 490 495Glu Gln Asn Glu Asn Tyr Lys Ala Lys Lys Asp Ala Glu Leu Glu Cys 500 505 510Glu Lys Leu Gly Leu Lys Ile Asn Ser Lys Asn Ile Leu Lys Leu Arg 515 520 525Leu Phe Lys Glu Gln Lys Glu Phe Cys Ala Tyr Ser Gly Glu Lys Ile 530 535 540Lys Ile Ser Asp Leu Gln Asp Glu Lys Met Leu Glu Ile Asp His Ile545 550 555 560Tyr Pro Tyr Ser Arg Ser Phe Asp Asp Ser Tyr Met Asn Lys Val Leu 565 570 575Val Phe Thr Lys Gln Asn Gln Glu Lys Leu Asn Gln Thr Pro Phe Glu 580 585 590Ala Phe Gly Asn Asp Ser Ala Lys Trp Gln Lys Ile Glu Val Leu Ala 595 600 605Lys Asn Leu Pro Thr Lys Lys Gln Lys Arg Ile Leu Asp Lys Asn Tyr 610 615 620Lys Asp Lys Glu Gln Lys Asn Phe Lys Asp Arg Asn Leu Asn Asp Thr625 630 635 640Arg Tyr Ile Ala Arg Leu Val Leu Asn Tyr Thr Lys Asp Tyr Leu Asp 645 650 655Phe Leu Pro Leu Ser Asp Asp Glu Asn Thr Lys Leu Asn Asp Thr Gln 660 665 670Lys Gly Ser Lys Val His Val Glu Ala Lys Ser Gly Met Leu Thr Ser 675 680 685Ala Leu Arg His Thr Trp Gly Phe Ser Ala Lys Asp Arg Asn Asn His 690 695 700Leu His His Ala Ile Asp Ala Val Ile Ile Ala Tyr Ala Asn Asn Ser705 710 715 720Ile Val Lys Ala Phe Ser Asp Phe Lys Lys Glu Gln Glu Ser Asn Ser 725 730 735Ala Glu Leu Tyr Ala Lys Lys Ile Ser Glu Leu Asp Tyr Lys Asn Lys 740 745 750Arg Lys Phe Phe Glu Pro Phe Ser Gly Phe Arg Gln Lys Val Leu Asp 755 760 765Lys Ile Asp Glu Ile Phe Val Ser Lys Pro Glu Arg Lys Lys Pro Ser 770 775 780Gly Ala Leu His Glu Glu Thr Phe Arg Lys Glu Glu Glu Phe Tyr Gln785 790 795 800Ser Tyr Gly Gly Lys Glu Gly Val Leu Lys Ala Leu Glu Leu Gly Lys 805 810 815Ile Arg Lys Val Asn Gly Lys Ile Val Lys Asn Gly Asp Met Phe Arg 820 825 830Val Asp Ile Phe Lys His Lys Lys Thr Asn Lys Phe Tyr Ala Val Pro 835 840 845Ile Tyr Thr Met Asp Phe Ala Leu Lys Val Leu Pro Asn Lys Ala Val 850 855 860Ala Arg Ser Lys Lys Gly Glu Ile Lys Asp Trp Ile Leu Met Asp Glu865 870 875 880Asn Tyr Glu Phe Cys Phe Ser Leu Tyr Lys Asp Ser Leu Ile Leu Ile 885 890 895Gln Thr Lys Asp Met Gln Glu Pro Glu Phe Val Tyr Tyr Asn Ala Phe 900 905 910Thr Ser Ser Thr Val Ser Leu Ile Val Ser Lys His Asp Asn Lys Phe 915 920 925Glu Thr Leu Ser Lys Asn Gln Lys Ile Leu Phe Lys Asn Ala Asn Glu 930 935 940Lys Glu Val Ile Ala Lys Ser Ile Gly Ile Gln Asn Leu Lys Val Phe945 950 955 960Glu Lys Tyr Ile Val Ser Ala Leu Gly Glu Val Thr Lys Ala Glu Phe 965 970 975Arg Gln Arg Glu Asp Phe Lys Lys 9801791236PRTNeisseria meningiditis 179Met Tyr Phe Tyr Lys Asn Lys Glu Asn Lys Leu Asn Lys Lys Val Val1 5 10 15Leu Gly Leu Asp Leu Gly Ile Ala Ser Val Gly Trp Cys Leu Thr Asp 20 25 30Ile Ser Gln Lys Glu Asp Asn Lys Phe Pro Ile Ile Leu His Gly Val 35 40 45Arg Leu Phe Glu Thr Val Asp Asp Ser Asp Asp Lys Leu Leu Asn Glu 50 55 60Thr Arg Arg Lys Lys Arg Gly Gln Arg Arg Arg Asn Arg Arg Leu Phe65 70 75 80Thr Arg Lys Arg Asp Phe Ile Lys Tyr Leu Ile Asp Asn Asn Ile Ile 85 90 95Glu Leu Glu Phe Asp Lys Asn Pro Lys Ile Leu Val Arg Asn Phe Ile 100 105 110Glu Lys Tyr Ile Asn Pro Phe Ser Lys Asn Leu Glu Leu Lys Tyr Lys 115 120 125Ser Val Thr Asn Leu Pro Ile Gly Phe His Asn Leu Arg Lys Ala Ala 130 135 140Ile Asn Glu Lys Tyr Lys Leu Asp Lys Ser Glu Leu Ile Val Leu Leu145 150 155 160Tyr Phe Tyr Leu Ser Leu Arg Gly Ala Phe Phe Asp Asn Pro Glu Asp 165 170 175Thr Lys Ser Lys Glu Met Asn Lys Asn Glu Ile Glu Ile Phe Asp Lys 180 185 190Asn Glu Ser Ile Lys Asn Ala Glu Phe Pro Ile Asp Lys Ile Ile Glu 195 200 205Phe Tyr Lys Ile Ser Gly Lys Ile Arg Ser Thr Ile Asn Leu Lys Phe 210 215 220Gly His Gln Asp Tyr Leu Lys Glu Ile Lys Gln Val Phe Glu Lys Gln225 230 235 240Asn Ile Asp Phe Met Asn Tyr Glu Lys Phe Ala Met Glu Glu Lys Ser 245 250 255Phe Phe Ser Arg Ile Arg Asn Tyr Ser Glu Gly Pro Gly Asn Glu Lys 260 265 270Ser Phe Ser Lys Tyr Gly Leu Tyr Ala Asn Glu Asn Gly Asn Pro Glu 275 280 285Leu Ile Ile Asn Glu Lys Gly Gln Lys Ile Tyr Thr Lys Ile Phe Lys 290 295 300Thr Leu Trp Glu Ser Lys Ile Gly Lys Cys Ser Tyr Asp Lys Lys Leu305 310 315 320Tyr Arg Ala Pro Lys Asn Ser Phe Ser Ala Lys Val Phe Asp Ile Thr 325 330 335Asn Lys Leu Thr Asp Trp Lys His Lys Asn Glu Tyr Ile Ser Glu Arg 340 345 350Leu Lys Arg Lys Ile Leu Leu Ser Arg Phe Leu Asn Lys Asp Ser Lys 355 360 365Ser Ala Val Glu Lys Ile Leu Lys Glu Glu Asn Ile Lys Phe Glu Asn 370 375 380Leu Ser Glu Ile Ala Tyr Asn Lys Asp Asp Asn Lys Ile Asn Leu Pro385 390 395 400Ile Ile Asn Ala Tyr His Ser Leu Thr Thr Ile Phe Lys Lys His Leu 405 410 415Ile Asn Phe Glu Asn Tyr Leu Ile Ser Asn Glu Asn Asp Leu Ser Lys 420 425 430Leu Met Ser Phe Tyr Lys Gln Gln Ser Glu Lys Leu Phe Val Pro Asn 435 440 445Glu Lys Gly Ser Tyr Glu Ile Asn Gln Asn Asn Asn Val Leu His Ile 450 455 460Phe Asp Ala Ile Ser Asn Ile Leu Asn Lys Phe Ser Thr Ile Gln Asp465 470 475 480Arg Ile Arg Ile Leu Glu Gly Tyr Phe Glu Phe Ser Asn Leu Lys Lys 485 490 495Asp Val Lys Ser Ser Glu Ile Tyr Ser Glu Ile Ala Lys Leu Arg Glu 500 505 510Phe Ser Gly Thr Ser Ser Leu Ser Phe Gly Ala Tyr Tyr Lys Phe Ile 515 520 525Pro Asn Leu Ile Ser Glu Gly Ser Lys Asn Tyr Ser Thr Ile Ser Tyr 530 535 540Glu Glu Lys Ala Leu Gln Asn Gln Lys Asn Asn Phe Ser His Ser Asn545 550 555 560Leu Phe Glu Lys Thr Trp Val Glu Asp Leu Ile Ala Ser Pro Thr Val 565 570 575Lys Arg Ser Leu Arg Gln Thr Met Asn Leu Leu Lys Glu Ile Phe Lys 580 585 590Tyr Ser Glu Lys Asn Asn Leu Glu Ile Glu Lys Ile Val Val Glu Val 595 600 605Thr Arg Ser Ser Asn Asn Lys His Glu Arg Lys Lys Ile Glu Gly Ile 610 615 620Asn Lys Tyr Arg Lys Glu Lys Tyr Glu Glu Leu Lys Lys Val Tyr Asp625 630 635 640Leu Pro Asn Glu Asn Thr Thr Leu Leu Lys Lys Leu Trp Leu Leu Arg 645 650 655Gln Gln Gln Gly Tyr Asp Ala Tyr Ser Leu Arg Lys Ile Glu Ala Asn 660 665 670Asp Val Ile Asn Lys Pro Trp Asn Tyr Asp Ile Asp His Ile Val Pro 675 680 685Arg Ser Ile Ser Phe Asp Asp Ser Phe Ser Asn Leu Val Ile Val Asn 690 695 700Lys Leu Asp Asn Ala Lys Lys Ser Asn Asp Leu Ser Ala Lys Gln Phe705 710 715 720Ile Glu Lys Ile Tyr Gly Ile Glu Lys Leu Lys Glu Ala Lys Glu Asn 725 730 735Trp Gly Asn Trp Tyr Leu Arg Asn Ala Asn Gly Lys Ala Phe Asn Asp 740 745 750Lys Gly Lys Phe Ile Lys Leu Tyr Thr Ile Asp Asn Leu Asp Glu Phe 755 760 765Asp Asn Ser Asp Phe Ile Asn Arg Asn Leu Ser Asp Thr Ser Tyr Ile 770 775 780Thr Asn Ala Leu Val Asn His Leu Thr Phe Ser Asn Ser Lys Tyr Lys785 790 795 800Tyr Ser Val Val Ser Val Asn Gly Lys Gln Thr Ser Asn Leu Arg Asn 805 810 815Gln Ile Ala Phe Val Gly Ile Lys Asn Asn Lys Glu Thr Glu Arg Glu 820 825 830Trp Lys Arg Pro Glu Gly Phe Lys Ser Ile Asn Ser Asn Asp Phe Leu 835 840 845Ile Arg Glu Glu Gly Lys Asn Asp Val Lys Asp Asp Val Leu Ile Lys 850 855 860Asp Arg Ser Phe Asn Gly His His Ala Glu Asp Ala Tyr Phe Ile Thr865 870 875 880Ile Ile Ser Gln Tyr Phe Arg Ser Phe Lys Arg Ile Glu Arg Leu Asn 885 890 895Val Asn Tyr Arg Lys Glu Thr Arg Glu Leu Asp Asp Leu Glu Lys Asn 900 905 910Asn Ile Lys Phe Lys Glu Lys Ala Ser Phe Asp Asn Phe Leu Leu Ile 915 920 925Asn Ala Leu Asp Glu Leu Asn Glu Lys Leu Asn Gln Met Arg Phe Ser 930 935 940Arg Met Val Ile Thr Lys Lys Asn Thr Gln Leu Phe Asn Glu Thr Leu945 950 955 960Tyr Ser Gly Lys Tyr Asp Lys Gly Lys Asn Thr Ile Lys Lys Val Glu 965 970 975Lys Leu Asn Leu Leu Asp Asn Arg Thr Asp Lys Ile Lys Lys Ile Glu 980 985 990Glu Phe Phe Asp Glu Asp Lys Leu Lys Glu Asn Glu Leu Thr Lys Leu 995 1000 1005His Ile Phe Asn His Asp Lys Asn Leu Tyr Glu Thr Leu Lys Ile 1010 1015 1020Ile Trp Asn Glu Val Lys Ile Glu Ile Lys Asn Lys Asn Leu Asn 1025 1030 1035Glu Lys Asn Tyr Phe Lys Tyr Phe Val Asn Lys Lys Leu Gln Glu 1040 1045 1050Gly Lys Ile Ser Phe Asn Glu Trp Val Pro Ile Leu Asp Asn Asp 1055 1060 1065Phe Lys Ile Ile Arg Lys Ile Arg Tyr Ile Lys Phe Ser Ser Glu 1070 1075 1080Glu Lys Glu Thr Asp Glu Ile Ile Phe Ser Gln Ser Asn Phe Leu 1085 1090 1095Lys Ile Asp Gln Arg Gln Asn Phe Ser Phe His Asn Thr Leu Tyr 1100 1105 1110Trp Val Gln Ile Trp Val Tyr Lys Asn Gln Lys Asp Gln Tyr Cys 1115 1120 1125Phe Ile Ser Ile Asp Ala Arg Asn Ser Lys Phe Glu Lys Asp Glu 1130 1135 1140Ile Lys Ile Asn Tyr Glu Lys Leu Lys Thr Gln Lys Glu Lys Leu 1145 1150 1155Gln Ile Ile Asn Glu Glu Pro Ile Leu Lys Ile Asn Lys Gly Asp 1160 1165 1170Leu Phe Glu Asn Glu Glu Lys Glu Leu Phe Tyr Ile Val Gly Arg

1175 1180 1185Asp Glu Lys Pro Gln Lys Leu Glu Ile Lys Tyr Ile Leu Gly Lys 1190 1195 1200Lys Ile Lys Asp Gln Lys Gln Ile Gln Lys Pro Val Lys Lys Tyr 1205 1210 1215Phe Pro Asn Trp Lys Lys Val Asn Leu Thr Tyr Met Gly Glu Ile 1220 1225 1230Phe Lys Lys 1235180305PRTStreptococcus pyogenes 180Lys Lys Tyr Ser Ile Gly Leu Ala Ile Gly Thr Asn Ser Val Gly Trp1 5 10 15Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe Lys Val 20 25 30Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile Gly Ala 35 40 45Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu Lys Arg 50 55 60Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Leu Tyr Leu65 70 75 80Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp Ser Phe Phe 85 90 95His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys His Glu 100 105 110Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr His Glu 115 120 125Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys Leu Val Asp Ser Thr 130 135 140Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His Met Ile145 150 155 160Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro Asp Asn 165 170 175Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr Asn Gln 180 185 190Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala Lys Ala 195 200 205Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn Leu Ile 210 215 220Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn Leu Ile225 230 235 240Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe Asp Leu 245 250 255Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp Asp Asp 260 265 270Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp Leu Phe 275 280 285Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp Ile Leu 290 295 300Arg305181326PRTStreptococcus pyogenes 181Lys Ala Pro Leu Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His His1 5 10 15Gln Asp Leu Thr Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro Glu 20 25 30Lys Tyr Lys Glu Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala Gly 35 40 45Tyr Ile Asp Gly Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile Lys 50 55 60Pro Ile Leu Glu Lys Met Asp Gly Thr Glu Glu Leu Leu Val Lys Leu65 70 75 80Asn Arg Glu Asp Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly Ser 85 90 95Ile Pro His Gln Ile His Leu Gly Glu Leu His Ala Ile Leu Arg Arg 100 105 110Gln Glu Asp Phe Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile Glu 115 120 125Lys Ile Leu Thr Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala Arg 130 135 140Gly Asn Ser Arg Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr Ile145 150 155 160Thr Pro Trp Asn Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala Gln 165 170 175Ser Phe Ile Glu Arg Met Thr Asn Phe Asp Lys Asn Leu Pro Asn Glu 180 185 190Lys Val Leu Pro Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val Tyr 195 200 205Asn Glu Leu Thr Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys Pro 210 215 220Ala Phe Leu Ser Gly Glu Gln Lys Lys Ala Ile Val Asp Leu Leu Phe225 230 235 240Lys Thr Asn Arg Lys Val Thr Val Lys Gln Leu Lys Glu Asp Tyr Phe 245 250 255Lys Lys Ile Glu Glu Phe Asp Ser Val Glu Ile Ser Gly Val Glu Asp 260 265 270Arg Phe Asn Ala Ser Leu Gly Thr Tyr His Asp Leu Leu Lys Ile Ile 275 280 285Lys Asp Lys Asp Phe Leu Asp Asn Glu Glu Asn Glu Asp Ile Leu Glu 290 295 300Asp Ile Val Leu Thr Leu Thr Leu Phe Glu Asp Arg Glu Met Ile Glu305 310 315 320Glu Arg Leu Lys Thr Tyr 32518270PRTStreptococcus pyogenes 182Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr Thr Gly Trp1 5 10 15Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp Lys Gln Ser 20 25 30Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe Ala Asn Arg 35 40 45Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe Lys Glu Asp 50 55 60Ile Gln Lys Ala Gln Val65 7018350PRTStreptococcus pyogenes 183Asp Ser Leu His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile1 5 10 15Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys 20 25 30Val Met Gly Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg 35 40 45Glu Asn 5018419PRTStreptococcus pyogenes 184Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu Glu Gly Ile Lys Glu1 5 10 15Leu Gly Ser185145PRTStreptococcus pyogenes 185Lys Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr1 5 10 15Leu Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu 20 25 30Asp Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp Ala Ile Val Pro Gln 35 40 45Ser Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser 50 55 60Asp Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val65 70 75 80Lys Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile 85 90 95Thr Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu 100 105 110Ser Glu Leu Asp Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr 115 120 125Arg Gln Ile Thr Lys His Val Ala Gln Ile Leu Asp Ser Arg Met Asn 130 135 140Thr14518658PRTStreptococcus pyogenes 186Arg Glu Val Lys Val Ile Thr Leu Lys Ser Lys Leu Val Ser Asp Phe1 5 10 15Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg Glu Ile Asn Asn Tyr His 20 25 30His Ala His Asp Ala Tyr Leu Asn Ala Val Val Gly Thr Ala Leu Ile 35 40 45Lys Lys Tyr Pro Lys Leu Glu Ser Glu Phe 50 5518719PRTStreptococcus pyogenes 187Gly Lys Ala Thr Ala Lys Tyr Phe Phe Tyr Ser Asn Ile Met Asn Phe1 5 10 15Phe Lys Thr188180PRTStreptococcus pyogenes 188Ile Glu Thr Asn Gly Glu Thr Gly Glu Ile Val Trp Asp Lys Gly Arg1 5 10 15Asp Phe Ala Thr Val Arg Lys Val Leu Ser Met Pro Gln Val Asn Ile 20 25 30Val Lys Lys Thr Glu Val Gln Thr Gly Gly Phe Ser Lys Glu Ser Ile 35 40 45Leu Pro Lys Arg Asn Ser Asp Lys Leu Ile Ala Arg Lys Lys Asp Trp 50 55 60Asp Pro Lys Lys Tyr Gly Gly Phe Asp Ser Pro Thr Val Ala Tyr Ser65 70 75 80Val Leu Val Val Ala Lys Val Glu Lys Gly Lys Ser Lys Lys Leu Lys 85 90 95Ser Val Lys Glu Leu Leu Gly Ile Thr Ile Met Glu Arg Ser Ser Phe 100 105 110Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala Lys Gly Tyr Lys Glu Val 115 120 125Lys Lys Asp Leu Ile Ile Lys Leu Pro Lys Tyr Ser Leu Phe Glu Leu 130 135 140Glu Asn Gly Arg Lys Arg Met Leu Ala Ser Ala Gly Glu Leu Gln Lys145 150 155 160Gly Asn Glu Leu Ala Leu Pro Ser Lys Tyr Val Asn Phe Leu Tyr Leu 165 170 175Ala Ser His Tyr 180189118PRTStreptococcus pyogenes 189Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln His Lys His1 5 10 15Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe Ser Lys Arg Val 20 25 30Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu Ser Ala Tyr Asn Lys 35 40 45His Arg Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn Ile Ile His Leu 50 55 60Phe Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp65 70 75 80Thr Thr Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp 85 90 95Ala Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile 100 105 110Asp Leu Ser Gln Leu Gly 11519097RNAStreptococcus pyogenes 190ggaaauuggg ugcgcuuggc guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60cguuaucaac uugagaaagu ggcaccgagu cggugcu 9719120DNAStreptococcus pyogenes 191gccaagcgca cccaatttcc 20192567PRTStreptococcus pyogenes 192Lys Lys Tyr Ser Ile Gly Leu Ala Ile Gly Thr Asn Ser Val Gly Trp1 5 10 15Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe Lys Val 20 25 30Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile Gly Ala 35 40 45Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu Lys Arg 50 55 60Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Leu Tyr Leu65 70 75 80Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp Ser Phe Phe 85 90 95His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys His Glu 100 105 110Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr His Glu 115 120 125Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys Leu Val Asp Ser Thr 130 135 140Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His Met Ile145 150 155 160Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro Asp Asn 165 170 175Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr Asn Gln 180 185 190Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala Lys Ala 195 200 205Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn Leu Ile 210 215 220Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn Leu Ile225 230 235 240Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe Asp Leu 245 250 255Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp Asp Asp 260 265 270Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp Leu Phe 275 280 285Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp Ile Leu 290 295 300Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser Met Ile305 310 315 320Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu Lys Ala Leu 325 330 335Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe Asp Gln 340 345 350Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser Gln Glu 355 360 365Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu Lys Met Asp Gly Thr 370 375 380Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp Leu Leu Arg Lys Gln385 390 395 400Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His Leu Gly Glu 405 410 415Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe Leu Lys 420 425 430Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile Pro Tyr 435 440 445Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp Met Thr 450 455 460Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu Val Val465 470 475 480Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu Arg Met Thr Asn Phe 485 490 495Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro Lys His Ser Leu Leu 500 505 510Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys Tyr Val 515 520 525Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln Lys Lys 530 535 540Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr Val Lys545 550 555 560Gln Leu Lys Glu Asp Tyr Phe 56519362PRTStreptococcus pyogenes 193Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu Gly Thr1 5 10 15Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp Asn 20 25 30Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu Thr Leu Thr Leu 35 40 45Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr 50 55 6019469PRTStreptococcus pyogenes 194Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr Thr Gly Trp1 5 10 15Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp Lys Gln Ser 20 25 30Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe Ala Asn Arg 35 40 45Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe Lys Glu Asp 50 55 60Ile Gln Lys Ala Gln6519546PRTStreptococcus pyogenes 195Asp Ser Leu His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile1 5 10 15Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys 20 25 30Val Met Gly Arg His Lys Pro Glu Asn Ile Val Ile Glu Met 35 40 4519694PRTStreptococcus pyogenes 196Arg Gln Leu Val Glu Thr Arg Gln Ile Thr Lys His Val Ala Gln Ile1 5 10 15Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp Glu Asn Asp Lys Leu Ile 20 25 30Arg Glu Val Lys Val Ile Thr Leu Lys Ser Lys Leu Val Ser Asp Phe 35 40 45Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg Glu Ile Asn Asn Tyr His 50 55 60His Ala His Asp Ala Tyr Leu Asn Ala Val Val Gly Thr Ala Leu Ile65 70 75 80Lys Lys Tyr Pro Lys Leu Glu Ser Glu Phe Val Tyr Gly Asp 85 9019710PRTStreptococcus pyogenes 197Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr1 5 1019850PRTStreptococcus pyogenes 198Thr Asn Gly Glu Thr Gly Glu Ile Val Trp Asp Lys Gly Arg Asp Phe1 5 10 15Ala Thr Val Arg Lys Val Leu Ser Met Pro Gln Val Asn Ile Val Lys 20 25 30Lys Thr Glu Val Gln Thr Gly Gly Phe Ser Lys Glu Ser Ile Leu Pro 35 40 45Lys Arg 50199127PRTStreptococcus pyogenes 199Asp Lys Leu Ile Ala Arg Lys Lys Asp Trp Asp Pro Lys Lys Tyr Gly1 5 10 15Gly Phe Asp Ser Pro Thr Val Ala Tyr Ser Val Leu Val Val Ala Lys 20 25 30Val Glu Lys Gly Lys Ser Lys Lys Leu Lys Ser Val Lys Glu Leu Leu 35 40 45Gly Ile Thr Ile Met Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp 50 55 60Phe Leu Glu Ala Lys Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile Ile65 70 75 80Lys Leu Pro Lys Tyr Ser Leu Phe Glu Leu Glu Asn Gly Arg Lys Arg 85 90 95Met Leu Ala Ser Ala Gly Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu 100 105 110Pro Ser Lys Tyr Val Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu 115

120 125200117PRTStreptococcus pyogenes 200Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln His Lys His Tyr1 5 10 15Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe Ser Lys Arg Val Ile 20 25 30Leu Ala Asp Ala Asn Leu Asp Lys Val Leu Ser Ala Tyr Asn Lys His 35 40 45Arg Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn Ile Ile His Leu Phe 50 55 60Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr65 70 75 80Thr Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp Ala 85 90 95Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile Asp 100 105 110Leu Ser Gln Leu Gly 11520197RNAStreptococcus pyogenes 201ggaaauuggg ugcgcuuggc guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60cguuaucaac uugagaaagu ggcaccgagu cggugcu 9720220DNAStreptococcus pyogenes 202gccaagcgca cccaatttcc 20

Claims

1-11. (canceled)

12. A method for reducing interaction of a Streptococcus pyogenes Cas9 (SpCas9) protein with a target DNA, comprising mutating one or more residues at Asn497, Trp659, Arg661, Gln695, Gln926, Glu1108, Leu169, Tyr450, Met495, Met694, or His698 of a corresponding wild-type SpCas9.

13. A method for reducing interaction of a Streptococcus pyogenes Cas9 (SpCas9) protein with backbone phosphate groups of a target DNA, comprising mutating one or more residues at Asn497, Trp659, Arg661, Gln695, Gln926, or Glu1108 of a corresponding wild-type SpCas9.

14. A method for reducing interaction of a Streptococcus pyogenes Cas9 (SpCas9) protein with C2' atoms of a target DNA, comprising mutating one or more residues at Leu169, Tyr450, Met495, Met694, or His698 of a corresponding wild-type SpCas9.

15. A composition comprising a Streptococcus pyogenes Cas9 (SpCas9) protein having reduced interaction with a target DNA, wherein the SpCas9 protein comprises one or more mutations at Asn497, Trp659, Arg661, Gln695, Gln926, Glu1108, Leu169, Tyr450, Met495, Met694, or His698 of a corresponding wild-type SpCas9.

16. The composition of claim 15, wherein the SpCas9 protein comprises one or more mutations at Asn497, Trp659, Arg661, Gln695, Gln926, or Glu1108 which reduces interaction with backbone phosphate groups of the target DNA.

17. The composition of claim 15, wherein the SpCas9 protein comprises one or more mutations at Leu169, Tyr450, Met495, Met694, or His698 which reduces interaction with C2' atoms of the target DNA.

18. The composition of claim 15, further comprising a CRISPR-Cas system guide RNA.

19. The composition of claim 18, wherein the SpCas9 protein and the guide RNA forms a CRISPR-Cas complex.